Allergan 10-Q 4 Nov 16 2016 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2016	Oct. 26, 2016
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q3
Trading Symbol	AGN
Entity Registrant Name	Allergan plc
Entity Central Index Key	1,578,845
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		375,080,162
Warner Chilcott Limited [Member]
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q3
Entity Registrant Name	WARNER CHILCOTT LIMITED
Entity Central Index Key	1,620,602
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Millions	Sep. 30, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 7,554.7	$ 1,096
Marketable securities	19,837.6	9.3
Accounts receivable, net	2,398.5	2,125.4
Inventories	705.5	757.5
Prepaid expenses and other current assets	771.7	495.3
Current assets held for sale	455.9	4,095.6
Total current assets	31,723.9	8,579.1
Property, plant and equipment, net	1,566.3	1,531.3
Investments and other assets	341.1	408.7
Non current assets held for sale	207.2	10,713.3
Deferred tax assets	120.7	49.5
Product rights and other intangibles	63,022.7	67,836.2
Goodwill	46,625.8	46,465.2
Total assets	143,607.7	135,583.3
Current liabilities:
Accounts payable and accrued expenses	5,425.4	4,148.6
Income taxes payable	784.6	53.7
Current portion of long-term debt and capital leases	1,591.8	2,396.5
Current liabilities held for sale	223.7	1,693.2
Total current liabilities	8,025.5	8,292
Long-term debt and capital leases	31,178.2	40,133.9
Other long-term liabilities	1,022.7	1,262
Long-term liabilities held for sale	23.8	535.4
Other taxes payable	815.6	801.9
Deferred tax liabilities	12,811.5	7,968.8
Total liabilities	53,877.3	58,994
Commitments and contingencies (Refer to Note 20)
Equity:
Preferred shares, $0.0001 par value per share, 5.1 million shares authorized, 5.1 million and 5.1 million shares issued and outstanding, respectively	4,929.7	4,929.7
Treasury shares, at cost, 1.7 million shares pending and zero shares, respectively	(400)
Additional paid-in capital	66,184.2	68,508.3
Retained earnings	18,412.7	3,647.5
Accumulated other comprehensive income / (loss)	599.3	(494.1)
Total shareholders’ equity	89,725.9	76,591.4
Noncontrolling interest	4.5	(2.1)
Total equity	89,730.4	76,589.3
Total liabilities and equity	143,607.7	135,583.3
Warner Chilcott Limited [Member]
Current assets:
Cash and cash equivalents	7,522.8	1,036.2
Marketable securities	19,837.6	9.3
Accounts receivable, net	2,398.5	2,125.4
Receivables from Parents	2,828.7	457.3
Inventories	705.5	757.5
Prepaid expenses and other current assets	769.6	492.8
Current assets held for sale	455.9	4,095.6
Total current assets	34,518.6	8,974.1
Property, plant and equipment, net	1,566.3	1,531.3
Investments and other assets	341.1	408.7
Non current receivables from Parents	3,985
Non current assets held for sale	207.2	10,713.3
Deferred tax assets	120.7	49.5
Product rights and other intangibles	63,022.7	67,836.2
Goodwill	46,625.8	46,465.2
Total assets	150,387.4	135,978.3
Current liabilities:
Accounts payable and accrued expenses	4,995.8	4,094.5
Payables to Parents	6,202.2	1,466.8
Income taxes payable	784.6	53.7
Current portion of long-term debt and capital leases	1,591.8	2,396.5
Current liabilities held for sale	223.7	1,693.2
Total current liabilities	13,798.1	9,704.7
Long-term debt and capital leases	31,178.2	40,133.9
Other long-term liabilities	1,022.7	1,262
Long-term payables to Parents	419
Long-term liabilities held for sale	23.8	535.4
Other taxes payable	815.6	801.9
Deferred tax liabilities	12,811.5	7,968.8
Total liabilities	60,068.9	60,406.7
Commitments and contingencies (Refer to Note 20)
Equity:
Member's capital	72,935.1	72,935.1
Retained earnings	16,779.6	3,132.7
Accumulated other comprehensive income / (loss)	599.3	(494.1)
Noncontrolling interest	4.5	(2.1)
Total equity	90,318.5	75,571.6
Total members’ equity	90,314	75,573.7
Total liabilities and equity	$ 150,387.4	$ 135,978.3

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2016	Dec. 31, 2015
Statement Of Financial Position [Abstract]
Preferred shares, par value	$ 0.0001	$ 0.0001
Preferred shares, shares authorized	5,100,000	5,100,000
Preferred shares, shares issued	5,100,000	5,100,000
Preferred shares, shares outstanding	5,100,000	5,100,000
Ordinary shares, par value	$ 0.0001	$ 0.0001
Ordinary shares, shares authorized	1,000,000,000	1,000,000,000
Ordinary shares, shares issued	383,200,000	394,500,000
Ordinary shares, shares outstanding	383,200,000	394,500,000
Treasury shares, shares pending	1,700,000	0

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Net revenues	$ 3,622.2	$ 3,469.5	$ 10,706.3	$ 9,081.2
Operating expenses:
Cost of sales (excludes amortization and impairment of acquired intangibles including product rights)	462.2	710.3	1,381.1	2,150
Research and development	622.8	1,260.5	1,662.4	1,927.9
Selling and marketing	796	683.6	2,429.6	2,017.2
General and administrative	361.2	339.1	1,033.9	1,188
Amortization	1,609.1	1,557.8	4,831.9	3,858.9
In-process research and development impairments	42	300	316.9	497.6
Asset sales and impairments, net	(4.7)	(4.4)	(24)	3.1
Total operating expenses	3,888.6	4,846.9	11,631.8	11,642.7
Operating (loss)	(266.4)	(1,377.4)	(925.5)	(2,561.5)
Non-Operating income (expense):
Interest income	18.1	3.5	23.5	7.6
Interest (expense)	(324.3)	(340.2)	(1,002.9)	(852)
Other (expense) income, net	33.6	0.2	184.2	(238.1)
Total other (expense), net	(272.6)	(336.5)	(795.2)	(1,082.5)
(Loss) before income taxes and noncontrolling interest	(539)	(1,713.9)	(1,720.7)	(3,644)
(Benefit) for income taxes	(158.9)	(838.9)	(825.8)	(1,491)
Net (loss) from continuing operations, net of tax	(380.1)	(875)	(894.9)	(2,153)
Income from discontinued operations, net of tax	15,601.9	6,177.6	15,873.2	6,701.7
Net income	15,221.8	5,302.6	14,978.3	4,548.7
(Income) attributable to noncontrolling interest	(1.8)	(1.4)	(4.3)	(2.6)
Net income attributable to shareholders	15,220	5,301.2	14,974	4,546.1
Dividends on preferred shares	69.6	69.6	208.8	162.4
Net income attributable to ordinary shareholders	$ 15,150.4	$ 5,231.6	$ 14,765.2	$ 4,383.7
(Loss) / income per share attributable to ordinary shareholders - basic:
Continuing operations	$ (1.15)	$ (2.40)	$ (2.81)	$ (6.46)
Discontinued operations	39.73	15.69	40.25	18.67
Net income per share - basic	38.58	13.29	37.44	12.21
(Loss) / income per share attributable to ordinary shareholders - diluted:
Continuing operations	(1.15)	(2.40)	(2.81)	(6.46)
Discontinued operations	39.73	15.69	40.25	18.67
Net income per share - diluted	$ 38.58	$ 13.29	$ 37.44	$ 12.21
Weighted average shares outstanding:
Basic	392.7	393.6	394.4	358.9
Diluted	392.7	393.6	394.4	358.9
Warner Chilcott Limited [Member]
Net revenues	$ 3,622.2	$ 3,469.5	$ 10,706.3	$ 9,081.2
Operating expenses:
Cost of sales (excludes amortization and impairment of acquired intangibles including product rights)	462.2	710.3	1,381.1	2,150
Research and development	622.8	1,260.5	1,662.4	1,927.9
Selling and marketing	796	683.6	2,429.6	2,017.2
General and administrative	312.2	333.8	966.2	1,174.9
Amortization	1,609.1	1,557.8	4,831.9	3,858.9
In-process research and development impairments	42	300	316.9	497.6
Asset sales and impairments, net	(4.7)	(4.4)	(24)	3.1
Total operating expenses	3,839.6	4,841.6	11,564.1	11,629.6
Operating (loss)	(217.4)	(1,372.1)	(857.8)	(2,548.4)
Non-Operating income (expense):
Interest income	18.1	3.5	23.5	7.6
Interest (expense)	(324.3)	(340.2)	(1,002.9)	(852)
Other (expense) income, net	33.6	0.2	34.2	(238.1)
Total other (expense), net	(272.6)	(336.5)	(945.2)	(1,082.5)
(Loss) before income taxes and noncontrolling interest	(490)	(1,708.6)	(1,803)	(3,630.9)
(Benefit) for income taxes	(158.9)	(838.9)	(825.8)	(1,491)
Net (loss) from continuing operations, net of tax	(331.1)	(869.7)	(977.2)	(2,139.9)
Income from discontinued operations, net of tax	15,601.9	6,177.6	15,873.2	6,701.7
Net income	15,270.8	5,307.9	14,896	4,561.8
(Income) attributable to noncontrolling interest	(1.8)	(1.4)	(4.3)	(2.6)
Net income attributable to shareholders	15,269	5,306.5	14,891.7	4,559.2
Net income attributable to members	$ 15,269	$ 5,306.5	$ 14,891.7	$ 4,559.2

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Net income	$ 15,221.8	$ 5,302.6	$ 14,978.3	$ 4,548.7
Other comprehensive income / (loss)
Foreign currency translation (losses) / gains	(19.1)	(42.4)	173.8	409
Unrealized gains (losses) / gains, net of tax	(609.3)	7.5	(625.2)	11.1
Total other comprehensive income / (loss), net of tax	916.4	(34.9)	1,093.4	420.1
Comprehensive income	16,138.2	5,267.7	16,071.7	4,968.8
Comprehensive (income) attributable to noncontrolling interest	(1.8)	(1.4)	(4.3)	(2.6)
Comprehensive income attributable to ordinary shareholders	16,136.4	5,266.3	16,067.4	4,966.2
Warner Chilcott Limited [Member]
Net income	15,270.8	5,307.9	14,896	4,561.8
Other comprehensive income / (loss)
Foreign currency translation (losses) / gains	(19.1)	(42.4)	173.8	409
Unrealized gains (losses) / gains, net of tax	(609.3)	7.5	(625.2)	11.1
Total other comprehensive income / (loss), net of tax	916.4	(34.9)	1,093.4	420.1
Comprehensive income	16,187.2	5,273	15,989.4	4,981.9
Comprehensive (income) attributable to noncontrolling interest	(1.8)	(1.4)	(4.3)	(2.6)
Comprehensive income attributable to ordinary shareholders	16,185.4	$ 5,271.6	15,985.1	$ 4,979.3
Teva Pharmaceutical Industries Ltd [Member]
Other comprehensive income / (loss)
Unrealized gains (losses) / gains, net of tax	664.2
Impact of Teva Transaction	1,544.8		1,544.8
Teva Pharmaceutical Industries Ltd [Member] | Warner Chilcott Limited [Member]
Other comprehensive income / (loss)
Impact of Teva Transaction	$ 1,544.8		$ 1,544.8

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Cash Flows From Operating Activities:
Net income	$ 14,978.3	$ 4,548.7
Reconciliation to net cash provided by operating activities:
Depreciation	117.6	183.9
Amortization	4,836.7	4,192.8
Provision for inventory reserve	162.7	108.6
Share-based compensation	269.9	510.5
Deferred income tax benefit	(517.1)	(7,470.9)
Pre-tax gain sale of generics business	(24,203.1)
Non-cash tax effect of gain on sale of generics business	5,749.9
In-process research and development impairments	316.9	497.6
Loss / (gain) on asset sales and impairments, net	(24)	57.2
Amortization of inventory step-up	42.4	1,019.8
Amortization of deferred financing costs	44.6	289.2
Contingent consideration adjustments, including accretion	76.7	89.2
Excess tax benefit from stock-based compensation	(26.6)	(54)
Other, net	(16)	54.9
Changes in assets and liabilities (net of effects of acquisitions):
Decrease / (increase) in accounts receivable, net	(40.4)	(364)
Decrease / (increase) in inventories	(221.6)	(270.1)
Decrease / (increase) in prepaid expenses and other current assets	158.9	(3.3)
Increase / (decrease) in accounts payable and accrued expenses	331.9	(290.6)
Increase / (decrease) in income and other taxes payable	(131.6)	(103.4)
Increase / (decrease) in other assets and liabilities	(397.5)	(21.6)
Net cash provided by operating activities	1,508.6	2,974.5
Cash Flows From Investing Activities:
Additions to property, plant and equipment	(250.5)	(350.7)
Additions to product rights and other intangibles		(91.1)
Sale of generics business	33,304.5
Additions to investments	(15,445.5)	(27)
Proceeds from sale of investments and other assets	40	855.8
Proceeds from sales of property, plant and equipment	33.3	133.6
Acquisitions of businesses, net of cash acquired	(74.5)	(35,242.7)
Net cash provided by / (used in) investing activities	17,607.3	(34,722.1)
Cash Flows From Financing Activities:
Proceeds from borrowings of long-term indebtedness		26,456.4
Proceeds from borrowings on credit facility and other	1,050	2,882
Debt issuance and other financing costs		(310.8)
Payments on debt, including capital lease obligations and credit facility	(10,831)	(4,326.7)
Proceeds from issuance of preferred shares		4,929.7
Proceeds from issuance of ordinary shares		4,071.1
Proceeds from stock plans	138	195.8
Payments of contingent consideration	(77.7)	(138.3)
Repurchase of ordinary shares	(2,758.6)	(108.2)
Dividends	(208.8)	(138.4)
Excess tax benefit from stock-based compensation	26.6	54
Net cash (used in) / provided by financing activities	(12,661.5)	33,566.6
Effect of currency exchange rate changes on cash and cash equivalents	4.3	(5.1)
Net increase in cash and cash equivalents	6,458.7	1,813.9
Cash and cash equivalents at beginning of period	1,096	250
Cash and cash equivalents at end of period	7,554.7	2,063.9
Supplemental Disclosure of Cash Flow Information
Taxes paid in connection with the sale of the generics business	2,571.7
Schedule of Non-Cash Investing and Financing Activities:
Dividends accrued	24.2	24
Teva Pharmaceutical Industries Ltd [Member]
Reconciliation to net cash provided by operating activities:
Deferred income tax benefit	5,273.9
Pre-tax gain sale of generics business	(24,202.7)
Cash Flows From Investing Activities:
Sale of generics business	33,304.5
Schedule of Non-Cash Investing and Financing Activities:
Receipt of ordinary shares in connection with the sale of the generics business	5,038.6
Warner Chilcott Limited [Member]
Cash Flows From Operating Activities:
Net income	14,896	4,561.8
Reconciliation to net cash provided by operating activities:
Depreciation	117.6	183.9
Amortization	4,836.7	4,192.8
Provision for inventory reserve	162.7	108.6
Share-based compensation	269.9	510.5
Deferred income tax benefit	(517.1)	(7,470.9)
Pre-tax gain sale of generics business	(24,203.1)
Non-cash tax effect of gain on sale of generics business	5,749.9
In-process research and development impairments	316.9	497.6
Loss / (gain) on asset sales and impairments, net	(24)	57.2
Amortization of inventory step-up	42.4	1,019.8
Amortization of deferred financing costs	44.6	289.2
Contingent consideration adjustments, including accretion	76.7	89.2
Other, net	(16)	54.9
Changes in assets and liabilities (net of effects of acquisitions):
Decrease / (increase) in accounts receivable, net	(40.4)	(363.3)
Decrease / (increase) in inventories	(221.6)	(270.1)
Decrease / (increase) in prepaid expenses and other current assets	156.8	(3.2)
Increase / (decrease) in accounts payable and accrued expenses	361.5	(257.5)
Increase / (decrease) in income and other taxes payable	(131.6)	(103.4)
Increase / (decrease) in other assets and liabilities	(1,899.4)	6.5
Net cash provided by operating activities	(21.5)	3,103.6
Cash Flows From Investing Activities:
Additions to property, plant and equipment	(250.5)	(350.7)
Additions to product rights and other intangibles		(91.1)
Sale of generics business	33,304.5
Additions to investments	(15,445.5)	(27)
Proceeds from sale of investments and other assets	40	855.8
Proceeds from sales of property, plant and equipment	33.3	133.6
Acquisitions of businesses, net of cash acquired	(74.5)	(35,242.7)
Net cash provided by / (used in) investing activities	17,607.3	(34,722.1)
Cash Flows From Financing Activities:
Proceeds from borrowings of long-term indebtedness		26,456.4
Proceeds from borrowings on credit facility and other	1,050	2,882
Debt issuance and other financing costs		(310.8)
Payments on debt, including capital lease obligations and credit facility	(10,831)	(4,326.7)
Payments of contingent consideration	(77.7)	(138.3)
Dividend to Parent	(1,244.8)	(138.4)
Contribution from Parent		9,000.8
Net cash (used in) / provided by financing activities	(11,103.5)	33,425
Effect of currency exchange rate changes on cash and cash equivalents	4.3	(5.1)
Net increase in cash and cash equivalents	6,486.6	1,801.4
Cash and cash equivalents at beginning of period	1,036.2	244.3
Cash and cash equivalents at end of period	$ 7,522.8	2,045.7
Allergan, Inc. [Member]
Schedule of Non-Cash Investing and Financing Activities:
Non-cash equity issuance for the Acquisition of net assets		$ 34,687.2

General

General	9 Months Ended
	Sep. 30, 2016
Organization Consolidation And Presentation Of Financial Statements [Abstract]
General	NOTE 1 — General Allergan plc is focused on developing, manufacturing and commercializing innovative branded pharmaceuticals (“brand”, “branded” or “specialty brand”) and select over-the-counter (“OTC”) products. Prior to completing the Teva Transaction (defined below), the Company also sold high-quality generic and OTC medicines and biologic products for patients around the world. Allergan markets a portfolio of best-in-class products that provide valuable treatments for the central nervous system, eye care, medical aesthetics, gastroenterology, women's health, urology, and anti-infective therapeutic categories, and operated the world's third-largest global generics business, providing patients around the globe with increased access to affordable, high-quality medicines. Allergan is an industry leader in research and development, with one of the broadest development pipelines in the pharmaceutical industry. With commercial operations in over 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives. Warner Chilcott Limited is a wholly-owned subsidiary of Allergan plc and has the same principal business activities. As a result of the Allergan Acquisition (defined below) which closed on March 17, 2015, the Company expanded its franchises to include ophthalmology, neurosciences and medical aesthetics/dermatology/plastic surgery, which complemented the Company’s existing central nervous system, gastroenterology, women’s health and urology franchises. The combined company benefits significantly from Allergan, Inc’s. (“Legacy Allergan”) global brand equity and consumer awareness of key products, including Botox ® ® On July 26, 2015 we entered into a master purchase agreement (the “Teva Agreement”), under which Teva Pharmaceutical Industries Ltd. (“Teva”) agreed to acquire our global generic pharmaceuticals business and certain other assets (the “Teva Transaction”). Upon the closing of the Teva Transaction on August 2, 2016, we received $33.3 billion in cash, net of cash acquired by Teva, which includes estimated working capital and other contractual adjustments, As part of the Teva Agreement, Teva acquired our global generics business, including the United States (“U.S.”) and international generic commercial units, our third-party supplier Medis, our global generic manufacturing operations, our global generic research and development (“R&D”) unit, our international OTC commercial unit (excluding OTC eye care products) and certain established international brands. On October 3, 2016, the Company completed the divestiture of the Anda Distribution business to Teva for an additional $500.0 million As a result of the Teva Transaction and the divestiture of the Company’s Anda Distribution business, and in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) number 2014-08 “Presentation of Financial Statements (Topic 205) and Property, Plant and Equipment (Topic 360): Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity”, the Company is accounting for the assets and liabilities divested as held for sale. Further, the financial results of the businesses held for sale have been reclassified to discontinued operations for all periods presented in our consolidated financial statements. The results of our discontinued operations include the results of our generic product development, manufacturing and distribution of off-patent pharmaceutical products, certain established international brands marketed similarly to generic products and out-licensed generic pharmaceutical products primarily in Europe through our Medis third-party business through August 2, 2016, as well as our Anda Distribution business. The accompanying consolidated financial statements should be read in conjunction with the Company’s annual report on Form 10-K for the year ended December 31, 2015 (“Annual Report”). Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with United States generally accepted accounting principles (“GAAP”) have been condensed or omitted from the accompanying consolidated financial statements. The accompanying year end consolidated balance sheet was derived from the audited financial statements included in the Annual Report as revised for discontinued operations treatment of our Anda Distribution business. The accompanying interim financial statements are unaudited and reflect all adjustments which are in the opinion of management necessary for a fair statement of the Company’s consolidated financial position, results of operations, comprehensive income and cash flows for the periods presented. Unless otherwise noted, all such adjustments are of a normal, recurring nature. All intercompany transactions and balances have been eliminated in consolidation. The Company’s results of operations, comprehensive income and cash flows for the interim periods are not necessarily indicative of the results of operations, comprehensive income and cash flows that it may achieve in future periods. In connection with the Allergan Acquisition, the Company changed its name from Actavis plc to Allergan plc. Actavis plc’s ordinary shares were traded on the NYSE under the symbol “ACT” until the opening of trading on June 15, 2015, at which time Actavis plc changed its corporate name to “Allergan plc” and changed its ticker symbol to “AGN.” Pursuant to Rule 12g-3(c) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), Allergan plc is the successor issuer to Actavis plc’s ordinary shares which are deemed to be registered under Section 12(b) of the Exchange Act, and Allergan plc is subject to the informational requirements of the Exchange Act, and the rules and regulations promulgated thereunder. References throughout to “we,” “our,” “us,” the “Company” or “Allergan” refer to financial information and transactions of Allergan plc. References to “Warner Chilcott Limited” refer to Warner Chilcott Limited, the Company’s indirect wholly-owned subsidiary, and, unless the context otherwise requires, its subsidiaries.

Reconciliation of Warner Chilco

Reconciliation of Warner Chilcott Limited Results to Allergan plc Results	9 Months Ended
	Sep. 30, 2016
Adjusted Earnings Before Interest Taxes Depreciation And Amortization And Other Non Cash Items [Abstract]
Reconciliation of Warner Chilcott Limited Results to Allergan plc Results	NOTE 2 – Reconciliation of Warner Chilcott Limited results to Allergan plc results Warner Chilcott Limited is an indirect wholly-owned subsidiary of Allergan plc (together with other Warner Chilcott Limited parents, the “Parent”), the ultimate parent of the group. The results of Warner Chilcott Limited are consolidated into the results of Allergan plc. Due to the deminimis activity between Allergan plc and Warner Chilcott Limited, references throughout this filing relate to both Allergan plc and Warner Chilcott Limited. Warner Chilcott Limited representations relate only to itself and not to any other company. Except where otherwise indicated, and excluding certain insignificant cash and non-cash transactions at the Allergan plc level, these notes relate to the consolidated financial statements for both separate registrants, Allergan plc and Warner Chilcott Limited. In addition to certain inter-company payable and receivable amounts between the entities, the following is a reconciliation of the financial position and results of operations of Warner Chilcott Limited to Allergan plc ($ in millions): As of September 30, 2016 As of December 31, 2015 Allergan plc Warner Chilcott Limited Difference Allergan plc Warner Chilcott Limited Difference Cash and cash equivalents $ 7,554.7 $ 7,522.8 $ 31.9 $ 1,096.0 $ 1,036.2 $ 59.8 Prepaid expenses and other current assets 771.7 769.6 2.1 495.3 492.8 2.5 Accounts payable and accrued liabilities 5,425.4 4,995.8 429.6 4,148.6 4,094.5 54.1 Three Months Ended September 30, 2016 Nine Months Ended September 30, 2016 Allergan plc Warner Chilcott Limited Difference Allergan plc Warner Chilcott Limited Difference General and administrative expenses $ 361.2 $ 312.2 $ 49.0 $ 1,033.9 $ 966.2 $ 67.7 Operating (loss) (266.4 ) (217.4 ) (49.0 ) (925.5 ) (857.8 ) (67.7 ) Other income / (expense) 33.6 33.6 - 184.2 34.2 150.0 (Loss) before income taxes and noncontrolling interest (539.0 ) (490.0 ) (49.0 ) (1,720.7 ) (1,803.0 ) 82.3 Net (loss) from continuing operations, net of tax (380.1 ) (331.1 ) (49.0 ) (894.9 ) (977.2 ) 82.3 Net income 15,221.8 15,270.8 (49.0 ) 14,978.3 14,896.0 82.3 Dividends on preferred stock 69.6 - 69.6 208.8 - 208.8 Net income attributable to ordinary shareholder/members 15,150.4 15,269.0 (118.6 ) 14,765.2 14,891.7 (126.5 ) Three Months Ended September 30, 2015 Nine Months Ended September 30, 2015 Allergan plc Warner Chilcott Limited Difference Allergan plc Warner Chilcott Limited Difference General and administrative expenses $ 339.1 $ 333.8 $ 5.3 $ 1,188.0 $ 1,174.9 $ 13.1 Operating (loss) (1,377.4 ) (1,372.1 ) (5.3 ) (2,561.5 ) (2,548.4 ) (13.1 ) (Loss) before income taxes and noncontrolling interest (1,713.9 ) (1,708.6 ) (5.3 ) (3,644.0 ) (3,630.9 ) (13.1 ) Net (loss) from continuing operations, net of tax (875.0 ) (869.7 ) (5.3 ) (2,153.0 ) (2,139.9 ) (13.1 ) Net income 5,302.6 5,307.9 (5.3 ) 4,548.7 4,561.8 (13.1 ) Dividends on preferred stock 69.6 - 69.6 162.4 - 162.4 Net income attributable to ordinary shareholder/members 5,231.6 5,306.5 (74.9 ) 4,383.7 4,559.2 (175.5 ) The difference between accounts payable and accrued liabilities as of September 30, 2016 primarily relates to accruals for the Company’s share repurchase program and dividends payable which are held by Allergan plc. The difference between general and administrative expenses in the three and nine months ended September 30, 2016 and 2015 were due to corporate related expenses incurred at Allergan plc as well as transaction costs. Movements in equity are due to historical differences in the results of operations of the companies and differences in equity awards.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2016
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	NOTE 3 — Summary of Significant Accounting Policies The following are interim updates to certain of the policies described in “Note 4” of the notes to the Company’s audited consolidated financial statements for the year ended December 31, 2015 included in the Annual Report. Reclassifications In April 2015, the FASB issued guidance which changes the classification of debt issuance costs from being an asset on the balance sheet to netting the costs against the carrying value of the debt. As a result, the Company reclassified debt issuance costs as of December 31, 2015 by decreasing “prepaid expenses and other current assets” and “current portion of long-term debt and capital leases” by $36.3 million as well as decreasing “investments and other assets” and “long-term debt and capital leases” by $159.5 million. In addition, the Company made certain presentation reclassifications relating to segment results and guarantor financial statements. Revenue Recognition General Revenue from product sales is recognized when title and risk of loss to the product transfers to the customer, which is based on the transaction shipping terms. Recognition of revenue also requires reasonable assurance of collection of sales proceeds, the seller’s price to the buyer to be fixed or determinable and the completion of all performance obligations. The Company warrants products against defects and for specific quality standards, permitting the return of products under certain circumstances. Product sales are recorded net of all sales-related deductions including, but not limited to: chargebacks, trade discounts, sales returns and allowances, commercial and government rebates, customer loyalty programs and fee-for-service arrangements with certain distributors, which we refer to in the aggregate as “SRA” allowances. Royalty and commission revenue is recognized as a component of net revenues in accordance with the terms of their respective contractual agreements when collectability is reasonably assured and when revenue can be reasonably measured. Provisions for SRAs As is customary in the pharmaceutical industry, our gross product sales are subject to a variety of deductions in arriving at reported net product sales. When the Company recognizes gross revenue from the sale of products, an estimate of SRA is recorded, which reduces the product revenues. Accounts receivable and/or accrued liabilities are also reduced and/or increased by the SRA amount depending on whether we have the right of offset with the customer. These provisions are estimated based on historical payment experience, historical relationship of the deductions to gross product revenues, government regulations, estimated utilization or redemption rates, estimated customer inventory levels and current contract sales terms. The estimation process used to determine our SRA provision has been applied on a consistent basis and no material revenue adjustments have been necessary to increase or decrease our reserves for SRA as a result of a significant change in underlying estimates. The Company uses a variety of methods to assess the adequacy of the SRA reserves to ensure that our financial statements are fairly stated. Chargebacks — A chargeback represents an amount payable in the future to a wholesaler for the difference between the invoice price paid by our wholesale customer for a particular product and the negotiated contract price that the wholesaler’s customer pays for that product. The chargeback provision and related reserve varies with changes in product mix, changes in customer pricing and changes to estimated wholesaler inventories. The provision for chargebacks also takes into account an estimate of the expected wholesaler sell-through levels to indirect customers at certain contract prices. The Company validates the chargeback accrual quarterly through a review of the inventory reports obtained from our largest wholesale customers. This customer inventory information is used to verify the estimated liability for future chargeback claims based on historical chargeback and contract rates. These large wholesalers represent the vast majority of the recipients of the Company’s chargeback payments. We continually monitor current pricing trends and wholesaler inventory levels to ensure the liability for future chargebacks is fairly stated. Rebates — Rebates include volume related incentives to direct and indirect customers, third-party managed care and Medicare Part D rebates, Medicaid rebates and other government rebates. Rebates are accrued based on an estimate of claims to be paid for product sold into trade by the Company. Volume rebates are generally offered to customers as an incentive to use the Company’s products and to encourage greater product sales. These rebate programs include contracted rebates based on customers’ purchases made during an applicable monthly, quarterly or annual period. The provision for third-party rebates is estimated based on our customers’ contracted rebate programs and the Company’s historical experience of rebates paid. Any significant changes to our customer rebate programs are considered in establishing the provision for rebates. The provisions for government rebates are based, in part, upon historical experience of claims submitted by the various states / authorities, contractual terms and government regulations. We monitor legislative changes to determine what impact such legislation may have on our provision. Cash Discounts — Cash discounts are provided to customers that pay within a specific period. The provision for cash discounts is estimated based upon invoice billings and historical customer payment experience. The Company’s experience of payment history is fairly consistent and most customer payments qualify for the cash discount. Returns and Other Allowances — The Company’s provision for returns and other allowances include returns, promotional allowances and loyalty cards. Consistent with industry practice, the Company maintains a returns policy that allows customers to return product for a credit. In accordance with the Company’s policy, credits for customer returns of products are applied against outstanding account activity or are settled in cash. Product exchanges are not permitted. Customer returns of product are generally not resalable. The Company’s estimate of the provision for returns is based upon historical experience and current trends of actual customer returns. Additionally, we consider other factors when estimating the current period returns provision, including levels of inventory in the distribution channel, as well as significant market changes which may impact future expected returns. Promotional allowances are credits that are issued in connection with a product launch or as an incentive for customers to carry our product. The Company establishes a reserve for promotional allowances based upon contractual terms. Loyalty cards allow the end user patients a discount per prescription and are accrued based on historical experience, contract terms and the volume of product and cards in the distribution channel. Accounts receivable balances in the Company’s consolidated financial statements are presented net of SRA estimates. SRA balances in accounts receivable were $243.8 million and $245.2 million at September 30, 2016 and December 31, 2015, respectively. SRA balances within accounts payable and accrued expenses were $1,797.3 million and $1,570.0 million at September 30, 2016 and December 31, 2015, respectively. The movements in the SRA reserve balances for continuing operations in the nine months ended September 30, 2016 are as follows ($ in millions): Balance as of December 31, 2015 $ 1,815.2 Provision to reduce gross product sales to net product sales 5,153.0 Payments and other (4,927.1 ) Balance as of September 30, 2016 $ 2,041.1 The provisions recorded to reduce gross product sales to net product sales, excluding discontinued operations, were as follows ($ in millions): Three Months Ended September 30, Nine Months Ended September 30, 2016 2015 2016 2015 Gross product sales $ 5,332.9 $ 4,918.4 $ 15,727.7 $ 12,825.8 Provisions to reduce gross product sales to net product sales (1,757.3 ) (1,503.5 ) (5,153.0 ) (3,871.3 ) Net product sales $ 3,575.6 $ 3,414.9 $ 10,574.7 $ 8,954.5 Percentage of provisions to gross sales 33.0 % 30.6 % 32.8 % 30.2 % The Company’s divested generics business also had the following type of SRA’s: • Pricing adjustments, included shelf stock adjustments which are credits issued to reflect price decreases in selling prices charged to the Company’s direct customers. Shelf stock adjustments are based upon the amount of product our customers have in their inventory at the time of an agreed-upon price reduction. The provision for shelf stock adjustments was based upon specific terms with the Company’s customers and includes estimates of existing customer inventory levels based upon their historical purchasing patterns. • Billback adjustments are credits that are issued to certain customers who purchase directly from us as well as indirectly through a wholesaler. These credits are issued in the event there was a difference between the customer’s direct and indirect contract price. The provision for billbacks was estimated based upon historical purchasing patterns of qualified customers who purchase product directly from us and supplement their purchases indirectly through our wholesale customers. The Company’s SRA reserves relating to discontinued operations were $15.5 million and $1,738.7 million as of September 30, 2016 and December 31, 2015, respectively. Goodwill and Intangible Assets with Indefinite-Lives General The Company tests goodwill and intangible assets with indefinite-lives for impairment annually in the second quarter by comparing the fair value of each of the Company’s reporting units to the respective carrying value of the reporting units. Additionally, the Company may perform interim tests if an event occurs or circumstances change that could potentially reduce the fair value of a reporting unit below its carrying amount. The carrying value of each reporting unit is determined by assigning the assets and liabilities, including the existing goodwill and intangible assets, to those reporting units. Goodwill is considered impaired if the carrying amount of the net assets exceeds the fair value of the reporting unit. Impairment, if any, would be recorded in operating income and this could result in a material impact to net income / (loss) and earnings / (loss) per share. Acquired in-process research and development (“IPR&D”) intangible assets represent the value assigned to acquired research and development projects that, as of the date acquired, represent the right to develop, use, sell and/or offer for sale a product or other intellectual property that the Company has acquired with respect to products and/or processes that have not been completed or approved. The IPR&D intangible assets are subject to impairment testing until completion or abandonment of each project. Upon abandonment, the assets are impaired. Impairment testing requires the development of significant estimates and assumptions involving the determination of estimated net cash flows for each year for each project or product (including net revenues, cost of sales, research and development (“R&D”) costs, selling and marketing costs and other costs which may be allocated), the appropriate discount rate to select in order to measure the risk inherent in each future cash flow stream, the assessment of each asset’s life cycle, the potential regulatory and commercial success risks, and competitive trends impacting the asset and each cash flow stream as well as other factors. The major risks and uncertainties associated with the timely and successful completion of the IPR&D projects include legal risk, market risk and regulatory risk. Changes in these assumptions could result in future impairment charges. No assurances can be given that the underlying assumptions used to prepare the discounted cash flow analysis will not change or the timely completion of each project to commercial success will occur. For these and other reasons, actual results may vary significantly from estimated results. Upon successful completion of each project and approval of the product, we will make a separate determination of the useful life of the intangible, transfer the amount to currently marketed products (“CMP”) and amortization expense will be recorded over the estimated useful life. Annual Testing In connection with the realignment of the Company’s operating segments in the second quarter of 2016, goodwill was reallocated to reporting units under the new segment structure. The Company evaluated goodwill for six reporting units during the second quarter of 2016. The Company performed its annual impairment test utilizing long-term growth rates for its reporting units ranging from 0% to 2.5% in its estimation of fair value and discount rates ranging from 8.0% to 9.5%. The factors used in evaluating goodwill for impairment are subject to change and are tracked against historical results by management. Changes in the key assumptions by management can change the results of testing. The Company determined there was no impairment associated with goodwill. During 2016, the Company tested its indefinite-lived trade name intangible assets for impairment noting no impairment. The Company performed its annual IPR&D impairment test during 2016 noting the impairment of an international eye care pipeline project of $35.0 million based on a decrease in projected cash flows due to market conditions as well as an impairment of $20.0 million for a specified indication of a Botox therapeutic product based on a decrease in projected cash flows due to a decline in market demand assumptions. In addition, during the nine months ended September 30, 2016, the Company impaired IPR&D projects relating to women’s healthcare for $24.0 million and osteoarthritis for approximately $190.0 million based on clinical results and during the three and nine months ended September 30, 2016, the Company impaired a gastroenterology project for $42.0 million based on the lack of future availability of active pharmaceutical ingredients. During the nine months ended September 30, 2015, the Company recorded a $197.6 million impairment related to IPR&D for select projects as the Company revised its sales forecast of certain assets as well as the timing of the launch of certain projects in connection with the Company’s annual review. In addition, during the three and nine months ended September 30, 2015, the Company made the decision to abandon a select IPR&D asset (acquired in connection with the Allergan Acquisition) based on review of research studies, resulting in an impairment of the full asset value of $300.0 million. Litigation and Contingencies The Company is involved in various legal proceedings in the normal course of its business, including product liability litigation, intellectual property litigation, employment litigation and other litigation. Additionally, the Company, in consultation with its counsel, assesses the need to record a liability for contingencies on a case-by-case basis in accordance with FASB Accounting Standards Codification (“ASC”) Topic 450 “Contingencies” (“ASC 450”). Accruals are recorded when the Company determines that a loss related to a matter is both probable and reasonably estimable. These accruals are adjusted periodically as assessment efforts progress or as additional information becomes available. Acquired contingencies in business combinations are recorded at fair value to the extent determinable, otherwise in accordance with ASC 450. Refer to “NOTE 20 — Commitments and Contingencies” for more information. Earnings Per Share (“EPS”) The Company computes EPS in accordance with ASC Topic 260, “Earnings Per Share” (“ASC 260”) and related guidance, which requires two calculations of EPS to be disclosed: basic and diluted. Basic EPS is computed by dividing net (loss) / income by the weighted average ordinary shares outstanding during a period. Diluted EPS is based on the treasury stock method and includes the effect from potential issuance of ordinary shares, such as shares issuable pursuant to the exercise of stock options and restricted stock units. Diluted EPS also includes the impact of ordinary share equivalents to be issued upon the mandatory conversion of the Company’s preferred shares. Ordinary share equivalents have been excluded where their inclusion would be anti-dilutive. A reconciliation of the numerators and denominators of basic and diluted EPS consisted of the following ($ in millions, except per share amounts): Three Months Ended September 30, Nine Months Ended September 30, 2016 2015 2016 2015 Net (loss) / income: Net (loss) attributable to ordinary shareholders excluding income from discontinued operations, net of tax $ (451.5 ) $ (946.0 ) $ (1,108.0 ) $ (2,318.0 ) Income from discontinued operations, net of tax 15,601.9 6,177.6 15,873.2 6,701.7 Net income attributable to ordinary shareholders $ 15,150.4 $ 5,231.6 $ 14,765.2 $ 4,383.7 Basic weighted average ordinary shares outstanding 392.7 393.6 394.4 358.9 Basic EPS: Continuing operations $ (1.15 ) $ (2.40 ) $ (2.81 ) $ (6.46 ) Discontinued operations $ 39.73 $ 15.69 $ 40.25 $ 18.67 Net income per share $ 38.58 $ 13.29 $ 37.44 $ 12.21 Diluted weighted average ordinary shares outstanding 392.7 393.6 394.4 358.9 Diluted EPS: Continuing operations $ (1.15 ) $ (2.40 ) $ (2.81 ) $ (6.46 ) Discontinued operations $ 39.73 $ 15.69 $ 40.25 $ 18.67 Net income per share $ 38.58 $ 13.29 $ 37.44 $ 12.21 Stock awards to purchase 4.4 million and 4.7 million ordinary shares for the three and nine months ended September 30, 2016, respectively, were outstanding, but not included in the computation of diluted EPS, because the awards were anti-dilutive for continuing operations and as such the treatment for discontinued operations is also anti-dilutive. The weighted average impact of ordinary share equivalents of 17.6 million for the three and nine months ended September 30, 2016, respectively, which are anticipated to result from the mandatory conversion of the Company’s preferred shares were not included in the calculation of diluted EPS as their impact would be anti-dilutive. As of September 30, 2016, the Company has repurchased 12.8 million shares under the Company’s share repurchase program. The impact of the share repurchase on basic EPS was 3.2 million weighted average shares and 1.1 million weighted average shares for the three and nine months ended September 30, 2016, respectively. Refer to “NOTE 16 –Shareholder’s Equity” for further discussion on the Company’s Share Repurchase Program. Stock awards to purchase 5.1 million and 5.2 million ordinary shares during the three and nine months ended September 30, 2015, respectively, were outstanding, but not included in the computation of diluted EPS, because the impact of the awards were anti-dilutive for continuing operations and as such the treatment for discontinued operations is also anti-dilutive. The weighted average impact of ordinary share equivalents of 17.6 million and 13.6 million for the three and nine months ended September 30, 2015, respectively, which are anticipated to result from the mandatory conversion of the Company’s preferred shares were not included in the calculation of diluted EPS as their impact would be anti-dilutive. Restructuring Costs The Company records liabilities for costs associated with exit or disposal activities in the period in which the liability is incurred. In accordance with existing benefit arrangements, employee severance costs are accrued when the restructuring actions are probable and estimable. Costs for one-time termination benefits in which the employee is required to render service until termination in order to receive the benefits are recognized ratably over the future service period. The Company also incurs costs with contract terminations and costs of transferring products as part of restructuring activities. Refer to “NOTE 19 — Business Restructuring Charges” for more information. Recent Accounting Pronouncements On May 28, 2014, the FASB issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers (Topic 606), with an effective date for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period, for public business entities, certain not-for-profit entities, and certain employee benefit plans. The effective date for ASU 2014-09 was deferred by one year through the issuance of ASU 2015-14, Revenue from Contracts with Customers – Deferral of the Effective Date, to annual reporting periods beginning after December 15, 2017, including interim reporting periods within that reporting period. Earlier application is permitted only as of annual reporting periods beginning after December 15, 2016, including interim reporting periods within that reporting period. The Company is evaluating the impact, if any, the pronouncement will have on our financial positions and results of operations. In January 2016, the FASB issued Accounting Standards Update 2016-01, which changes the requirement to require equity securities (including other ownership interests, such as partnerships, unincorporated joint ventures, and limited liability companies) to be measured at fair value with changes in the fair value recognized through net income. This update is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. The adoption of this guidance is not anticipated to have a material impact on the Company’s financial position or results of operations. In February 2016, the FASB issued Accounting Standards Update 2016-02, which states that a lessee should recognize the assets and liabilities that arise from leases. This update is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The Company is evaluating the impact, if any, the pronouncement will have on our financial positions and results of operations. In March 2016, the FASB issued ASU No. 2016-07: Simplifying the Transition to the Equity Method of Accounting. This guidance eliminates the requirement to retroactively adopt the equity method of accounting when there is an increase in the level of ownership interest or degree of influence. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2016. Management believes that the adoption of this guidance will not have a material impact on our financial statements. In March 2016, the FASB has issued ASU No. 2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net). The amendments relate to when another party, along with the entity, is involved in providing a good or service to a customer. Topic 606 Revenue from Contracts with Customers requires an entity to determine whether the nature of its promise is to provide that good or service to the customer (i.e., the entity is a principal) or to arrange for the good or service to be provided to the customer by the other party (i.e., the entity is an agent). The amendments are intended to improve the operability and understandability of the implementation guidance on principal versus agent considerations. The effective date and transition of these amendments is the same as the effective date and transition requirements in Topic 606. The Company is evaluating the impact, if any, the pronouncement will have on our financial positions and results of operations. In March 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The amendments are intended to improve the accounting for employee share-based payments and affect all organizations that issue share-based payment awards to their employees. Several aspects of the accounting for share-based payment award transactions are simplified, including: (a) income tax consequences; (b) classification of awards as either equity or liabilities; and (c) classification on the statement of cash flows. The amendments are effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods. Early adoption is permitted for any organization in any interim or annual period. The Company is evaluating the impact the pronouncement will have on our financial positions and results of operations . In April 2016, the FASB issued Accounting Standards Update (“ASU”) No. 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing. The amendments clarify the following two aspects of Topic 606: (a) identifying performance obligations; and (b) the licensing implementation guidance. The amendments do not change the core principle of the guidance in Topic 606. The effective date and transition requirements for the amendments are the same as the effective date and transition requirements in Topic 606. The Company is evaluating the impact, if any, the pronouncement will have on our financial positions and results of operations. In May 2016, the FASB issued ASU No. 2016-12, Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients. The amendments do not change the core revenue recognition principle in Topic 606. The amendments provide clarifying guidance in certain narrow areas and add some practical expedients, which include assessing the specific collectability criterion and accounting for contracts that do not meet the criteria for Step 1 to determine whether a contract is valid and represents a genuine transaction; presentation of sales taxes and other similar taxes collected from customers; noncash consideration; contract modifications at transition; and completed contracts at transition. The amendments also clarify that an entity that retrospectively applies the guidance in Topic 606 to each prior reporting period is not required to disclose the effect of the accounting change for the period of adoption, however, an entity is still required to disclose the effect of the changes on any prior periods retrospectively adjusted. The effective date and transition requirements for the amendments are the same as the effective date and transition requirements for Topic 606. The Company is evaluating the impact, if any, the pronouncement will have on our financial positions and results of operations. In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The ASU is intended to improve financial reporting by requiring timelier recording of credit losses on loans and other financial instruments held by financial institutions and other organizations. In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments, to address diversity in how certain cash receipts and cash payments are presented and classified in the statement of cash flows. The amendments provide guidance on specific cash flow issues including: (1) Debt Prepayment or Debt Extinguishment Costs; (2) Settlement of Zero-Coupon Debt Instruments or Other Debt Instruments with Coupon Interest Rates That Are Insignificant in Relation to the Effective Interest Rate of the Borrowing; (3) Contingent Consideration Payments Made after a Business Combination; (4) Proceeds from the Settlement of Insurance Claims; (5) Proceeds from the Settlement of Corporate-Owned Life Insurance Policies, including Bank-Owned; (6) Life Insurance Policies; (7) Distributions Received from Equity Method Investees; (8) Beneficial Interests in Securitization Transactions; and (9) Separately Identifiable Cash Flows and Application of the Predominance Principle. The amendments are effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. The amendments should be applied using a retrospective transition method to each period presented. If it is impracticable to apply the amendments retrospectively for some of the issues, the amendments for those issues would be applied prospectively as of the earliest date practicable. The Company is evaluating the impact, if any, the pronouncement will have on our statement of cash flows. In October 2016, the FASB issued Accounting Standards Update No. 2016-16, Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other Than Inventory .

Acquisitions and Other Agreemen

Acquisitions and Other Agreements	9 Months Ended
	Sep. 30, 2016
Business Combinations [Abstract]
Acquisitions and Other Agreements	NOTE 4 — Acquisitions and Other Agreements During the nine months ended September 30, 2015, the Company acquired material assets and businesses. The pro forma results of the businesses acquired that materially impacted the reported results of the Company are as follows (unaudited; $ in millions except per share information): Nine Months Ended September 30, 2015 As reported Allergan Acquisition Pro Forma Net Revenue $ 9,081.2 $ 1,523.0 $ 10,604.2 Net income attributable to ordinary shareholders $ 4,383.7 $ 377.7 $ 4,761.4 Net (loss) per share Basic $ 12.21 $ 11.58 Diluted $ 12.21 $ 11.58 2016 Transactions The following are the significant transactions that were completed in the nine months ended September 30, 2016. Refer to “NOTE 5 – Discontinued Operations” for material divestitures that were completed / entered into in the nine months ended September 30, 2016. Acquisitions ForSight VISION 5 On September 23, 2016, the Company acquired ForSight VISION 5 (“ForSight’), a privately held, clinical-stage biotechnology company focused on eye care, in an all cash transaction of approximately $95.0 million. Under the terms of the agreement, the Company acquired ForSight for an acquisition accounting purchase price of $74.5 million plus the payment of outstanding indebtedness of $14.8 million and other miscellaneous charges. ForSight shareholders are eligible to receive contingent consideration of up to $125.0 million, which has an initial estimated fair value of $79.8 million, relating to commercialization milestones (the “ForSight Acquisition”). The Company acquired ForSight for its lead development program, a peri-ocular ring designed for extended drug delivery and reducing elevated intraocular pressure (“IOP”) in glaucoma patients. Assets Acquired and Liabilities Assumed at Fair Value The ForSight Acquisition has been accounted for using the acquisition method of accounting. This method requires that assets acquired and liabilities assumed in a business combination be recognized at their fair values as of the acquisition date. The following table summarizes the final fair values of the assets acquired and liabilities assumed at the acquisition date ($ in millions): Amount Cash and cash equivalents $ 1.0 IPR&D intangible asset 158.0 Goodwill 54.2 Current liabilities (15.8 ) Contingent consideration (79.8 ) Deferred tax liabilities, net (43.1 ) Net assets acquired $ 74.5 IPR&D and Intangible Assets IPR&D intangible assets represent the value assigned to acquired R&D projects that, as of the acquisition date, had not established technological feasibility and had no alternative future use. The IPR&D intangible assets are capitalized and accounted for as indefinite-lived intangible assets and will be subject to impairment testing until completion or abandonment of the projects. Upon successful completion of each project and launch of the product, the Company will make a separate determination of the estimated useful life of the IPR&D intangible asset and the related amortization will be recorded as an expense over the estimated useful life (“IPR&D Acquisition Accounting”). The estimated fair value of the IPR&D intangible assets was determined using the “income approach,” which is a valuation technique that provides an estimate of the fair value of an asset based on market participant expectations of the cash flows an asset would generate over its remaining useful life. Some of the more significant assumptions inherent in the development of those asset valuations include the estimated net cash flows for each year for each asset or product (including net revenues, cost of sales, R&D costs, selling and marketing costs and working capital/asset contributory asset charges), the appropriate discount rate to select in order to measure the risk inherent in each future cash flow stream, the assessment of each asset’s life cycle, the potential regulatory and commercial success risks, competitive trends impacting the asset and each cash flow stream as well as other factors (the “IPR&D and Intangible Asset Valuation Technique”). The fair value of the IPR&D intangible assets was determined using the IPR&D and Intangible Asset Valuation Technique. The discount rate used to arrive at the present value for IPR&D intangible assets was 13.0% to reflect the internal rate of return and incremental commercial uncertainty in the cash flow projections. The discount rate of the acquisition was driven by the early stage of the product and the therapeutic indication. No assurances can be given that the underlying assumptions used to prepare the discounted cash flow analysis will not change. For these and other reasons, actual results may vary significantly from estimated results. Goodwill Among the reasons the Company acquired ForSight and the factors that contributed to the preliminary recognition of goodwill was the expansion of the Company’s pipeline of eye care products. Goodwill from the ForSight Acquisition of $54.2 million was assigned to the US Specialized Therapeutics segment and is non-deductible for tax purposes. Contingent Consideration As part of the acquisition, the Company is required to pay the former shareholders of ForSight up to $125.0 million based on the timing of the first commercial sale, if any. The Company estimated the fair value of the contingent consideration to be $79.8 million using a probability weighted average approach that considered the possible outcomes of scenarios related to the specified product. Long-Term Deferred Tax Liabilities and Other Tax Liabilities Long-term deferred tax liabilities and other tax liabilities result from identifiable intangible assets’ fair value adjustments. These adjustments create excess book basis over the tax basis which is multiplied by the statutory tax rate for the jurisdiction in which the deferred taxes exist. Licenses and Other Transactions Accounted for as Asset Acquisitions RetroSense Therapeutics, LLC On September 6, 2016, the Company acquired certain assets of RetroSense Therapeutics LLC (“RetroSense”), a private, clinical-stage biotechnology company focused on novel gene therapy approaches to restore vision in patients suffering from blindness. Under the terms of the transaction, RetroSense received approximately $60.0 million upfront, and is eligible to receive up to $495.0 million in contingent regulatory and commercialization milestone payments related to its lead development program, RST-001, a novel gene therapy for the treatment of Retinitis Pigmentosa (the “RetroSense Transaction”). The Company concluded based on the stage of development of the assets, the lack of acquired employees as well as certain other inputs and processes that the transaction did not qualify as a business. The total upfront net payment of $59.7 million was expensed as a component of R&D expense and the future milestones will be recorded if the corresponding events become probable. Akarna Therapeutics, Ltd On August 26, 2016, the Company acquired Akarna Therapeutics, Ltd (“Akarna”), a biopharmaceutical company developing novel small molecule therapeutics that target inflammatory and fibrotic diseases. Under the terms of the transaction, Akarna shareholders received approximately $50.0 million upfront and are eligible to receive contingent development and commercialization milestones of up to $1,015.0 million (the “Akarna Transaction”). The Company concluded based on the stage of development of the assets as well as a lack of certain other inputs and processes that the transaction did not qualify as a business. The total upfront net payment of $48.2 million was expensed as a component of R&D expense and the future milestones will be recorded if the corresponding events become probable. Topokine Therapeutics On April 21, 2016, the Company acquired Topokine Therapeutics (“Topokine”), a privately held, clinical-stage biotechnology company focused on development stage topical medicines for fat reduction. Under the terms of the agreement, Topokine shareholders received an upfront payment of approximately $85.0 million and are eligible to receive contingent development and commercilization milestones of up to $260.0 million for XAF5, a first-in-class topical agent in development for the treatment of steatoblepharon, also known as undereye bags (the “Topokine Transaction”). The Company concluded based on the stage of development of the assets, the lack of acquired employees as well as certain other inputs and processes that the transaction did not qualify as a business. The total upfront net payment of approximately $85.0 million was expensed as a component of R&D expense and the future milestones will be recorded if the corresponding events become probable. Heptares Therapeutics On April 6, 2016, the Company entered into an agreement with Heptares Therapeutics (“Heptares”), under which the Company licensed exclusive global rights to a portfolio of novel subtype-selective muscarinic receptor agonists in development for the treatment of major neurological disorders, including Alzheimer's disease. Under the terms of the agreement, Heptares received an upfront payment of $125.0 million and is eligible to receive contingent milestone payments of up to approximately $665.0 million contingent upon the successful Phase 1, 2 and 3 clinical development and launch of the first three licensed compounds for multiple indications and up to approximately $2.575 billion associated with achieving certain annual sales thresholds during the several years following launch (the “Heptares Transaction”). In addition, Heptares is eligible to receive contingent tiered royalties on net sales of all products resulting from the partnership. The Company concluded based on the stage of development of the assets, the lack of acquired employees as well as certain other inputs and processes that the transaction did not qualify as a business. The total upfront payment of approximately $125.0 million was expensed as a component of R&D expense and the future milestones will be recorded when the event becomes probable. Anterios, Inc. On January 6, 2016, the Company acquired Anterios, Inc. (“Anterios”), a clinical stage biopharmaceutical company developing a next generation delivery system and botulinum toxin-based prescription products. Under the terms of the agreement, Anterios shareholders received an upfront net payment of approximately $90.0 million and are eligible to receive contingent development and commercialization milestone payments up to $387.5 million related to an investigational topical formulation of botulinum toxin type A in development for the potential treatment of hyperhidrosis, acne, and crow’s feet lines and the related NDS™, Anterios' proprietary platform delivery technology that enables local, targeted delivery of neurotoxins through the skin without the need for injections (“the Anterios Transaction”). The Company concluded based on the stage of development of the assets, the lack of acquired employees as well as certain other inputs and processes that the transaction did not qualify as a business. The total upfront net payment of approximately $90.0 million was expensed as a component of R&D expense and the future milestones will be recorded if the corresponding events become probable. 2015 Transactions The following are the significant transactions that were completed in the year ended December 31, 2015. Acquisitions AqueSys, Inc. On October 16, 2015, the Company acquired AqueSys, Inc. (“AqueSys”), a private, clinical-stage medical device company focused on developing ocular implants that reduce IOP associated with glaucoma, in an all-cash transaction. Under the terms of the agreement, the Company acquired AqueSys for an acquisition accounting purchase price of $298.9 million, including $193.5 million for the estimated fair value of contingent consideration relating to the regulatory approval and commercialization milestone payments. The Company acquired AqueSys for its development program, including XEN45, a soft shunt that is implanted in the sub conjunctival space in the eye through a minimally invasive procedure with a single use, pre-loaded proprietary injector (the “AqueSys Acquisition”). Assets Acquired and Liabilities Assumed at Fair Value The AqueSys Acquisition has been accounted for using the acquisition method of accounting. This method requires that assets acquired and liabilities assumed in a business combination be recognized at their fair values as of the acquisition date. The following table summarizes the final fair values of the assets acquired and liabilities assumed at the acquisition date ($ in millions): Amount Cash and cash equivalents $ 6.2 Current assets 1.2 IPR&D intangible assets 302.0 Intangible assets 221.0 Goodwill 138.5 Current liabilities (6.9 ) Contingent consideration (193.5 ) Deferred tax liabilities, net (169.6 ) Net assets acquired $ 298.9 Kythera Biopharmaceuticals On October 1, 2015, the Company acquired Kythera Biopharmaceuticals (“Kythera”) for $75.00 per share, or an acquisition accounting purchase price of $2,089.5 million (the “Kythera Acquisition”). Kythera was focused on the discovery, development and commercialization of novel prescription aesthetic products. Kythera’s lead product, Kybella ® Assets Acquired and Liabilities Assumed at Fair Value The Kythera Acquisition has been accounted for using the acquisition method of accounting. This method requires that assets acquired and liabilities assumed in a business combination be recognized at their fair values as of the acquisition date. The following table summarizes the final fair values of the assets acquired and liabilities assumed at the acquisition date ($ in millions): Amount Cash and cash equivalents $ 78.1 Marketable securities 79.9 Inventory 18.2 Other current assets 14.5 IPR&D intangible assets 320.0 Intangible assets 2,120.0 Goodwill 328.7 Other current liabilities (48.6 ) Deferred tax, net (766.7 ) Outstanding indebtedness (54.6 ) Net assets acquired $ 2,089.5 Allergan, Inc. On March 17, 2015, the Company acquired Legacy Allergan for approximately $77.0 billion including outstanding indebtedness assumed of $2.2 billion, cash consideration of $40.1 billion and equity consideration of $34.7 billion, which includes outstanding equity awards (the “Allergan Acquisition”). Under the terms of the agreement, Legacy Allergan shareholders received 111.2 million of the Company’s ordinary shares, 7.0 million of the Company’s non-qualified stock options and 0.5 million of the Company’s share units. The addition of Legacy Allergan’s therapeutic franchises in ophthalmology, neurosciences and medical aesthetics/dermatology/plastic surgery complements the Company’s existing central nervous system, gastroenterology, women’s health and urology franchises. The combined company also benefited significantly from Legacy Allergan’s global brand equity and consumer awareness of key products, including Botox ® ® Inventories The fair value of inventories acquired included an acquisition accounting fair market value step-up of $923.9 million. In the nine months ended September 30, 2016, the Company recognized $21.6 million as a component of cost of sales as the inventory acquired was sold to the Company’s customers. In the three and nine months ended September 30, 2015, the Company recognized $274.5 million and $778.9 million, respectively, as a component of cost of sales as the inventory acquired was sold to the Company’s customers. Acquisition-Related Expenses As a result of the Allergan Acquisition, the Company incurred the following transaction and integration costs in the three months ended September 30, 2016 and 2015, respectively ($ in millions): Three Months Ended September 30, 2016 Three Months Ended September 30, 2015 Cost of sales Stock-based compensation acquired for Legacy Allergan employees $ 2.2 $ 4.7 Acquisition, integration and restructuring related charges 6.6 0.3 Research and development Stock-based compensation acquired for Legacy Allergan employees 9.3 16.6 Acquisition, integration and restructuring related charges 6.8 17.5 Selling and marketing Stock-based compensation acquired for Legacy Allergan employees 15.8 23.6 Acquisition, integration and restructuring related charges (1.2 ) 5.4 General and administrative Stock-based compensation acquired for Legacy Allergan employees 9.9 16.8 Acquisition, integration and restructuring related charges 50.4 65.7 Total transaction and integration costs $ 99.8 $ 150.6 As a result of the Allergan Acquisition, the Company incurred the following transaction and integration costs in the nine months ended September 30, 2016 and 2015, respectively ($ in millions): Nine Months Ended September 30, 2016 Nine Months Ended September 30, 2015 Cost of sales Stock-based compensation acquired for Legacy Allergan employees $ 7.4 $ 18.9 Acquisition, integration and restructuring related charges 12.4 12.4 Research and development Stock-based compensation acquired for Legacy Allergan employees 32.6 108.2 Acquisition, integration and restructuring related charges 10.6 83.7 Selling and marketing Stock-based compensation acquired for Legacy Allergan employees 53.0 86.5 Acquisition, integration and restructuring related charges 11.7 65.9 General and administrative Stock-based compensation acquired for Legacy Allergan employees 28.2 243.0 Acquisition-related expenditures - 65.5 Acquisition, integration and restructuring related charges 144.0 231.4 Other (expense) income Bridge loan facilities expense - (264.9 ) Interest rate lock - 30.9 Total transaction and integration costs $ 299.9 $ 1,149.5 Licenses and Other Transactions Accounted for as Asset Acquisitions Naurex, Inc. On August 28, 2015, the Company acquired certain products in early stage development of Naurex, Inc. (“Naurex”) in an all-cash transaction of $571.7 million (the “Naurex Transaction”) plus future contingent payments of up to $1,150.0 million, which was accounted for as an asset acquisition. The Company recognized the upfront consideration of $571.7 million as a component of R&D expenses in the three and nine months ended September 30, 2015. The Company concluded based on the stage of development of the assets, the lack of acquired employees and manufacturing as well as certain other inputs and processes that the transaction did not qualify as a business. The Naurex Transaction expands our pipeline with Naurex’s two leading product candidates GLYX-13 and NRX-1074, two compounds that utilize NMDA modulation as a potential new approach to the treatment of Major Depressive Disorder (“MDD”), a disease that can lead to suicidality among the most severe patients. Migraine License On August 17, 2015, the Company entered into an agreement with Merck & Co. (“Merck”) under which the Company acquired the exclusive worldwide rights to Merck’s early development stage investigational small molecule oral calcitonin gene-related peptide receptor antagonists, which are being developed for the treatment and prevention of migraines (the “Merck Transaction”). The Merck Transaction was accounted for as an asset acquisition. The Company acquired these rights for an upfront charge of $250.0 million that was recorded as a component of R&D expense in the three and nine months ended September 30, 2015. The Company concluded based on the stage of development of the assets, the lack of acquired employees and manufacturing as well as certain other inputs and processes that the transaction did not qualify as a business. The Company paid $125.0 million of the initial charge in the year ended December 31, 2015 and the remaining $125.0 million was paid in April 2016. In the quarter ended September 30, 2016, the Company incurred $100.0 million of milestones under the agreement, which were included as a component of R&D expense. Additionally, Merck is owed additional contingent payments based on commercial and development milestones of up to $865.0 million as well as royalties. Divestitures Respiratory Business As part of the Forest Acquisition (defined below), we acquired certain assets that comprised Legacy Forest’s branded respiratory business in the U.S. and Canada (the “Respiratory Business”). During the year ended December 31, 2014, we held for sale respiratory assets of $734.0 million, including allocated goodwill to this unit of $309.1 million. On March 2, 2015, the Company sold the Respiratory Business to AstraZeneca plc (“AstraZeneca”) for consideration of $600.0 million upon closing, additional funds to be received for the sale of certain of our inventory to AstraZeneca and low single-digit royalties above a certain revenue threshold. AstraZeneca also paid Allergan an additional $100.0 million and Allergan has agreed to a number of contractual consents and approvals, including certain amendments to the ongoing collaboration agreements between AstraZeneca and Allergan (the “Respiratory Sale”). As a result of the final terms of the agreement, in the nine months ended September 30, 2015, the Company recognized an incremental charge in cost of sales (including the acquisition accounting fair value mark-up of inventory) relating to inventory that will not be sold to AstraZeneca of $35.3 million. The Company recognized a loss in other (expense) income, net of the sale of the business for $5.3 million in the nine months ended September 30, 2015. 2014 Transactions The following are the significant transactions that were completed in the year ended December 31, 2014. Durata Therapeutics, Inc. On November 17, 2014, the Company completed its tender offer to purchase all of the outstanding shares of Durata Therapeutics, Inc. (“Durata”), an innovative pharmaceutical company focused on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses (the “Durata Acquisition”). The Company purchased all outstanding shares of Durata, which were valued at approximately $724.5 million, including the assumption of debt. Additionally, there is one contingent value right (“CVR”) per share, entitling the holder to receive additional cash payments of up to $5.00 per CVR if certain regulatory or commercial milestones related to Durata’s lead product Dalvance ® Contingent Consideration At the time of the Durata Acquisition, additional consideration was conditionally due to the seller based upon the approval of Dalvance ® ® Forest Laboratories, Inc. On July 1, 2014, the Company acquired Forest Laboratories, Inc. (“Legacy Forest”) for $30.9 billion including outstanding indebtedness assumed of $3.3 billion, equity consideration of $20.6 billion, which includes outstanding equity awards, and cash consideration of $7.1 billion (the “Forest Acquisition”). Under the terms of the transaction, Legacy Forest shareholders received 89.8 million Allergan plc ordinary shares, 6.1 million Allergan plc non-qualified stock options and 1.1 million Allergan plc share units. Legacy Forest was a leading, fully integrated, specialty pharmaceutical company largely focused on the United States market. Legacy Forest marketed a portfolio of branded drug products and developed new medicines to treat patients suffering from diseases principally in the following therapeutic areas: central nervous system, cardiovascular, gastrointestinal, respiratory, anti-infective, and cystic fibrosis. A portion of the assets acquired were divested as part of the Teva Transaction. Inventories The fair value of inventories acquired included an acquisition accounting fair market value step-up of $1,036.3 million. In the nine months ended September 30, 2016, the Company recognized $20.1 million as a component of cost of sales as the inventory acquired on July 1, 2014 was sold to the Company’s customers. In the three and nine months ended September 30, 2015, the Company recognized $15.4 million and $202.0 million, respectively, as a component of cost of sales as the inventory acquired on July 1, 2014 was sold to the Company’s customers in addition to a write-off associated with the Respiratory Sale. A portion of these amounts are included in discontinued operations in the nine months ended September 30, 2015. As a result of the Forest Acquisition, the Company incurred the following transaction and integration costs in the three months ended September 30, 2016 and 2015, respectively ($ in millions): Three Months Ended September 30, 2016 Three Months Ended September 30, 2015 Cost of sales Stock-based compensation acquired for Forest employees $ 0.2 $ 0.9 Research and development Stock-based compensation acquired for Forest employees 2.0 5.5 Acquisition, integration and restructuring related charges 0.2 0.4 Selling and marketing Stock-based compensation acquired for Forest employees 6.9 9.4 Acquisition, integration and restructuring related charges - 0.4 General and administrative Stock-based compensation acquired for Forest employees 5.9 10.7 Acquisition, integration and restructuring related charges 0.5 19.6 Total transaction and integration costs $ 15.7 $ 46.9 As a result of the Forest Acquisition, the Company incurred the following transaction and integration costs in the three and nine months ended September 30, 2016 and 2015, respectively ($ in millions): Nine Months Ended September 30, 2016 Nine Months Ended September 30, 2015 Cost of sales Stock-based compensation acquired for Forest employees $ 1.4 $ 3.6 Acquisition, integration and restructuring related charges - 1.1 Research and development Stock-based compensation acquired for Forest employees 10.9 30.0 Acquisition, integration and restructuring related charges 0.5 9.2 Selling and marketing Stock-based compensation acquired for Forest employees 21.7 37.8 Acquisition, integration and restructuring related charges - 17.3 General and administrative Stock-based compensation acquired for Forest employees 24.6 43.0 Acquisition, integration and restructuring related charges 1.7 66.8 Total transaction and integration costs $ 60.8 $ 208.8

Discontinued Operations

Discontinued Operations	9 Months Ended
	Sep. 30, 2016
Global Generics [Member]
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Discontinued Operations	NOTE 5 — Discontinued Operations Global Generics Business On July 27, 2015, the Company announced that it entered into the Teva Transaction, which closed on August 2, 2016. Under the Teva Agreement, Teva acquired Allergan's global generics business, including the U.S. and international generic commercial units, our third-party supplier Medis, our global generic manufacturing operations, our global generic R&D unit, our international OTC commercial unit (excluding OTC eye care products) and some established international brands. Allergan retained its global branded pharmaceutical and medical aesthetics businesses, as well as its biosimilars development programs, and certain OTC products. The Company will also have continuing involvement with Teva after the close of the transaction. As a result of the Teva Transaction, the Company holds equity in Teva and purchases product manufactured by Teva for sale in our US General Medicine segment as part of ongoing transitional service and contract manufacturing agreements. The Company notes the following reconciliation of the proceeds received in the Teva Transaction to the gain recognized in income from discontinued operations ($ in millions): Net cash proceeds received $ 33,304.5 August 2, 2016 fair value of Teva shares 5,038.6 Total Proceeds $ 38,343.1 Net assets sold to Teva, excluding cash (12,076.7 ) Other comprehensive income disposed (1,544.8 ) Deferral of proceeds relating to additional elements of agreements with Teva (518.9 ) Pre-tax gain on sale of generics business $ 24,202.7 Income taxes (8,321.2 ) Net gain on sale of generics business $ 15,881.5 In October 2016, pursuant to the Teva Agreement, Teva provided its proposed estimated adjustment to the closing date working capital balance to the Company. The final amount of any agreed contractual adjustment could vary materially from the adjustment calculated by the Company at the time of the closing of the Teva Transaction and any agreed adjustment to the Company’s proceeds from the Teva Transaction could have a material adverse effect on the Company’s results of operations and cash flows. The Company expects the amount of the adjustment will be determined in accordance with and subject to the terms of the Teva Agreement. The Teva Shares are recorded within “Marketable securities” on the Company’s Consolidated Balance Sheet. During the three and nine months ended September 30, 2016, the Company recorded a $664.2 million unrealized loss on the Teva Shares due to movements in the share price, which was recorded as a component of “Other comprehensive income.” On October 3, 2016, the Company completed the divestiture of the Anda Distribution business for an additional $500.0 million Financial results of the global generics business through August 2, 2016 and the Anda Distribution business are presented as “Income from discontinued operations” on the Consolidated Statements of Operations for the three and nine months ended September 30, 2016 and 2015; and assets and liabilities of the businesses are presented as “Current assets held for sale”, “Non current assets held for sale”, “Current liabilities held for sale” and “Long term liabilities held for sale” on the Consolidated Balance Sheet as applicable. The following table presents key financial results of the businesses included in "Income from discontinued operations" for the three and nine months ended September 30, 2016 and 2015 ($ in millions): Three Months Ended September 30, Nine Months Ended September 30, 2016 2015 2016 2015 Net revenues $ 756.5 $ 1,984.8 $ 4,504.3 $ 6,362.3 Operating expenses: Cost of sales (excludes amortization and impairment of acquired intangibles including product rights) 531.0 1,243.3 2,798.3 3,647.1 Research and development 37.3 98.9 269.6 317.4 Selling and marketing 69.1 159.3 352.6 542.2 General and administrative 90.3 204.0 399.4 528.3 Amortization - 36.1 4.8 333.9 Asset sales and impairments, net - 3.2 - 54.1 Total operating expenses 727.7 1,744.8 3,824.7 5,423.0 Operating income 28.8 240.0 679.6 939.3 Other (expense) income, net 15,881.5 (0.3 ) 15,881.1 (8.4 ) Provision / (benefit) for income taxes 308.4 (5,937.9 ) 687.5 (5,770.8 ) Net income from discontinued operations $ 15,601.9 $ 6,177.6 $ 15,873.2 $ 6,701.7 “Other (expense) income, net” included the gain on sale of the generics business to Teva. For the nine months ended September 30, 2015, the Company recorded a deferred tax benefit of $5,985.4 million related to investments in certain subsidiaries. The recognition of this benefit has been reflected in “Income from discontinued operations, net of tax” with the deferred tax asset reflected in non-current “Deferred tax liabilities” on the December 31, 2015 balance sheet as adjusted for activity in the fourth quarter of 2015. For the nine months ended September 30, 2016, the Company recorded a deferred tax expense of $474.7 million to adjust its deferred tax asset related to investments in certain subsidiaries. The recognition of this expense has been reflected in “Income from discontinued operations, net of tax.” Upon the closing of the Teva Transaction, the Company recorded the reversal of the corresponding deferred tax asset of $5,273.9 million against the current income taxes payable in continuing operations. The following table presents the aggregate carrying amounts of the major classes of assets and liabilities related to the businesses ($ in millions): September 30, 2016 December 31, 2015 Assets: Accounts receivable, net $ 164.3 $ 2,365.9 Inventories 270.8 1,390.7 Prepaid expenses and other current assets 16.3 329.7 Property, plant and equipment, net 23.6 1,398.2 Investments and other assets 6.6 42.2 Non-current deferred tax assets - 162.1 Product rights and other intangibles 90.7 3,014.8 Goodwill 86.3 6,096.0 Total assets $ 658.6 $ 14,799.6 Liabilities: Accounts payable and accrued expenses $ 223.7 $ 1,656.7 Income taxes payable - 34.4 Debt and capital leases - 5.8 Other long-term liabilities 3.9 92.0 Other taxes payable - 69.0 Long-term deferred tax liabilities 19.9 370.7 Total liabilities $ 247.5 $ 2,228.6 Depreciation and amortization was ceased upon the determination that the held for sale criteria were met, which was the announcement date of the Teva Transaction and June 30, 2016 for the Anda Distribution business. The depreciation, amortization and significant operating and investing non-cash items of the discontinued operations were as follows ($ in millions): Nine Months Ended September 30, 2016 2015 Depreciation from discontinued operations $ 2.1 $ 86.4 Amortization from discontinued operations 4.8 333.9 Capital expenditures 85.3 182.6 Deferred income taxes expense / (benefit) 5,893.4 (6,301.6 )

Other Income (Expense)

Other Income (Expense)	9 Months Ended
	Sep. 30, 2016
Other Income And Expenses [Abstract]
Other Income/(Expense)	NOTE 6 – Other Income/(Expense) On November 23, 2015, the Company announced that it entered into a definitive merger agreement (the “Pfizer Agreement”) under which Pfizer Inc. (“Pfizer”), a global innovative biopharmaceutical company, and Allergan plc would merge in a stock and cash transaction. On April 6, 2016, the Company announced that its merger agreement with Pfizer was terminated by mutual agreement. In connection with the termination of the merger agreement, Pfizer has paid Allergan plc $150.0 million for expenses associated with the transaction which is included as a component of other income (expense) in the nine months ended September 30, 2016. In addition, as part of the then pending Pfizer Agreement, the Company incurred transaction related expenses of $18.0 million and $92.9 million in the three and nine months ended September 30, 2016, respectively. As a result of the Teva Transaction, the Company acquired 100.3 million Teva ordinary shares. During the three and nine months ended September 30, 2016, the Company received dividend income of $34.1 million.

Share-Based Compensation

Share-Based Compensation	9 Months Ended
	Sep. 30, 2016
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Share-Based Compensation	NOTE 7 — Share-Based Compensation The Company recognizes compensation expense for all share-based compensation awards made to employees and directors based on the fair value of the awards on the date of grant. A summary of the Company’s share-based compensation plans is presented below. Equity Award Plans The Company has adopted several equity award plans which authorize the granting of options, restricted shares, restricted stock units and other forms of equity awards of the Company’s ordinary shares, subject to certain conditions. The Company granted/grants awards with the following features: • Time-based vesting restricted stock and restricted stock units awards; • Performance-based restricted stock unit awards measured to the EBITDA, as defined, of the Company or other performance-based targets defined by the Company; • Performance-based restricted stock unit awards based on pre-established total shareholder returns metrics; • Non-qualified options to purchase outstanding shares; and • Cash-settled awards recorded as a liability. These cash settled awards are based on pre-established total shareholder returns metrics. Option award plans require options to be granted at the fair value of the shares underlying the options at the date of the grant and generally become exercisable over periods ranging from three to five years. Each option granted expires ten years from the date of the grant. Restricted stock awards are grants that entitle the holder to ordinary shares, subject to certain terms. Restricted stock unit awards are grants that entitle the holder the right to receive an ordinary share, subject to certain terms. Restricted stock and restricted stock unit awards (both time-based vesting and performance-based vesting) generally have restrictions lapsed over a one to four year vesting period. Restrictions generally lapse for non-employee directors after one year. Certain restricted stock units are performance-based awards issued at a target number with the actual number of ordinary shares issued ranging based on achievement of the performance criteria. The Company’s equity awards include the acquired awards from the Allergan and Kythera acquisitions (“2015 Acquired Awards”). Fair Value Assumptions All restricted stock and restricted stock units (whether time-based vesting or performance-based vesting), are granted and expensed, using the fair value per share on the applicable grant date, over the applicable vesting period. Non-qualified options to purchase ordinary shares are granted to employees at exercise prices per share equal to the closing market price per share on the date of grant. The fair value of non-qualified options is determined on the applicable grant dates using the Black-Scholes method of valuation and that amount is recognized as an expense over the vesting period. Using the Black-Scholes valuation model, the fair value of options is based on the following assumptions: 2016 Grants 2015 Grants 2015 Acquired Awards Dividend yield 0% 0% 0% Expected volatility 27.0% 26.0-29.0% 26.0-27.0% Risk-free interest rate 1.3%-1.6% 1.9-2.1% 0.1-2.1% Expected term (years) 7.0 7.0 - 7.5 up to 6.9 Share-Based Compensation Expense Share-based compensation expense recognized in the Company’s results of operations for the three months ended September 30, 2016 and 2015 were as follows ($ in millions): Three Months Ended September 30, 2016 2015 Equity based compensation awards $ 81.1 $ 109.8 Cash-settled equity awards in connection with the ForSight Acquisition 3.1 - Non equity-settled awards other 7.4 20.4 Total stock-based compensation expense $ 91.6 $ 130.2 Included in the table above is stock-based compensation relating to discontinued operations of $3.2 million and $7.9 million for the three months ended September 30, 2016 and 2015, respectively. Share-based compensation expense recognized in the Company’s results of operations for the nine months ended September 30, 2016 and 2015 were as follows ($ in millions): Nine Months Ended September 30, 2016 2015 Equity-based compensation awards $ 269.9 $ 510.5 Cash-settled equity awards in connection with the ForSight Acquisition 3.1 - Cash-settled equity awards in connection with the Allergan Acquisition - 127.1 Non equity-settled awards other 14.0 20.4 Total stock-based compensation expense $ 287.0 $ 658.0 Included in the table above is stock-based compensation relating to discontinued operations of $16.0 million and $27.4 million for the nine months ended September 30, 2016 and 2015, respectively. Included in the equity-based compensation awards for the three and nine months ended September 30, 2016 and 2015 is the impact of accelerations and step-ups relating to the acquisition accounting treatment of outstanding awards acquired in the Allergan and Forest acquisitions as follows ($ in millions): Three Months Ended Nine Months Ended September 30, 2016 September 30, 2015 September 30, 2016 September 30, 2015 Allergan Acquisition $ 26.8 $ 44.6 $ 86.8 $ 269.8 Forest Acquisition 10.3 18.2 37.5 89.1 Total $ 37.1 $ 62.8 $ 124.3 $ 358.9 Unrecognized future stock-based compensation expense was $554.3 million as of September 30, 2016, including $178.2 million from the Allergan Acquisition and $44.4 million from the Forest Acquisition. This amount will be recognized as an expense over a remaining weighted average period of 1.4 years. Stock-based compensation is being amortized and charged to operations over the same period as the restrictions are eliminated for the participants, which is generally on a straight-line basis. Share Activity The following is a summary of equity award activity for unvested restricted stock and stock units in the period from December 31, 2015 through September 30, 2016: (in millions, except per share data) Shares Weighted Average Grant Date Fair Value Weighted Average Remaining Contractual Term (Years) Aggregate Grant Date Fair Value Restricted shares / units outstanding at December 31, 2015 2.0 $ 209.90 1.7 $ 419.8 Granted 0.6 281.26 168.8 Vested (0.7 ) (168.55 ) (118.0 ) Forfeited (0.3 ) (228.53 ) (70.1 ) Restricted shares / units outstanding at September 30, 2016 1.6 $ 254.37 1.7 $ 400.5 The following is a summary of equity award activity for non-qualified options to purchase ordinary shares in the period from December 31, 2015 through September 30, 2016: (in millions, except per share data) Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Outstanding, December 31, 2015 10.5 $ 149.11 6.7 $ 1,707.8 Granted 0.2 280.72 Exercised (1.2 ) (113.07 ) Cancelled (0.2 ) (153.42 ) Outstanding, September 30, 2016 9.3 $ 112.17 6.0 $ 1,098.8 Vested and expected to vest at September 30, 2016 8.8 $ 112.89 6.0 $ 1,036.1

Reportable Segments

Reportable Segments	9 Months Ended
	Sep. 30, 2016
Segment Reporting [Abstract]
Reportable Segments	NOTE 8 — Reportable Segments During 2016, Allergan announced a realignment of its businesses to streamline operations. Prior to the realignment, the Company operated and managed its business as four distinct operating segments: US Brands, US Medical Aesthetics, International and Anda Distribution. Under the new organizational structure being reported, and the decision to sell our Anda Distribution business, the Company organized its businesses into the following segments: US Specialized Therapeutics, US General Medicine and International. In addition, certain revenues and shared costs, and the results of corporate initiatives, are managed outside of the three segments. Prior period results have been recast to align to the current segment presentation. The operating segments are organized as follows: • The US Specialized Therapeutics segment includes sales and expenses relating to branded products within the US, including Medical Aesthetics, Medical Dermatology, Eye Care, Neurosciences and Urology therapeutic products. • The US General Medicine segment includes sales and expenses relating to branded products within the US that do not fall into the US Specialized Therapeutics business units, including Central Nervous System, Gastrointestinal, Women’s Health, Anti-Infectives and Established Brands. • The International segment includes sales and expenses relating to products sold outside the US. The Company evaluates segment performance based on segment contribution. Segment contribution for our segments represents net revenues less cost of sales (defined below), selling and marketing expenses, and select general and administrative expenses. Included in segment revenues are products’ sales that are sold through the Anda Distribution business once the Anda Distribution business has sold the product to a third party customer. These sales are included in segment results and are reclassified into revenues from discontinued operations through a reduction of Corporate revenues which eliminates the sales made by our Anda Distribution business from results of continuing operations. Cost of sales for these products in discontinued operations is equal to our average third party cost of sales for third party branded products distributed by Anda Distribution. The Company does not evaluate the following items at the segment level: • Revenues and operating expenses within cost of sales, selling and marketing expenses, and general and administrative expenses that result from the impact of corporate initiatives. Corporate initiatives primarily include integration, restructuring, acquisition and other shared costs. • General and administrative expenses that result from shared infrastructure, including certain expenses located within the United States. • Total assets including capital expenditures. • Other select revenues and operating expenses including R&D expenses, amortization, IPR&D impairments and asset sales and impairments, net, as not all such information has been accounted for at the segment level, or such information has not been used by all segments. The Company defines segment net revenues as product sales and other revenue derived from branded products or licensing agreements. In March 2015, as a result of the Allergan Acquisition, we began to promote Restasis ® ® ® ® ® ® Cost of sales within segment contribution includes standard production and packaging costs for the products we manufacture, third party acquisition costs for products manufactured by others, profit-sharing or royalty payments for products sold pursuant to licensing agreements and finished goods inventory reserve charges. Cost of sales included within segment contribution does not include non-standard production costs, such as non-finished goods inventory obsolescence charges, manufacturing variances and excess capacity utilization charges, where applicable. Cost of sales does not include amortization or impairment costs for acquired product rights or other acquired intangibles. Selling and marketing expenses consist mainly of personnel-related costs, product promotion costs, distribution costs, professional service costs, insurance, depreciation and travel costs. General and administrative expenses consist mainly of personnel-related costs, facilities costs, transaction costs, insurance, depreciation, litigation and settlement costs and professional services costs which are general in nature and attributable to the segment. Segment net revenues, segment operating expenses and segment contribution information consisted of the following for the three months ended September 30, 2016 and 2015 ($ in millions): Three Months Ended September 30, 2016 US Specialized US General Therapeutics Medicine International Total Net revenues $ 1,453.2 $ 1,488.1 $ 697.8 $ 3,639.1 Operating expenses: Cost of sales (1) 69.2 215.1 95.1 379.4 Selling and marketing 292.4 292.8 188.2 773.4 General and administrative 41.2 42.3 28.0 111.5 Segment Contribution $ 1,050.4 $ 937.9 $ 386.5 $ 2,374.8 Contribution margin 72.3 % 63.0 % 55.4 % 65.3 % Corporate 372.0 Research and development 622.8 Amortization 1,609.1 In-process research and development impairments 42.0 Asset sales and impairments, net (4.7 ) Operating (loss) $ (266.4 ) Operating margin (7.3 )% (1) Three Months Ended September 30, 2015 US Specialized US General Therapeutics Medicine International Total Net revenues $ 1,296.6 $ 1,552.0 $ 660.6 $ 3,509.2 Operating expenses: Cost of sales (1) 71.6 227.5 108.3 407.4 Selling and marketing 236.2 262.8 155.8 654.8 General and administrative 17.2 17.5 33.3 68.0 Segment Contribution $ 971.6 $ 1,044.2 $ 363.2 $ 2,379.0 Contribution margin 74.9 % 67.3 % 55.0 % 67.8 % Corporate 642.5 Research and development 1,260.5 Amortization 1,557.8 In-process research and development impairments 300.0 Asset sales and impairments, net (4.4 ) Operating (loss) $ (1,377.4 ) Operating margin (39.3 )% (1) The following is a reconciliation of net revenues for the operating segments to the Company’s net revenues for the three months ended September 30, 2016 and 2015 ($ in millions): Three Months Ended September 30, 2016 2015 Segment net revenues $ 3,639.1 $ 3,509.2 Corporate revenues (16.9 ) (39.7 ) Net revenues $ 3,622.2 $ 3,469.5 No country outside of the United States represents ten percent or more of net revenues. The US Specialized Therapeutics and US General Medicine segments are comprised solely of sales within the United States. Segment net revenues, segment operating expenses and segment contribution information consisted of the following for the nine months ended September 30, 2016 and 2015 ($ in millions): Nine Months Ended September 30, 2016 US Specialized US General Therapeutics Medicine International Total Net revenues $ 4,240.8 $ 4,390.9 $ 2,128.1 $ 10,759.8 Operating expenses: Cost of sales (1) 215.0 649.6 309.3 1,173.9 Selling and marketing 844.8 902.8 582.7 2,330.3 General and administrative 126.4 128.2 86.5 341.1 Segment Contribution $ 3,054.6 $ 2,710.3 $ 1,149.6 $ 6,914.5 Contribution margin 72.0 % 61.7 % 54.0 % 64.3 % Corporate 1,052.8 Research and development 1,662.4 Amortization 4,831.9 In-process research and development impairments 316.9 Asset sales and impairments, net (24.0 ) Operating (loss) (925.5 ) Operating margin (8.6 )% (1) Nine Months Ended September 30, 2015 US Specialized US General Therapeutics Medicine International Total Net revenues $ 2,889.6 $ 4,803.7 $ 1,496.4 $ 9,189.7 Operating expenses: Cost of sales (1) 160.2 674.0 243.8 1,078.0 Selling and marketing 525.0 917.1 394.2 1,836.3 General and administrative 46.1 88.8 75.7 210.6 Segment Contribution $ 2,158.3 $ 3,123.8 $ 782.7 $ 6,064.8 Contribution margin 74.7 % 65.0 % 52.3 % 66.0 % Corporate 2,338.8 Research and Development 1,927.9 Amortization 3,858.9 In-process research and development impairments 497.6 Asset sales and impairments, net 3.1 Operating (loss) (2,561.5 ) Operating margin (27.9 )% (1) The following is a reconciliation of net revenues for the operating segments to the Company’s net revenues for the nine months ended September 30, 2016 and 2015 ($ in millions): Nine Months Ended September 30, 2016 2015 Segment net revenues $ 10,759.8 $ 9,189.7 Corporate revenues (53.5 ) (108.5 ) Net revenues $ 10,706.3 $ 9,081.2 No country outside of the United States represents ten percent or more of net revenues. The US Specialized Therapeutics and US General Medicine segments are comprised solely of sales within the United States. The following tables present global net revenues for the top products of the Company for the three and nine months ended September 30, 2016 and 2015 ($ in millions): Three Months Ended September 30, Global U.S. International 2016 2015 2016 2015 2016 2015 Botox ® $ 689.7 $ 604.4 $ 496.3 $ 435.6 $ 193.4 $ 168.8 Restasis ® 371.8 328.3 356.4 312.8 15.4 15.5 Fillers 201.8 167.6 105.0 89.7 96.8 77.9 Linzess ® ® 168.7 118.6 164.4 117.5 4.3 1.1 Lumigan ® ® 164.9 157.9 78.3 71.7 86.6 86.2 Bystolic ® 164.4 155.7 163.9 155.3 0.5 0.4 Namenda XR ® 146.9 214.5 146.9 214.5 - - Alphagan ® ® 134.7 120.8 93.4 81.4 41.3 39.4 Lo Loestrin ® 105.7 90.8 105.7 89.8 - 1.0 Estrace ® 98.6 87.4 98.6 87.4 - - Viibryd ® ® 87.6 84.5 87.6 84.5 - - Breast Implants 86.7 85.5 51.1 50.9 35.6 34.6 Asacol ® ® 86.4 157.2 72.2 141.9 14.2 15.3 Minastrin ® 84.9 74.4 84.9 74.4 - - Aczone ® 69.0 48.0 69.0 48.0 - - Ozurdex ® 64.3 51.6 20.9 17.6 43.4 34.0 Carafate ® ® 57.0 52.9 56.4 52.9 0.6 - Namenda ® 2.9 54.9 2.9 54.9 - - Other Products Revenues ** 859.9 857.9 694.2 671.5 165.7 186.4 Less product sold through Anda Distribution business (23.7 ) (43.4 ) (23.7 ) (43.4 ) - - Total Net Revenues ** $ 3,622.2 $ 3,469.5 $ 2,924.4 $ 2,808.9 $ 697.8 $ 660.6 ** Includes an adjustment of $31.7 million recorded in the three months ended September 30, 2015 related to International other product revenues for the six months ended June 30, 2015 that were reported in discontinued operations instead of continuing operations during the six months ended June 30, 2015. The impact of this out-of-period adjustment is not material to the six months ended June 30, 2015 or the three months ended September 30, 2015, and had no impact on the nine months ended September 30, 2015. Nine Months Ended September 30, Global U.S. International 2016 2015 2016 2015 2016 2015 Botox ® $ 2,046.9 $ 1,319.8 $ 1,454.0 $ 926.4 $ 592.9 $ 393.4 Restasis ® 1,076.1 683.2 1,026.4 651.4 49.7 31.8 Fillers 629.5 388.2 325.3 206.7 304.2 181.5 Lumigan ® ® 509.6 355.6 240.4 165.9 269.2 189.7 Namenda XR ® 486.5 569.8 486.5 569.8 - - Bystolic ® 479.1 476.9 477.8 476.1 1.3 0.8 Linzess ® ® 464.7 328.0 452.0 325.1 12.7 2.9 Alphagan ® ® 401.6 272.3 274.3 184.9 127.3 87.4 Asacol ® ® 338.4 455.6 297.9 407.8 40.5 47.8 Lo Loestrin ® 296.0 253.3 296.0 251.7 - 1.6 Estrace ® 276.4 229.4 276.4 229.4 - - Breast Implants 261.7 198.4 149.2 112.8 112.5 85.6 Viibryd ® ® 252.7 244.8 252.6 244.8 0.1 - Minastrin ® 248.9 195.9 247.5 195.3 1.4 0.6 Ozurdex ® 192.0 109.6 61.8 36.9 130.2 72.7 Carafate ® ® 169.4 153.4 167.7 153.4 1.7 - Aczone ® 156.1 114.3 156.1 114.3 - - Namenda ® 12.8 532.9 12.8 532.9 - - Other Products Revenues 2,487.9 2,313.6 2,003.5 1,913.0 484.4 400.6 Less product sold through Anda Distribution business (80.0 ) (113.8 ) (80.0 ) (113.8 ) - - Total Net Revenues $ 10,706.3 $ 9,081.2 $ 8,578.2 $ 7,584.8 $ 2,128.1 $ 1,496.4 Unless included above, no product represents ten percent or more of total net revenues. The following table presents top product sales and net revenues for the US Specialized Therapeutics segment for the three and nine months ended September 30, 2016 and 2015 ($ in millions): Three Months Ended September 30, Nine Months Ended September 30, 2016 2015 2016 2015 Total Eye Care $ 608.5 $ 539.9 $ 1,777.6 $ 1,213.2 Restasis ® 356.4 312.8 1,026.4 651.4 Alphagan ® ® 93.4 81.4 274.3 184.9 Lumigan ® ® 78.3 71.7 240.4 165.9 Ozurdex ® 20.9 17.6 61.8 36.9 Eye Drops 50.2 45.3 140.1 131.8 Other Eye Care 9.3 11.1 34.6 42.3 Total Medical Aesthetics 388.9 340.1 1,182.6 761.4 Facial Aesthetics 293.7 249.0 893.3 547.9 Botox ® 174.5 159.3 529.8 341.2 Fillers 105.0 89.7 325.3 206.7 Kybella ® 14.2 - 38.2 - Plastic Surgery 52.2 54.3 153.1 122.5 Breast Implants 51.1 50.9 149.2 112.8 Other Plastic Surgery 1.1 3.4 3.9 9.7 Skin Care 43.0 36.8 136.2 91.0 SkinMedica ® 25.8 23.0 81.5 51.6 Latisse ® 17.2 13.8 54.7 39.4 Total Medical Dermatology 116.1 107.8 282.2 249.4 Aczone ® 69.0 48.0 156.1 114.3 Tazorac ® 27.5 27.6 68.0 65.7 Botox ® 16.3 15.0 48.9 35.5 Other Medical Dermatology 3.3 17.2 9.2 33.9 Total Neuroscience and Urology 330.7 291.4 963.8 637.2 Botox ® 305.5 261.3 875.3 549.7 Rapaflo ® 25.2 30.1 87.6 87.5 Other Neuroscience and Urology - - 0.9 - Other Revenues 9.0 17.4 34.6 28.4 Net revenues $ 1,453.2 $ 1,296.6 $ 4,240.8 $ 2,889.6 The following table presents top product sales and revenues for the US General Medicine segment for the three and nine months ended September 30, 2016 and 2015 ($ in millions): Three Months Ended September 30, Nine Months Ended September 30, 2016 2015 2016 2015 Total Central Nervous System (CNS) $ 325.5 $ 406.7 $ 964.6 $ 1,485.1 Namenda XR ® 146.9 214.5 486.5 569.8 Viibryd ® ® 87.6 84.5 252.6 244.8 Saphris ® 40.8 51.1 123.6 134.3 Vraylar ™ 32.4 - 51.1 - Namzaric ® 14.9 1.7 38.0 3.3 Namenda ® 2.9 54.9 12.8 532.9 Total Gastrointestinal (GI) 431.4 398.6 1,277.0 1,138.4 Linzess ® 164.4 117.5 452.0 325.1 Asacol ® ® 72.2 141.9 297.9 407.8 Carafate ® ® 56.4 52.9 167.7 153.4 Zenpep ® 52.5 43.1 145.1 121.5 Canasa ® ® 47.2 34.6 135.0 102.2 Viberzi ® 30.9 - 55.3 - Other GI 7.8 8.6 24.0 28.4 Total Women's Health 305.3 268.0 865.1 716.7 Lo Loestrin ® 105.7 89.8 296.0 251.7 Estrace ® 98.6 87.4 276.4 229.4 Minastrin ® 84.9 74.4 247.5 195.3 Liletta ® 4.4 5.8 15.0 10.7 Other Women's Health 11.7 10.6 30.2 29.6 Total Anti-Infectives 52.5 52.3 167.1 138.3 Teflaro ® 33.3 35.8 101.9 105.3 Dalvance ® 10.3 4.9 26.7 11.3 Avycaz ® 4.8 7.5 26.9 12.9 Other Anti-Infectives 4.1 4.1 11.6 8.8 Established Brands 319.3 400.5 1,038.8 1,267.7 Bystolic ® 163.9 155.3 477.8 476.1 Armour Thyroid 39.1 34.7 121.8 88.9 Savella ® 28.1 29.0 74.1 80.6 Lexapro ® 15.6 17.8 50.8 53.6 Enablex ® 1.9 17.2 14.7 51.5 PacPharma 6.2 27.4 49.7 56.6 Other Established Brands 64.5 119.1 249.9 460.4 Other Revenues 54.1 25.9 78.3 57.5 Net revenues $ 1,488.1 $ 1,552.0 $ 4,390.9 $ 4,803.7 The following table presents top product sales and net revenues for the International segment for the three and nine months ended September 30, 2016 and 2015 ($ in millions): Three Months Ended September 30, Nine Months Ended September 30, 2016 2015 2016 2015 Total Eye Care $ 294.2 $ 281.5 $ 904.4 $ 623.7 Lumigan ® ® 86.6 86.2 269.2 189.7 Alphagan ® ® 41.3 39.4 127.3 87.4 Ozurdex ® 43.4 34.0 130.2 72.7 Optive ® 25.6 23.2 75.7 51.9 Restasis ® 15.4 15.5 49.7 31.8 Other Eye Drops 42.1 44.0 131.2 99.5 Other Eye Care 39.8 39.2 121.1 90.7 Total Medical Aesthetics 251.0 214.8 780.0 509.9 Facial Aesthetics 212.6 176.5 658.7 416.4 Botox ® 115.3 98.6 352.9 234.9 Fillers 96.8 77.9 304.2 181.5 Belkyra ® ® 0.5 - 1.6 - Plastic Surgery 35.8 34.6 112.9 85.6 Breast Implants 35.6 34.6 112.5 85.6 Earfold ™ 0.2 - 0.4 - Skin Care 2.6 3.7 8.4 7.9 Botox ® 134.6 155.5 399.0 321.5 Botox ® 78.1 70.2 240.0 158.5 Asacol ® ® 14.2 15.3 40.5 47.8 Constella ® 4.3 1.1 12.7 2.9 Other Products ** 38.0 68.9 105.8 112.3 Other Revenues 18.0 8.8 44.7 41.3 Net revenues ** $ 697.8 $ 660.6 $ 2,128.1 $ 1,496.4 ** Includes an adjustment of $31.7 million recorded in the three months ended September 30, 2015 related to International other product revenues for the six months ended June 30, 2015 that were reported in discontinued operations instead of continuing operations during the six months ended June 30, 2015. The impact of this out-of-period adjustment is not material to the six months ended June 30, 2015 or the three months ended September 30, 2015, and had no impact on the nine months ended September 30, 2015.

Inventories

Inventories	9 Months Ended
	Sep. 30, 2016
Inventory Disclosure [Abstract]
Inventories	NOTE 9 — Inventories Inventories consist of finished goods held for sale and distribution, raw materials and work-in-process. Inventories are stated at the lower of cost (first-in, first-out method) or market (net realizable value). The Company writes down inventories to net realizable value based on forecasted demand, market conditions or other factors, which may differ from actual results. Inventories consisted of the following ($ in millions): September 30, December 31, 2016 2015 Raw materials $ 276.2 $ 242.4 Work-in-process 142.2 149.7 Finished goods 389.5 451.9 807.9 844.0 Less: inventory reserves 102.4 86.5 Total Inventories $ 705.5 $ 757.5 Included in finished goods was $46.1 million related to the fair-value step-up of acquired inventory as of December 31, 2015.

Investments and Other Assets

Investments and Other Assets	9 Months Ended
	Sep. 30, 2016
Investments All Other Investments [Abstract]
Investments and Other Assets	NOTE 10 — Investments and Other Assets Investments in marketable securities, including those classified in cash and cash equivalents due to the maturity term of the instrument, other investments and other assets consisted of the following ($ in millions): September 30, 2016 December 31, 2015 Marketable securities: U.S. Treasury and agency securities — maturing within one year $ 15,463.2 $ 9.3 Teva shares 4,374.4 - Total marketable securities $ 19,837.6 $ 9.3 Investments and other assets: Legacy Allergan deferred executive compensation investments $ 114.3 $ 118.1 Equity method investments 13.0 17.3 Cost method investments 15.0 16.7 Other long-term investments 70.5 78.2 Taxes receivable 41.4 39.6 Other assets 86.9 138.8 Total investments and other assets $ 341.1 $ 408.7 Investments in securities as of September 30, 2016 included the following: Investments in Securities as of September 30, 2016: Level 1 Carrying amount Unrecognized gain Unrecognized loss Estimated fair value Cash & cash equivalents Marketable securities Money market funds $ 4,649.4 $ - $ - $ 4,649.4 $ 4,649.4 $ - Commercial paper 1,357.7 - - 1,357.7 1,357.7 - Certificates of deposit 250.0 - - 250.0 250.0 - Total $ 6,257.1 $ - $ - $ 6,257.1 $ 6,257.1 $ - Level 2 Carrying amount Unrecognized gain Unrecognized loss Estimated fair value Cash & cash equivalents Marketable securities Commercial paper 11,155.1 6.9 - 11,162.0 - 11,162.0 Investment in Teva ordinary shares 5,038.6 - (664.2 ) 4,374.4 - 4,374.4 Certificates of deposit 4,301.0 0.2 - 4,301.2 - 4,301.2 Total $ 20,494.7 $ 7.1 $ (664.2 ) $ 19,837.6 $ - $ 19,837.6 Fair value is the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants. Fair values determined based on Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities. Fair values determined based on Level 2 inputs utilize observable quoted prices for similar assets and liabilities in active markets and observable quoted prices for identical or similar assets in markets that are not very active. Fair values determined based on Level 3 inputs utilize unobservable inputs and include valuations of assets or liabilities for which there is little, if any, market activity. A financial asset or liability’s classification within the above hierarchy is determined based on the lowest level input that is significant to the fair value measurement. Marketable securities and investments consist of available-for-sale investments in U.S. treasury and agency securities and publicly traded equity securities for which market prices are readily available. Unrealized gains or losses on marketable securities and investments are recorded in accumulated other comprehensive (loss) / income. Realized gains or losses on marketable securities and investments are recorded in interest income. The Company’s marketable securities and other long-term investments are classified as available-for-sale and are recorded at fair value based on quoted market prices using the specific identification method. These investments are classified as either current or non-current, as appropriate, in the Company’s consolidated balance sheets. The Company may sell certain of its marketable securities prior to their stated maturities for strategic reasons including, but not limited to, anticipation of credit deterioration and maturity management. The Company considers the declines in market value of its marketable securities investment portfolio to be temporary in nature. The Company typically invests in highly-rated securities, and its investment policy generally limits the amount of credit exposure to any one issuer. The policy requires investments to be investment grade, with the primary objective of minimizing the potential risk of principal loss. Fair values were determined for each individual security in the investment portfolio.

Accounts Payable and Accrued Ex

Accounts Payable and Accrued Expenses	9 Months Ended
	Sep. 30, 2016
Payables And Accruals [Abstract]
Accounts Payable and Accrued Expenses	NOTE 11 — Accounts Payable and Accrued Expenses Accounts payable and accrued expenses consisted of the following ($ in millions): September 30, 2016 December 31, 2015 Accrued expenses: Accrued third-party rebates $ 1,513.6 $ 1,281.6 Accrued payroll and related benefits 446.2 401.0 Contractual commitments related to the Teva Transaction 501.6 - Accrued stock repurchases 400.0 - Accrued pharmaceutical fees 388.1 162.2 Current portion of contingent consideration obligations 349.1 79.9 Accrued returns 283.7 288.4 Interest payable 170.4 312.0 Royalties payable 167.2 119.1 Litigation-related reserves and legal fees 139.9 191.7 Accrued R&D expenditures 111.7 384.1 Accrued severance, retention and other shutdown costs 83.7 108.5 Accrued non-provision taxes 47.2 98.1 Accrued selling and marketing expenditures 29.6 127.2 Dividends payable 24.2 24.0 Other accrued expenses 472.7 354.9 Total accrued expenses $ 5,128.9 $ 3,932.7 Accounts payable 296.5 215.9 Total Accounts Payable and Accrued Expenses $ 5,425.4 $ 4,148.6

Goodwill, Product Rights and Ot

Goodwill, Product Rights and Other Intangible Assets	9 Months Ended
	Sep. 30, 2016
Goodwill And Intangible Assets Disclosure [Abstract]
Goodwill, Product Rights and Other Intangible Assets	NOTE 12 — Goodwill, Product Rights and Other Intangible Assets During 2016, there was a strategic shift in the business to streamline our operations. Under the new organizational structure being reported, the Company organized its business into the following segments: US Specialized Therapeutics, US General Medicine and International. The Company recast goodwill by segment as a result of this change. The Company’s goodwill by segment consisted of the following ($ in millions): US Therapeutics US General Medicine International Total Balance as of December 31, 2015 $ 18,347.2 $ 21,340.5 $ 6,777.5 $ 46,465.2 Additions through acquisitions 54.2 - - 54.2 Foreign exchange and other adjustments - (26.6 ) 133.0 106.4 Balance as of September 30, 2016 $ 18,401.4 $ 21,313.9 $ 6,910.5 $ 46,625.8 As of September 30, 2016 and December 31, 2015, the gross balance of goodwill, pre-impairments, was $46,643.1 million and $46,482.5 million, respectively. Goodwill in discontinued operations was $86.3 million and $6,096.0 million as of September 30, 2016 and December 31, 2015, respectively. The following items had a significant impact on goodwill in the nine months ended September 30, 2016: • An increase in goodwill of $54.2 million resulting from the ForSight Acquisition. Product rights and other intangible assets consisted of the following ($ in millions): Cost Basis Balance as of December 31, 2015 Acquisitions Impairments IPR&D to CMP Transfers Disposals/ Held for Sale/ Other Foreign Currency Translation Balance as of September 30, 2016 Intangibles with definite lives: Product rights and other related intangibles $ 64,366.0 $ 41.6 $ - $ 1,342.4 $ (194.6 ) $ 108.6 $ 65,664.0 Trade name 690.0 - - - - - 690.0 Total definite-lived intangible assets $ 65,056.0 $ 41.6 $ - $ 1,342.4 $ (194.6 ) $ 108.6 $ 66,354.0 Intangibles with indefinite lives: IPR&D $ 11,128.2 $ 158.0 $ (316.9 ) $ (1,342.4 ) $ - $ 15.9 $ 9,642.8 Total indefinite-lived intangible assets $ 11,128.2 $ 158.0 $ (316.9 ) $ (1,342.4 ) $ - $ 15.9 $ 9,642.8 Total product rights and related intangibles $ 76,184.2 $ 199.6 $ (316.9 ) $ - $ (194.6 ) $ 124.5 $ 75,996.8 Accumulated Balance as of December 31, 2015 Amortization Disposals/ Held for Sale/ Other Foreign Currency Translation Balance as of September 30, 2016 Intangibles with definite lives: Product rights and other related intangibles $ (8,288.5 ) $ (4,773.6 ) $ 176.9 $ 28.9 $ (12,856.3 ) Trade name (59.5 ) (58.3 ) - - (117.8 ) Total definite-lived intangible assets $ (8,348.0 ) $ (4,831.9 ) $ 176.9 $ 28.9 $ (12,974.1 ) Total product rights and $ (8,348.0 ) $ (4,831.9 ) $ 176.9 $ 28.9 $ (12,974.1 ) Net Product Rights and Other Intangibles $ 67,836.2 $ 63,022.7 The following items had a significant impact on net product rights and other intangibles in the three and nine months ended September 30, 2016: • The Company acquired $158.0 million in IPR&D assets in connection with the ForSight Acquisition; • The Company recognized approximately $42.0 million in IPR&D impairments on a gastroenterology project based on the lack of future availability of active pharmaceutical ingredients; The following items had a significant impact on net product rights and other intangibles in the nine months ended September 30, 2016: • The Company recognized approximately $190.0 million in IPR&D impairments due to the termination of an osteoarthritis R&D project due to clinical results; • The Company impaired IPR&D assets relating to an international eye care pipeline project of $35.0 million based on a decrease in projected cash flows due to market conditions; • The Company impaired IPR&D assets relating to a specified indication of a Botox ® • The Company recognized $24.0 million in IPR&D impairments due to the termination of a women’s healthcare R&D project due to clinical results; and • During the nine months ended September 30, 2016, the Company reclassified certain intangible assets from IPR&D to CMP primarily related to Aczone ® ® ® ® Assuming no additions, disposals or adjustments are made to the carrying values and/or useful lives of the intangible assets, annual amortization expense on product rights and other related intangibles as of September 30, 2016 over the remainder of 2016 and each of the next five years is estimated to be as follows ($ in millions): Amortization Expense 2016 remaining $ 1,610.9 2017 $ 6,474.4 2018 $ 5,964.4 2019 $ 5,857.4 2020 $ 5,606.1 2021 $ 4,732.6 The above amortization expense is an estimate. Actual amounts may change from such estimated amounts due to fluctuations in foreign currency exchange rates, additional intangible asset acquisitions, finalization of preliminary fair value estimates, potential impairments, accelerated amortization or other events.

Long-Term Debt and Capital Leas

Long-Term Debt and Capital Leases	9 Months Ended
	Sep. 30, 2016
Debt Disclosure [Abstract]
Long-Term Debt and Capital Leases	NOTE 13 — Long-Term Debt and Capital Leases Total debt and capital leases consisted of the following ($ in millions): Balance As of Fair Market Value As of September 30, 2016 December 31, 2015 September 30, 2016 December 31, 2015 Senior Notes: Floating Rate Notes $500.0 million floating rate notes due September 1, 2016 $ - $ 500.0 $ - $ 500.5 $500.0 million floating rate notes due March 12, 2018 500.0 500.0 504.0 499.6 $500.0 million floating rate notes due March 12, 2020 500.0 500.0 509.0 496.2 1,000.0 1,500.0 1,013.0 1,496.3 Fixed Rate Notes $800.0 million 5.750% notes due April 1, 2016 - 800.0 - 808.4 $1,000.0 million 1.850% notes due March 1, 2017 1,000.0 1,000.0 1,002.3 1,001.5 $500.0 million 1.300% notes due June 15, 2017 500.0 500.0 499.6 496.3 $1,200.0 million 1.875% notes due October 1, 2017 1,200.0 1,200.0 1,204.2 1,196.0 $3,000.0 million 2.350% notes due March 12, 2018 3,000.0 3,000.0 3,031.0 3,004.6 $250.0 million 1.350% notes due March 15, 2018 250.0 250.0 248.9 244.9 $1,050.0 million 4.375% notes due February 1, 2019 1,050.0 1,050.0 1,105.8 1,099.5 $500.0 million 2.450% notes due June 15, 2019 500.0 500.0 508.2 494.4 $400.0 million 6.125% notes due August 14, 2019 400.0 400.0 447.4 444.2 $3,500.0 million 3.000% notes due March 12, 2020 3,500.0 3,500.0 3,614.5 3,505.1 $650.0 million 3.375% notes due September 15, 2020 650.0 650.0 680.3 656.6 $750.0 million 4.875% notes due February 15, 2021 750.0 750.0 830.2 807.4 $1,200.0 million 5.000% notes due December 15, 2021 1,200.0 1,200.0 1,345.6 1,299.4 $3,000.0 million 3.450% notes due March 15, 2022 3,000.0 3,000.0 3,149.5 3,006.8 $1,700.0 million 3.250% notes due October 1, 2022 1,700.0 1,700.0 1,759.6 1,669.6 $350.0 million 2.800% notes due March 15, 2023 350.0 350.0 348.1 327.7 $1,200.0 million 3.850% notes due June 15, 2024 1,200.0 1,200.0 1,274.0 1,202.6 $4,000.0 million 3.800% notes due March 15, 2025 4,000.0 4,000.0 4,227.2 3,984.6 $2,500.0 million 4.550% notes due March 15, 2035 2,500.0 2,500.0 2,653.1 2,462.2 $1,000.0 million 4.625% notes due October 1, 2042 1,000.0 1,000.0 1,066.8 956.1 $1,500.0 million 4.850% notes due June 15, 2044 1,500.0 1,500.0 1,653.0 1,483.6 $2,500.0 million 4.750% notes due March 15, 2045 2,500.0 2,500.0 2,739.8 2,452.7 31,750.0 32,550.0 33,389.1 32,604.2 Total Senior Notes Gross 32,750.0 34,050.0 34,402.1 34,100.5 Unamortized premium 182.8 225.9 - - Unamortized discount (98.7 ) (107.4 ) - - Total Senior Notes Net 32,834.1 34,168.5 34,402.1 34,100.5 Term Loan Indebtedness: WC Term Loan WC October 1, 2016 - 191.5 WC Five Year Tranche variable rate debt maturing October 1, 2018 - 498.8 - 690.3 ACT Term Loan 2017 Term Loan variable rate debt maturing October 31, 2017 - 572.1 2019 Term Loan variable rate debt maturing July 1, 2019 - 1,700.0 - 2,272.1 AGN Term Loan AGN Three Year Tranche variable rate debt maturing March 17, 2018 - 2,750.0 AGN Five Year Tranche variable rate debt maturing March 17, 2020 - 2,543.8 - 5,293.8 Total Term Loan Indebtedness - 8,256.2 Other Indebtedness Revolver Borrowings - 200.0 Debt Issuance Costs (151.5 ) (195.8 ) Other 85.2 97.4 Total Other Borrowings (66.3 ) 101.6 Capital Leases 2.2 4.1 Total Indebtedness $ 32,770.0 $ 42,530.4 Fair market value in the table above is determined in accordance with ASC Topic 820 “Fair Value Measurement” (“ASC 820”) under Level 2 based upon quoted prices for similar items in active markets. The book value of the outstanding term loan indebtedness approximates fair value as the debt is at variable interest rates and re-prices frequently. Unless otherwise indicated, the remaining loan balances after the quarterly required payments are due upon maturity. Floating Rate Notes On March 4, 2015, Actavis Funding SCS, a limited partnership (société en commandite simple) organized under the laws of the Grand Duchy of Luxembourg and an indirect wholly-owned subsidiary of Allergan plc, issued floating rate notes due 2016 (the “2016 Floating Rate Notes”), floating rate notes due 2018 (the “2018 Floating Rate Notes”), floating rate notes due 2020 (the “2020 Floating Rate Notes”), 1.850% notes due 2017 (the “1.850% 2017 Notes”), 2.350% notes due 2018 (the “2.350% 2018 Notes”), 3.000% notes due 2020 (the “3.000% 2020 Notes”), 3.450% notes due 2022 (the “3.450% 2022 Notes”), 3.800% notes due 2025 (the “3.800% 2025 Notes”), 4.550% notes due 2035 (the “4.550% 2035 Notes”) and 4.750% notes due 2045 (the “4.750% 2045 Notes”). The notes are fully and unconditionally guaranteed by Actavis Funding SCS’s indirect parents, Warner Chilcott Limited and Actavis Capital S.a.r.l. (“Actavis Capital”), and by Actavis Finance, LLC (formerly known as Actavis, Inc.), a subsidiary of Actavis Capital, on an unsecured and unsubordinated basis. Allergan plc has not guaranteed the notes. The 2016 Floating Rate Notes were fully repaid on September 1, 2016 and bore interest at the three-month LIBOR plus 0.875%. The 2018 Floating Rate Notes and the 2020 Floating Rate Notes bear interest at a floating rate equal to three-month LIBOR plus 1.080% and 1.255% per annum, respectively. Interest on the 2018 Floating Rate Notes and the 2020 Floating Rate Notes is payable quarterly on March 12, June 12, September 12 and December 12 of each year, and began on June 12, 2015. Fixed Rate Notes The Company has issued fixed rate notes over multiple issuances for various business needs. Interest on the various notes is generally payable semi-annually with various payment dates. Acquired Allergan Notes On March 17, 2015 in connection with the Allergan Acquisition, the Company acquired, and subsequently guaranteed, along with Warner Chilcott Limited, the indebtedness of Allergan, Inc. comprised of the $350.0 million 2.800% senior notes due 2023, the $650.0 million 3.375% senior notes due 2020, the $250.0 million 1.350% senior notes due 2018 and the $800.0 million 5.750% senior notes due 2016. Interest payments are due on the $350.0 million senior notes semi-annually on the principal amount of the notes at a rate of 2.80% per annum, and are redeemable at any time at the Company’s option, subject to a make-whole provision based on the present value of remaining interest payments at the time of the redemption, if the redemption occurs prior to December 15, 2022 (three months prior to the maturity of the 2023 senior notes). If the redemption occurs on or after December 15, 2022, then such redemption is not subject to the make-whole provision. Interest payments are due on the $650.0 million senior notes semi-annually on the principal amount of the notes at a rate of 3.375% per annum, and are redeemable at any time at the Company’s option, subject to a make-whole provision based on the present value of remaining interest payments at the time of the redemption. Interest payments are due on the $250.0 million senior notes semi-annually on the principal amount of the notes at a rate of 1.350% per annum, and are redeemable at any time at the Company’s option, subject to a make-whole provision based on the present value of remaining interest payments at the time of the redemption. Interest payments were due on the $800.0 million senior notes semi-annually on the principal amount of the notes at a rate of 5.750% per annum. The fair value of the acquired senior notes was determined to be $2,087.5 million as of March 17, 2015. As such, as part of acquisition accounting, the company recorded a premium of $37.5 million to be amortized as contra interest over the life of the notes. The $800.0 million 5.750% senior notes were paid in full on April 1, 2016 with proceeds from the first quarter of 2016 borrowings under the revolving credit facility of $900.0 million. Credit Facility Indebtedness On August 2, 2016, the Company repaid the remaining balances of all outstanding term-loan indebtedness and terminated its then existing revolving credit facility with proceeds from the Teva Transaction. WC Term Loan On December 17, 2014, Allergan plc and certain of its subsidiaries entered into a second amendment agreement (the “WC Term Loan Amendment”) among Allergan plc, Warner Chilcott Limited, Warner Chilcott Finance, LLC, Actavis WC 2 S.à r.l. (“Actavis WC 2”), Warner Chilcott Company, LLC (“WCCL”), Warner Chilcott Corporation (“WC Corporation” and together with Actavis WC 2 and WCCL, the “WC Borrowers”), Bank of America, N.A. (“BofA”), as administrative agent, and the lenders party thereto. The WC Term Loan Amendment amended and restated Allergan plc’s existing amended and restated WC term loan credit and guaranty agreement, dated as of June 9, 2014 (such agreement, prior to its amendment and restatement pursuant to the WC Term Loan Amendment, the “2014 WC Term Loan”), among the WC Borrowers, Allergan plc, Warner Chilcott Limited, Warner Chilcott Finance, LLC, the lenders from time to time party thereto and BofA, as administrative agent, which amended and restated Allergan plc’s existing WC term loan credit and guaranty agreement, dated as of August 1, 2013 (such agreement, prior to its amendment and restatement pursuant to the 2014 WC Term Loan Amendment, the “Existing WC Term Loan”) among the WC Borrowers, Warner Chilcott Finance, LLC, Actavis Limited, BofA, as administrative agent and a syndicate of banks participating as lenders. Pursuant to the Existing WC Term Loan, on October 1, 2013 (the “WC Closing Date”), the lenders party thereto provided term loans in a total aggregate principal amount of $2.0 billion, comprised of (i) a $1.0 billion tranche that would have matured on October 1, 2016 (the “WC Three Year Tranche”) and (ii) a $1.0 billion tranche that would have matured on October 1, 2018 (the “WC Five Year Tranche”). The proceeds of borrowings under the Existing WC Term Loan Agreement, together with $41.0 million of cash on hand, were used to finance the repayment in full of all amounts outstanding under Warner Chilcott’s then-existing Credit Agreement, dated as of March 17, 2011, as amended by Amendment No. 1 on August 20, 2012, among the WC Borrowers, Warner Chilcott Holdings Company III, Limited, BofA, as administrative agent and a syndicate of banks participating as lenders. Borrowings under the WC Term Loan Agreement bore interest at the applicable borrower’s choice of a per annum rate equal to either (a) a base rate plus an applicable margin per annum varying from (x) 0.00% per annum to 0.75% per annum under the WC Three Year Tranche and (y) 0.125% per annum to 0.875% per annum under the WC Five Year Tranche, depending on the publicly announced debt ratings for non-credit-enhanced, senior unsecured long-term indebtedness of Allergan plc (such applicable debt rating the “Debt Rating”) or (b) a Eurodollar rate, plus an applicable margin varying from (x) 1.00% per annum to 1.75% per annum under the WC Three Year Tranche and (y) 1.125% per annum to 1.875% per annum under the WC Five Year Tranche, depending on the Debt Rating. ACT Term Loan On December 17, 2014, Allergan plc and certain of its subsidiaries entered into a third amendment agreement (the “ACT Term Loan Amendment”) among Allergan plc, Warner Chilcott Limited, Actavis Capital, Actavis Finance LLC, Actavis Funding SCS, BofA, as administrative agent, and the lenders party thereto. The ACT Term Loan Amendment amends and restates Allergan plc’s existing second amended and restated Allergan term loan credit and guaranty agreement, dated as of March 31, 2014 (such agreement, prior to its amendment and restatement pursuant to the ACT Term Loan Amendment, the “2014 ACT Term Loan Agreement” and together with the Existing ACT Term Loan Agreement (defined below), the “ACT Term Loan”) among Actavis Capital, Allergan plc, Warner Chilcott Limited, Actavis Finance, LLC, Actavis Funding SCS, BofA, as administrative agent, and the lenders from time to time party thereto, which amended and restated Allergan plc’s existing amended and restated Allergan term loan credit and guaranty agreement, dated as of October 1, 2013 (such agreement, prior to its amendment and restatement pursuant to the ACT Term Loan Amendment, the “Existing ACT Term Loan Agreement”) among Actavis Capital, Allergan plc, Actavis Finance, LLC, BofA, as administrative agent, and the lenders from time to time party thereto. The Existing ACT Term Loan Agreement amended and restated Actavis Finance, LLC’s $1,800.0 million senior unsecured term loan credit facility, dated as of June 22, 2012. At the closing of the Existing ACT Term Loan Agreement, an aggregate principal amount of $1,572.5 million was outstanding (the “2017 Term Loan”). On March 31, 2014, Allergan plc, Actavis Capital, Actavis Finance, LLC, BofA, as Administrative Agent, and a syndicate of banks participating as lenders entered into the 2014 ACT Term Loan Agreement to amend and restate the Existing ACT Term Loan Agreement. On July 1, 2014, in connection with the Forest Acquisition, the Company borrowed $2.0 billion of term loan indebtedness under tranche A-2 of the 2014 ACT Term Loan Agreement, which was due July 1, 2019 (the “2019 Term Loan”). Loans under the ACT Term Loan bore interest, at the Company’s choice, of a per annum rate equal to either (a) a base rate, plus an applicable margin per annum varying from (x) 0.00% per annum to 1.00% per annum with respect to the 2017 term-loan and (y) 0.125% per annum to 0.875% per annum with respect to the 2019 term-loan, depending on the Debt Rating or (b) a Eurodollar rate, plus an applicable margin varying from (x) 1.00% per annum to 2.00% per annum with respect to the 2017 term-loan and (y) 1.125% per annum to 1.875% per annum with respect to the 2019 term-loan, depending on the Debt Rating. AGN Term Loan On December 17, 2014, Allergan, Inc., and certain of its subsidiaries entered into a senior unsecured term loan credit agreement (the “AGN Term Loan”), among Actavis Capital, as borrower, Allergan plc, Warner Chilcott Limited, Actavis Finance, LLC, Actavis Funding SCS, the lenders from time to time party thereto (the “Term Lenders”), JPMorgan Chase Bank, N.A. (“JPMCB”), as administrative agent and the other financial institutions party thereto. Under the AGN Term Loan, the Term Lenders provided (i) a $2.75 billion tranche maturing on March 17, 2018 (the “AGN Three Year Tranche”) and (ii) a $2.75 billion tranche and maturing on March 17, 2020 (the “AGN Five Year Tranche”). The proceeds of borrowings under the AGN Term Loan were used to finance, in part, the cash component of the Allergan Acquisition consideration and certain fees and expenses incurred in connection with the Allergan Acquisition. Borrowings under the AGN Term Loan bore interest at our choice of a per annum rate equal to either (a) a base rate plus an applicable margin per annum varying from (x) 0.00% per annum to 1.00% per annum under the AGN Three Year Tranche and (y) 0.125% per annum to 1.250% per annum under the AGN Five Year Tranche, depending on the Debt Rating or (b) a Eurodollar rate, plus an applicable margin varying from (x) 1.00% per annum to 2.00% per annum under the AGN Three Year Tranche and (y) 1.125% per annum to 2.250% per annum under the AGN Five Year Tranche, depending on the Debt Rating. The outstanding principal amount of loans under the AGN Three Year Tranche was not subject to quarterly amortization and was payable in full on the maturity date. The outstanding principal amount of loans under the AGN Five Year Tranche was payable in equal quarterly amounts of 2.50% per quarter prior to March 17, 2020, with the remaining balance payable on March 17, 2020. Cash Bridge Loan Facility On March 11, 2015, Allergan and certain of its subsidiaries entered into a 60-day senior unsecured bridge credit agreement (the “Cash Bridge Loan Facility”), among Actavis Capital, as borrower, Allergan plc, Warner Chilcott Limited, Actavis Finance, LLC, Actavis Funding SCS, the lenders from time to time party thereto (the “Cash Bridge Lenders”), JPMCB, as administrative agent and the other financial institutions party thereto. Under the Cash Bridge Loan Facility, the Cash Bridge Lenders committed to provide, subject to certain conditions, unsecured bridge financing, of which $2.8 billion was drawn to finance the Allergan Acquisition on March 17, 2015. The outstanding balance of the Cash Bridge Loan Facility was repaid on April 9, 2015. Borrowings under the Cash Bridge Loan Facility bore interest at our choice of a per annum rate equal to either (a) a base rate plus an applicable margin per annum varying from 0.00% per annum to 1.00% per annum, depending on the Debt Rating or (b) a Eurodollar rate, plus an applicable margin varying from 1.00% per annum to 2.00% per annum, depending on the Debt Rating. Annual Debt Maturities As of September 30, 2016, annual debt maturities were as follows ($ in millions): Total Payments 2016 remaining $ - 2017 2,700.0 2018 3,750.0 2019 1,950.0 2020 4,650.0 2021 1,950.0 2022 and after 17,750.0 $ 32,750.0 Capital leases 2.2 Debt issuance costs (151.5 ) Other short-term borrowings 85.2 Unamortized premium 182.8 Unamortized discount (98.7 ) Total Indebtedness $ 32,770.0 Amounts represent total anticipated cash payments assuming scheduled repayments.

Other Long-Term Liabilities

Other Long-Term Liabilities	9 Months Ended
	Sep. 30, 2016
Other Liabilities Disclosure [Abstract]
Other Long-Term Liabilities	NOTE 14 — Other Long-Term Liabilities Other long-term liabilities consisted of the following ($ in millions): September 30, December 31, 2016 2015 Acquisition related contingent consideration liabilities $ 602.0 $ 788.1 Long-term pension and post retirement liability 190.1 222.1 Legacy Allergan deferred executive compensation 114.3 117.9 Product warranties 28.1 28.4 Long-term contractual obligations 26.8 26.4 Long-term severance and restructuring liabilities 24.9 34.9 Deferred revenue 16.9 18.2 Other long-term liabilities 19.6 26.0 Total other long-term liabilities $ 1,022.7 $ 1,262.0

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2016
Income Tax Disclosure [Abstract]
Income Taxes	NOTE 15 — Income Taxes The Company’s effective tax rate for the nine months ended September 30, 2016 was 48.0% compared to 40.9% for the nine months ended September 30, 2015. The effective tax rate for the nine months ended September 30, 2016 was impacted by income earned in jurisdictions with tax rates lower than the Irish statutory rate and U.S. losses tax benefited at rates greater than the Irish statutory rate. Additionally, the tax benefit for the nine months ended September 30, 2016 included, but is not limited to, the following items: an expense of $179.5 million primarily related to a change in a valuation allowance on a portion of U.S. capital loss carryforwards resulting from restructuring associated with the sale of the global generics business, a benefit of $48.2 million related to the change in tax rates applicable to certain temporary differences, a benefit of $40.3 million for the recognition of previously unrecognized tax benefits and a benefit of $37.9 million for the New Jersey Grow income tax credit. The effective tax rate for the nine months ended September 30, 2015 was impacted by income earned in jurisdictions with tax rates lower than the Irish statutory rate and U.S. losses tax benefited at rates greater than the Irish statutory rate. Additionally, the tax benefit for the nine months ended September 30, 2015 included, but is not limited to, the following items: a benefit of $318.9 million for the reversal of a valuation allowance on a portion of U.S. capital loss carryforwards resulting from restructuring associated with the sale of the generics business, a benefit of $36.8 million for the recognition of previously unrecognized tax benefits, a benefit of $41.3 million for certain IPR&D impairments and a benefit of $44.0 million for acquired tax attributes. The increase in the effective tax rate for the period ended September 30, 2016 as compared to the period ended September 30, 2015 is primarily the result of a decrease in acquisition related expenses benefited at lower tax rates. During the third quarter, the United States Department of the Treasury issued final and temporary regulations under Section 385 of the Internal Revenue Code which are applicable to the federal income tax treatment of certain related party debt. The Company does not expect the regulations to have a material impact on its consolidated financial statements. During the period ended September 30, 2016 the Company’s non-current deferred tax liability increased by $4,842.7 million primarily due to the reversal of deferred tax assets related to investments in certain U.S. subsidiaries of $5,273.9 million partially offset by the reversal of deferred tax liabilities of $673.9 million related to investments in certain non-U.S. subsidiaries. Refer to “NOTE 5 – Discontinued Operations” for further discussion and additional disclosures related to our income tax provision reported as part of discontinued operations. The Company conducts business globally and, as a result, it files U.S. federal, state and foreign tax returns. The Company strives to resolve open matters with each tax authority at the examination level and could reach agreement with a tax authority at any time. While the Company has accrued for amounts it believes are in accordance with the accounting standard, the final outcome with a tax authority may result in a tax liability that is more or less than that reflected in the consolidated financial statements. Furthermore, the Company may later decide to challenge any assessments, if made, and may exercise its right to appeal. The uncertain tax positions are reviewed quarterly and adjusted as events occur that affect potential liabilities for additional taxes, such as lapsing of applicable statutes of limitations, proposed assessments by tax authorities, negotiations with tax authorities, identification of new issues and issuance of new legislation, regulations or case law. The Company has several concurrent audits still pending with the IRS as set forth below: IRS Audits Tax Years Actavis W.C. Holding, Inc. 2013 and 2014 Forest Laboratories, Inc. 2010, 2011, 2012, 2013 and 2014 Warner Chilcott Corporation 2010, 2011, 2012 and 2013 Durata Therapeutics Inc. 2012 Allergan, Inc. 2009, 2010, 2011, 2012 and 2013

Shareholders' Equity

Shareholders' Equity	9 Months Ended
	Sep. 30, 2016
Equity [Abstract]
Shareholders' Equity	NOTE 16 — Shareholders’ Equity A summary of the changes in shareholders’ equity for the nine months ended September 30, 2016 consisted of the following ($ in millions): Allergan plc Shareholders’ equity as of December 31, 2015 $ 76,591.4 Increase in additional paid in capital for share-based compensation plans 269.9 Net income attributable to ordinary shareholders 14,765.2 Proceeds from stock plans 138.0 Excess tax benefit from employee stock plans 26.6 Other comprehensive income of the Teva Transaction 1,544.8 Repurchase of ordinary shares, including accrued repurchases, under the Share Repurchase Program (3,089.9 ) Repurchase of ordinary shares (68.7 ) Other comprehensive income (451.4 ) Shareholders’ equity as of September 30, 2016 $ 89,725.9 Warner Chilcott Limited Members' equity as of December 31, 2015 $ 75,573.7 Net income attributable to members 14,891.7 Dividend to Parent (1,244.8 ) Other comprehensive income (451.4 ) Other comprehensive income of the Teva Transaction 1,544.8 Members' equity as of September 30, 2016 $ 90,314.0 Share Repurchase Program During the nine months ended September 30, 2016, the Company announced that the Board of Directors approved a $10.0 billion share repurchase program. As of September 30, 2016, the Company has repurchased/accrued for $3,089.9 million of ordinary shares. The Company completed the initial $5.0 billion share repurchase program during the fourth quarter of 2016. Accumulated Other Comprehensive Income / (Loss) For most of the Company’s international operations, the local currency has been determined to be the functional currency. The results of its non-U.S. dollar based operations are translated to U.S. dollars at the average exchange rates during the period. Assets and liabilities are translated at the rate of exchange prevailing on the balance sheet date. Equity is translated at the prevailing rate of exchange at the date of the equity transaction. Translation adjustments are reflected in shareholders’ equity and are included as a component of other comprehensive income / (loss). The effects of converting non-functional currency assets and liabilities into the functional currency are recorded as transaction gains/losses in general and administrative expenses in the consolidated statements of operations. The movements in accumulated other comprehensive income / (loss) for the three and nine months ended September 30, 2016 were as follows ($ in millions): Foreign Currency Translation Items Unrealized (losses) / gains net of tax Total Accumulated Other Comprehensive Income / (Loss) Balance as of December 31, 2015 $ (564.3 ) $ 70.2 $ (494.1 ) Other comprehensive gain / (loss) before reclassifications into general and administrative 192.9 (15.9 ) 177.0 Total other comprehensive income / (loss) 192.9 (15.9 ) 177.0 Balance as of June 30, 2016 $ (371.4 ) $ 54.3 $ (317.1 ) Other comprehensive gain / (loss) before reclassifications into general and administrative (19.1 ) 54.9 35.8 Impact of Teva Transaction 1,540.6 4.2 1,544.8 Investment in Teva ordinary shares fair value movement - (664.2 ) (664.2 ) Total other comprehensive income / (loss) 1,521.5 (605.1 ) 916.4 Balance as of September 30, 2016 $ 1,150.1 $ (550.8 ) $ 599.3 The movements in accumulated other comprehensive (loss) / income for the three and nine months ended September 30, 2015 were as follows ($ in millions): Foreign Currency Translation Items Unrealized gains net of tax Total Accumulated Other Comprehensive Income / (Loss) Balance as of December 31, 2014 $ (434.4 ) $ (31.0 ) $ (465.4 ) Other comprehensive income before reclassifications into general and administrative 451.4 3.6 455.0 Total other comprehensive income 451.4 3.6 455.0 Balance as of June 30, 2015 $ 17.0 $ (27.4 ) $ (10.4 ) Other comprehensive (loss) / income before reclassifications into general and administrative (42.4 ) 7.5 (34.9 ) Total other comprehensive (loss) / income (42.4 ) 7.5 (34.9 ) Balance as of September 30, 2015 $ (25.4 ) $ (19.9 ) $ (45.3 )

Derivative Instruments and Hedg

Derivative Instruments and Hedging Activities	9 Months Ended
	Sep. 30, 2016
Derivative Instruments And Hedging Activities Disclosure [Abstract]
Derivative Instruments and Hedging Activities	NOTE 17 — Derivative Instruments and Hedging Activities The Company’s revenue, earnings, cash flows and fair value of its assets and liabilities can be impacted by fluctuations in foreign exchange risks and interest rates, as applicable. The Company manages the impact of foreign exchange risk and interest rate movements through operational means and through the use of various financial instruments, including derivative instruments such as foreign currency derivatives. Foreign Currency Derivatives Overall, the Company is a net recipient of currencies other than the U.S. dollar and, as such, benefits from a weaker dollar and is adversely affected by a stronger dollar relative to major currencies worldwide. Accordingly, changes in exchange rates, and in particular a strengthening of the U.S. dollar, may negatively affect the Company’s consolidated revenues and favorably impact operating expenses in U.S. dollars. The Company enters into foreign currency derivatives to reduce current and future earnings and cash flow volatility associated with foreign exchange rate changes to allow management to focus its attention on its core business issues. Accordingly, the Company enters into various contracts which change in value as foreign exchange rates change to economically offset the effect of changes in the value of foreign currency assets and liabilities, commitments and anticipated foreign currency denominated sales and operating expenses. The Company enters into foreign currency derivatives in amounts between minimum and maximum anticipated foreign exchange exposures. The Company does not designate the current derivative instruments as accounting hedges. The Company uses foreign currency derivatives, which provide for the sale or purchase or the option to sell or purchase foreign currencies to economically hedge the currency exchange risks associated with probable but not firmly committed transactions that arise in the normal course of the Company’s business. Probable but not firmly committed transactions are comprised primarily of sales of products and purchases of raw materials in currencies other than the U.S. dollar. The foreign currency derivatives are entered into to reduce the volatility of earnings generated in currencies other than the U.S. dollar. While these instruments are subject to fluctuations in value, such fluctuations are anticipated to offset changes in the value of the underlying exposures. The Company recognized realized and unrealized gains on such contracts of $9.1 million and $5.7 million during the three and nine months ended September 30, 2016, respectively. The Company recognized realized and unrealized losses on such contracts of $6.4 million and $5.8 million during the three and nine months ended September 30, 2015, respectively. The fair value of outstanding foreign currency derivatives are recorded in “Prepaid expenses and other current assets” or “Investments and other assets” or “Accounts payable and accrued expenses.” At September 30, 2016 and December 31, 2015, foreign currency derivative assets associated with the foreign exchange option contracts of $23.2 million and $25.0 million, respectively, were included in “Prepaid expenses and other current assets.” At September 30, 2016 and December 31, 2015, foreign currency derivative assets associated with the foreign exchange option contracts of $28.8 million and $48.5 million, respectively, were included in “Investments and other assets.” At December 31, 2015, there were $0.3 million in foreign currency derivative liabilities associated with the foreign exchange forward contracts included in “Accounts payable and accrued expenses.”

Fair Value Measurement

Fair Value Measurement	9 Months Ended
	Sep. 30, 2016
Fair Value Disclosures [Abstract]
Fair Value Measurement	NOTE 18 — Fair Value Measurement Fair value is the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants. Fair values determined based on Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities. Fair values determined based on Level 2 inputs utilize observable quoted prices for similar assets and liabilities in active markets and observable quoted prices for identical or similar assets in markets that are not very active. Fair values determined based on Level 3 inputs utilize unobservable inputs and include valuations of assets or liabilities for which there is little, if any, market activity. A financial asset or liability’s classification within the above hierarchy is determined based on the lowest level input that is significant to the fair value measurement. Assets and liabilities measured at fair value or disclosed at fair value on a recurring basis as of September 30, 2016 and December 31, 2015 consisted of the following ($ in millions): Fair Value Measurements as of September 30, 2016 Using: Total Level 1 Level 2 Level 3 Assets: Cash equivalents $ 6,257.1 $ 6,257.1 $ - $ - Marketable securities 15,463.2 - 15,463.2 - Deferred executive compensation investments 114.3 92.0 22.3 - Foreign currency derivatives 52.0 - 52.0 - Investment in Teva ordinary shares 4,374.4 - 4,374.4 - Investments and other 98.5 98.5 - - Total assets $ 26,359.5 $ 6,447.6 $ 19,911.9 $ - Liabilities: Deferred executive compensation liabilities 114.3 92.0 22.3 - Contingent consideration obligations 951.1 - - 951.1 Total liabilities $ 1,065.4 $ 92.0 $ 22.3 $ 951.1 Fair Value Measurements as of December 31, 2015 Using: Total Level 1 Level 2 Level 3 Assets: Marketable securities $ 29.9 $ 29.9 $ - $ - Deferred executive compensation investments 118.1 102.3 15.8 - Foreign currency derivatives 73.2 - 73.2 - Investments and other 112.2 112.2 - - Total assets $ 333.4 $ 244.4 $ 89.0 $ - Liabilities: Deferred executive compensation liabilities 117.9 102.1 15.8 - Contingent consideration obligations 868.0 - - 868.0 Total liabilities $ 985.9 $ 102.1 $ 15.8 $ 868.0 Foreign Currency Contracts At September 30, 2016 and December 31, 2015, the notional principal and fair value of the Company’s outstanding foreign currency derivative financial instruments were as follows ($ in millions, except average contract rate or strike amount): September 30, 2016 December 31, 2015 Notional Principal Average Rate or Strike Amount Notional Principal Average Contract Rate or Strike Amount Foreign currency forward exchange contracts: (Receive U.S. dollar/pay foreign currency) Russian ruble $ 21.6 63.73 $ 18.8 72.97 $ 21.6 $ 18.8 Estimated fair value $ 0.1 $ (0.3 ) Foreign currency sold - put options: Euro $ 259.9 1.41 $ 340.5 1.41 $ 259.9 $ 340.5 Estimated fair value $ 51.9 $ 73.5 The notional principal amounts provide one measure of the transaction volume outstanding as of September 30, 2016 and December 31, 2015, and do not represent the amount of the Company’s exposure to market loss. The estimates of fair value are based on applicable and commonly used pricing models using prevailing financial market information as of September 30, 2016 and December 31, 2015. The amounts ultimately realized upon settlement of these financial instruments, together with the gains and losses on the underlying exposures, will depend on actual market conditions during the remaining life of the instruments. Contingent Consideration Obligations The fair value measurement of the contingent consideration obligations is determined using Level 3 inputs and is based on a probability-weighted income approach. The measurement is based upon unobservable inputs supported by little or no market activity based on our own assumptions. Changes in the fair value of the contingent consideration obligations, including accretion, are recorded in our consolidated statements of operations as follows ($ in millions): Three Months Ended Expense / (income) September 30, 2016 September 30, 2015 Cost of sales $ 10.4 $ 20.6 Research and development 5.5 60.1 General and administrative - 0.6 Total $ 15.9 $ 81.3 Nine Months Ended Expense / (income) September 30, 2016 September 30, 2015 Cost of sales $ 13.4 $ 53.1 Research and development 65.8 34.7 General and administrative 0.1 (0.5 ) Total $ 79.3 $ 87.3 The table below provides a summary of the changes in fair value, including net transfers in and/or out, of all financial assets and liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) for the nine months ended September 30, 2016 and 2015 ($ in millions): Balance as of December 31, 2015 Net transfers in to (out of) Level 3 Purchases and settlements, net Net accretion and fair value adjustments Foreign currency translation Balance as of September 30, 2016 Liabilities: Contingent consideration obligations $ 868.0 $ - $ 3.7 $ 79.3 $ 0.1 $ 951.1 Balance as of December 31, 2014 Net transfers in to (out of) Level 3 Purchases and settlements, net Net accretion and fair value adjustments Foreign currency translation Balance as of September 30, 2015 Liabilities: Contingent consideration obligations $ 373.8 $ - $ 317.8 $ 87.3 $ (5.0 ) $ 773.9 During the nine months ended September 30, 2016, the following activity in contingent consideration obligations was incurred ($ in millions): Balance as of December 31, 2015 Acquisitions Fair Value Adjustments and Accretion Payments and Other Balance as of September 30, 2016 Allergan Acquisition $ 329.7 $ - $ 41.4 $ (40.0 ) $ 331.1 AqueSys Acquisition 193.5 - 13.8 - 207.3 Medicines 360 acquisition 144.1 - 13.6 (0.5 ) 157.2 Oculeve Acquisition 90.0 - 8.8 - 98.8 ForSight Acquisition - 79.8 - - 79.8 Metrogel acquisition 30.9 - (7.5 ) (4.5 ) 18.9 Forest Acquisition 20.4 - (4.7 ) (1.0 ) 14.7 Uteron acquisition 8.2 - - 0.1 8.3 Durata Acquisition 24.5 - 2.2 (26.7 ) - Other 26.7 - 11.7 (3.4 ) 35.0 Total $ 868.0 $ 79.8 $ 79.3 $ (76.0 ) $ 951.1

Business Restructuring Charges

Business Restructuring Charges	9 Months Ended
	Sep. 30, 2016
Restructuring And Related Activities [Abstract]
Business Restructuring Charges	NOTE 19 — Business Restructuring Charges During 2016, activity related to our business restructuring and facility rationalization activities primarily related to the cost optimization initiatives in conjunction with the Allergan Acquisition. Restructuring activities for the nine months ended September 30, 2016 were as follows ($ in millions): Severance Retention Share-Based Compensation Other Total Reserve balance at December 31, 2015 $ 96.7 $ - $ 48.6 $ 145.3 Charged to expense Cost of sales 3.5 0.5 5.2 9.2 Research and development 6.5 0.9 0.7 8.1 Selling and marketing 8.0 9.3 1.3 18.6 General and administrative 17.4 9.7 9.0 36.1 Total expense 35.4 20.4 16.2 72.0 Cash payments (62.9 ) - (25.1 ) (88.0 ) Other reserve impact - (20.4 ) (0.3 ) (20.7 ) Reserve balance at September 30, 2016 $ 69.2 $ - $ 39.4 $ 108.6 During the three months ended September 30, 2016 and 2015, the Company recognized restructuring charges of $37.7 million and $42.1 million, respectively. During the nine months ended September 30, 2016 and 2015, the Company recognized restructuring charges of $72.0 million and $674.8 million, respectively.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2016
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	NOTE 20 — The Company and its affiliates are involved in various disputes, governmental and/or regulatory inspections, inquires, investigations and proceedings, and litigation matters that arise from time to time in the ordinary course of business. The process of resolving matters through litigation or other means is inherently uncertain and it is possible that an unfavorable resolution of these matters will adversely affect the Company, its results of operations, financial condition and cash flows. The Company’s general practice is to expense legal fees as services are rendered in connection with legal matters, and to accrue for liabilities when losses are probable and reasonably estimable. The Company evaluates, on a quarterly basis, developments in legal proceedings and other matters that could cause an increase or decrease in the amount of the liability that is accrued. As of September 30, 2016, the Company’s consolidated balance sheet includes accrued loss contingencies of approximately $115.0 million, which includes approximately $22.0 million which was assumed by Teva as part of the closing of the sale of the Anda Distribution business on October 3, 2016. The Company’s legal proceedings range from cases brought by a single plaintiff to mass tort actions and class actions with thousands of putative class members. These legal proceedings, as well as other matters, involve various aspects of our business and a variety of claims (including, but not limited to, qui tam actions, antitrust, product liability, breach of contract, securities, patent infringement and trade practices), some of which present novel factual allegations and/or unique legal theories. In addition, a number of the matters pending against us are at very early stages of the legal process (which in complex proceedings of the sort faced by us often extend for several years). As a result, some matters have not yet progressed sufficiently through discovery and/or development of important factual information and legal issues to enable us to estimate a range of possible loss. In those proceedings in which plaintiffs do request publicly quantified amounts of relief, the Company does not believe that the quantified amounts are meaningful because they are merely stated jurisdictional limits, exaggerated and/or unsupported by the evidence or applicable burdens of proof. As noted above, on October 3, 2016, the Company completed the divestiture of the Anda Distribution business to Teva. At closing Teva assumed certain liabilities and claims of the Company described below under “Teva Assumed Liabilities.” Antitrust Litigation Asacol ® On June 22, 2015, two class action complaints were filed in federal court in Massachusetts on behalf of a putative class of indirect purchasers. In each complaint plaintiffs allege that they paid higher prices for Warner Chilcott’s Asacol ® HD and Delzicol ® products as a result of Warner Chilcott’s alleged actions preventing or delaying generic competition in the market for Warner Chilcott’s older Asacol ® product in violation of U.S. federal antitrust laws and/or state laws. Plaintiffs seek unspecified injunctive relief, treble damages and/or attorneys’ fees. All of the actions were consolidated in the federal district court. On September 21, 2015, three additional complaints were filed on behalf of putative classes of indirect purchasers, each raising similar allegations to the complaints filed in June 2015. Defendants have moved to dismiss the indirect purchasers’ complaint. A hearing was held on the motion to dismiss on May 11, 2016. On July 20, 2016, the court issued a decision granting the motion in part, dismissing the indirect purchaser plaintiffs’ claims based on purported reverse payments and dismissed several of indirect purchaser plaintiffs’ claims based on state laws. On August 15, 2016,the indirect purchaser plaintiffs filed a second amended complaint . The Company filed an answer to the second amended complaint on October 4, 2016. A complaint was filed on behalf of a putative class of direct purchasers of Asacol ® in federal court in New York on April 26, 2016. The direct purchaser complaint makes similar allegations to the complaints filed by the indirect purchaser plaintiffs. On May 25, 2016, defendants filed a motion to transfer the direct purchaser action to the federal court in Massachusetts where it could be consolidated with the indirect purchaser cases. Two additional direct purchaser putative class action complaints were filed in federal court in New York on June 29, 2016. On September 7, 2016, direct purchaser plaintiffs agreed to transfer the cases filed in New York to the federal court in Massachusetts where they were consolidated. On October 11, 2016, the Company filed a motion to dismiss the direct purchasers’ consolidated complaint. The Company believes it has substantial meritorious defenses and intends to defend itself vigorously. However, these actions, if successful, could adversely affect the Company and could have a material adverse effect on the Company’s business, results of operations, financial condition and cash flows. Botox ® . On February 24, 2015, a class action complaint was filed in federal court in California. The complaint alleges unlawful market allocation in violation of Section 1 of the Sherman Act, 15 U.S.C. §1, agreement in restraint of trade in violation of 15 U.S.C. §1 of the Sherman Act, unlawful maintenance of monopoly market power in violation of Section 2 of the Sherman Act, 15 U.S.C. §2 of the Sherman Act, violations of California’s Cartwright Act, Section 16700 et seq. of Calif. Bus. and Prof. Code., and violations of California’s unfair competition law, Section 17200 et seq. of Calif. Bus. and Prof. Code. Plaintiffs filed an amended complaint on May 29, 2015. On June 29, 2015, the Company filed a motion to dismiss the complaint. On October 20, 2015, the Court denied the Company’s motion to dismiss the complaint. On December 18, 2015, plaintiffs filed a motion for partial judgment on the pleadings or, in the alternative, for partial summary judgment or adjudication. The Company filed a response to the motion for judgment on the pleadings on February 11, 2016. The court held oral argument on plaintiff’s motion on March 4, 2016 and took the matter under submission. On May 31, 2016, the court denied plaintiffs’ motion for partial judgment on the pleadings or, in the alternative, for partial summary judgment or adjudication. On June 14, 2016, plaintiffs filed a motion for reconsideration of the court’s denial of the motion. On July 19, 2016, plaintiffs filed a motion for class certification. On October 14, 2016, the Company filed an opposition to plaintiffs’ motion for class certification. The Company believes it has substantial meritorious defenses and intends to defend itself vigorously. However, these actions, if successful, could adversely affect the Company and could have a material adverse effect on the Company’s business, results of operations, financial condition and cash flows. Doryx ® . In July 2012, Mylan Pharmaceuticals Inc. (“Mylan”) filed a complaint against Warner Chilcott and Mayne Pharma International Pty. Ltd. (“Mayne”) in federal court in Pennsylvania alleging that Warner Chilcott and Mayne prevented or delayed Mylan’s generic competition to Warner Chilcott’s Doryx ® products in violation of U.S. federal antitrust laws and tortiously interfered with Mylan’s prospective economic relationships under Pennsylvania state law. In the complaint, Mylan seeks unspecified treble and punitive damages and attorneys’ fees. Following the filing of Mylan’s complaint, three putative class actions were filed against Warner Chilcott and Mayne by purported direct purchasers, and one putative class action was filed by purported indirect purchasers. In addition, four retailers filed in the same court a civil antitrust complaint in their individual capacities. In each of the class and individual cases the plaintiffs allege that they paid higher prices for Warner Chilcott’s Doryx ® products as a result of Warner Chilcott’s and Mayne’s alleged actions preventing or delaying generic competition in violation of U.S. federal antitrust laws and/or state laws. Plaintiffs seek unspecified injunctive relief, treble damages and/or attorneys’ fees. All of the actions were consolidated in the federal district court. Warner Chilcott and Mayne’s motion to dismiss was denied without prejudice by the court in June 2013. Thereafter, Warner Chilcott and Mayne reached agreements to settle the claims of the Direct Purchaser Plaintiff class representatives, the Indirect Purchaser Plaintiff class representatives and each of the individual retailer plaintiffs. Warner Chilcott and Mylan filed motions for summary judgment on March 10, 2014. On April 16, 2015, the court issued an order granting Warner Chilcott and Mayne’s motion for summary judgment, denying Mylan’s summary judgment motion and entering judgment in favor of Warner Chilcott and Mayne on all counts. Mylan appealed the district court’s decision to the Third Circuit Court of Appeals. On September 28, 2016, the Court of Appeals issued its decision and affirmed the ruling of the district court. On October 12, 2016 Mylan petitioned the Third Circuit for a rehearing en banc. The Company intends to vigorously defend its rights in the litigations. However, it is impossible to predict with certainty the outcome of any litigation and whether any additional similar suits will be filed. Loestrin ® On April 5, 2013, two putative class were filed in the federal district court against Warner Chilcott and certain affiliates alleging that Warner Chilcott’s 2009 patent lawsuit settlements with Watson Laboratories and Lupin related to Loestrin ® 24 Fe (norethindrone acetate/ethinyl estradiol tablets and ferrous fumarate tablets, “Loestrin ® 24”) were unlawful. The complaints, both asserted on behalf of putative classes of end-payors, generally allege that Watson and Lupin improperly delayed launching generic versions of Loestrin ® 24 in exchange for substantial payments from Warner Chilcott in violation of federal and state antitrust and consumer protection laws. The complaints each seek declaratory and injunctive relief and damages. Additional complaints have been filed by different plaintiffs seeking to represent the same putative class of end-payors. In addition to the end-payor suits, two lawsuits have been filed on behalf of a class of direct payors. After a hearing on September 26, 2013, the JPML issued an order transferring all related Loestrin ® 24 cases to the federal court for the District of Rhode Island. On September 4, 2014, the court granted the defendants’ motion to dismiss the complaint. The plaintiffs appealed the district court’s decision to the First Circuit Court of Appeals and oral argument was held on December 7, 2015. On February 22, 2016 the First Circuit issued its decision vacating the decision of, and remanding the matter to, the district court. On June 11, 2016, defendants filed an omnibus motion to dismiss the claims of the direct purchaser class plaintiffs, end-payor class plaintiffs and individual direct purchaser plaintiffs. Namenda ® . On September 15, 2014, the State of New York, through the Office of the Attorney General of the State of New York, filed a lawsuit in the United States District Court for the Southern District of New York alleging that Forest was acting to prevent or delay generic competition to Forest’s immediate-release product Namenda ® in violation of federal and New York antitrust laws and committed other fraudulent acts in connection with its commercial plans for Namenda ® XR. In the complaint, the state seeks unspecified monetary damages and injunctive relief. On September 24, 2014, the state filed a motion for a preliminary injunction prohibiting Forest from discontinuing or otherwise limiting the availability of immediate-release Namenda ® until the conclusion of the litigation. A hearing was held in November 2014 on the state’s preliminary injunction motion. On December 11, 2014, the district court issued a ruling granting the state’s injunction motion and issued an injunction on December 15, 2014. On May 22, 2015, the Court of Appeals for the Second Circuit affirmed the preliminary injunction. On June 5, 2015, Forest filed a petition with the Second Circuit for rehearing en banc which was denied. Forest and the New York Attorney General reached a settlement on November 24, 2015. On May 29, 2015, a putative class action was filed on behalf of a class of direct purchasers and on June 8, 2015 a similar putative class action was filed on behalf of a class of indirect purchasers. Since that time, additional complaints have been filed on behalf of putative classes of direct and indirect purchasers. The class action complaints make claims similar to those asserted by the New York Attorney General and also include claims that Namenda ® patent litigation settlements between Forest and generic companies also violated the antitrust laws. On December 22, 2015, Forest and its co-defendants filed motions to dismiss the pending complaints of the putative classes of direct and indirect purchasers. On September 13, 2016, the court issued a decision denying the Company’s motion to dismiss. On September 27, 2016 the Company filed an answer to the amended complaint. The Company believes it has substantial meritorious defenses and intends to defend both its brand and generic defendant entities vigorously. However, these actions, if successful, could adversely affect the Company and could have a material adverse effect on the Company’s business, results of operations, financial condition and cash flows. Zymar ® ® . On February 16, 2012, Apotex Inc. and Apotex Corp. filed a complaint in the federal district court in Delaware against Senju Pharmaceuticals Co., Ltd. (“Senju”), Kyorin Pharmaceutical Co., Ltd. (“Kyorin”), and Allergan, Inc. (“Allergan”) alleging monopolization in violation of Section 2 of the Sherman Act, conspiracy to monopolize, and unreasonable restraint of trade in the market for gatifloxacin ophthalmic formulations, which includes Allergan’s ZYMAR ® gatifloxacin ophthalmic solution 0.3% and ZYMAXID ® gatifloxacin ophthalmic solution 0.5% products. On May 24, 2012, Allergan filed a motion to dismiss the complaint to the extent it seeks to impose liability for alleged injuries occurring prior to August 19, 2011, which is the date Apotex obtained final approval of its proposed generic product. Allergan and the other defendants also moved to dismiss. Defendants also filed a motion to stay the action pending resolution of related patent actions in the federal court in Delaware and in the U.S. Court of Appeals for the Federal Circuit. On February 7, 2013, the court granted defendants’ motion to stay the proceedings pending resolution of the appeal in the patent dispute and denied the motion to dismiss without prejudice to renew. On September 18, 2014, defendants filed a new motion to dismiss the Apotex plaintiffs’ complaint. The court dismissed Allergan’s motion on May 2, 2015. Thereafter, Allergan filed an answer to Apotex’s complaint on June 1, 2015. On June 6, 2014, a separate antitrust class action complaint was filed in the federal district court in Delaware against the same defendants as in the Apotex case. The complaint alleges that defendants unlawfully excluded or delayed generic competition in the gatifloxacin ophthalmic formulations market (generic versions of ZYMAR ® and ZYMAXID ® ). On September 18, 2014, Allergan filed a motion to dismiss for lack of subject matter jurisdiction and joined in co-defendants’ motion to dismiss for failure to state a claim. On August 19, 2015, the court granted Allergan’s motion to dismiss. On September 18, 2015, plaintiff filed a notice of appeal with the U.S. Court of Appeals for the Third Circuit. The Third Circuit oral argument was held on June 13, 2016. On September 7, 2016, the U.S. Court of Appeals for the Third Circuit vacated the District Court’s granting of Allergan’s motion to dismiss and remanded to the District Court for further proceedings. The Company believes it has substantial meritorious defenses and intends to defend itself vigorously. However, these actions, if successful, could adversely affect the Company and could have a material adverse effect on the Company’s business, results of operations, financial condition and cash flows. Commercial Litigation Celexa ® ® . Forest and certain of its affiliates were named as defendants in three federal court actions filed on behalf of individuals who purchased Celexa ® and/or Lexapro ® for pediatric use, all of which have been consolidated for pretrial purposes in an MDL proceeding in the federal district court Massachusetts (the “Celexa ® /Lexapro ® MDL”). These actions, two of which were originally filed as putative nationwide class actions, and one of which is a putative California-wide class action, allege that Forest marketed Celexa ® and/or Lexapro ® for off-label pediatric use and paid illegal kickbacks to physicians to induce prescriptions of Celexa ® and Lexapro ® . The complaints assert various similar claims, including claims under the state consumer protection statutes and state common laws. Plaintiffs in the various actions sought to have certified California, Missouri, Illinois and New York state-wide classes. However, only the Missouri state class was certified. Forest subsequently reached an agreement with the MDL plaintiffs to settle the Missouri class claims, including claims by both individuals and third party payors that purchased Celexa ® or Lexapro ® for use by a minor from 1998 to December 31, 2013, for $7.65 million with a potential to increase the amount to $10.35 million if settling plaintiffs meet certain thresholds. On September 8, 2014 the court granted final approval for the settlement. Additional actions relating to the promotion of Celexa ® ® ® ® ® ® ® ® ® ® ® ® ® ® ® ® ® ® Forest and certain of its affiliates were also named as defendants in two actions filed on behalf of entities or individuals who purchased or reimbursed certain purchases of Celexa ® ® ® ® ® ® The Company intends to continue to vigorously defend against these actions. At this time, the Company does not believe losses, if any, would have a material effect on the results of operations or financial position taken as a whole. Telephone Consumer Protection Act Litigation. In October 2012, Forest and certain of its affiliates were named as defendants, in a putative class action in federal court in Missouri. This suit alleges that Forest and another defendant violated the TCPA and was filed on behalf of a proposed class that includes all persons who, from four years prior to the filing of the action, were sent telephone facsimile messages of material advertising the commercial availability of any property, goods, or services by or on behalf of defendants, which did not display an opt-out notice compliant with a certain regulation promulgated by the FCC. On July 17, 2013, the district court granted Forest’s motion to stay the action pending the administrative proceeding initiated by the pending FCC Petition and a separate petition Forest filed. On October 31, 2015, another class action complaint was filed in Missouri state court against Allergan USA, Inc., Warner Chilcott Corporation and Actavis, Inc. alleging violations of the Telephone Consumer Protection Act, the Missouri Consumer Fraud and Protection Act and conversion on behalf of a putative nationwide class of plaintiffs to who defendant Warner Chilcott Corporation sent unsolicited facsimile advertisements. Defendants removed this action to the federal district court for the Western District of Missouri on December 10, 2015 and responded to the complaint on February 8, 2016. On February 17, 2016, plaintiffs voluntarily dismissed defendants Allergan USA, Inc. and Actavis, Inc. from the litigation. In a related matter, on June 27, 2013, Forest filed a Petition for Declaratory Ruling with the FCC requesting that the FCC find that (1) the faxes at issue in the action complied, or substantially complied with the FCC regulation, and thus did not violate it, or (2) the FCC regulation was not properly promulgated under the TCPA. On January 31, 2014, the FCC issued a Public Notice seeking comment on Forest’s and several other similar petitions. On October 30, 2014, the FCC issued a final order on the FCC Petition granting Forest and several other petitioners a retroactive waiver of the opt-out notice requirement for all faxes sent with express consent. The litigation plaintiffs, who had filed comments on the January 2014 Public Notice, have appealed the final order to the Court of Appeals for the District of Columbia. Forest and other petitioners have moved to intervene in the appeal seeking review of that portion of the FCC final order addressing the statutory basis for the opt out/express consent portion of the regulation. Warner Chilcott has filed a similar petition with the FCC. Forest and Warner Chilcott believe they have substantial meritorious defenses to the putative class actions brought under the TCPA, and intend to defend the actions vigorously. However, these actions, if successful, could have a material adverse effect on the Company’s business, results of operations, financial condition and cash flows. Prescription Drug Abuse Litigation . On May 21, 2014, the California counties Santa Clara and Orange filed a lawsuit in California state court on behalf of the State of California against several pharmaceutical manufacturers. Plaintiffs named Actavis plc in the suit. The California plaintiffs filed an amended complaint on June 9, 2014. On June 2, 2014, the City of Chicago also filed a complaint in Illinois state court against the same set of defendants, including Actavis plc, that were sued in the California Action. Co-defendants in the action removed the matter to the federal court in Illinois. Both the California and Chicago complaints allege that the manufacturer defendants engaged in a deceptive campaign to promote their products in violation of state and local laws. Each of the complaints seeks unspecified monetary damages, penalties and injunctive relief. Defendants have moved to dismiss the complaints in each action. On May 8, 2015, the court in the Chicago litigation granted the Company’s motion to dismiss the complaint. On August 26, 2015, the City of Chicago filed a second amended complaint. On September 29, 2016, the court in the Chicago litigation granted in part and denied in part defendants’ motion to dismiss the second amended complaint. In the California action, on August 27, 2015, the court stayed the action based on primary jurisdiction arguments raised in the motions to dismiss. On June 3, 2016, the California plaintiffs filed a motion to lift the stay and a motion for leave to file a third amended complaint. On July 1, 2016, the Company and codefendants filed joint oppositions to the California plaintiffs’ motion to lift the stay and motion for leave to file a third amended complaint. On July 27, 2016, the court ordered the California plaintiffs to file another motion for leave to file an amended complaint along with a proposed amended complaint. On October 19, 2016, the court in the California litigation lifted the stay in part permitting defendants to challenge the third amended complaint and for the parties to discuss settlement and maintaining the stay in all other respects. On December 15, 2015, the State of Mississippi filed a lawsuit in Mississippi state court against several pharmaceutical manufacturers. The Mississippi action parallels the allegations in the California and Chicago matters and seeks monetary and equitable relief. In March and April 2016, the defendants filed motions to dismiss, stay, and transfer venue in the Mississippi action. The Company anticipates that additional suits will be filed. The Company believes it has several meritorious defenses to the claims alleged. However, an adverse determination in these actions could have an adverse effect on the Company’s business, results of operations, financial condition and cash flows. Testosterone Replacement Therapy Class Action . On November 24, 2014, the Company was served with a putative class action complaint filed on behalf a class of third party payers in federal court in Illinois. The suit alleges that the Company and other named pharmaceutical defendants violated various laws including the federal Racketeer Influenced and Corrupt Organizations Act and state consumer protection laws in connection with the sale and marketing of certain testosterone replacement therapy pharmaceutical products (“TRT Products”), including the Company’s Androderm ® product. This matter was filed in the TRT Products Liability MDL, described in more detail below, notwithstanding that it is not a product liability matter. Plaintiff alleges that it reimbursed third parties for dispensing TRT Products to beneficiaries of its insurance policies. Plaintiff seeks to obtain certain equitable relief, including injunctive relief and an order requiring restitution and/or disgorgement, and to recover damages and multiple damages in an unspecified amount. Defendants filed a joint motion to dismiss the complaint, after which plaintiff amended its complaint. Defendants jointly filed a motion to dismiss the amended complaint, which was granted in part and denied in part on February 3, 2016. The Court dismissed plaintiff’s substantive RICO claims for mail and wire fraud for failure to plead with particularity under Rule 9(b) but granted plaintiffs leave to replead. The court also dismissed plaintiff’s state law statutory claims and common law claims for fraud and unjust enrichment. The Court declined to dismiss plaintiff’s conspiracy claims pursuant to 18 U.S.C. § 1962(d) and its claims for negligent misrepresentation. On March 2, 2016, the defendants jointly filed a Motion for Reconsideration of the court’s ruling on plaintiff’s claims under 18 U.S.C. § 1962(d). Plaintiff filed its Third Amended Complaint on April 7, 2016. Defendants jointly filed a motion to dismiss the Third Amended Complaint on May 5, 2016, plaintiffs filed opposition to same on June 20, 2016 and defendants jointly filed a reply on July 7, 2016. On August 2, 2016, the Court dismissed all claims in the Third Amended Complaint against the Company except Count XXIV alleging conspiracy under 18 U.S.C. § 1962(d). On August 29, 2016, the Company filed a Motion for Reconsideration or, in the Alternative, Motion to Certify for Interlocutory Appeal, which the Court denied on the September 8, 2016. Discovery is in the early stages. The Company believes it has substantial meritorious defenses to the claims alleged and intends to vigorously defend the action. However, an adverse determination in the case could have an adverse effect on the Company’s business, results of operations, financial condition and cash flows. TNS Products Litigation . On March 19, 2014, a complaint was filed in the federal district court in California. The complaint alleges violations of the California Unfair Competition Law, the Consumers Legal Remedies Act, and the False Advertising Law, and deceit. On June 2, 2014, Plaintiff filed a first amended complaint. On June 23, 2014, Allergan filed a motion to dismiss the first amended complaint. On September 5, 2014, the court granted-in-part and denied-in-part Allergan’s motion to dismiss. On September 8, 2014, the court set trial for September 1, 2015. On November 4, 2014, Allergan and SkinMedica filed a motion to dismiss. On January 7, 2015, Allergan and SkinMedica’s motion to dismiss was denied. On January 15, 2015, the court set a trial date of February 16, 2016. On February 19, 2015 Plaintiff filed a third amended complaint. On May 27, 2015, the case was stayed pending the decision of the Ninth Circuit Court of Appeals in another matter involving similar legal issues. The Company believes it has substantial meritorious defenses and intends to defend itself vigorously. However, these actions, if successful, could adversely affect the Company and could have a material adverse effect on the Company’s business, results of operations, financial condition and cash flows. Xaleron Dispute. On February 5, 2016, Xaleron Pharmaceuticals, Inc. filed a lawsuit against Allergan, Inc. and Actavis, Inc. in state court in New York. The complaint, filed on February 26, 2016, alleges Allergan misappropriated Xaleron’s confidential business information and asserts claims for unfair competition, tortious interference with prospective economic advantage and unjust enrichment. The company filed a motion to dismiss the complaint on April 15, 2016. On September 13, 2016 the court issued a decision denying the Company’s motion. The Company filed an answer to the complaint and the parties are now engaged in discovery. The Company intends to vigorously defend against this action. However, this action, if successful, could adversely affect the Company and could have a material adverse effect on the Company’s business, results of operations, financial condition and cash flows. Employment Litigation In July 2012, Forest and certain of its affiliates were named as defendants in an action brought by certain former company sales representatives and specialty sales representatives in the federal district court in New York. The action is a putative class and collective action, and alleges class claims under Title VII for gender discrimination with respect to pay and promotions, as well as discrimination on the basis of pregnancy, and a collective action claim under the Equal Pay Act. The proposed Title VII gender class includes all current and former female sales representatives employed by the Company throughout the U.S. from 2008 to the date of judgment, and the proposed Title VII pregnancy sub-class includes all current and former female sales representatives who have been, are, or will become pregnant while employed by the Company throughout the U.S. from 2008 to the date of judgment. The proposed Equal Pay Act collective action class includes current, former, and future female sales representatives who were not compensated equally to similarly-situated male employees during the applicable liability period. The Second Amended Complaint also includes non-class claims on behalf of certain of the named Plaintiffs for sexual harassment and retaliation under Title VII, and for violations of the Family and Medical Leave Act. On August 14, 2014, the court issued a decision on the Company’s motion to dismiss, granting it in part and denying it in part, striking the plaintiffs’ proposed class definition and instead limiting the proposed class to a smaller set of potential class members and dismissing certain of the individual plaintiffs’ claims. Plaintiffs filed a motion for conditional certification of an Equal Pay Act collective action on May 22, 2015 which the Company has opposed. On September 2, 2015, the court granted plaintiffs motion to conditionally certify a collective action. The Company intends to continue to vigorously defend against this action. At this time, the Company does not believe losses, if any, would have a material effect on the results of operations or financial position taken as a whole. Patent Litigation Patent Enforcement Matters Amrix ® . In August 2014, Aptalis Pharmatech, Inc. (“Aptalis”) and Ivax International GmbH (“Ivax”), Aptalis’s licensee for Amrix, brought an action for infringement of U.S. Patent No. 7,790,199 (the “’199 patent”), and 7,829,121 (the “’121 patent”) in the U.S. District Court for the District of Delaware against Apotex Inc. and Apotex Corp. (collectively “Apotex”). Apotex has notified Aptalis that it has filed an ANDA with the FDA seeking to obtain approval to market a generic version of Amrix before these patents expire. (The ’199 and ’121 patents expire in November 2023.) This lawsuit triggered an automatic stay of approval of Apotex’s ANDA until no earlier than December 27, 2016 (unless there is a final court decision adverse to Forest sooner, and subject to any other exclusivities, such as a first filer 180 day market exclusivity). A bench trial concluded on November 17, 2015. Post-trial briefing concluded on April 8, 2016. On September 29, 2016, Adare Pharmaceuticals, Inc., and Ivax filed suit in U.S. District Court for the District of Delaware against Apotex asserting that Apotex’s generic product will infringe U.S. Patent No. 9,399,025. No schedule has been set. The Company believes it has meritorious cla

Warner Chilcott Limited ("WCL")

Warner Chilcott Limited ("WCL") Guarantor and Non-Guarantor Condensed Consolidating Financial Information	9 Months Ended
	Sep. 30, 2016
Warner Chilcott Acquisition [Member]
Warner Chilcott Limited ("WCL") Guarantor and Non-Guarantor Condensed Consolidating Financial Information	NOTE 21 — Warner Chilcott Limited (“WCL”) Guarantor and Non-Guarantor Condensed Consolidating Financial Information The following financial information is presented to segregate the financial results of WCL, Actavis Funding SCS, and Actavis Finance, LLC (the issuers of the long-term notes), the guarantor subsidiaries for the long-term notes and the non-guarantor subsidiaries. The guarantors jointly and severally, and fully and unconditionally, guarantee the Company’s obligation under the long-term notes. The information includes elimination entries necessary to consolidate the guarantor and the non-guarantor subsidiaries. Investments in subsidiaries are accounted for using the equity method of accounting. The principal elimination entries eliminate investments in subsidiaries, equity and intercompany balances and transactions. WCL, Actavis Capital S.a.r.l. and Actavis Finance, LLC are guarantors of the long-term notes. Warner Chilcott Limited has revised its consolidating financial statements as previously presented in Footnote 21 of the September 30, 2015 Quarterly Report on Form 10-Q and its December 31, 2015 balance sheet in Footnote 26 of the Annual Report due to a change in the Company’s legal entity structure and other reclassifications that occurred during the nine months ended September 30, 2016. As a result, prior period information has been recast to conform to the current period presentation. The following financial information presents the consolidating balance sheets as of September 30, 2016 and December 31, 2015, the related statement of operations for the three and nine months ended September 30, 2016 and 2015 and the statement of cash flows for the nine months ended September 30, 2016 and 2015. Warner Chilcott Limited Consolidating Balance Sheets As of September 30, 2016 (Unaudited; in millions) Current assets: Warner Chilcott Limited (Parent Guarantor) Actavis Capital S.a.r.l. (Guarantor) Actavis Funding SCS (Issuer) Actavis Guarantor) Non- guarantors Eliminations Consolidated Warner Chilcott Limited Cash and cash equivalents $ 0.1 $ 2,101.1 $ - $ - $ 5,421.6 $ - $ 7,522.8 Marketable securities - - - - 19,837.6 - 19,837.6 Accounts receivable, net - - - - 2,398.5 - 2,398.5 Receivable from Parents - - - - 2,828.7 - 2,828.7 Inventories, net - - - - 705.5 - 705.5 Intercompany receivables - 22,969.8 3,400.3 78.7 23,471.2 (49,920.0 ) - Prepaid expenses and other current assets - 9.2 - 21.3 739.1 - 769.6 Current assets held for sale - - - - 455.9 - 455.9 Total current assets 0.1 25,080.1 3,400.3 100.0 55,858.1 (49,920.0 ) 34,518.6 Property, plant and equipment, net - - - - 1,566.3 - 1,566.3 Investments and other assets - - - 16.4 324.7 - 341.1 Investment in subsidiaries 90,318.4 90,267.6 - 73,710.3 - (254,296.3 ) - Non current intercompany receivables - 46,647.4 22,483.3 - 57,859.6 (126,990.3 ) - Non current receivables from Parents - - - - 3,985.0 - 3,985.0 Non current assets held for sale - - - - 207.2 - 207.2 Deferred tax assets - - - - 120.7 - 120.7 Product rights and other intangibles - - - - 63,022.7 - 63,022.7 Goodwill - - - - 46,625.8 - 46,625.8 Total assets $ 90,318.5 $ 161,995.1 $ 25,883.6 $ 73,826.7 $ 229,570.1 $ (431,206.6 ) $ 150,387.4 Current liabilities: Accounts payable and accrued expenses - - 74.1 - 4,921.7 - 4,995.8 Intercompany payables - 12,347.1 1,796.5 9,327.6 26,448.8 (49,920.0 ) - Payable to Parents - 5,000.0 - - 1,202.2 - 6,202.2 Income taxes payable - - - - 784.6 - 784.6 Current portion of long-term debt and capital leases - - 1,527.3 - 64.5 - 1,591.8 Current liabilities held for sale - - - - 223.7 - 223.7 Total current liabilities - 17,347.1 3,397.9 9,327.6 33,645.5 (49,920.0 ) 13,798.1 Long-term debt and capital leases - - 22,483.3 4,275.6 4,419.3 - 31,178.2 Other long-term liabilities - - - - 1,022.7 - 1,022.7 Long-term intercompany payables - 57,859.6 - - 69,130.7 (126,990.3 ) - Long-term payables to Parents - - - - 419.0 - 419.0 Non current liabilities held for sale - - - 23.8 23.8 Other taxes payable - - - - 815.6 - 815.6 Deferred tax liabilities - - - - 12,811.5 - 12,811.5 Total liabilities - 75,206.7 25,881.2 13,603.2 122,288.1 (176,910.3 ) 60,068.9 Total equity / (deficit) 90,318.5 86,788.4 2.4 60,223.5 107,282.0 (254,296.3 ) 90,318.5 Total liabilities and equity $ 90,318.5 $ 161,995.1 $ 25,883.6 $ 73,826.7 $ 229,570.1 $ (431,206.6 ) $ 150,387.4 Warner Chilcott Limited Consolidating Balance Sheets As of December 31, 2015 ($ in millions) Current assets: Warner Chilcott Limited (Parent Guarantor) Actavis Capital S.a.r.l. (Guarantor) Actavis Funding SCS (Issuer) Actavis Finance, LLC (Issuer and Guarantor) Non- guarantors Eliminations Consolidated Warner Chilcott Limited Cash and cash equivalents $ - $ 13.5 $ - $ 2.0 $ 1,020.7 $ - $ 1,036.2 Marketable securities - - - - 9.3 - 9.3 Accounts receivable, net - - - - 2,125.4 - 2,125.4 Receivable from Parents - - - - 457.3 - 457.3 Inventories - - - - 757.5 - 757.5 Intercompany receivables - 55,415.1 25,225.6 302.4 60,464.0 (141,407.1 ) - Prepaid expenses and other current assets - 5.0 - 6.1 481.7 - 492.8 Current assets held for sale - - - - 4,095.6 - 4,095.6 Total current assets - 55,433.6 25,225.6 310.5 69,411.5 (141,407.1 ) 8,974.1 Property, plant and equipment, net - - - 34.3 1,497.0 - 1,531.3 Investments and other assets - - - 33.6 375.1 - 408.7 Investment in subsidiaries 75,571.6 79,597.3 - 73,037.7 - (228,206.6 ) - Non current intercompany receivables - 39,584.1 - - 41,400.8 (80,984.9 ) - Non current receivables from Parents - - - - - - - Non current assets held for sale - - - 45.8 10,667.5 - 10,713.3 Deferred tax assets - - - - 49.5 - 49.5 Product rights and other intangibles - - - - 67,836.2 - 67,836.2 Goodwill - - - - 46,465.2 - 46,465.2 Total assets $ 75,571.6 $ 174,615.0 $ 25,225.6 $ 73,461.9 $ 237,702.8 $ (450,598.6 ) $ 135,978.3 Current liabilities: Accounts payable and accrued expenses - 3.9 210.5 171.5 3,708.6 - 4,094.5 Intercompany payables - 51,148.7 526.3 8,789.0 80,943.1 (141,407.1 ) - Payable to Parents - - - - 1,466.8 - 1,466.8 Income taxes payable - - - 44.1 9.6 - 53.7 Current portion of long-term debt and capital leases - 749.1 475.5 - 1,171.9 - 2,396.5 Current liabilities held for sale - - - 23.3 1,669.9 - 1,693.2 Total current liabilities - 51,901.7 1,212.3 9,027.9 88,969.9 (141,407.1 ) 9,704.7 Long-term debt and capital leases - 6,995.0 24,013.0 4,269.4 4,856.5 - 40,133.9 Other long-term liabilities - - - - 1,262.0 - 1,262.0 Long-term intercompany payables - 40,944.8 - 456.0 39,584.1 (80,984.9 ) - Long-term payables to Parents - - - - - - - Non current liabilities for sale - - - - 535.4 - 535.4 Other taxes payable - - - 72.1 729.8 - 801.9 Deferred tax liabilities - - - - 7,968.8 - 7,968.8 Total liabilities - 99,841.5 25,225.3 13,825.4 143,906.5 (222,392.0 ) 60,406.7 Total equity / (deficit) 75,571.6 74,773.5 0.3 59,636.5 93,796.3 (228,206.6 ) 75,571.6 Total liabilities and equity $ 75,571.6 $ 174,615.0 $ 25,225.6 $ 73,461.9 $ 237,702.8 $ (450,598.6 ) $ 135,978.3 Warner Chilcott Limited Consolidating Statements of Operations For the Three Months Ended September 30, 2016 (Unaudited; in millions) Warner Chilcott Limited (Parent Guarantor) Actavis Capital S.a.r.l. (Guarantor) Actavis Funding SCS (Issuer) Actavis Finance, LLC (Issuer and Guarantor) Non- guarantors Eliminations Consolidated Warner Chilcott Limited Net revenues $ - $ - $ - $ - $ 3,622.2 $ - $ 3,622.2 Operating expenses: Cost of sales (excludes amortization and impairment of acquired intangibles including product rights) - - - - 462.2 - 462.2 Research and development - - - - 622.8 - 622.8 Selling and marketing - - - - 796.0 - 796.0 General and administrative - 4.1 - - 308.1 - 312.2 Amortization - - - - 1,609.1 - 1,609.1 In-process research and development impairments - - - - 42.0 - 42.0 Asset sales and impairments, net - - - - (4.7 ) - (4.7 ) Total operating expenses - 4.1 - - 3,835.5 - 3,839.6 Operating (loss) - (4.1 ) - - (213.3 ) - (217.4 ) Non-operating income (expense): Interest income / (expense), net - 911.6 (216.6 ) (40.3 ) (960.9 ) - (306.2 ) Other income (expense), net - - - - 33.6 - 33.6 Total other income (expense), net - 911.6 (216.6 ) (40.3 ) (927.3 ) - (272.6 ) Income / (loss) before income taxes and noncontrolling interest - 907.5 (216.6 ) (40.3 ) (1,140.6 ) - (490.0 ) Provision / (benefit) for income taxes - - - (22.6 ) (136.3 ) - (158.9 ) (Earnings) / losses of equity interest subsidiaries (15,269.0 ) (11,485.0 ) - 747.6 - 26,006.4 - Net income / (loss) from continuing operations, net of tax $ 15,269.0 $ 12,392.5 $ (216.6 ) $ (765.3 ) $ (1,004.3 ) $ (26,006.4 ) $ (331.1 ) Income from discontinued operations - - - - 15,601.9 - 15,601.9 Net income / (loss) $ 15,269.0 $ 12,392.5 $ (216.6 ) $ (765.3 ) $ 14,597.6 $ (26,006.4 ) $ 15,270.8 (Income) attributable to noncontrolling interest - - - - (1.8 ) - (1.8 ) Net income / (loss) attributable to ordinary shareholders $ 15,269.0 $ 12,392.5 $ (216.6 ) $ (765.3 ) $ 14,595.8 $ (26,006.4 ) $ 15,269.0 Other comprehensive income / (loss) 916.4 958.4 - 900.2 916.4 (2,775.0 ) 916.4 Comprehensive income / (loss) $ 16,185.4 $ 13,350.9 $ (216.6 ) $ 134.9 $ 15,512.2 $ (28,781.4 ) $ 16,185.4 Warner Chilcott Limited Consolidating Statements of Operations For the Nine Months Ended September 30, 2016 (Unaudited; in millions) Warner Chilcott Limited (Parent Guarantor) Actavis Capital S.a.r.l. (Guarantor) Actavis Funding SCS (Issuer) Actavis Finance, LLC (Issuer and Guarantor) Non- guarantors Eliminations Consolidated Warner Chilcott Limited Net revenues - - - - 10,706.3 - 10,706.3 Operating expenses: Cost of sales (excludes amortization and impairment of acquired intangibles including product rights) - - - - 1,381.1 - 1,381.1 Research and development - - - - 1,662.4 - 1,662.4 Selling and marketing - - - - 2,429.6 - 2,429.6 General and administrative - 4.6 - 19.8 941.8 - 966.2 Amortization - - - - 4,831.9 - 4,831.9 In process research and development impairments - - - - 316.9 - 316.9 Asset sales and impairments, net - - - - (24.0 ) - (24.0 ) Total operating expenses - 4.6 - 19.8 11,539.7 - 11,564.1 Operating (loss) - (4.6 ) - (19.8 ) (833.4 ) - (857.8 ) Non-operating income (expense): Interest income / (expense), net - 1,349.2 2.2 (117.2 ) (2,213.6 ) - (979.4 ) Other income (expense), net - - - - 34.2 - 34.2 Total other income (expense), net - 1,349.2 2.2 (117.2 ) (2,179.4 ) - (945.2 ) Income / (loss) before income taxes and noncontrolling interest - 1,344.6 2.2 (137.0 ) (3,012.8 ) - (1,803.0 ) Provision / (benefit) for income taxes - - - (51.4 ) (774.4 ) - (825.8 ) (Earnings) / losses of equity interest subsidiaries (14,891.7 ) (10,701.3 ) - 198.6 - 25,394.4 - Net income / (loss) from continuing operations, net of tax $ 14,891.7 $ 12,045.9 $ 2.2 $ (284.2 ) $ (2,238.4 ) $ (25,394.4 ) $ (977.2 ) Income from discontinued operations - - - - 15,873.2 - 15,873.2 Net income / (loss) $ 14,891.7 $ 12,045.9 $ 2.2 $ (284.2 ) $ 13,634.8 $ (25,394.4 ) $ 14,896.0 (Income) attributable to noncontrolling interest - - - - (4.3 ) - (4.3 ) Net income / (loss) attributable to ordinary shareholders $ 14,891.7 $ 12,045.9 $ 2.2 $ (284.2 ) $ 13,630.5 $ (25,394.4 ) $ 14,891.7 Other comprehensive income / (loss) 1,093.4 1,213.8 - 871.1 1,093.4 (3,178.3 ) 1,093.4 Comprehensive income / (loss) $ 15,985.1 $ 13,259.7 $ 2.2 $ 586.9 $ 14,723.9 $ (28,572.7 ) $ 15,985.1 Warner Chilcott Limited Consolidating Statements of Operations For the Three Months Ended September 30, 2015 (Unaudited; in millions) Warner Chilcott Limited (Parent Guarantor) Actavis Capital S.a.r.l. (Guarantor) Actavis Funding SCS (Issuer) Actavis Finance, LLC (Issuer and Guarantor) Non- guarantors Eliminations Consolidated Warner Chilcott Limited Net revenues $ - $ - $ - $ - $ 3,469.5 $ - $ 3,469.5 Operating expenses: Cost of sales (excludes amortization and impairment of acquired intangibles including product rights) - - - - 710.3 - 710.3 Research and development - - - - 1,260.5 - 1,260.5 Selling and marketing - - - - 683.6 - 683.6 General and administrative - - - 79.1 254.7 - 333.8 Amortization - - - - 1,557.8 - 1,557.8 In process research and development impairments - - - - 300.0 - 300.0 Asset sales and impairments, net - - - - (4.4 ) - (4.4 ) Total operating expenses - - - 79.1 4,762.5 - 4,841.6 Operating (loss) - - - (79.1 ) (1,293.0 ) - (1,372.1 ) Non-operating income (expense): Interest income / (expense), net - 444.3 0.3 (40.3 ) (741.0 ) - (336.7 ) Other income (expense), net - - - (0.1 ) 0.3 - 0.2 Total other income (expense), net - 444.3 0.3 (40.4 ) (740.7 ) - (336.5 ) Income / (loss) before income taxes and noncontrolling interest - 444.3 0.3 (119.5 ) (2,033.7 ) - (1,708.6 ) (Benefit) for income taxes - - - (28.0 ) (810.9 ) - (838.9 ) (Earnings) / losses of equity interest subsidiaries (5,306.5 ) 1,857.2 - 117.7 - 3,331.6 - Net income / (loss) from continuing operations, net of tax $ 5,306.5 $ (1,412.9 ) $ 0.3 $ (209.2 ) $ (1,222.8 ) $ (3,331.6 ) $ (869.7 ) Income from discontinued operations - - - - 6,177.6 - 6,177.6 Net income / (loss) $ 5,306.5 $ (1,412.9 ) $ 0.3 $ (209.2 ) $ 4,954.8 $ (3,331.6 ) $ 5,307.9 (Income) attributable to noncontrolling interest - - - - (1.4 ) - (1.4 ) Net income / (loss) attributable to ordinary shareholders $ 5,306.5 $ (1,412.9 ) $ 0.3 $ (209.2 ) $ 4,953.4 $ (3,331.6 ) $ 5,306.5 Other comprehensive income / (loss) (34.9 ) (35.3 ) - 24.0 (34.9 ) 46.2 (34.9 ) Comprehensive income / (loss) $ 5,271.6 $ (1,448.2 ) $ 0.3 $ (185.2 ) $ 4,918.5 $ (3,285.4 ) $ 5,271.6 Warner Chilcott Limited Consolidating Statements of Operations For the Nine Months Ended September 30, 2015 (Unaudited; in millions) Warner Chilcott Limited (Parent Guarantor) Actavis Capital S.a.r.l. (Guarantor) Actavis Funding SCS (Issuer) Actavis Finance, LLC (Issuer and Guarantor) Non- guarantors Eliminations Consolidated Warner Chilcott Limited Net revenues $ - $ - $ - $ - $ 9,081.2 $ - $ 9,081.2 Operating expenses: Cost of sales (excludes amortization and impairment of acquired intangibles including product rights) - - - - 2,150.0 - 2,150.0 Research and development - - - - 1,927.9 - 1,927.9 Selling and marketing - - - - 2,017.2 - 2,017.2 General and administrative - 213.2 16.1 148.8 796.8 - 1,174.9 Amortization - - - - 3,858.9 - 3,858.9 In process research and development impairments - - - - 497.6 - 497.6 Asset sales and impairments, net - - - - 3.1 - 3.1 Total operating expenses - 213.2 16.1 148.8 11,251.5 - 11,629.6 Operating (loss) - (213.2 ) (16.1 ) (148.8 ) (2,170.3 ) - (2,548.4 ) Non-operating income (expense): Interest income / (expense), net - 732.6 (14.4 ) (127.7 ) (1,434.9 ) - (844.4 ) Other income (expense), net - (265.4 ) 31.0 - (3.7 ) - (238.1 ) Total other income (expense), net - 467.2 16.6 (127.7 ) (1,438.6 ) - (1,082.5 ) Income / (loss) before income taxes and noncontrolling interest - 254.0 0.5 (276.5 ) (3,608.9 ) - (3,630.9 ) (Benefit) for income taxes - - - (95.8 ) (1,395.2 ) - (1,491.0 ) (Earnings) / losses of equity interest subsidiaries (4,559.2 ) 2,466.7 - (242.2 ) - 2,334.7 - Net income /(loss) from continuing operations, net of tax $ 4,559.2 $ (2,212.7 ) $ 0.5 $ 61.5 $ (2,213.7 ) $ (2,334.7 ) $ (2,139.9 ) Income from discontinued operations - - - - 6,701.7 - 6,701.7 Net income / (loss) $ 4,559.2 $ (2,212.7 ) $ 0.5 $ 61.5 $ 4,488.0 $ (2,334.7 ) $ 4,561.8 (Income) attributable to noncontrolling interest - - - - (2.6 ) - (2.6 ) Net income / (loss) income attributable to ordinary shareholders $ 4,559.2 $ (2,212.7 ) $ 0.5 $ 61.5 $ 4,485.4 $ (2,334.7 ) $ 4,559.2 Other comprehensive income / (loss) 420.1 485.3 - 859.8 420.1 (1,765.2 ) 420.1 Comprehensive income/ (loss) income $ 4,979.3 $ (1,727.4 ) $ 0.5 $ 921.3 $ 4,905.5 $ (4,099.9 ) $ 4,979.3 Warner Chilcott Limited Consolidating Statement of Cash Flows For the Nine Months Ended September 30, 2016 (Unaudited; in millions) Warner Chilcott Limited (Parent Guarantor) Actavis Capital S.a.r.l. (Guarantor) Actavis Funding SCS (Issuer) Actavis Finance, LLC (Issuer and Guarantor) Non- guarantors Eliminations Consolidated Warner Chilcott Limited Cash Flows From Operating Activities: Net income / (loss) $ 14,891.7 $ 12,045.9 $ 2.2 $ (284.2 ) $ 13,634.8 $ (25,394.4 ) $ 14,896.0 Reconciliation to net cash provided by operating activities: (Earnings) / losses of equity interest subsidiaries (14,891.7 ) (10,701.3 ) - 198.6 - 25,394.4 - Depreciation - - - - 117.6 - 117.6 Amortization - - - - 4,836.7 - 4,836.7 Provision for inventory reserve - - - - 162.7 - 162.7 Share-based compensation - - - - 269.9 - 269.9 Deferred income tax benefit - - - - (517.1 ) - (517.1 ) Pre-tax gain sale of generics business - - - - (24,203.1 ) - (24,203.1 ) Non-cash tax effect of gain on sale of generics business - - - - 5,749.9 - 5,749.9 In-process research and development impairments - - - - 316.9 - 316.9 Loss on asset sales and impairments, net - - - - (24.0 ) - (24.0 ) Amortization of inventory step-up - - - - 42.4 - 42.4 Amortization of deferred financing costs - 21.7 18.3 3.2 1.4 - 44.6 Contingent consideration adjustments, including accretion - - - - 76.7 - 76.7 Dividends from subsidiaries 1,244.8 1,244.8 - - - (2,489.6 ) - Other, net - - - - (16.0 ) - (16.0 ) Changes in assets and liabilities (net of effects of acquisitions) 0.1 8,487.2 479.5 80.4 (10,821.9 ) - (1,774.7 ) Net cash provided by / (used in) operating activities 1,244.9 11,098.3 500.0 (2.0 ) (10,373.1 ) (2,489.6 ) (21.5 ) Cash Flows From Investing Activities: Additions to property plant and equipment - - - - (250.5 ) - (250.5 ) Additions to product rights and other intangibles - - - - - - - Sale of generics business - - - - 33,304.5 - 33,304.5 Additions to investments - - - - (15,445.5 ) - (15,445.5 ) Proceeds from sale of investments and other assets - - - - 40.0 - 40.0 Proceeds from sales of property, plant and equipment - - - - 33.3 - 33.3 Acquisitions of business, net of cash acquired - - - - (74.5 ) - (74.5 ) Net cash provided by investing activities - - - - 17,607.3 - 17,607.3 Cash Flows From Financing Activities: Proceeds from borrowings of long-term indebtedness - - - - - - - Proceeds from borrowings on credit facility - 1,050.0 - - - 1,050.0 Debt issuance and other financing costs - - - - - - - Payments on debt, including capital lease obligations - (8,815.9 ) (500.0 ) - (1,515.1 ) - (10,831.0 ) Payments of contingent consideration - - - - (77.7 ) - (77.7 ) Dividends to Parent (1,244.8 ) (1,244.8 ) - - (1,244.8 ) 2,489.6 (1,244.8 ) Contribution from Parent - - - - - - - Net cash (used in) financing activities (1,244.8 ) (9,010.7 ) (500.0 ) - (2,837.6 ) 2,489.6 (11,103.5 ) Effect of currency exchange rate changes on cash and cash equivalents - - - - 4.3 - 4.3 Net increase / (decrease) in cash and cash equivalents 0.1 2,087.6 - (2.0 ) 4,400.9 - 6,486.6 Cash and cash equivalents at beginning of period - 13.5 - 2.0 1,020.7 - 1,036.2 Cash and cash equivalents at end of period $ 0.1 $ 2,101.1 $ - $ - $ 5,421.6 $ - $ 7,522.8 Warner Chilcott Limited Consolidating Statement of Cash Flows For the Nine Months Ended September 30, 2015 (Unaudited; in millions) Warner Chilcott Limited (Parent Guarantor) Actavis Capital S.a.r.l. (Guarantor) Actavis Funding SCS (Issuer) Actavis Finance, LLC (Issuer and Guarantor) Non- guarantors Eliminations Consolidated Warner Chilcott Limited Cash Flows From Operating Activities: Net income / (loss) $ 4,559.2 $ (2,212.7 ) $ 0.5 $ 61.5 $ 4,488.0 $ (2,334.7 ) $ 4,561.8 Reconciliation to net cash provided by operating activities: (Earnings) / losses of equity interest subsidiaries (4,559.2 ) 2,466.7 - (242.2 ) - 2,334.7 - Depreciation - - - 0.2 183.7 - 183.9 Amortization - - - - 4,192.8 - 4,192.8 Provision for inventory reserve - - - - 108.6 - 108.6 Share-based compensation - - - 35.6 474.9 - 510.5 Deferred income tax benefit - - - - (7,470.9 ) - (7,470.9 ) In-process research and development impairments - - - - 497.6 - 497.6 Loss / (gain) on asset sales and impairments, net - - - - 57.2 - 57.2 Amortization of inventory step-up - - - - 1,019.8 - 1,019.8 Amortization of deferred financing costs - 268.8 14.8 3.1 2.5 - 289.2 Contingent consideration adjustments, including accretion - - - - 89.2 - 89.2 Dividends from subsidiaries 138.4 138.4 - - - (276.8 ) - Other, net - - - - 54.9 - 54.9 Changes in assets and liabilities (net of effects of acquisitions) (0.1 ) (4,977.5 ) (20,827.2 ) 179.8 24,634.0 - (991.0 ) Net cash provided by / (used in) operating activities 138.3 (4,316.3 ) (20,811.9 ) 38.0 28,332.3 (276.8 ) 3,103.6 Cash Flows From Investing Activities: Additions to property plant and equipment - - - (35.5 ) (315.2 ) - (350.7 ) Additions to product rights and other intangibles - - - - (91.1 ) - (91.1 ) Additions to investments (9,000.8 ) (9,000.8 ) - - (27.0 ) 18,001.6 (27.0 ) Proceeds from sale of investments and other assets - - - - 855.8 - 855.8 Proceeds from sales of property, plant and equipment - - - - 133.6 - 133.6 Acquisitions of business, net of cash acquired - - - - (35,242.7 ) - (35,242.7 ) Net cash (used in) investing activities (9,000.8 ) (9,000.8 ) - (35.5 ) (34,686.6 ) 18,001.6 (34,722.1 ) Cash Flows From Financing Activities: Proceeds from borrowings of long-term indebtedness - 5,500.0 20,955.6 - 0.8 - 26,456.4 Proceeds from borrowings on credit facility - 2,810.0 - 72.0 - 2,882.0 Debt issuance and other financing costs - (167.1 ) (143.7 ) - - - (310.8 ) Payments on debt, including capital lease obligations - (3,692.5 ) - - (634.2 ) - (4,326.7 ) Payments of contingent consideration - - - - (138.3 ) - (138.3 ) Dividends to Parent (138.4 ) (138.4 ) - - (138.4 ) 276.8 (138.4 ) Contribution from Parent 9,000.8 9,000.8 - - 9,000.8 (18,001.6 ) 9,000.8 Net cash provided by financing activities 8,862.4 13,312.8 20,811.9 - 8,162.7 (17,724.8 ) 33,425.0 Effect of currency exchange rate changes on cash and cash equivalents - - - - (5.1 ) - (5.1 ) Movement in cash held for sale - - - - - - - Net (decrease) / increase in cash and cash equivalents (0.1 ) (4.3 ) - 2.5 1,803.3 - 1,801.4 Cash and cash equivalents at beginning of period 0.1 5.5 - 1.5 237.2 - 244.3 Cash and cash equivalents at end of period $ - $ 1.2 $ - $ 4.0 $ 2,040.5 $ - $ 2,045.7

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2016
Subsequent Events [Abstract]
Subsequent Events	NOTE 22 — Subsequent Events Tobira Therapeutics, Inc. On November 1, 2016, the Company completed the acquisition of Tobira Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for non-alcoholic steatohepatitis (“NASH”) and other liver diseases for $28.35 per share, in cash, plus contingent consideration of up to $49.84 per share in CVRs that may be payable based on the successful completion of certain development, regulatory and commercial milestones, for a total potential consideration of up to approximately $1.7 billion. The acquisition adds Cenicriviroc and Evogliptin, two differentiated, complementary development programs for the treatment of the multi-factorial elements of NASH, including inflammation, metabolic syndromes and fibrosis, to Allergan's global Gastroenterology R&D pipeline. Vitae Pharmaceuticals, Inc. On October 25, 2016, the Company completed the acquisition of Vitae Pharmaceuticals, Inc., a clinical-stage biotechnology company for $21.00 per share, in cash, for a total transaction value of approximately $600.0 million. The acquisition will strengthen Allergan’s dermatology product pipeline, with the addition of VTP-43742, a Phase II first-in-class, orally active RORyt (retinoic acid receptor-related orphan receptor gamma) inhibitor for the potential treatment of psoriasis and other autoimmune disorders. VTP-43742 acts through the potent inhibition of IL-17 activity. AstraZeneca License On October 2, 2016, the Company entered into a licensing agreement with MedImmune, AstraZeneca's global biologics research and development arm, for the global rights to Brazikumab. Brazikumab is an anti-IL-23 monoclonal antibody currently in Phase IIb clinical development for the treatment of patients with moderate-to-severe Crohn's disease and is Phase II ready for ulcerative colitis and other related conditions. Under the terms of the agreement, AstraZeneca will receive $250.0 million for the exclusive, worldwide license to develop and commercialize Brazikumab and is eligible to receive contingent consideration of up to $1.27 billion, payable over a period of up to 15 years, including development and launch milestone payments of up to $435.0 million and sales-based milestone payments of $725.0 million, as well as tiered royalties on sales of the product. The transaction is expected to close in the fourth quarter of 2016 and is subject to customary closing conditions. CNS Other The Company entered into an acquisition agreement with a clinical-stage biopharmaceutical company focused on CNS. The Company agreed to pay $125.0 million upfront plus potential regulatory and commercial milestones of up to $875.0 million. The transaction may close in the fourth quarter of 2016 and is subject to customary closing conditions. Motus Therapeutics On October 27, 2016, the Company announced that it agreed to exercise its option to acquire Motus Therapeutics (“Motus”) for $200.0 million. Motus has the worldwide rights to RM-131 (relamorelin), a peptide ghrelin agonist being developed by Motus for the treatment of diabetic gastroparesis. Under the terms of the agreement, Motus is eligible to receive contingent consideration of $185.0 million in connection with the commercial launch of the product. Accelerated Share Repurchase Program and Quarterly Dividend On November 2, 2016, the Company announced that its Board of Directors has approved the expansion of its previously announced share repurchase program and the initiation of a regular quarterly cash dividend for shareholders. Under the authorization, the Company will enter into an accelerated share repurchase agreement to purchase an additional $10.0 billion of Allergan common stock. This new program follows completion of the Company’s repurchase of $5.0 billion in common stock as part of its previously announced share repurchase program. The Board of Directors has also authorized the initiation of a quarterly dividend of $0.70 per share with the first payment on March 28, 2017, to shareholders of record at the close of business on February 28, 2017.

Summary of Significant Accoun29

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2016
Accounting Policies [Abstract]
Reclassifications	Reclassifications In April 2015, the FASB issued guidance which changes the classification of debt issuance costs from being an asset on the balance sheet to netting the costs against the carrying value of the debt. As a result, the Company reclassified debt issuance costs as of December 31, 2015 by decreasing “prepaid expenses and other current assets” and “current portion of long-term debt and capital leases” by $36.3 million as well as decreasing “investments and other assets” and “long-term debt and capital leases” by $159.5 million. In addition, the Company made certain presentation reclassifications relating to segment results and guarantor financial statements.
Revenue Recognition	Revenue Recognition General Revenue from product sales is recognized when title and risk of loss to the product transfers to the customer, which is based on the transaction shipping terms. Recognition of revenue also requires reasonable assurance of collection of sales proceeds, the seller’s price to the buyer to be fixed or determinable and the completion of all performance obligations. The Company warrants products against defects and for specific quality standards, permitting the return of products under certain circumstances. Product sales are recorded net of all sales-related deductions including, but not limited to: chargebacks, trade discounts, sales returns and allowances, commercial and government rebates, customer loyalty programs and fee-for-service arrangements with certain distributors, which we refer to in the aggregate as “SRA” allowances. Royalty and commission revenue is recognized as a component of net revenues in accordance with the terms of their respective contractual agreements when collectability is reasonably assured and when revenue can be reasonably measured.
Provisions for SRAs	Provisions for SRAs As is customary in the pharmaceutical industry, our gross product sales are subject to a variety of deductions in arriving at reported net product sales. When the Company recognizes gross revenue from the sale of products, an estimate of SRA is recorded, which reduces the product revenues. Accounts receivable and/or accrued liabilities are also reduced and/or increased by the SRA amount depending on whether we have the right of offset with the customer. These provisions are estimated based on historical payment experience, historical relationship of the deductions to gross product revenues, government regulations, estimated utilization or redemption rates, estimated customer inventory levels and current contract sales terms. The estimation process used to determine our SRA provision has been applied on a consistent basis and no material revenue adjustments have been necessary to increase or decrease our reserves for SRA as a result of a significant change in underlying estimates. The Company uses a variety of methods to assess the adequacy of the SRA reserves to ensure that our financial statements are fairly stated. Chargebacks — A chargeback represents an amount payable in the future to a wholesaler for the difference between the invoice price paid by our wholesale customer for a particular product and the negotiated contract price that the wholesaler’s customer pays for that product. The chargeback provision and related reserve varies with changes in product mix, changes in customer pricing and changes to estimated wholesaler inventories. The provision for chargebacks also takes into account an estimate of the expected wholesaler sell-through levels to indirect customers at certain contract prices. The Company validates the chargeback accrual quarterly through a review of the inventory reports obtained from our largest wholesale customers. This customer inventory information is used to verify the estimated liability for future chargeback claims based on historical chargeback and contract rates. These large wholesalers represent the vast majority of the recipients of the Company’s chargeback payments. We continually monitor current pricing trends and wholesaler inventory levels to ensure the liability for future chargebacks is fairly stated. Rebates — Rebates include volume related incentives to direct and indirect customers, third-party managed care and Medicare Part D rebates, Medicaid rebates and other government rebates. Rebates are accrued based on an estimate of claims to be paid for product sold into trade by the Company. Volume rebates are generally offered to customers as an incentive to use the Company’s products and to encourage greater product sales. These rebate programs include contracted rebates based on customers’ purchases made during an applicable monthly, quarterly or annual period. The provision for third-party rebates is estimated based on our customers’ contracted rebate programs and the Company’s historical experience of rebates paid. Any significant changes to our customer rebate programs are considered in establishing the provision for rebates. The provisions for government rebates are based, in part, upon historical experience of claims submitted by the various states / authorities, contractual terms and government regulations. We monitor legislative changes to determine what impact such legislation may have on our provision. Cash Discounts — Cash discounts are provided to customers that pay within a specific period. The provision for cash discounts is estimated based upon invoice billings and historical customer payment experience. The Company’s experience of payment history is fairly consistent and most customer payments qualify for the cash discount. Returns and Other Allowances — The Company’s provision for returns and other allowances include returns, promotional allowances and loyalty cards. Consistent with industry practice, the Company maintains a returns policy that allows customers to return product for a credit. In accordance with the Company’s policy, credits for customer returns of products are applied against outstanding account activity or are settled in cash. Product exchanges are not permitted. Customer returns of product are generally not resalable. The Company’s estimate of the provision for returns is based upon historical experience and current trends of actual customer returns. Additionally, we consider other factors when estimating the current period returns provision, including levels of inventory in the distribution channel, as well as significant market changes which may impact future expected returns. Promotional allowances are credits that are issued in connection with a product launch or as an incentive for customers to carry our product. The Company establishes a reserve for promotional allowances based upon contractual terms. Loyalty cards allow the end user patients a discount per prescription and are accrued based on historical experience, contract terms and the volume of product and cards in the distribution channel. Accounts receivable balances in the Company’s consolidated financial statements are presented net of SRA estimates. SRA balances in accounts receivable were $243.8 million and $245.2 million at September 30, 2016 and December 31, 2015, respectively. SRA balances within accounts payable and accrued expenses were $1,797.3 million and $1,570.0 million at September 30, 2016 and December 31, 2015, respectively. The movements in the SRA reserve balances for continuing operations in the nine months ended September 30, 2016 are as follows ($ in millions): Balance as of December 31, 2015 $ 1,815.2 Provision to reduce gross product sales to net product sales 5,153.0 Payments and other (4,927.1 ) Balance as of September 30, 2016 $ 2,041.1 The provisions recorded to reduce gross product sales to net product sales, excluding discontinued operations, were as follows ($ in millions): Three Months Ended September 30, Nine Months Ended September 30, 2016 2015 2016 2015 Gross product sales $ 5,332.9 $ 4,918.4 $ 15,727.7 $ 12,825.8 Provisions to reduce gross product sales to net product sales (1,757.3 ) (1,503.5 ) (5,153.0 ) (3,871.3 ) Net product sales $ 3,575.6 $ 3,414.9 $ 10,574.7 $ 8,954.5 Percentage of provisions to gross sales 33.0 % 30.6 % 32.8 % 30.2 % The Company’s divested generics business also had the following type of SRA’s: • Pricing adjustments, included shelf stock adjustments which are credits issued to reflect price decreases in selling prices charged to the Company’s direct customers. Shelf stock adjustments are based upon the amount of product our customers have in their inventory at the time of an agreed-upon price reduction. The provision for shelf stock adjustments was based upon specific terms with the Company’s customers and includes estimates of existing customer inventory levels based upon their historical purchasing patterns. • Billback adjustments are credits that are issued to certain customers who purchase directly from us as well as indirectly through a wholesaler. These credits are issued in the event there was a difference between the customer’s direct and indirect contract price. The provision for billbacks was estimated based upon historical purchasing patterns of qualified customers who purchase product directly from us and supplement their purchases indirectly through our wholesale customers. The Company’s SRA reserves relating to discontinued operations were $15.5 million and $1,738.7 million as of September 30, 2016 and December 31, 2015, respectively.
Goodwill and Intangible Assets with Indefinite-Lives	Goodwill and Intangible Assets with Indefinite-Lives General The Company tests goodwill and intangible assets with indefinite-lives for impairment annually in the second quarter by comparing the fair value of each of the Company’s reporting units to the respective carrying value of the reporting units. Additionally, the Company may perform interim tests if an event occurs or circumstances change that could potentially reduce the fair value of a reporting unit below its carrying amount. The carrying value of each reporting unit is determined by assigning the assets and liabilities, including the existing goodwill and intangible assets, to those reporting units. Goodwill is considered impaired if the carrying amount of the net assets exceeds the fair value of the reporting unit. Impairment, if any, would be recorded in operating income and this could result in a material impact to net income / (loss) and earnings / (loss) per share. Acquired in-process research and development (“IPR&D”) intangible assets represent the value assigned to acquired research and development projects that, as of the date acquired, represent the right to develop, use, sell and/or offer for sale a product or other intellectual property that the Company has acquired with respect to products and/or processes that have not been completed or approved. The IPR&D intangible assets are subject to impairment testing until completion or abandonment of each project. Upon abandonment, the assets are impaired. Impairment testing requires the development of significant estimates and assumptions involving the determination of estimated net cash flows for each year for each project or product (including net revenues, cost of sales, research and development (“R&D”) costs, selling and marketing costs and other costs which may be allocated), the appropriate discount rate to select in order to measure the risk inherent in each future cash flow stream, the assessment of each asset’s life cycle, the potential regulatory and commercial success risks, and competitive trends impacting the asset and each cash flow stream as well as other factors. The major risks and uncertainties associated with the timely and successful completion of the IPR&D projects include legal risk, market risk and regulatory risk. Changes in these assumptions could result in future impairment charges. No assurances can be given that the underlying assumptions used to prepare the discounted cash flow analysis will not change or the timely completion of each project to commercial success will occur. For these and other reasons, actual results may vary significantly from estimated results. Upon successful completion of each project and approval of the product, we will make a separate determination of the useful life of the intangible, transfer the amount to currently marketed products (“CMP”) and amortization expense will be recorded over the estimated useful life. Annual Testing In connection with the realignment of the Company’s operating segments in the second quarter of 2016, goodwill was reallocated to reporting units under the new segment structure. The Company evaluated goodwill for six reporting units during the second quarter of 2016. The Company performed its annual impairment test utilizing long-term growth rates for its reporting units ranging from 0% to 2.5% in its estimation of fair value and discount rates ranging from 8.0% to 9.5%. The factors used in evaluating goodwill for impairment are subject to change and are tracked against historical results by management. Changes in the key assumptions by management can change the results of testing. The Company determined there was no impairment associated with goodwill. During 2016, the Company tested its indefinite-lived trade name intangible assets for impairment noting no impairment. The Company performed its annual IPR&D impairment test during 2016 noting the impairment of an international eye care pipeline project of $35.0 million based on a decrease in projected cash flows due to market conditions as well as an impairment of $20.0 million for a specified indication of a Botox therapeutic product based on a decrease in projected cash flows due to a decline in market demand assumptions. In addition, during the nine months ended September 30, 2016, the Company impaired IPR&D projects relating to women’s healthcare for $24.0 million and osteoarthritis for approximately $190.0 million based on clinical results and during the three and nine months ended September 30, 2016, the Company impaired a gastroenterology project for $42.0 million based on the lack of future availability of active pharmaceutical ingredients. During the nine months ended September 30, 2015, the Company recorded a $197.6 million impairment related to IPR&D for select projects as the Company revised its sales forecast of certain assets as well as the timing of the launch of certain projects in connection with the Company’s annual review. In addition, during the three and nine months ended September 30, 2015, the Company made the decision to abandon a select IPR&D asset (acquired in connection with the Allergan Acquisition) based on review of research studies, resulting in an impairment of the full asset value of $300.0 million.
Litigation and Contingencies	Litigation and Contingencies The Company is involved in various legal proceedings in the normal course of its business, including product liability litigation, intellectual property litigation, employment litigation and other litigation. Additionally, the Company, in consultation with its counsel, assesses the need to record a liability for contingencies on a case-by-case basis in accordance with FASB Accounting Standards Codification (“ASC”) Topic 450 “Contingencies” (“ASC 450”). Accruals are recorded when the Company determines that a loss related to a matter is both probable and reasonably estimable. These accruals are adjusted periodically as assessment efforts progress or as additional information becomes available. Acquired contingencies in business combinations are recorded at fair value to the extent determinable, otherwise in accordance with ASC 450. Refer to “NOTE 20 — Commitments and Contingencies” for more information.
Earnings Per Share ("EPS")	Earnings Per Share (“EPS”) The Company computes EPS in accordance with ASC Topic 260, “Earnings Per Share” (“ASC 260”) and related guidance, which requires two calculations of EPS to be disclosed: basic and diluted. Basic EPS is computed by dividing net (loss) / income by the weighted average ordinary shares outstanding during a period. Diluted EPS is based on the treasury stock method and includes the effect from potential issuance of ordinary shares, such as shares issuable pursuant to the exercise of stock options and restricted stock units. Diluted EPS also includes the impact of ordinary share equivalents to be issued upon the mandatory conversion of the Company’s preferred shares. Ordinary share equivalents have been excluded where their inclusion would be anti-dilutive. A reconciliation of the numerators and denominators of basic and diluted EPS consisted of the following ($ in millions, except per share amounts): Three Months Ended September 30, Nine Months Ended September 30, 2016 2015 2016 2015 Net (loss) / income: Net (loss) attributable to ordinary shareholders excluding income from discontinued operations, net of tax $ (451.5 ) $ (946.0 ) $ (1,108.0 ) $ (2,318.0 ) Income from discontinued operations, net of tax 15,601.9 6,177.6 15,873.2 6,701.7 Net income attributable to ordinary shareholders $ 15,150.4 $ 5,231.6 $ 14,765.2 $ 4,383.7 Basic weighted average ordinary shares outstanding 392.7 393.6 394.4 358.9 Basic EPS: Continuing operations $ (1.15 ) $ (2.40 ) $ (2.81 ) $ (6.46 ) Discontinued operations $ 39.73 $ 15.69 $ 40.25 $ 18.67 Net income per share $ 38.58 $ 13.29 $ 37.44 $ 12.21 Diluted weighted average ordinary shares outstanding 392.7 393.6 394.4 358.9 Diluted EPS: Continuing operations $ (1.15 ) $ (2.40 ) $ (2.81 ) $ (6.46 ) Discontinued operations $ 39.73 $ 15.69 $ 40.25 $ 18.67 Net income per share $ 38.58 $ 13.29 $ 37.44 $ 12.21 Stock awards to purchase 4.4 million and 4.7 million ordinary shares for the three and nine months ended September 30, 2016, respectively, were outstanding, but not included in the computation of diluted EPS, because the awards were anti-dilutive for continuing operations and as such the treatment for discontinued operations is also anti-dilutive. The weighted average impact of ordinary share equivalents of 17.6 million for the three and nine months ended September 30, 2016, respectively, which are anticipated to result from the mandatory conversion of the Company’s preferred shares were not included in the calculation of diluted EPS as their impact would be anti-dilutive. As of September 30, 2016, the Company has repurchased 12.8 million shares under the Company’s share repurchase program. The impact of the share repurchase on basic EPS was 3.2 million weighted average shares and 1.1 million weighted average shares for the three and nine months ended September 30, 2016, respectively. Refer to “NOTE 16 –Shareholder’s Equity” for further discussion on the Company’s Share Repurchase Program. Stock awards to purchase 5.1 million and 5.2 million ordinary shares during the three and nine months ended September 30, 2015, respectively, were outstanding, but not included in the computation of diluted EPS, because the impact of the awards were anti-dilutive for continuing operations and as such the treatment for discontinued operations is also anti-dilutive. The weighted average impact of ordinary share equivalents of 17.6 million and 13.6 million for the three and nine months ended September 30, 2015, respectively, which are anticipated to result from the mandatory conversion of the Company’s preferred shares were not included in the calculation of diluted EPS as their impact would be anti-dilutive.
Restructuring Costs	Restructuring Costs The Company records liabilities for costs associated with exit or disposal activities in the period in which the liability is incurred. In accordance with existing benefit arrangements, employee severance costs are accrued when the restructuring actions are probable and estimable. Costs for one-time termination benefits in which the employee is required to render service until termination in order to receive the benefits are recognized ratably over the future service period. The Company also incurs costs with contract terminations and costs of transferring products as part of restructuring activities. Refer to “NOTE 19 — Business Restructuring Charges” for more information.
Recent Accounting Pronouncements	Recent Accounting Pronouncements On May 28, 2014, the FASB issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers (Topic 606), with an effective date for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period, for public business entities, certain not-for-profit entities, and certain employee benefit plans. The effective date for ASU 2014-09 was deferred by one year through the issuance of ASU 2015-14, Revenue from Contracts with Customers – Deferral of the Effective Date, to annual reporting periods beginning after December 15, 2017, including interim reporting periods within that reporting period. Earlier application is permitted only as of annual reporting periods beginning after December 15, 2016, including interim reporting periods within that reporting period. The Company is evaluating the impact, if any, the pronouncement will have on our financial positions and results of operations. In January 2016, the FASB issued Accounting Standards Update 2016-01, which changes the requirement to require equity securities (including other ownership interests, such as partnerships, unincorporated joint ventures, and limited liability companies) to be measured at fair value with changes in the fair value recognized through net income. This update is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. The adoption of this guidance is not anticipated to have a material impact on the Company’s financial position or results of operations. In February 2016, the FASB issued Accounting Standards Update 2016-02, which states that a lessee should recognize the assets and liabilities that arise from leases. This update is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The Company is evaluating the impact, if any, the pronouncement will have on our financial positions and results of operations. In March 2016, the FASB issued ASU No. 2016-07: Simplifying the Transition to the Equity Method of Accounting. This guidance eliminates the requirement to retroactively adopt the equity method of accounting when there is an increase in the level of ownership interest or degree of influence. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2016. Management believes that the adoption of this guidance will not have a material impact on our financial statements. In March 2016, the FASB has issued ASU No. 2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net). The amendments relate to when another party, along with the entity, is involved in providing a good or service to a customer. Topic 606 Revenue from Contracts with Customers requires an entity to determine whether the nature of its promise is to provide that good or service to the customer (i.e., the entity is a principal) or to arrange for the good or service to be provided to the customer by the other party (i.e., the entity is an agent). The amendments are intended to improve the operability and understandability of the implementation guidance on principal versus agent considerations. The effective date and transition of these amendments is the same as the effective date and transition requirements in Topic 606. The Company is evaluating the impact, if any, the pronouncement will have on our financial positions and results of operations. In March 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The amendments are intended to improve the accounting for employee share-based payments and affect all organizations that issue share-based payment awards to their employees. Several aspects of the accounting for share-based payment award transactions are simplified, including: (a) income tax consequences; (b) classification of awards as either equity or liabilities; and (c) classification on the statement of cash flows. The amendments are effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods. Early adoption is permitted for any organization in any interim or annual period. The Company is evaluating the impact the pronouncement will have on our financial positions and results of operations . In April 2016, the FASB issued Accounting Standards Update (“ASU”) No. 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing. The amendments clarify the following two aspects of Topic 606: (a) identifying performance obligations; and (b) the licensing implementation guidance. The amendments do not change the core principle of the guidance in Topic 606. The effective date and transition requirements for the amendments are the same as the effective date and transition requirements in Topic 606. The Company is evaluating the impact, if any, the pronouncement will have on our financial positions and results of operations. In May 2016, the FASB issued ASU No. 2016-12, Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients. The amendments do not change the core revenue recognition principle in Topic 606. The amendments provide clarifying guidance in certain narrow areas and add some practical expedients, which include assessing the specific collectability criterion and accounting for contracts that do not meet the criteria for Step 1 to determine whether a contract is valid and represents a genuine transaction; presentation of sales taxes and other similar taxes collected from customers; noncash consideration; contract modifications at transition; and completed contracts at transition. The amendments also clarify that an entity that retrospectively applies the guidance in Topic 606 to each prior reporting period is not required to disclose the effect of the accounting change for the period of adoption, however, an entity is still required to disclose the effect of the changes on any prior periods retrospectively adjusted. The effective date and transition requirements for the amendments are the same as the effective date and transition requirements for Topic 606. The Company is evaluating the impact, if any, the pronouncement will have on our financial positions and results of operations. In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The ASU is intended to improve financial reporting by requiring timelier recording of credit losses on loans and other financial instruments held by financial institutions and other organizations. In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments, to address diversity in how certain cash receipts and cash payments are presented and classified in the statement of cash flows. The amendments provide guidance on specific cash flow issues including: (1) Debt Prepayment or Debt Extinguishment Costs; (2) Settlement of Zero-Coupon Debt Instruments or Other Debt Instruments with Coupon Interest Rates That Are Insignificant in Relation to the Effective Interest Rate of the Borrowing; (3) Contingent Consideration Payments Made after a Business Combination; (4) Proceeds from the Settlement of Insurance Claims; (5) Proceeds from the Settlement of Corporate-Owned Life Insurance Policies, including Bank-Owned; (6) Life Insurance Policies; (7) Distributions Received from Equity Method Investees; (8) Beneficial Interests in Securitization Transactions; and (9) Separately Identifiable Cash Flows and Application of the Predominance Principle. The amendments are effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. The amendments should be applied using a retrospective transition method to each period presented. If it is impracticable to apply the amendments retrospectively for some of the issues, the amendments for those issues would be applied prospectively as of the earliest date practicable. The Company is evaluating the impact, if any, the pronouncement will have on our statement of cash flows. In October 2016, the FASB issued Accounting Standards Update No. 2016-16, Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other Than Inventory .

Reconciliation of Warner Chil30

Reconciliation of Warner Chilcott Limited Results to Allergan plc Results (Tables)	9 Months Ended
	Sep. 30, 2016
Adjusted Earnings Before Interest Taxes Depreciation And Amortization And Other Non Cash Items [Abstract]
Summary of Financial Position Reconciliation Results of Warner Chilcott Limited to Allergan Plc	As of September 30, 2016 As of December 31, 2015 Allergan plc Warner Chilcott Limited Difference Allergan plc Warner Chilcott Limited Difference Cash and cash equivalents $ 7,554.7 $ 7,522.8 $ 31.9 $ 1,096.0 $ 1,036.2 $ 59.8 Prepaid expenses and other current assets 771.7 769.6 2.1 495.3 492.8 2.5 Accounts payable and accrued liabilities 5,425.4 4,995.8 429.6 4,148.6 4,094.5 54.1
Summary of Operations Reconciliation Results of Warner Chilcott Limited to Allergan Plc	Three Months Ended September 30, 2016 Nine Months Ended September 30, 2016 Allergan plc Warner Chilcott Limited Difference Allergan plc Warner Chilcott Limited Difference General and administrative expenses $ 361.2 $ 312.2 $ 49.0 $ 1,033.9 $ 966.2 $ 67.7 Operating (loss) (266.4 ) (217.4 ) (49.0 ) (925.5 ) (857.8 ) (67.7 ) Other income / (expense) 33.6 33.6 - 184.2 34.2 150.0 (Loss) before income taxes and noncontrolling interest (539.0 ) (490.0 ) (49.0 ) (1,720.7 ) (1,803.0 ) 82.3 Net (loss) from continuing operations, net of tax (380.1 ) (331.1 ) (49.0 ) (894.9 ) (977.2 ) 82.3 Net income 15,221.8 15,270.8 (49.0 ) 14,978.3 14,896.0 82.3 Dividends on preferred stock 69.6 - 69.6 208.8 - 208.8 Net income attributable to ordinary shareholder/members 15,150.4 15,269.0 (118.6 ) 14,765.2 14,891.7 (126.5 ) Three Months Ended September 30, 2015 Nine Months Ended September 30, 2015 Allergan plc Warner Chilcott Limited Difference Allergan plc Warner Chilcott Limited Difference General and administrative expenses $ 339.1 $ 333.8 $ 5.3 $ 1,188.0 $ 1,174.9 $ 13.1 Operating (loss) (1,377.4 ) (1,372.1 ) (5.3 ) (2,561.5 ) (2,548.4 ) (13.1 ) (Loss) before income taxes and noncontrolling interest (1,713.9 ) (1,708.6 ) (5.3 ) (3,644.0 ) (3,630.9 ) (13.1 ) Net (loss) from continuing operations, net of tax (875.0 ) (869.7 ) (5.3 ) (2,153.0 ) (2,139.9 ) (13.1 ) Net income 5,302.6 5,307.9 (5.3 ) 4,548.7 4,561.8 (13.1 ) Dividends on preferred stock 69.6 - 69.6 162.4 - 162.4 Net income attributable to ordinary shareholder/members 5,231.6 5,306.5 (74.9 ) 4,383.7 4,559.2 (175.5 )

Summary of Significant Accoun31

Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2016
Summary Of Significant Accounting Policies [Line Items]
Summary of Activity in Gross-to-Net Revenue Excluding Discontinued Operations	The provisions recorded to reduce gross product sales to net product sales, excluding discontinued operations, were as follows ($ in millions): Three Months Ended September 30, Nine Months Ended September 30, 2016 2015 2016 2015 Gross product sales $ 5,332.9 $ 4,918.4 $ 15,727.7 $ 12,825.8 Provisions to reduce gross product sales to net product sales (1,757.3 ) (1,503.5 ) (5,153.0 ) (3,871.3 ) Net product sales $ 3,575.6 $ 3,414.9 $ 10,574.7 $ 8,954.5 Percentage of provisions to gross sales 33.0 % 30.6 % 32.8 % 30.2 %
Earnings Per Share	A reconciliation of the numerators and denominators of basic and diluted EPS consisted of the following ($ in millions, except per share amounts): Three Months Ended September 30, Nine Months Ended September 30, 2016 2015 2016 2015 Net (loss) / income: Net (loss) attributable to ordinary shareholders excluding income from discontinued operations, net of tax $ (451.5 ) $ (946.0 ) $ (1,108.0 ) $ (2,318.0 ) Income from discontinued operations, net of tax 15,601.9 6,177.6 15,873.2 6,701.7 Net income attributable to ordinary shareholders $ 15,150.4 $ 5,231.6 $ 14,765.2 $ 4,383.7 Basic weighted average ordinary shares outstanding 392.7 393.6 394.4 358.9 Basic EPS: Continuing operations $ (1.15 ) $ (2.40 ) $ (2.81 ) $ (6.46 ) Discontinued operations $ 39.73 $ 15.69 $ 40.25 $ 18.67 Net income per share $ 38.58 $ 13.29 $ 37.44 $ 12.21 Diluted weighted average ordinary shares outstanding 392.7 393.6 394.4 358.9 Diluted EPS: Continuing operations $ (1.15 ) $ (2.40 ) $ (2.81 ) $ (6.46 ) Discontinued operations $ 39.73 $ 15.69 $ 40.25 $ 18.67 Net income per share $ 38.58 $ 13.29 $ 37.44 $ 12.21
Continuing Operations [Member]
Summary Of Significant Accounting Policies [Line Items]
Movements in SRA Reserve Balances	The movements in the SRA reserve balances for continuing operations in the nine months ended September 30, 2016 are as follows ($ in millions): Balance as of December 31, 2015 $ 1,815.2 Provision to reduce gross product sales to net product sales 5,153.0 Payments and other (4,927.1 ) Balance as of September 30, 2016 $ 2,041.1

Acquisitions and Other Agreem32

Acquisitions and Other Agreements (Tables)	9 Months Ended
	Sep. 30, 2016
Pro Forma Results of Businesses Acquired	The pro forma results of the businesses acquired that materially impacted the reported results of the Company are as follows (unaudited; $ in millions except per share information): Nine Months Ended September 30, 2015 As reported Allergan Acquisition Pro Forma Net Revenue $ 9,081.2 $ 1,523.0 $ 10,604.2 Net income attributable to ordinary shareholders $ 4,383.7 $ 377.7 $ 4,761.4 Net (loss) per share Basic $ 12.21 $ 11.58 Diluted $ 12.21 $ 11.58
ForSight VISION 5 [Member]
Summary of Fair Values of Assets Acquired and Liabilities Assumed at Acquisition Date	The following table summarizes the final fair values of the assets acquired and liabilities assumed at the acquisition date ($ in millions): Amount Cash and cash equivalents $ 1.0 IPR&D intangible asset 158.0 Goodwill 54.2 Current liabilities (15.8 ) Contingent consideration (79.8 ) Deferred tax liabilities, net (43.1 ) Net assets acquired $ 74.5
AqueSys, Inc. [Member]
Summary of Fair Values of Assets Acquired and Liabilities Assumed at Acquisition Date	The following table summarizes the final fair values of the assets acquired and liabilities assumed at the acquisition date ($ in millions): Amount Cash and cash equivalents $ 6.2 Current assets 1.2 IPR&D intangible assets 302.0 Intangible assets 221.0 Goodwill 138.5 Current liabilities (6.9 ) Contingent consideration (193.5 ) Deferred tax liabilities, net (169.6 ) Net assets acquired $ 298.9
Kythera Biopharmaceuticals [Member]
Summary of Fair Values of Assets Acquired and Liabilities Assumed at Acquisition Date	The following table summarizes the final fair values of the assets acquired and liabilities assumed at the acquisition date ($ in millions): Amount Cash and cash equivalents $ 78.1 Marketable securities 79.9 Inventory 18.2 Other current assets 14.5 IPR&D intangible assets 320.0 Intangible assets 2,120.0 Goodwill 328.7 Other current liabilities (48.6 ) Deferred tax, net (766.7 ) Outstanding indebtedness (54.6 ) Net assets acquired $ 2,089.5
Allergan, Inc. [Member]
Summary of Transaction and Integration Costs	As a result of the Allergan Acquisition, the Company incurred the following transaction and integration costs in the three months ended September 30, 2016 and 2015, respectively ($ in millions): Three Months Ended September 30, 2016 Three Months Ended September 30, 2015 Cost of sales Stock-based compensation acquired for Legacy Allergan employees $ 2.2 $ 4.7 Acquisition, integration and restructuring related charges 6.6 0.3 Research and development Stock-based compensation acquired for Legacy Allergan employees 9.3 16.6 Acquisition, integration and restructuring related charges 6.8 17.5 Selling and marketing Stock-based compensation acquired for Legacy Allergan employees 15.8 23.6 Acquisition, integration and restructuring related charges (1.2 ) 5.4 General and administrative Stock-based compensation acquired for Legacy Allergan employees 9.9 16.8 Acquisition, integration and restructuring related charges 50.4 65.7 Total transaction and integration costs $ 99.8 $ 150.6 As a result of the Allergan Acquisition, the Company incurred the following transaction and integration costs in the nine months ended September 30, 2016 and 2015, respectively ($ in millions): Nine Months Ended September 30, 2016 Nine Months Ended September 30, 2015 Cost of sales Stock-based compensation acquired for Legacy Allergan employees $ 7.4 $ 18.9 Acquisition, integration and restructuring related charges 12.4 12.4 Research and development Stock-based compensation acquired for Legacy Allergan employees 32.6 108.2 Acquisition, integration and restructuring related charges 10.6 83.7 Selling and marketing Stock-based compensation acquired for Legacy Allergan employees 53.0 86.5 Acquisition, integration and restructuring related charges 11.7 65.9 General and administrative Stock-based compensation acquired for Legacy Allergan employees 28.2 243.0 Acquisition-related expenditures - 65.5 Acquisition, integration and restructuring related charges 144.0 231.4 Other (expense) income Bridge loan facilities expense - (264.9 ) Interest rate lock - 30.9 Total transaction and integration costs $ 299.9 $ 1,149.5
Forest Laboratories Inc. [Member]
Summary of Transaction and Integration Costs	As a result of the Forest Acquisition, the Company incurred the following transaction and integration costs in the three months ended September 30, 2016 and 2015, respectively ($ in millions): Three Months Ended September 30, 2016 Three Months Ended September 30, 2015 Cost of sales Stock-based compensation acquired for Forest employees $ 0.2 $ 0.9 Research and development Stock-based compensation acquired for Forest employees 2.0 5.5 Acquisition, integration and restructuring related charges 0.2 0.4 Selling and marketing Stock-based compensation acquired for Forest employees 6.9 9.4 Acquisition, integration and restructuring related charges - 0.4 General and administrative Stock-based compensation acquired for Forest employees 5.9 10.7 Acquisition, integration and restructuring related charges 0.5 19.6 Total transaction and integration costs $ 15.7 $ 46.9 As a result of the Forest Acquisition, the Company incurred the following transaction and integration costs in the three and nine months ended September 30, 2016 and 2015, respectively ($ in millions): Nine Months Ended September 30, 2016 Nine Months Ended September 30, 2015 Cost of sales Stock-based compensation acquired for Forest employees $ 1.4 $ 3.6 Acquisition, integration and restructuring related charges - 1.1 Research and development Stock-based compensation acquired for Forest employees 10.9 30.0 Acquisition, integration and restructuring related charges 0.5 9.2 Selling and marketing Stock-based compensation acquired for Forest employees 21.7 37.8 Acquisition, integration and restructuring related charges - 17.3 General and administrative Stock-based compensation acquired for Forest employees 24.6 43.0 Acquisition, integration and restructuring related charges 1.7 66.8 Total transaction and integration costs $ 60.8 $ 208.8

Discontinued Operations (Tables

Discontinued Operations (Tables)	9 Months Ended
	Sep. 30, 2016
Discontinued Operations And Disposal Groups [Abstract]
Schedule of Reconciliation of Proceeds Received in Teva Transaction to Gain Recognized in Income from Discontinued Operations	The Company notes the following reconciliation of the proceeds received in the Teva Transaction to the gain recognized in income from discontinued operations ($ in millions): Net cash proceeds received $ 33,304.5 August 2, 2016 fair value of Teva shares 5,038.6 Total Proceeds $ 38,343.1 Net assets sold to Teva, excluding cash (12,076.7 ) Other comprehensive income disposed (1,544.8 ) Deferral of proceeds relating to additional elements of agreements with Teva (518.9 ) Pre-tax gain on sale of generics business $ 24,202.7 Income taxes (8,321.2 ) Net gain on sale of generics business $ 15,881.5
Summary of Key Financial Results of Businesses Income from Discontinued Operations	The following table presents key financial results of the businesses included in "Income from discontinued operations" for the three and nine months ended September 30, 2016 and 2015 ($ in millions): Three Months Ended September 30, Nine Months Ended September 30, 2016 2015 2016 2015 Net revenues $ 756.5 $ 1,984.8 $ 4,504.3 $ 6,362.3 Operating expenses: Cost of sales (excludes amortization and impairment of acquired intangibles including product rights) 531.0 1,243.3 2,798.3 3,647.1 Research and development 37.3 98.9 269.6 317.4 Selling and marketing 69.1 159.3 352.6 542.2 General and administrative 90.3 204.0 399.4 528.3 Amortization - 36.1 4.8 333.9 Asset sales and impairments, net - 3.2 - 54.1 Total operating expenses 727.7 1,744.8 3,824.7 5,423.0 Operating income 28.8 240.0 679.6 939.3 Other (expense) income, net 15,881.5 (0.3 ) 15,881.1 (8.4 ) Provision / (benefit) for income taxes 308.4 (5,937.9 ) 687.5 (5,770.8 ) Net income from discontinued operations $ 15,601.9 $ 6,177.6 $ 15,873.2 $ 6,701.7
Schedule of Aggregate Carrying Amounts of Major Classes of Assets and Liabilities	The following table presents the aggregate carrying amounts of the major classes of assets and liabilities related to the businesses ($ in millions): September 30, 2016 December 31, 2015 Assets: Accounts receivable, net $ 164.3 $ 2,365.9 Inventories 270.8 1,390.7 Prepaid expenses and other current assets 16.3 329.7 Property, plant and equipment, net 23.6 1,398.2 Investments and other assets 6.6 42.2 Non-current deferred tax assets - 162.1 Product rights and other intangibles 90.7 3,014.8 Goodwill 86.3 6,096.0 Total assets $ 658.6 $ 14,799.6 Liabilities: Accounts payable and accrued expenses $ 223.7 $ 1,656.7 Income taxes payable - 34.4 Debt and capital leases - 5.8 Other long-term liabilities 3.9 92.0 Other taxes payable - 69.0 Long-term deferred tax liabilities 19.9 370.7 Total liabilities $ 247.5 $ 2,228.6
Schedule of Depreciation Amortization and Significant Operating and Investing Noncash Items of Discontinued Operations	The depreciation, amortization and significant operating and investing non-cash items of the discontinued operations were as follows ($ in millions): Nine Months Ended September 30, 2016 2015 Depreciation from discontinued operations $ 2.1 $ 86.4 Amortization from discontinued operations 4.8 333.9 Capital expenditures 85.3 182.6 Deferred income taxes expense / (benefit) 5,893.4 (6,301.6 )

Share-Based Compensation (Table

Share-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2016
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Schedule of Fair Value Assumptions of Options based on Black-Scholes Valuation Model	Using the Black-Scholes valuation model, the fair value of options is based on the following assumptions: 2016 Grants 2015 Grants 2015 Acquired Awards Dividend yield 0% 0% 0% Expected volatility 27.0% 26.0-29.0% 26.0-27.0% Risk-free interest rate 1.3%-1.6% 1.9-2.1% 0.1-2.1% Expected term (years) 7.0 7.0 - 7.5 up to 6.9
Share-Based Compensation Expense Recognized in Company's Results of Operations	Share-based compensation expense recognized in the Company’s results of operations for the three months ended September 30, 2016 and 2015 were as follows ($ in millions): Three Months Ended September 30, 2016 2015 Equity based compensation awards $ 81.1 $ 109.8 Cash-settled equity awards in connection with the ForSight Acquisition 3.1 - Non equity-settled awards other 7.4 20.4 Total stock-based compensation expense $ 91.6 $ 130.2 Share-based compensation expense recognized in the Company’s results of operations for the nine months ended September 30, 2016 and 2015 were as follows ($ in millions): Nine Months Ended September 30, 2016 2015 Equity-based compensation awards $ 269.9 $ 510.5 Cash-settled equity awards in connection with the ForSight Acquisition 3.1 - Cash-settled equity awards in connection with the Allergan Acquisition - 127.1 Non equity-settled awards other 14.0 20.4 Total stock-based compensation expense $ 287.0 $ 658.0
Summary of Impact of Accelerations and Step-ups Relating to Acquisition Accounting Treatment of Outstanding Awards	Included in the equity-based compensation awards for the three and nine months ended September 30, 2016 and 2015 is the impact of accelerations and step-ups relating to the acquisition accounting treatment of outstanding awards acquired in the Allergan and Forest acquisitions as follows ($ in millions): Three Months Ended Nine Months Ended September 30, 2016 September 30, 2015 September 30, 2016 September 30, 2015 Allergan Acquisition $ 26.8 $ 44.6 $ 86.8 $ 269.8 Forest Acquisition 10.3 18.2 37.5 89.1 Total $ 37.1 $ 62.8 $ 124.3 $ 358.9
Summary of Equity Award Activity for Unvested Restricted Stock and Stock Units	The following is a summary of equity award activity for unvested restricted stock and stock units in the period from December 31, 2015 through September 30, 2016: (in millions, except per share data) Shares Weighted Average Grant Date Fair Value Weighted Average Remaining Contractual Term (Years) Aggregate Grant Date Fair Value Restricted shares / units outstanding at December 31, 2015 2.0 $ 209.90 1.7 $ 419.8 Granted 0.6 281.26 168.8 Vested (0.7 ) (168.55 ) (118.0 ) Forfeited (0.3 ) (228.53 ) (70.1 ) Restricted shares / units outstanding at September 30, 2016 1.6 $ 254.37 1.7 $ 400.5
Summary of Equity Award Activity for Non-Qualified Options to Purchase Ordinary Shares	The following is a summary of equity award activity for non-qualified options to purchase ordinary shares in the period from December 31, 2015 through September 30, 2016: (in millions, except per share data) Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Outstanding, December 31, 2015 10.5 $ 149.11 6.7 $ 1,707.8 Granted 0.2 280.72 Exercised (1.2 ) (113.07 ) Cancelled (0.2 ) (153.42 ) Outstanding, September 30, 2016 9.3 $ 112.17 6.0 $ 1,098.8 Vested and expected to vest at September 30, 2016 8.8 $ 112.89 6.0 $ 1,036.1

Reportable Segments (Tables)

Reportable Segments (Tables)	9 Months Ended
	Sep. 30, 2016
Schedule of Net Revenues, Operating Expenses Contribution Information by Reportable Segment	Segment net revenues, segment operating expenses and segment contribution information consisted of the following for the three months ended September 30, 2016 and 2015 ($ in millions): Three Months Ended September 30, 2016 US Specialized US General Therapeutics Medicine International Total Net revenues $ 1,453.2 $ 1,488.1 $ 697.8 $ 3,639.1 Operating expenses: Cost of sales (1) 69.2 215.1 95.1 379.4 Selling and marketing 292.4 292.8 188.2 773.4 General and administrative 41.2 42.3 28.0 111.5 Segment Contribution $ 1,050.4 $ 937.9 $ 386.5 $ 2,374.8 Contribution margin 72.3 % 63.0 % 55.4 % 65.3 % Corporate 372.0 Research and development 622.8 Amortization 1,609.1 In-process research and development impairments 42.0 Asset sales and impairments, net (4.7 ) Operating (loss) $ (266.4 ) Operating margin (7.3 )% (1) Three Months Ended September 30, 2015 US Specialized US General Therapeutics Medicine International Total Net revenues $ 1,296.6 $ 1,552.0 $ 660.6 $ 3,509.2 Operating expenses: Cost of sales (1) 71.6 227.5 108.3 407.4 Selling and marketing 236.2 262.8 155.8 654.8 General and administrative 17.2 17.5 33.3 68.0 Segment Contribution $ 971.6 $ 1,044.2 $ 363.2 $ 2,379.0 Contribution margin 74.9 % 67.3 % 55.0 % 67.8 % Corporate 642.5 Research and development 1,260.5 Amortization 1,557.8 In-process research and development impairments 300.0 Asset sales and impairments, net (4.4 ) Operating (loss) $ (1,377.4 ) Operating margin (39.3 )% (1) Segment net revenues, segment operating expenses and segment contribution information consisted of the following for the nine months ended September 30, 2016 and 2015 ($ in millions): Nine Months Ended September 30, 2016 US Specialized US General Therapeutics Medicine International Total Net revenues $ 4,240.8 $ 4,390.9 $ 2,128.1 $ 10,759.8 Operating expenses: Cost of sales (1) 215.0 649.6 309.3 1,173.9 Selling and marketing 844.8 902.8 582.7 2,330.3 General and administrative 126.4 128.2 86.5 341.1 Segment Contribution $ 3,054.6 $ 2,710.3 $ 1,149.6 $ 6,914.5 Contribution margin 72.0 % 61.7 % 54.0 % 64.3 % Corporate 1,052.8 Research and development 1,662.4 Amortization 4,831.9 In-process research and development impairments 316.9 Asset sales and impairments, net (24.0 ) Operating (loss) (925.5 ) Operating margin (8.6 )% (1) Nine Months Ended September 30, 2015 US Specialized US General Therapeutics Medicine International Total Net revenues $ 2,889.6 $ 4,803.7 $ 1,496.4 $ 9,189.7 Operating expenses: Cost of sales (1) 160.2 674.0 243.8 1,078.0 Selling and marketing 525.0 917.1 394.2 1,836.3 General and administrative 46.1 88.8 75.7 210.6 Segment Contribution $ 2,158.3 $ 3,123.8 $ 782.7 $ 6,064.8 Contribution margin 74.7 % 65.0 % 52.3 % 66.0 % Corporate 2,338.8 Research and Development 1,927.9 Amortization 3,858.9 In-process research and development impairments 497.6 Asset sales and impairments, net 3.1 Operating (loss) (2,561.5 ) Operating margin (27.9 )% (1)
Schedule of Reconciliation of Net Revenues for Operating Segments	The following is a reconciliation of net revenues for the operating segments to the Company’s net revenues for the three months ended September 30, 2016 and 2015 ($ in millions): Three Months Ended September 30, 2016 2015 Segment net revenues $ 3,639.1 $ 3,509.2 Corporate revenues (16.9 ) (39.7 ) Net revenues $ 3,622.2 $ 3,469.5 The following is a reconciliation of net revenues for the operating segments to the Company’s net revenues for the nine months ended September 30, 2016 and 2015 ($ in millions): Nine Months Ended September 30, 2016 2015 Segment net revenues $ 10,759.8 $ 9,189.7 Corporate revenues (53.5 ) (108.5 ) Net revenues $ 10,706.3 $ 9,081.2
Schedule Of Revenue Classified By Products	The following tables present global net revenues for the top products of the Company for the three and nine months ended September 30, 2016 and 2015 ($ in millions): Three Months Ended September 30, Global U.S. International 2016 2015 2016 2015 2016 2015 Botox ® $ 689.7 $ 604.4 $ 496.3 $ 435.6 $ 193.4 $ 168.8 Restasis ® 371.8 328.3 356.4 312.8 15.4 15.5 Fillers 201.8 167.6 105.0 89.7 96.8 77.9 Linzess ® ® 168.7 118.6 164.4 117.5 4.3 1.1 Lumigan ® ® 164.9 157.9 78.3 71.7 86.6 86.2 Bystolic ® 164.4 155.7 163.9 155.3 0.5 0.4 Namenda XR ® 146.9 214.5 146.9 214.5 - - Alphagan ® ® 134.7 120.8 93.4 81.4 41.3 39.4 Lo Loestrin ® 105.7 90.8 105.7 89.8 - 1.0 Estrace ® 98.6 87.4 98.6 87.4 - - Viibryd ® ® 87.6 84.5 87.6 84.5 - - Breast Implants 86.7 85.5 51.1 50.9 35.6 34.6 Asacol ® ® 86.4 157.2 72.2 141.9 14.2 15.3 Minastrin ® 84.9 74.4 84.9 74.4 - - Aczone ® 69.0 48.0 69.0 48.0 - - Ozurdex ® 64.3 51.6 20.9 17.6 43.4 34.0 Carafate ® ® 57.0 52.9 56.4 52.9 0.6 - Namenda ® 2.9 54.9 2.9 54.9 - - Other Products Revenues ** 859.9 857.9 694.2 671.5 165.7 186.4 Less product sold through Anda Distribution business (23.7 ) (43.4 ) (23.7 ) (43.4 ) - - Total Net Revenues ** $ 3,622.2 $ 3,469.5 $ 2,924.4 $ 2,808.9 $ 697.8 $ 660.6 ** Includes an adjustment of $31.7 million recorded in the three months ended September 30, 2015 related to International other product revenues for the six months ended June 30, 2015 that were reported in discontinued operations instead of continuing operations during the six months ended June 30, 2015. The impact of this out-of-period adjustment is not material to the six months ended June 30, 2015 or the three months ended September 30, 2015, and had no impact on the nine months ended September 30, 2015. Nine Months Ended September 30, Global U.S. International 2016 2015 2016 2015 2016 2015 Botox ® $ 2,046.9 $ 1,319.8 $ 1,454.0 $ 926.4 $ 592.9 $ 393.4 Restasis ® 1,076.1 683.2 1,026.4 651.4 49.7 31.8 Fillers 629.5 388.2 325.3 206.7 304.2 181.5 Lumigan ® ® 509.6 355.6 240.4 165.9 269.2 189.7 Namenda XR ® 486.5 569.8 486.5 569.8 - - Bystolic ® 479.1 476.9 477.8 476.1 1.3 0.8 Linzess ® ® 464.7 328.0 452.0 325.1 12.7 2.9 Alphagan ® ® 401.6 272.3 274.3 184.9 127.3 87.4 Asacol ® ® 338.4 455.6 297.9 407.8 40.5 47.8 Lo Loestrin ® 296.0 253.3 296.0 251.7 - 1.6 Estrace ® 276.4 229.4 276.4 229.4 - - Breast Implants 261.7 198.4 149.2 112.8 112.5 85.6 Viibryd ® ® 252.7 244.8 252.6 244.8 0.1 - Minastrin ® 248.9 195.9 247.5 195.3 1.4 0.6 Ozurdex ® 192.0 109.6 61.8 36.9 130.2 72.7 Carafate ® ® 169.4 153.4 167.7 153.4 1.7 - Aczone ® 156.1 114.3 156.1 114.3 - - Namenda ® 12.8 532.9 12.8 532.9 - - Other Products Revenues 2,487.9 2,313.6 2,003.5 1,913.0 484.4 400.6 Less product sold through Anda Distribution business (80.0 ) (113.8 ) (80.0 ) (113.8 ) - - Total Net Revenues $ 10,706.3 $ 9,081.2 $ 8,578.2 $ 7,584.8 $ 2,128.1 $ 1,496.4
US Specialized Therapeutics [Member]
Schedule Of Top Product Sales and Net Revenues by Segment	The following table presents top product sales and net revenues for the US Specialized Therapeutics segment for the three and nine months ended September 30, 2016 and 2015 ($ in millions): Three Months Ended September 30, Nine Months Ended September 30, 2016 2015 2016 2015 Total Eye Care $ 608.5 $ 539.9 $ 1,777.6 $ 1,213.2 Restasis ® 356.4 312.8 1,026.4 651.4 Alphagan ® ® 93.4 81.4 274.3 184.9 Lumigan ® ® 78.3 71.7 240.4 165.9 Ozurdex ® 20.9 17.6 61.8 36.9 Eye Drops 50.2 45.3 140.1 131.8 Other Eye Care 9.3 11.1 34.6 42.3 Total Medical Aesthetics 388.9 340.1 1,182.6 761.4 Facial Aesthetics 293.7 249.0 893.3 547.9 Botox ® 174.5 159.3 529.8 341.2 Fillers 105.0 89.7 325.3 206.7 Kybella ® 14.2 - 38.2 - Plastic Surgery 52.2 54.3 153.1 122.5 Breast Implants 51.1 50.9 149.2 112.8 Other Plastic Surgery 1.1 3.4 3.9 9.7 Skin Care 43.0 36.8 136.2 91.0 SkinMedica ® 25.8 23.0 81.5 51.6 Latisse ® 17.2 13.8 54.7 39.4 Total Medical Dermatology 116.1 107.8 282.2 249.4 Aczone ® 69.0 48.0 156.1 114.3 Tazorac ® 27.5 27.6 68.0 65.7 Botox ® 16.3 15.0 48.9 35.5 Other Medical Dermatology 3.3 17.2 9.2 33.9 Total Neuroscience and Urology 330.7 291.4 963.8 637.2 Botox ® 305.5 261.3 875.3 549.7 Rapaflo ® 25.2 30.1 87.6 87.5 Other Neuroscience and Urology - - 0.9 - Other Revenues 9.0 17.4 34.6 28.4 Net revenues $ 1,453.2 $ 1,296.6 $ 4,240.8 $ 2,889.6
US General Medicine [Member]
Schedule Of Top Product Sales and Net Revenues by Segment	The following table presents top product sales and revenues for the US General Medicine segment for the three and nine months ended September 30, 2016 and 2015 ($ in millions): Three Months Ended September 30, Nine Months Ended September 30, 2016 2015 2016 2015 Total Central Nervous System (CNS) $ 325.5 $ 406.7 $ 964.6 $ 1,485.1 Namenda XR ® 146.9 214.5 486.5 569.8 Viibryd ® ® 87.6 84.5 252.6 244.8 Saphris ® 40.8 51.1 123.6 134.3 Vraylar ™ 32.4 - 51.1 - Namzaric ® 14.9 1.7 38.0 3.3 Namenda ® 2.9 54.9 12.8 532.9 Total Gastrointestinal (GI) 431.4 398.6 1,277.0 1,138.4 Linzess ® 164.4 117.5 452.0 325.1 Asacol ® ® 72.2 141.9 297.9 407.8 Carafate ® ® 56.4 52.9 167.7 153.4 Zenpep ® 52.5 43.1 145.1 121.5 Canasa ® ® 47.2 34.6 135.0 102.2 Viberzi ® 30.9 - 55.3 - Other GI 7.8 8.6 24.0 28.4 Total Women's Health 305.3 268.0 865.1 716.7 Lo Loestrin ® 105.7 89.8 296.0 251.7 Estrace ® 98.6 87.4 276.4 229.4 Minastrin ® 84.9 74.4 247.5 195.3 Liletta ® 4.4 5.8 15.0 10.7 Other Women's Health 11.7 10.6 30.2 29.6 Total Anti-Infectives 52.5 52.3 167.1 138.3 Teflaro ® 33.3 35.8 101.9 105.3 Dalvance ® 10.3 4.9 26.7 11.3 Avycaz ® 4.8 7.5 26.9 12.9 Other Anti-Infectives 4.1 4.1 11.6 8.8 Established Brands 319.3 400.5 1,038.8 1,267.7 Bystolic ® 163.9 155.3 477.8 476.1 Armour Thyroid 39.1 34.7 121.8 88.9 Savella ® 28.1 29.0 74.1 80.6 Lexapro ® 15.6 17.8 50.8 53.6 Enablex ® 1.9 17.2 14.7 51.5 PacPharma 6.2 27.4 49.7 56.6 Other Established Brands 64.5 119.1 249.9 460.4 Other Revenues 54.1 25.9 78.3 57.5 Net revenues $ 1,488.1 $ 1,552.0 $ 4,390.9 $ 4,803.7
International [Member]
Schedule Of Top Product Sales and Net Revenues by Segment	The following table presents top product sales and net revenues for the International segment for the three and nine months ended September 30, 2016 and 2015 ($ in millions): Three Months Ended September 30, Nine Months Ended September 30, 2016 2015 2016 2015 Total Eye Care $ 294.2 $ 281.5 $ 904.4 $ 623.7 Lumigan ® ® 86.6 86.2 269.2 189.7 Alphagan ® ® 41.3 39.4 127.3 87.4 Ozurdex ® 43.4 34.0 130.2 72.7 Optive ® 25.6 23.2 75.7 51.9 Restasis ® 15.4 15.5 49.7 31.8 Other Eye Drops 42.1 44.0 131.2 99.5 Other Eye Care 39.8 39.2 121.1 90.7 Total Medical Aesthetics 251.0 214.8 780.0 509.9 Facial Aesthetics 212.6 176.5 658.7 416.4 Botox ® 115.3 98.6 352.9 234.9 Fillers 96.8 77.9 304.2 181.5 Belkyra ® ® 0.5 - 1.6 - Plastic Surgery 35.8 34.6 112.9 85.6 Breast Implants 35.6 34.6 112.5 85.6 Earfold ™ 0.2 - 0.4 - Skin Care 2.6 3.7 8.4 7.9 Botox ® 134.6 155.5 399.0 321.5 Botox ® 78.1 70.2 240.0 158.5 Asacol ® ® 14.2 15.3 40.5 47.8 Constella ® 4.3 1.1 12.7 2.9 Other Products ** 38.0 68.9 105.8 112.3 Other Revenues 18.0 8.8 44.7 41.3 Net revenues ** $ 697.8 $ 660.6 $ 2,128.1 $ 1,496.4 ** Includes an adjustment of $31.7 million recorded in the three months ended September 30, 2015 related to International other product revenues for the six months ended June 30, 2015 that were reported in discontinued operations instead of continuing operations during the six months ended June 30, 2015. The impact of this out-of-period adjustment is not material to the six months ended June 30, 2015 or the three months ended September 30, 2015, and had no impact on the nine months ended September 30, 2015.

Inventories (Tables)

Inventories (Tables)	9 Months Ended
	Sep. 30, 2016
Inventory Disclosure [Abstract]
Schedule of Inventories	Inventories consisted of the following ($ in millions): September 30, December 31, 2016 2015 Raw materials $ 276.2 $ 242.4 Work-in-process 142.2 149.7 Finished goods 389.5 451.9 807.9 844.0 Less: inventory reserves 102.4 86.5 Total Inventories $ 705.5 $ 757.5

Investments and Other Assets (T

Investments and Other Assets (Tables)	9 Months Ended
	Sep. 30, 2016
Investments All Other Investments [Abstract]
Marketable Securities, Including Cash and Cash Equivalents, Other Investments and Other Assets	Investments in marketable securities, including those classified in cash and cash equivalents due to the maturity term of the instrument, other investments and other assets consisted of the following ($ in millions): September 30, 2016 December 31, 2015 Marketable securities: U.S. Treasury and agency securities — maturing within one year $ 15,463.2 $ 9.3 Teva shares 4,374.4 - Total marketable securities $ 19,837.6 $ 9.3 Investments and other assets: Legacy Allergan deferred executive compensation investments $ 114.3 $ 118.1 Equity method investments 13.0 17.3 Cost method investments 15.0 16.7 Other long-term investments 70.5 78.2 Taxes receivable 41.4 39.6 Other assets 86.9 138.8 Total investments and other assets $ 341.1 $ 408.7
Investments in Securities	Investments in securities as of September 30, 2016 included the following: Investments in Securities as of September 30, 2016: Level 1 Carrying amount Unrecognized gain Unrecognized loss Estimated fair value Cash & cash equivalents Marketable securities Money market funds $ 4,649.4 $ - $ - $ 4,649.4 $ 4,649.4 $ - Commercial paper 1,357.7 - - 1,357.7 1,357.7 - Certificates of deposit 250.0 - - 250.0 250.0 - Total $ 6,257.1 $ - $ - $ 6,257.1 $ 6,257.1 $ - Level 2 Carrying amount Unrecognized gain Unrecognized loss Estimated fair value Cash & cash equivalents Marketable securities Commercial paper 11,155.1 6.9 - 11,162.0 - 11,162.0 Investment in Teva ordinary shares 5,038.6 - (664.2 ) 4,374.4 - 4,374.4 Certificates of deposit 4,301.0 0.2 - 4,301.2 - 4,301.2 Total $ 20,494.7 $ 7.1 $ (664.2 ) $ 19,837.6 $ - $ 19,837.6

Accounts Payable and Accrued 38

Accounts Payable and Accrued Expenses (Tables)	9 Months Ended
	Sep. 30, 2016
Payables And Accruals [Abstract]
Summary of Accounts Payable and Accrued Expenses	Accounts payable and accrued expenses consisted of the following ($ in millions): September 30, 2016 December 31, 2015 Accrued expenses: Accrued third-party rebates $ 1,513.6 $ 1,281.6 Accrued payroll and related benefits 446.2 401.0 Contractual commitments related to the Teva Transaction 501.6 - Accrued stock repurchases 400.0 - Accrued pharmaceutical fees 388.1 162.2 Current portion of contingent consideration obligations 349.1 79.9 Accrued returns 283.7 288.4 Interest payable 170.4 312.0 Royalties payable 167.2 119.1 Litigation-related reserves and legal fees 139.9 191.7 Accrued R&D expenditures 111.7 384.1 Accrued severance, retention and other shutdown costs 83.7 108.5 Accrued non-provision taxes 47.2 98.1 Accrued selling and marketing expenditures 29.6 127.2 Dividends payable 24.2 24.0 Other accrued expenses 472.7 354.9 Total accrued expenses $ 5,128.9 $ 3,932.7 Accounts payable 296.5 215.9 Total Accounts Payable and Accrued Expenses $ 5,425.4 $ 4,148.6

Goodwill, Product Rights and 39

Goodwill, Product Rights and Other Intangible Assets (Tables)	9 Months Ended
	Sep. 30, 2016
Goodwill And Intangible Assets Disclosure [Abstract]
Schedule of Goodwill	The Company’s goodwill by segment consisted of the following ($ in millions): US Therapeutics US General Medicine International Total Balance as of December 31, 2015 $ 18,347.2 $ 21,340.5 $ 6,777.5 $ 46,465.2 Additions through acquisitions 54.2 - - 54.2 Foreign exchange and other adjustments - (26.6 ) 133.0 106.4 Balance as of September 30, 2016 $ 18,401.4 $ 21,313.9 $ 6,910.5 $ 46,625.8
Schedule of Cost Basis on Product Rights and Other Intangible Assets	Product rights and other intangible assets consisted of the following ($ in millions): Cost Basis Balance as of December 31, 2015 Acquisitions Impairments IPR&D to CMP Transfers Disposals/ Held for Sale/ Other Foreign Currency Translation Balance as of September 30, 2016 Intangibles with definite lives: Product rights and other related intangibles $ 64,366.0 $ 41.6 $ - $ 1,342.4 $ (194.6 ) $ 108.6 $ 65,664.0 Trade name 690.0 - - - - - 690.0 Total definite-lived intangible assets $ 65,056.0 $ 41.6 $ - $ 1,342.4 $ (194.6 ) $ 108.6 $ 66,354.0 Intangibles with indefinite lives: IPR&D $ 11,128.2 $ 158.0 $ (316.9 ) $ (1,342.4 ) $ - $ 15.9 $ 9,642.8 Total indefinite-lived intangible assets $ 11,128.2 $ 158.0 $ (316.9 ) $ (1,342.4 ) $ - $ 15.9 $ 9,642.8 Total product rights and related intangibles $ 76,184.2 $ 199.6 $ (316.9 ) $ - $ (194.6 ) $ 124.5 $ 75,996.8 Accumulated Balance as of December 31, 2015 Amortization Disposals/ Held for Sale/ Other Foreign Currency Translation Balance as of September 30, 2016 Intangibles with definite lives: Product rights and other related intangibles $ (8,288.5 ) $ (4,773.6 ) $ 176.9 $ 28.9 $ (12,856.3 ) Trade name (59.5 ) (58.3 ) - - (117.8 ) Total definite-lived intangible assets $ (8,348.0 ) $ (4,831.9 ) $ 176.9 $ 28.9 $ (12,974.1 ) Total product rights and $ (8,348.0 ) $ (4,831.9 ) $ 176.9 $ 28.9 $ (12,974.1 ) Net Product Rights and Other Intangibles $ 67,836.2 $ 63,022.7
Schedule of Annual Amortization Expense on Product Rights and Other Related Intangibles	Assuming no additions, disposals or adjustments are made to the carrying values and/or useful lives of the intangible assets, annual amortization expense on product rights and other related intangibles as of September 30, 2016 over the remainder of 2016 and each of the next five years is estimated to be as follows ($ in millions): Amortization Expense 2016 remaining $ 1,610.9 2017 $ 6,474.4 2018 $ 5,964.4 2019 $ 5,857.4 2020 $ 5,606.1 2021 $ 4,732.6

Long-Term Debt and Capital Le40

Long-Term Debt and Capital Leases (Tables)	9 Months Ended
	Sep. 30, 2016
Debt Disclosure [Abstract]
Schedule of Long-Term Debt and Capital Leases	Total debt and capital leases consisted of the following ($ in millions): Balance As of Fair Market Value As of September 30, 2016 December 31, 2015 September 30, 2016 December 31, 2015 Senior Notes: Floating Rate Notes $500.0 million floating rate notes due September 1, 2016 $ - $ 500.0 $ - $ 500.5 $500.0 million floating rate notes due March 12, 2018 500.0 500.0 504.0 499.6 $500.0 million floating rate notes due March 12, 2020 500.0 500.0 509.0 496.2 1,000.0 1,500.0 1,013.0 1,496.3 Fixed Rate Notes $800.0 million 5.750% notes due April 1, 2016 - 800.0 - 808.4 $1,000.0 million 1.850% notes due March 1, 2017 1,000.0 1,000.0 1,002.3 1,001.5 $500.0 million 1.300% notes due June 15, 2017 500.0 500.0 499.6 496.3 $1,200.0 million 1.875% notes due October 1, 2017 1,200.0 1,200.0 1,204.2 1,196.0 $3,000.0 million 2.350% notes due March 12, 2018 3,000.0 3,000.0 3,031.0 3,004.6 $250.0 million 1.350% notes due March 15, 2018 250.0 250.0 248.9 244.9 $1,050.0 million 4.375% notes due February 1, 2019 1,050.0 1,050.0 1,105.8 1,099.5 $500.0 million 2.450% notes due June 15, 2019 500.0 500.0 508.2 494.4 $400.0 million 6.125% notes due August 14, 2019 400.0 400.0 447.4 444.2 $3,500.0 million 3.000% notes due March 12, 2020 3,500.0 3,500.0 3,614.5 3,505.1 $650.0 million 3.375% notes due September 15, 2020 650.0 650.0 680.3 656.6 $750.0 million 4.875% notes due February 15, 2021 750.0 750.0 830.2 807.4 $1,200.0 million 5.000% notes due December 15, 2021 1,200.0 1,200.0 1,345.6 1,299.4 $3,000.0 million 3.450% notes due March 15, 2022 3,000.0 3,000.0 3,149.5 3,006.8 $1,700.0 million 3.250% notes due October 1, 2022 1,700.0 1,700.0 1,759.6 1,669.6 $350.0 million 2.800% notes due March 15, 2023 350.0 350.0 348.1 327.7 $1,200.0 million 3.850% notes due June 15, 2024 1,200.0 1,200.0 1,274.0 1,202.6 $4,000.0 million 3.800% notes due March 15, 2025 4,000.0 4,000.0 4,227.2 3,984.6 $2,500.0 million 4.550% notes due March 15, 2035 2,500.0 2,500.0 2,653.1 2,462.2 $1,000.0 million 4.625% notes due October 1, 2042 1,000.0 1,000.0 1,066.8 956.1 $1,500.0 million 4.850% notes due June 15, 2044 1,500.0 1,500.0 1,653.0 1,483.6 $2,500.0 million 4.750% notes due March 15, 2045 2,500.0 2,500.0 2,739.8 2,452.7 31,750.0 32,550.0 33,389.1 32,604.2 Total Senior Notes Gross 32,750.0 34,050.0 34,402.1 34,100.5 Unamortized premium 182.8 225.9 - - Unamortized discount (98.7 ) (107.4 ) - - Total Senior Notes Net 32,834.1 34,168.5 34,402.1 34,100.5 Term Loan Indebtedness: WC Term Loan WC October 1, 2016 - 191.5 WC Five Year Tranche variable rate debt maturing October 1, 2018 - 498.8 - 690.3 ACT Term Loan 2017 Term Loan variable rate debt maturing October 31, 2017 - 572.1 2019 Term Loan variable rate debt maturing July 1, 2019 - 1,700.0 - 2,272.1 AGN Term Loan AGN Three Year Tranche variable rate debt maturing March 17, 2018 - 2,750.0 AGN Five Year Tranche variable rate debt maturing March 17, 2020 - 2,543.8 - 5,293.8 Total Term Loan Indebtedness - 8,256.2 Other Indebtedness Revolver Borrowings - 200.0 Debt Issuance Costs (151.5 ) (195.8 ) Other 85.2 97.4 Total Other Borrowings (66.3 ) 101.6 Capital Leases 2.2 4.1 Total Indebtedness $ 32,770.0 $ 42,530.4
Schedule of Annual Debt Maturities	As of September 30, 2016, annual debt maturities were as follows ($ in millions): Total Payments 2016 remaining $ - 2017 2,700.0 2018 3,750.0 2019 1,950.0 2020 4,650.0 2021 1,950.0 2022 and after 17,750.0 $ 32,750.0 Capital leases 2.2 Debt issuance costs (151.5 ) Other short-term borrowings 85.2 Unamortized premium 182.8 Unamortized discount (98.7 ) Total Indebtedness $ 32,770.0

Other Long-Term Liabilities (Ta

Other Long-Term Liabilities (Tables)	9 Months Ended
	Sep. 30, 2016
Other Liabilities Disclosure [Abstract]
Summary of Other Long-Term Liabilities	Other long-term liabilities consisted of the following ($ in millions): September 30, December 31, 2016 2015 Acquisition related contingent consideration liabilities $ 602.0 $ 788.1 Long-term pension and post retirement liability 190.1 222.1 Legacy Allergan deferred executive compensation 114.3 117.9 Product warranties 28.1 28.4 Long-term contractual obligations 26.8 26.4 Long-term severance and restructuring liabilities 24.9 34.9 Deferred revenue 16.9 18.2 Other long-term liabilities 19.6 26.0 Total other long-term liabilities $ 1,022.7 $ 1,262.0

Income Taxes (Tables)

Income Taxes (Tables)	9 Months Ended
	Sep. 30, 2016
Income Tax Disclosure [Abstract]
Summary of Acquired U.S. Entities and Taxable Years that are Currently under Audit by IRS	The Company has several concurrent audits still pending with the IRS as set forth below: IRS Audits Tax Years Actavis W.C. Holding, Inc. 2013 and 2014 Forest Laboratories, Inc. 2010, 2011, 2012, 2013 and 2014 Warner Chilcott Corporation 2010, 2011, 2012 and 2013 Durata Therapeutics Inc. 2012 Allergan, Inc. 2009, 2010, 2011, 2012 and 2013

Shareholders' Equity (Tables)

Shareholders' Equity (Tables)	9 Months Ended
	Sep. 30, 2016
Equity [Abstract]
Summary of Changes in Shareholders' Equity	A summary of the changes in shareholders’ equity for the nine months ended September 30, 2016 consisted of the following ($ in millions): Allergan plc Shareholders’ equity as of December 31, 2015 $ 76,591.4 Increase in additional paid in capital for share-based compensation plans 269.9 Net income attributable to ordinary shareholders 14,765.2 Proceeds from stock plans 138.0 Excess tax benefit from employee stock plans 26.6 Other comprehensive income of the Teva Transaction 1,544.8 Repurchase of ordinary shares, including accrued repurchases, under the Share Repurchase Program (3,089.9 ) Repurchase of ordinary shares (68.7 ) Other comprehensive income (451.4 ) Shareholders’ equity as of September 30, 2016 $ 89,725.9 Warner Chilcott Limited Members' equity as of December 31, 2015 $ 75,573.7 Net income attributable to members 14,891.7 Dividend to Parent (1,244.8 ) Other comprehensive income (451.4 ) Other comprehensive income of the Teva Transaction 1,544.8 Members' equity as of September 30, 2016 $ 90,314.0
Summary of Movements in Accumulated Other Comprehensive Income /(Loss)	The movements in accumulated other comprehensive income / (loss) for the three and nine months ended September 30, 2016 were as follows ($ in millions): Foreign Currency Translation Items Unrealized (losses) / gains net of tax Total Accumulated Other Comprehensive Income / (Loss) Balance as of December 31, 2015 $ (564.3 ) $ 70.2 $ (494.1 ) Other comprehensive gain / (loss) before reclassifications into general and administrative 192.9 (15.9 ) 177.0 Total other comprehensive income / (loss) 192.9 (15.9 ) 177.0 Balance as of June 30, 2016 $ (371.4 ) $ 54.3 $ (317.1 ) Other comprehensive gain / (loss) before reclassifications into general and administrative (19.1 ) 54.9 35.8 Impact of Teva Transaction 1,540.6 4.2 1,544.8 Investment in Teva ordinary shares fair value movement - (664.2 ) (664.2 ) Total other comprehensive income / (loss) 1,521.5 (605.1 ) 916.4 Balance as of September 30, 2016 $ 1,150.1 $ (550.8 ) $ 599.3 The movements in accumulated other comprehensive (loss) / income for the three and nine months ended September 30, 2015 were as follows ($ in millions): Foreign Currency Translation Items Unrealized gains net of tax Total Accumulated Other Comprehensive Income / (Loss) Balance as of December 31, 2014 $ (434.4 ) $ (31.0 ) $ (465.4 ) Other comprehensive income before reclassifications into general and administrative 451.4 3.6 455.0 Total other comprehensive income 451.4 3.6 455.0 Balance as of June 30, 2015 $ 17.0 $ (27.4 ) $ (10.4 ) Other comprehensive (loss) / income before reclassifications into general and administrative (42.4 ) 7.5 (34.9 ) Total other comprehensive (loss) / income (42.4 ) 7.5 (34.9 ) Balance as of September 30, 2015 $ (25.4 ) $ (19.9 ) $ (45.3 )

Fair Value Measurement (Tables)

Fair Value Measurement (Tables)	9 Months Ended
	Sep. 30, 2016
Fair Value Disclosures [Abstract]
Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis	Assets and liabilities measured at fair value or disclosed at fair value on a recurring basis as of September 30, 2016 and December 31, 2015 consisted of the following ($ in millions): Fair Value Measurements as of September 30, 2016 Using: Total Level 1 Level 2 Level 3 Assets: Cash equivalents $ 6,257.1 $ 6,257.1 $ - $ - Marketable securities 15,463.2 - 15,463.2 - Deferred executive compensation investments 114.3 92.0 22.3 - Foreign currency derivatives 52.0 - 52.0 - Investment in Teva ordinary shares 4,374.4 - 4,374.4 - Investments and other 98.5 98.5 - - Total assets $ 26,359.5 $ 6,447.6 $ 19,911.9 $ - Liabilities: Deferred executive compensation liabilities 114.3 92.0 22.3 - Contingent consideration obligations 951.1 - - 951.1 Total liabilities $ 1,065.4 $ 92.0 $ 22.3 $ 951.1 Fair Value Measurements as of December 31, 2015 Using: Total Level 1 Level 2 Level 3 Assets: Marketable securities $ 29.9 $ 29.9 $ - $ - Deferred executive compensation investments 118.1 102.3 15.8 - Foreign currency derivatives 73.2 - 73.2 - Investments and other 112.2 112.2 - - Total assets $ 333.4 $ 244.4 $ 89.0 $ - Liabilities: Deferred executive compensation liabilities 117.9 102.1 15.8 - Contingent consideration obligations 868.0 - - 868.0 Total liabilities $ 985.9 $ 102.1 $ 15.8 $ 868.0
Summary of Notional Principal and Fair Value of Company's Outstanding Foreign Currency Derivative Financial Instruments	At September 30, 2016 and December 31, 2015, the notional principal and fair value of the Company’s outstanding foreign currency derivative financial instruments were as follows ($ in millions, except average contract rate or strike amount): September 30, 2016 December 31, 2015 Notional Principal Average Rate or Strike Amount Notional Principal Average Contract Rate or Strike Amount Foreign currency forward exchange contracts: (Receive U.S. dollar/pay foreign currency) Russian ruble $ 21.6 63.73 $ 18.8 72.97 $ 21.6 $ 18.8 Estimated fair value $ 0.1 $ (0.3 ) Foreign currency sold - put options: Euro $ 259.9 1.41 $ 340.5 1.41 $ 259.9 $ 340.5 Estimated fair value $ 51.9 $ 73.5
Change in Fair Value of Contingent Consideration Obligations	Changes in the fair value of the contingent consideration obligations, including accretion, are recorded in our consolidated statements of operations as follows ($ in millions): Three Months Ended Expense / (income) September 30, 2016 September 30, 2015 Cost of sales $ 10.4 $ 20.6 Research and development 5.5 60.1 General and administrative - 0.6 Total $ 15.9 $ 81.3 Nine Months Ended Expense / (income) September 30, 2016 September 30, 2015 Cost of sales $ 13.4 $ 53.1 Research and development 65.8 34.7 General and administrative 0.1 (0.5 ) Total $ 79.3 $ 87.3
Summary of Changes in Fair Value of all Financial Assets and Liabilities Measured at Fair Value on Recurring Basis Using Significant Unobservable Inputs	The table below provides a summary of the changes in fair value, including net transfers in and/or out, of all financial assets and liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) for the nine months ended September 30, 2016 and 2015 ($ in millions): Balance as of December 31, 2015 Net transfers in to (out of) Level 3 Purchases and settlements, net Net accretion and fair value adjustments Foreign currency translation Balance as of September 30, 2016 Liabilities: Contingent consideration obligations $ 868.0 $ - $ 3.7 $ 79.3 $ 0.1 $ 951.1 Balance as of December 31, 2014 Net transfers in to (out of) Level 3 Purchases and settlements, net Net accretion and fair value adjustments Foreign currency translation Balance as of September 30, 2015 Liabilities: Contingent consideration obligations $ 373.8 $ - $ 317.8 $ 87.3 $ (5.0 ) $ 773.9
Schedule of Contingent Consideration Obligations	During the nine months ended September 30, 2016, the following activity in contingent consideration obligations was incurred ($ in millions): Balance as of December 31, 2015 Acquisitions Fair Value Adjustments and Accretion Payments and Other Balance as of September 30, 2016 Allergan Acquisition $ 329.7 $ - $ 41.4 $ (40.0 ) $ 331.1 AqueSys Acquisition 193.5 - 13.8 - 207.3 Medicines 360 acquisition 144.1 - 13.6 (0.5 ) 157.2 Oculeve Acquisition 90.0 - 8.8 - 98.8 ForSight Acquisition - 79.8 - - 79.8 Metrogel acquisition 30.9 - (7.5 ) (4.5 ) 18.9 Forest Acquisition 20.4 - (4.7 ) (1.0 ) 14.7 Uteron acquisition 8.2 - - 0.1 8.3 Durata Acquisition 24.5 - 2.2 (26.7 ) - Other 26.7 - 11.7 (3.4 ) 35.0 Total $ 868.0 $ 79.8 $ 79.3 $ (76.0 ) $ 951.1

Business Restructuring Charges

Business Restructuring Charges (Tables)	9 Months Ended
	Sep. 30, 2016
Restructuring And Related Activities [Abstract]
Schedule of Activity Related to Business Restructuring and Facility Rationalization Activities	During 2016, activity related to our business restructuring and facility rationalization activities primarily related to the cost optimization initiatives in conjunction with the Allergan Acquisition. Restructuring activities for the nine months ended September 30, 2016 were as follows ($ in millions): Severance Retention Share-Based Compensation Other Total Reserve balance at December 31, 2015 $ 96.7 $ - $ 48.6 $ 145.3 Charged to expense Cost of sales 3.5 0.5 5.2 9.2 Research and development 6.5 0.9 0.7 8.1 Selling and marketing 8.0 9.3 1.3 18.6 General and administrative 17.4 9.7 9.0 36.1 Total expense 35.4 20.4 16.2 72.0 Cash payments (62.9 ) - (25.1 ) (88.0 ) Other reserve impact - (20.4 ) (0.3 ) (20.7 ) Reserve balance at September 30, 2016 $ 69.2 $ - $ 39.4 $ 108.6

Warner Chilcott Limited ("WCL46

Warner Chilcott Limited ("WCL") Guarantor and Non-Guarantor Condensed Consolidating Financial Information (Tables) - Warner Chilcott Acquisition [Member]	9 Months Ended
	Sep. 30, 2016
Consolidating Balance Sheets	Warner Chilcott Limited Consolidating Balance Sheets As of September 30, 2016 (Unaudited; in millions) Current assets: Warner Chilcott Limited (Parent Guarantor) Actavis Capital S.a.r.l. (Guarantor) Actavis Funding SCS (Issuer) Actavis Guarantor) Non- guarantors Eliminations Consolidated Warner Chilcott Limited Cash and cash equivalents $ 0.1 $ 2,101.1 $ - $ - $ 5,421.6 $ - $ 7,522.8 Marketable securities - - - - 19,837.6 - 19,837.6 Accounts receivable, net - - - - 2,398.5 - 2,398.5 Receivable from Parents - - - - 2,828.7 - 2,828.7 Inventories, net - - - - 705.5 - 705.5 Intercompany receivables - 22,969.8 3,400.3 78.7 23,471.2 (49,920.0 ) - Prepaid expenses and other current assets - 9.2 - 21.3 739.1 - 769.6 Current assets held for sale - - - - 455.9 - 455.9 Total current assets 0.1 25,080.1 3,400.3 100.0 55,858.1 (49,920.0 ) 34,518.6 Property, plant and equipment, net - - - - 1,566.3 - 1,566.3 Investments and other assets - - - 16.4 324.7 - 341.1 Investment in subsidiaries 90,318.4 90,267.6 - 73,710.3 - (254,296.3 ) - Non current intercompany receivables - 46,647.4 22,483.3 - 57,859.6 (126,990.3 ) - Non current receivables from Parents - - - - 3,985.0 - 3,985.0 Non current assets held for sale - - - - 207.2 - 207.2 Deferred tax assets - - - - 120.7 - 120.7 Product rights and other intangibles - - - - 63,022.7 - 63,022.7 Goodwill - - - - 46,625.8 - 46,625.8 Total assets $ 90,318.5 $ 161,995.1 $ 25,883.6 $ 73,826.7 $ 229,570.1 $ (431,206.6 ) $ 150,387.4 Current liabilities: Accounts payable and accrued expenses - - 74.1 - 4,921.7 - 4,995.8 Intercompany payables - 12,347.1 1,796.5 9,327.6 26,448.8 (49,920.0 ) - Payable to Parents - 5,000.0 - - 1,202.2 - 6,202.2 Income taxes payable - - - - 784.6 - 784.6 Current portion of long-term debt and capital leases - - 1,527.3 - 64.5 - 1,591.8 Current liabilities held for sale - - - - 223.7 - 223.7 Total current liabilities - 17,347.1 3,397.9 9,327.6 33,645.5 (49,920.0 ) 13,798.1 Long-term debt and capital leases - - 22,483.3 4,275.6 4,419.3 - 31,178.2 Other long-term liabilities - - - - 1,022.7 - 1,022.7 Long-term intercompany payables - 57,859.6 - - 69,130.7 (126,990.3 ) - Long-term payables to Parents - - - - 419.0 - 419.0 Non current liabilities held for sale - - - 23.8 23.8 Other taxes payable - - - - 815.6 - 815.6 Deferred tax liabilities - - - - 12,811.5 - 12,811.5 Total liabilities - 75,206.7 25,881.2 13,603.2 122,288.1 (176,910.3 ) 60,068.9 Total equity / (deficit) 90,318.5 86,788.4 2.4 60,223.5 107,282.0 (254,296.3 ) 90,318.5 Total liabilities and equity $ 90,318.5 $ 161,995.1 $ 25,883.6 $ 73,826.7 $ 229,570.1 $ (431,206.6 ) $ 150,387.4 Warner Chilcott Limited Consolidating Balance Sheets As of December 31, 2015 ($ in millions) Current assets: Warner Chilcott Limited (Parent Guarantor) Actavis Capital S.a.r.l. (Guarantor) Actavis Funding SCS (Issuer) Actavis Finance, LLC (Issuer and Guarantor) Non- guarantors Eliminations Consolidated Warner Chilcott Limited Cash and cash equivalents $ - $ 13.5 $ - $ 2.0 $ 1,020.7 $ - $ 1,036.2 Marketable securities - - - - 9.3 - 9.3 Accounts receivable, net - - - - 2,125.4 - 2,125.4 Receivable from Parents - - - - 457.3 - 457.3 Inventories - - - - 757.5 - 757.5 Intercompany receivables - 55,415.1 25,225.6 302.4 60,464.0 (141,407.1 ) - Prepaid expenses and other current assets - 5.0 - 6.1 481.7 - 492.8 Current assets held for sale - - - - 4,095.6 - 4,095.6 Total current assets - 55,433.6 25,225.6 310.5 69,411.5 (141,407.1 ) 8,974.1 Property, plant and equipment, net - - - 34.3 1,497.0 - 1,531.3 Investments and other assets - - - 33.6 375.1 - 408.7 Investment in subsidiaries 75,571.6 79,597.3 - 73,037.7 - (228,206.6 ) - Non current intercompany receivables - 39,584.1 - - 41,400.8 (80,984.9 ) - Non current receivables from Parents - - - - - - - Non current assets held for sale - - - 45.8 10,667.5 - 10,713.3 Deferred tax assets - - - - 49.5 - 49.5 Product rights and other intangibles - - - - 67,836.2 - 67,836.2 Goodwill - - - - 46,465.2 - 46,465.2 Total assets $ 75,571.6 $ 174,615.0 $ 25,225.6 $ 73,461.9 $ 237,702.8 $ (450,598.6 ) $ 135,978.3 Current liabilities: Accounts payable and accrued expenses - 3.9 210.5 171.5 3,708.6 - 4,094.5 Intercompany payables - 51,148.7 526.3 8,789.0 80,943.1 (141,407.1 ) - Payable to Parents - - - - 1,466.8 - 1,466.8 Income taxes payable - - - 44.1 9.6 - 53.7 Current portion of long-term debt and capital leases - 749.1 475.5 - 1,171.9 - 2,396.5 Current liabilities held for sale - - - 23.3 1,669.9 - 1,693.2 Total current liabilities - 51,901.7 1,212.3 9,027.9 88,969.9 (141,407.1 ) 9,704.7 Long-term debt and capital leases - 6,995.0 24,013.0 4,269.4 4,856.5 - 40,133.9 Other long-term liabilities - - - - 1,262.0 - 1,262.0 Long-term intercompany payables - 40,944.8 - 456.0 39,584.1 (80,984.9 ) - Long-term payables to Parents - - - - - - - Non current liabilities for sale - - - - 535.4 - 535.4 Other taxes payable - - - 72.1 729.8 - 801.9 Deferred tax liabilities - - - - 7,968.8 - 7,968.8 Total liabilities - 99,841.5 25,225.3 13,825.4 143,906.5 (222,392.0 ) 60,406.7 Total equity / (deficit) 75,571.6 74,773.5 0.3 59,636.5 93,796.3 (228,206.6 ) 75,571.6 Total liabilities and equity $ 75,571.6 $ 174,615.0 $ 25,225.6 $ 73,461.9 $ 237,702.8 $ (450,598.6 ) $ 135,978.3
Consolidating Statements of Operations	Warner Chilcott Limited Consolidating Statements of Operations For the Three Months Ended September 30, 2016 (Unaudited; in millions) Warner Chilcott Limited (Parent Guarantor) Actavis Capital S.a.r.l. (Guarantor) Actavis Funding SCS (Issuer) Actavis Finance, LLC (Issuer and Guarantor) Non- guarantors Eliminations Consolidated Warner Chilcott Limited Net revenues $ - $ - $ - $ - $ 3,622.2 $ - $ 3,622.2 Operating expenses: Cost of sales (excludes amortization and impairment of acquired intangibles including product rights) - - - - 462.2 - 462.2 Research and development - - - - 622.8 - 622.8 Selling and marketing - - - - 796.0 - 796.0 General and administrative - 4.1 - - 308.1 - 312.2 Amortization - - - - 1,609.1 - 1,609.1 In-process research and development impairments - - - - 42.0 - 42.0 Asset sales and impairments, net - - - - (4.7 ) - (4.7 ) Total operating expenses - 4.1 - - 3,835.5 - 3,839.6 Operating (loss) - (4.1 ) - - (213.3 ) - (217.4 ) Non-operating income (expense): Interest income / (expense), net - 911.6 (216.6 ) (40.3 ) (960.9 ) - (306.2 ) Other income (expense), net - - - - 33.6 - 33.6 Total other income (expense), net - 911.6 (216.6 ) (40.3 ) (927.3 ) - (272.6 ) Income / (loss) before income taxes and noncontrolling interest - 907.5 (216.6 ) (40.3 ) (1,140.6 ) - (490.0 ) Provision / (benefit) for income taxes - - - (22.6 ) (136.3 ) - (158.9 ) (Earnings) / losses of equity interest subsidiaries (15,269.0 ) (11,485.0 ) - 747.6 - 26,006.4 - Net income / (loss) from continuing operations, net of tax $ 15,269.0 $ 12,392.5 $ (216.6 ) $ (765.3 ) $ (1,004.3 ) $ (26,006.4 ) $ (331.1 ) Income from discontinued operations - - - - 15,601.9 - 15,601.9 Net income / (loss) $ 15,269.0 $ 12,392.5 $ (216.6 ) $ (765.3 ) $ 14,597.6 $ (26,006.4 ) $ 15,270.8 (Income) attributable to noncontrolling interest - - - - (1.8 ) - (1.8 ) Net income / (loss) attributable to ordinary shareholders $ 15,269.0 $ 12,392.5 $ (216.6 ) $ (765.3 ) $ 14,595.8 $ (26,006.4 ) $ 15,269.0 Other comprehensive income / (loss) 916.4 958.4 - 900.2 916.4 (2,775.0 ) 916.4 Comprehensive income / (loss) $ 16,185.4 $ 13,350.9 $ (216.6 ) $ 134.9 $ 15,512.2 $ (28,781.4 ) $ 16,185.4 Warner Chilcott Limited Consolidating Statements of Operations For the Nine Months Ended September 30, 2016 (Unaudited; in millions) Warner Chilcott Limited (Parent Guarantor) Actavis Capital S.a.r.l. (Guarantor) Actavis Funding SCS (Issuer) Actavis Finance, LLC (Issuer and Guarantor) Non- guarantors Eliminations Consolidated Warner Chilcott Limited Net revenues - - - - 10,706.3 - 10,706.3 Operating expenses: Cost of sales (excludes amortization and impairment of acquired intangibles including product rights) - - - - 1,381.1 - 1,381.1 Research and development - - - - 1,662.4 - 1,662.4 Selling and marketing - - - - 2,429.6 - 2,429.6 General and administrative - 4.6 - 19.8 941.8 - 966.2 Amortization - - - - 4,831.9 - 4,831.9 In process research and development impairments - - - - 316.9 - 316.9 Asset sales and impairments, net - - - - (24.0 ) - (24.0 ) Total operating expenses - 4.6 - 19.8 11,539.7 - 11,564.1 Operating (loss) - (4.6 ) - (19.8 ) (833.4 ) - (857.8 ) Non-operating income (expense): Interest income / (expense), net - 1,349.2 2.2 (117.2 ) (2,213.6 ) - (979.4 ) Other income (expense), net - - - - 34.2 - 34.2 Total other income (expense), net - 1,349.2 2.2 (117.2 ) (2,179.4 ) - (945.2 ) Income / (loss) before income taxes and noncontrolling interest - 1,344.6 2.2 (137.0 ) (3,012.8 ) - (1,803.0 ) Provision / (benefit) for income taxes - - - (51.4 ) (774.4 ) - (825.8 ) (Earnings) / losses of equity interest subsidiaries (14,891.7 ) (10,701.3 ) - 198.6 - 25,394.4 - Net income / (loss) from continuing operations, net of tax $ 14,891.7 $ 12,045.9 $ 2.2 $ (284.2 ) $ (2,238.4 ) $ (25,394.4 ) $ (977.2 ) Income from discontinued operations - - - - 15,873.2 - 15,873.2 Net income / (loss) $ 14,891.7 $ 12,045.9 $ 2.2 $ (284.2 ) $ 13,634.8 $ (25,394.4 ) $ 14,896.0 (Income) attributable to noncontrolling interest - - - - (4.3 ) - (4.3 ) Net income / (loss) attributable to ordinary shareholders $ 14,891.7 $ 12,045.9 $ 2.2 $ (284.2 ) $ 13,630.5 $ (25,394.4 ) $ 14,891.7 Other comprehensive income / (loss) 1,093.4 1,213.8 - 871.1 1,093.4 (3,178.3 ) 1,093.4 Comprehensive income / (loss) $ 15,985.1 $ 13,259.7 $ 2.2 $ 586.9 $ 14,723.9 $ (28,572.7 ) $ 15,985.1 Warner Chilcott Limited Consolidating Statements of Operations For the Three Months Ended September 30, 2015 (Unaudited; in millions) Warner Chilcott Limited (Parent Guarantor) Actavis Capital S.a.r.l. (Guarantor) Actavis Funding SCS (Issuer) Actavis Finance, LLC (Issuer and Guarantor) Non- guarantors Eliminations Consolidated Warner Chilcott Limited Net revenues $ - $ - $ - $ - $ 3,469.5 $ - $ 3,469.5 Operating expenses: Cost of sales (excludes amortization and impairment of acquired intangibles including product rights) - - - - 710.3 - 710.3 Research and development - - - - 1,260.5 - 1,260.5 Selling and marketing - - - - 683.6 - 683.6 General and administrative - - - 79.1 254.7 - 333.8 Amortization - - - - 1,557.8 - 1,557.8 In process research and development impairments - - - - 300.0 - 300.0 Asset sales and impairments, net - - - - (4.4 ) - (4.4 ) Total operating expenses - - - 79.1 4,762.5 - 4,841.6 Operating (loss) - - - (79.1 ) (1,293.0 ) - (1,372.1 ) Non-operating income (expense): Interest income / (expense), net - 444.3 0.3 (40.3 ) (741.0 ) - (336.7 ) Other income (expense), net - - - (0.1 ) 0.3 - 0.2 Total other income (expense), net - 444.3 0.3 (40.4 ) (740.7 ) - (336.5 ) Income / (loss) before income taxes and noncontrolling interest - 444.3 0.3 (119.5 ) (2,033.7 ) - (1,708.6 ) (Benefit) for income taxes - - - (28.0 ) (810.9 ) - (838.9 ) (Earnings) / losses of equity interest subsidiaries (5,306.5 ) 1,857.2 - 117.7 - 3,331.6 - Net income / (loss) from continuing operations, net of tax $ 5,306.5 $ (1,412.9 ) $ 0.3 $ (209.2 ) $ (1,222.8 ) $ (3,331.6 ) $ (869.7 ) Income from discontinued operations - - - - 6,177.6 - 6,177.6 Net income / (loss) $ 5,306.5 $ (1,412.9 ) $ 0.3 $ (209.2 ) $ 4,954.8 $ (3,331.6 ) $ 5,307.9 (Income) attributable to noncontrolling interest - - - - (1.4 ) - (1.4 ) Net income / (loss) attributable to ordinary shareholders $ 5,306.5 $ (1,412.9 ) $ 0.3 $ (209.2 ) $ 4,953.4 $ (3,331.6 ) $ 5,306.5 Other comprehensive income / (loss) (34.9 ) (35.3 ) - 24.0 (34.9 ) 46.2 (34.9 ) Comprehensive income / (loss) $ 5,271.6 $ (1,448.2 ) $ 0.3 $ (185.2 ) $ 4,918.5 $ (3,285.4 ) $ 5,271.6 Warner Chilcott Limited Consolidating Statements of Operations For the Nine Months Ended September 30, 2015 (Unaudited; in millions) Warner Chilcott Limited (Parent Guarantor) Actavis Capital S.a.r.l. (Guarantor) Actavis Funding SCS (Issuer) Actavis Finance, LLC (Issuer and Guarantor) Non- guarantors Eliminations Consolidated Warner Chilcott Limited Net revenues $ - $ - $ - $ - $ 9,081.2 $ - $ 9,081.2 Operating expenses: Cost of sales (excludes amortization and impairment of acquired intangibles including product rights) - - - - 2,150.0 - 2,150.0 Research and development - - - - 1,927.9 - 1,927.9 Selling and marketing - - - - 2,017.2 - 2,017.2 General and administrative - 213.2 16.1 148.8 796.8 - 1,174.9 Amortization - - - - 3,858.9 - 3,858.9 In process research and development impairments - - - - 497.6 - 497.6 Asset sales and impairments, net - - - - 3.1 - 3.1 Total operating expenses - 213.2 16.1 148.8 11,251.5 - 11,629.6 Operating (loss) - (213.2 ) (16.1 ) (148.8 ) (2,170.3 ) - (2,548.4 ) Non-operating income (expense): Interest income / (expense), net - 732.6 (14.4 ) (127.7 ) (1,434.9 ) - (844.4 ) Other income (expense), net - (265.4 ) 31.0 - (3.7 ) - (238.1 ) Total other income (expense), net - 467.2 16.6 (127.7 ) (1,438.6 ) - (1,082.5 ) Income / (loss) before income taxes and noncontrolling interest - 254.0 0.5 (276.5 ) (3,608.9 ) - (3,630.9 ) (Benefit) for income taxes - - - (95.8 ) (1,395.2 ) - (1,491.0 ) (Earnings) / losses of equity interest subsidiaries (4,559.2 ) 2,466.7 - (242.2 ) - 2,334.7 - Net income /(loss) from continuing operations, net of tax $ 4,559.2 $ (2,212.7 ) $ 0.5 $ 61.5 $ (2,213.7 ) $ (2,334.7 ) $ (2,139.9 ) Income from discontinued operations - - - - 6,701.7 - 6,701.7 Net income / (loss) $ 4,559.2 $ (2,212.7 ) $ 0.5 $ 61.5 $ 4,488.0 $ (2,334.7 ) $ 4,561.8 (Income) attributable to noncontrolling interest - - - - (2.6 ) - (2.6 ) Net income / (loss) income attributable to ordinary shareholders $ 4,559.2 $ (2,212.7 ) $ 0.5 $ 61.5 $ 4,485.4 $ (2,334.7 ) $ 4,559.2 Other comprehensive income / (loss) 420.1 485.3 - 859.8 420.1 (1,765.2 ) 420.1 Comprehensive income/ (loss) income $ 4,979.3 $ (1,727.4 ) $ 0.5 $ 921.3 $ 4,905.5 $ (4,099.9 ) $ 4,979.3
Consolidating Statement of Cash Flows	Warner Chilcott Limited Consolidating Statement of Cash Flows For the Nine Months Ended September 30, 2016 (Unaudited; in millions) Warner Chilcott Limited (Parent Guarantor) Actavis Capital S.a.r.l. (Guarantor) Actavis Funding SCS (Issuer) Actavis Finance, LLC (Issuer and Guarantor) Non- guarantors Eliminations Consolidated Warner Chilcott Limited Cash Flows From Operating Activities: Net income / (loss) $ 14,891.7 $ 12,045.9 $ 2.2 $ (284.2 ) $ 13,634.8 $ (25,394.4 ) $ 14,896.0 Reconciliation to net cash provided by operating activities: (Earnings) / losses of equity interest subsidiaries (14,891.7 ) (10,701.3 ) - 198.6 - 25,394.4 - Depreciation - - - - 117.6 - 117.6 Amortization - - - - 4,836.7 - 4,836.7 Provision for inventory reserve - - - - 162.7 - 162.7 Share-based compensation - - - - 269.9 - 269.9 Deferred income tax benefit - - - - (517.1 ) - (517.1 ) Pre-tax gain sale of generics business - - - - (24,203.1 ) - (24,203.1 ) Non-cash tax effect of gain on sale of generics business - - - - 5,749.9 - 5,749.9 In-process research and development impairments - - - - 316.9 - 316.9 Loss on asset sales and impairments, net - - - - (24.0 ) - (24.0 ) Amortization of inventory step-up - - - - 42.4 - 42.4 Amortization of deferred financing costs - 21.7 18.3 3.2 1.4 - 44.6 Contingent consideration adjustments, including accretion - - - - 76.7 - 76.7 Dividends from subsidiaries 1,244.8 1,244.8 - - - (2,489.6 ) - Other, net - - - - (16.0 ) - (16.0 ) Changes in assets and liabilities (net of effects of acquisitions) 0.1 8,487.2 479.5 80.4 (10,821.9 ) - (1,774.7 ) Net cash provided by / (used in) operating activities 1,244.9 11,098.3 500.0 (2.0 ) (10,373.1 ) (2,489.6 ) (21.5 ) Cash Flows From Investing Activities: Additions to property plant and equipment - - - - (250.5 ) - (250.5 ) Additions to product rights and other intangibles - - - - - - - Sale of generics business - - - - 33,304.5 - 33,304.5 Additions to investments - - - - (15,445.5 ) - (15,445.5 ) Proceeds from sale of investments and other assets - - - - 40.0 - 40.0 Proceeds from sales of property, plant and equipment - - - - 33.3 - 33.3 Acquisitions of business, net of cash acquired - - - - (74.5 ) - (74.5 ) Net cash provided by investing activities - - - - 17,607.3 - 17,607.3 Cash Flows From Financing Activities: Proceeds from borrowings of long-term indebtedness - - - - - - - Proceeds from borrowings on credit facility - 1,050.0 - - - 1,050.0 Debt issuance and other financing costs - - - - - - - Payments on debt, including capital lease obligations - (8,815.9 ) (500.0 ) - (1,515.1 ) - (10,831.0 ) Payments of contingent consideration - - - - (77.7 ) - (77.7 ) Dividends to Parent (1,244.8 ) (1,244.8 ) - - (1,244.8 ) 2,489.6 (1,244.8 ) Contribution from Parent - - - - - - - Net cash (used in) financing activities (1,244.8 ) (9,010.7 ) (500.0 ) - (2,837.6 ) 2,489.6 (11,103.5 ) Effect of currency exchange rate changes on cash and cash equivalents - - - - 4.3 - 4.3 Net increase / (decrease) in cash and cash equivalents 0.1 2,087.6 - (2.0 ) 4,400.9 - 6,486.6 Cash and cash equivalents at beginning of period - 13.5 - 2.0 1,020.7 - 1,036.2 Cash and cash equivalents at end of period $ 0.1 $ 2,101.1 $ - $ - $ 5,421.6 $ - $ 7,522.8 Warner Chilcott Limited Consolidating Statement of Cash Flows For the Nine Months Ended September 30, 2015 (Unaudited; in millions) Warner Chilcott Limited (Parent Guarantor) Actavis Capital S.a.r.l. (Guarantor) Actavis Funding SCS (Issuer) Actavis Finance, LLC (Issuer and Guarantor) Non- guarantors Eliminations Consolidated Warner Chilcott Limited Cash Flows From Operating Activities: Net income / (loss) $ 4,559.2 $ (2,212.7 ) $ 0.5 $ 61.5 $ 4,488.0 $ (2,334.7 ) $ 4,561.8 Reconciliation to net cash provided by operating activities: (Earnings) / losses of equity interest subsidiaries (4,559.2 ) 2,466.7 - (242.2 ) - 2,334.7 - Depreciation - - - 0.2 183.7 - 183.9 Amortization - - - - 4,192.8 - 4,192.8 Provision for inventory reserve - - - - 108.6 - 108.6 Share-based compensation - - - 35.6 474.9 - 510.5 Deferred income tax benefit - - - - (7,470.9 ) - (7,470.9 ) In-process research and development impairments - - - - 497.6 - 497.6 Loss / (gain) on asset sales and impairments, net - - - - 57.2 - 57.2 Amortization of inventory step-up - - - - 1,019.8 - 1,019.8 Amortization of deferred financing costs - 268.8 14.8 3.1 2.5 - 289.2 Contingent consideration adjustments, including accretion - - - - 89.2 - 89.2 Dividends from subsidiaries 138.4 138.4 - - - (276.8 ) - Other, net - - - - 54.9 - 54.9 Changes in assets and liabilities (net of effects of acquisitions) (0.1 ) (4,977.5 ) (20,827.2 ) 179.8 24,634.0 - (991.0 ) Net cash provided by / (used in) operating activities 138.3 (4,316.3 ) (20,811.9 ) 38.0 28,332.3 (276.8 ) 3,103.6 Cash Flows From Investing Activities: Additions to property plant and equipment - - - (35.5 ) (315.2 ) - (350.7 ) Additions to product rights and other intangibles - - - - (91.1 ) - (91.1 ) Additions to investments (9,000.8 ) (9,000.8 ) - - (27.0 ) 18,001.6 (27.0 ) Proceeds from sale of investments and other assets - - - - 855.8 - 855.8 Proceeds from sales of property, plant and equipment - - - - 133.6 - 133.6 Acquisitions of business, net of cash acquired - - - - (35,242.7 ) - (35,242.7 ) Net cash (used in) investing activities (9,000.8 ) (9,000.8 ) - (35.5 ) (34,686.6 ) 18,001.6 (34,722.1 ) Cash Flows From Financing Activities: Proceeds from borrowings of long-term indebtedness - 5,500.0 20,955.6 - 0.8 - 26,456.4 Proceeds from borrowings on credit facility - 2,810.0 - 72.0 - 2,882.0 Debt issuance and other financing costs - (167.1 ) (143.7 ) - - - (310.8 ) Payments on debt, including capital lease obligations - (3,692.5 ) - - (634.2 ) - (4,326.7 ) Payments of contingent consideration - - - - (138.3 ) - (138.3 ) Dividends to Parent (138.4 ) (138.4 ) - - (138.4 ) 276.8 (138.4 ) Contribution from Parent 9,000.8 9,000.8 - - 9,000.8 (18,001.6 ) 9,000.8 Net cash provided by financing activities 8,862.4 13,312.8 20,811.9 - 8,162.7 (17,724.8 ) 33,425.0 Effect of currency exchange rate changes on cash and cash equivalents - - - - (5.1 ) - (5.1 ) Movement in cash held for sale - - - - - - - Net (decrease) / increase in cash and cash equivalents (0.1 ) (4.3 ) - 2.5 1,803.3 - 1,801.4 Cash and cash equivalents at beginning of period 0.1 5.5 - 1.5 237.2 - 244.3 Cash and cash equivalents at end of period $ - $ 1.2 $ - $ 4.0 $ 2,040.5 $ - $ 2,045.7

General - Additional Informatio

General - Additional Information (Detail) shares in Millions, $ in Millions	Aug. 02, 2016USD ($)shares	Sep. 30, 2016USD ($)CountryManufacturer	Oct. 03, 2016USD ($)
Segment Reporting Information [Line Items]
Number of operating countries | Country		100
Anda Distribution Business [Member]
Segment Reporting Information [Line Items]
Number of manufacturers | Manufacturer		300
Teva Pharmaceutical Industries Ltd [Member]
Segment Reporting Information [Line Items]
Ordinary shares received from divestiture of businesses | shares	100.3
Stock value received in divestiture of businesses		$ 5,038.6
Gain on sale of global generics business		15,881.5
Teva Pharmaceutical Industries Ltd [Member] | Anda Distribution Business [Member] | Subsequent Event [Member]
Segment Reporting Information [Line Items]
Additional consideration amount on divestiture of business			$ 500
Allergan Global Generic Pharmaceuticals Business and Certain Other Assets | Teva Pharmaceutical Industries Ltd [Member]
Segment Reporting Information [Line Items]
Proceeds Received From Divestiture of Businesses	$ 33,300
Ordinary shares received from divestiture of businesses | shares	100.3
Stock value received in divestiture of businesses	$ 5,000
Discounted rate due to lack of marketability in divestiture of business	5.90%
Gain on sale of global generics business		15,881.5
Deferred liabilities relating to other elements of arrangements		$ 518.9

Reconciliation of Warner Chil48

Reconciliation of Warner Chilcott Limited Results to Allergan Plc Results - Summary of Financial Position Reconciliation Results of Warner Chilcott Limited to Allergan Plc (Detail) - USD ($) $ in Millions	Sep. 30, 2016	Dec. 31, 2015	Sep. 30, 2015	Dec. 31, 2014
Schedule Of Reconciliation Of Subsidiary Results [Line Items]
Cash and cash equivalents	$ 7,554.7	$ 1,096	$ 2,063.9	$ 250
Prepaid expenses and other current assets	771.7	495.3
Accounts payable and accrued liabilities	5,425.4	4,148.6
Material Reconciling Items [Member] | Allergan plc [Member]
Schedule Of Reconciliation Of Subsidiary Results [Line Items]
Cash and cash equivalents	7,554.7	1,096
Prepaid expenses and other current assets	771.7	495.3
Accounts payable and accrued liabilities	5,425.4	4,148.6
Material Reconciling Items [Member] | Warner Chilcott Limited [Member]
Schedule Of Reconciliation Of Subsidiary Results [Line Items]
Cash and cash equivalents	7,522.8	1,036.2
Prepaid expenses and other current assets	769.6	492.8
Accounts payable and accrued liabilities	4,995.8	4,094.5
Material Reconciling Items [Member] | Difference [Member]
Schedule Of Reconciliation Of Subsidiary Results [Line Items]
Cash and cash equivalents	31.9	59.8
Prepaid expenses and other current assets	2.1	2.5
Accounts payable and accrued liabilities	$ 429.6	$ 54.1

Reconciliation of Warner Chil49

Reconciliation of Warner Chilcott Limited Results to Allergan Plc Results - Summary of Operations Reconciliation Results of Warner Chilcott Limited to Allergan Plc (Detail) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Schedule Of Reconciliation Of Subsidiary Results [Line Items]
General and administrative expenses	$ 361.2	$ 339.1	$ 1,033.9	$ 1,188
Operating (loss)	(266.4)	(1,377.4)	(925.5)	(2,561.5)
Other income / (expense)	33.6	0.2	184.2	(238.1)
(Loss) before income taxes and noncontrolling interest	(539)	(1,713.9)	(1,720.7)	(3,644)
Net (loss) from continuing operations, net of tax	(380.1)	(875)	(894.9)	(2,153)
Net income	15,221.8	5,302.6	14,978.3	4,548.7
Dividends on preferred shares	69.6	69.6	208.8	162.4
Net (loss) / income attributable to ordinary shareholder/members	15,150.4	5,231.6	14,765.2	4,383.7
Material Reconciling Items [Member] | Allergan plc [Member]
Schedule Of Reconciliation Of Subsidiary Results [Line Items]
General and administrative expenses	361.2	339.1	1,033.9	1,188
Operating (loss)	(266.4)	(1,377.4)	(925.5)	(2,561.5)
Other income / (expense)	33.6		184.2
(Loss) before income taxes and noncontrolling interest	(539)	(1,713.9)	(1,720.7)	(3,644)
Net (loss) from continuing operations, net of tax	(380.1)	(875)	(894.9)	(2,153)
Net income	15,221.8	5,302.6	14,978.3	4,548.7
Dividends on preferred shares	69.6	69.6	208.8	162.4
Net (loss) / income attributable to ordinary shareholder/members	15,150.4	5,231.6	14,765.2	4,383.7
Material Reconciling Items [Member] | Warner Chilcott Limited [Member]
Schedule Of Reconciliation Of Subsidiary Results [Line Items]
General and administrative expenses	312.2	333.8	966.2	1,174.9
Operating (loss)	(217.4)	(1,372.1)	(857.8)	(2,548.4)
Other income / (expense)	33.6		34.2
(Loss) before income taxes and noncontrolling interest	(490)	(1,708.6)	(1,803)	(3,630.9)
Net (loss) from continuing operations, net of tax	(331.1)	(869.7)	(977.2)	(2,139.9)
Net income	15,270.8	5,307.9	14,896	4,561.8
Net (loss) / income attributable to ordinary shareholder/members	15,269	5,306.5	14,891.7	4,559.2
Material Reconciling Items [Member] | Difference [Member]
Schedule Of Reconciliation Of Subsidiary Results [Line Items]
General and administrative expenses	49	5.3	67.7	13.1
Operating (loss)	(49)	(5.3)	(67.7)	(13.1)
Other income / (expense)			150
(Loss) before income taxes and noncontrolling interest	(49)	(5.3)	82.3	(13.1)
Net (loss) from continuing operations, net of tax	(49)	(5.3)	82.3	(13.1)
Net income	(49)	(5.3)	82.3	(13.1)
Dividends on preferred shares	69.6	69.6	208.8	162.4
Net (loss) / income attributable to ordinary shareholder/members	$ (118.6)	$ (74.9)	$ (126.5)	$ (175.5)

Summary of Significant Accoun50

Summary of Significant Accounting Policies - Additional Information (Detail) shares in Millions	3 Months Ended			9 Months Ended		12 Months Ended
	Sep. 30, 2016USD ($)shares	Jun. 30, 2016Segment	Sep. 30, 2015USD ($)shares	Sep. 30, 2016USD ($)shares	Sep. 30, 2015USD ($)shares	Dec. 31, 2015USD ($)
Summary Of Significant Accounting Policies [Line Items]
Decrease prepaid expenses and other currents assets and current portion of long-term debt and capital leases						$ 36,300,000
Investments and other assets and long-term debt and capital leases						159,500,000
Number of reporting units | Segment		6
Impairment of goodwill				$ 0
Impairment of intangible assets				$ 316,900,000	$ 497,600,000
Repurchased under share repurchase program | shares				12.8
Repurchase of share on EPS basis | shares	3.2			1.1
Ordinary Shares [Member]
Summary Of Significant Accounting Policies [Line Items]
Shares not included in the computation of diluted EPS | shares	17.6		17.6	17.6	13.6
Stock Awards [Member]
Summary Of Significant Accounting Policies [Line Items]
Shares not included in the computation of diluted EPS | shares	4.4		5.1	4.7	5.2
In Process Research and Development [Member]
Summary Of Significant Accounting Policies [Line Items]
Impairment of intangible assets					$ 197,600,000
Allergan Acquisition [Member]
Summary Of Significant Accounting Policies [Line Items]
Impairment of intangible assets			$ 300,000,000		$ 300,000,000
International Eye Care Pipeline Project [Member]
Summary Of Significant Accounting Policies [Line Items]
Impairment of intangible assets				$ 35,000,000
Botox Therapeutic Product [Member]
Summary Of Significant Accounting Policies [Line Items]
Impairment of intangible assets				20,000,000
Women's Healthcare Research and Development Project [Member]
Summary Of Significant Accounting Policies [Line Items]
Impairment of intangible assets				24,000,000
Osteoarthritis Research and Development Project [Member]
Summary Of Significant Accounting Policies [Line Items]
Impairment of intangible assets				190,000,000
Gastroenterology Project [Member]
Summary Of Significant Accounting Policies [Line Items]
Impairment of intangible assets	$ 42,000,000			42,000,000
Trade Name [Member]
Summary Of Significant Accounting Policies [Line Items]
Impairment of intangible assets				$ 0
Minimum [Member]
Summary Of Significant Accounting Policies [Line Items]
Long term growth rates				0.00%
Long term discount rates				8.00%
Maximum [Member]
Summary Of Significant Accounting Policies [Line Items]
Long term growth rates				2.50%
Long term discount rates				9.50%
Continuing Operations [Member] | Sales Return and Allowances [Member]
Summary Of Significant Accounting Policies [Line Items]
Valuation allowance	2,041,100,000			$ 2,041,100,000		1,815,200,000
Continuing Operations [Member] | Sales Return and Allowances [Member] | In accounts receivable [Member]
Summary Of Significant Accounting Policies [Line Items]
Valuation allowance	243,800,000			243,800,000		245,200,000
Continuing Operations [Member] | Sales Return and Allowances [Member] | Within Accounts Payable and Accrued Expenses [Member]
Summary Of Significant Accounting Policies [Line Items]
Valuation allowance	1,797,300,000			1,797,300,000		1,570,000,000
Discontinued Operations [Member] | Sales Return and Allowances [Member]
Summary Of Significant Accounting Policies [Line Items]
Valuation allowance	$ 15,500,000			$ 15,500,000		$ 1,738,700,000

Summary of Significant Accoun51

Summary of Significant Accounting Policies - Movements in SRA Reserve Balances (Detail) - Continuing Operations [Member] - Sales Return and Allowances [Member] $ in Millions	9 Months Ended
	Sep. 30, 2016USD ($)
Valuation And Qualifying Accounts Disclosure [Line Items]
Beginning Balance	$ 1,815.2
Provision to reduce gross product sales to net product sales	5,153
Payments and other	(4,927.1)
Ending Balance	$ 2,041.1

Summary of Significant Accoun52

Summary of Significant Accounting Policies - Summary of Activity in Gross-to-Net Revenue Excluding Discontinued Operations (Detail) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Gross product sales	$ 5,332.9	$ 4,918.4	$ 15,727.7	$ 12,825.8
Provisions to reduce gross product sales to net product sales	(1,757.3)	(1,503.5)	(5,153)	(3,871.3)
Net product sales	$ 3,575.6	$ 3,414.9	$ 10,574.7	$ 8,954.5
Percentage of provisions to gross sales	33.00%	30.60%	32.80%	30.20%

Summary of Significant Accoun53

Summary of Significant Accounting Policies - Earnings Per Share (Detail) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Net (loss) / income:
Net (loss) attributable to ordinary shareholders excluding income from discontinued operations, net of tax	$ (451.5)	$ (946)	$ (1,108)	$ (2,318)
Income from discontinued operations, net of tax	15,601.9	6,177.6	15,873.2	6,701.7
Net income attributable to ordinary shareholders	$ 15,150.4	$ 5,231.6	$ 14,765.2	$ 4,383.7
Basic weighted average ordinary shares outstanding	392.7	393.6	394.4	358.9
Basic EPS:
Continuing operations	$ (1.15)	$ (2.40)	$ (2.81)	$ (6.46)
Discontinued operations	39.73	15.69	40.25	18.67
Net income per share - basic	$ 38.58	$ 13.29	$ 37.44	$ 12.21
Diluted weighted average ordinary shares outstanding	392.7	393.6	394.4	358.9
Diluted EPS:
Continuing operations	$ (1.15)	$ (2.40)	$ (2.81)	$ (6.46)
Discontinued operations	39.73	15.69	40.25	18.67
Net income per share - diluted	$ 38.58	$ 13.29	$ 37.44	$ 12.21

Acquisitions and Other Agreem54

Acquisitions and Other Agreements, Pro Forma Results of Businesses Acquired (Detail) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Business Acquisition [Line Items]
Net Revenue	$ 3,622.2	$ 3,469.5	$ 10,706.3	$ 9,081.2
Net income attributable to ordinary shareholders	$ 15,150.4	$ 5,231.6	$ 14,765.2	$ 4,383.7
Net (loss) per share
Basic	$ 38.58	$ 13.29	$ 37.44	$ 12.21
Diluted	$ 38.58	$ 13.29	$ 37.44	$ 12.21
Pro Forma [Member]
Business Acquisition [Line Items]
Net Revenue				$ 10,604.2
Net income attributable to ordinary shareholders				$ 4,761.4
Net (loss) per share
Basic				$ 11.58
Diluted				$ 11.58
Allergan, Inc. [Member]
Business Acquisition [Line Items]
Net Revenue				$ 1,523
Net income attributable to ordinary shareholders				$ 377.7

Acquisitions and Other Agreem55

Acquisitions and Other Agreements - Additional Information (Detail) $ / shares in Units, shares in Millions

Sep. 23, 2016USD ($)

Sep. 06, 2016USD ($)

Aug. 26, 2016USD ($)

Apr. 21, 2016USD ($)

Apr. 06, 2016USD ($)

Jan. 06, 2016USD ($)

Oct. 16, 2015USD ($)

Oct. 01, 2015USD ($)$ / shares

Aug. 28, 2015USD ($)

Mar. 17, 2015USD ($)shares

Nov. 17, 2014USD ($)Contingent_Value_Right$ / shares

Jun. 30, 2014USD ($)shares

Apr. 30, 2016USD ($)

Sep. 30, 2016USD ($)

Sep. 30, 2015USD ($)

Mar. 31, 2015USD ($)

Sep. 30, 2016USD ($)

Sep. 30, 2015USD ($)

Dec. 31, 2015USD ($)

Mar. 02, 2015USD ($)

Dec. 31, 2014USD ($)

Jul. 01, 2014USD ($)

Business Acquisition [Line Items]

Goodwill

$ 46,625,800,000

$ 46,625,800,000

$ 46,465,200,000

Research and development

622,800,000

$ 1,260,500,000

1,662,400,000

$ 1,927,900,000

Asset held for sale

455,900,000

455,900,000

4,095,600,000

Payment of contingent consideration

$ 77,700,000

138,300,000

AstraZeneca [Member]

Business Acquisition [Line Items]

Consideration amount on sale of business

$ 600,000,000

Additional consideration amount on sale of business

$ 100,000,000

Respiratory Therapeutic Area [Member]

Business Acquisition [Line Items]

Asset held for sale

$ 734,000,000

Goodwill

$ 309,100,000

Incremental charge in cost of sales relating to inventory

35,300,000

Other (Expense) Income [Member] | AstraZeneca [Member]

Business Acquisition [Line Items]

Gain (loss) on sale of business

(5,300,000)

Migraine License Acquisition [Member]

Business Acquisition [Line Items]

Payment for license upfront fees

$ 125,000,000

100,000,000

$ 125,000,000

Migraine License Acquisition [Member] | R&D Expense [Member]

Business Acquisition [Line Items]

Upfront charge

250,000,000

250,000,000

Maximum [Member]

Business Acquisition [Line Items]

Long term discount rates

9.50%

Maximum [Member] | Migraine License Acquisition [Member]

Business Acquisition [Line Items]

Additional contingent payments based on commercial and development milestones

865,000,000

$ 865,000,000

ForSight VISION 5 [Member]

Business Acquisition [Line Items]

Acquisition purchase price

$ 74,500,000

Payment of outstanding indebtedness

14,800,000

Payments to acquire business, cash

95,000,000

Business acquisition date

Sep. 23, 2016

Contingent consideration liability

79,800,000

Goodwill

54,200,000

ForSight VISION 5 [Member] | US Specialized Therapeutics Segment [Member]

Business Acquisition [Line Items]

Goodwill

$ 54,200,000

ForSight VISION 5 [Member] | IPR&D [Member]

Business Acquisition [Line Items]

Long term discount rates

13.00%

ForSight VISION 5 [Member] | Maximum [Member]

Business Acquisition [Line Items]

Acquisition purchase price

$ 125,000,000

RetroSense Therapeutics LLC [Member]

Business Acquisition [Line Items]

Business acquisition date

Sep. 6, 2016

Payment for license upfront fees

$ 60,000,000

Research and development

$ 59,700,000

RetroSense Therapeutics LLC [Member] | Maximum [Member]

Business Acquisition [Line Items]

Contingent payments based on commercial and development milestones

$ 495,000,000

Akarna Therapeutics, Ltd [Member]

Business Acquisition [Line Items]

Business acquisition date

Aug. 26, 2016

Payment for license upfront fees

$ 50,000,000

Research and development

$ 48,200,000

Akarna Therapeutics, Ltd [Member] | Maximum [Member]

Business Acquisition [Line Items]

Contingent payments based on commercial and development milestones

$ 1,015,000,000

Topokine Therapeutics [Member]

Business Acquisition [Line Items]

Business acquisition date

Apr. 21, 2016

Payment for license upfront fees

$ 85,000,000

Research and development

$ 85,000,000

Topokine Therapeutics [Member] | Maximum [Member]

Business Acquisition [Line Items]

Contingent payments based on commercial and development milestones

$ 260,000,000

Heptares Therapeutics [Member]

Business Acquisition [Line Items]

Business acquisition date

Apr. 6, 2016

Payment for license upfront fees

$ 125,000,000

Research and development

$ 125,000,000

Heptares Therapeutics [Member] | Maximum [Member]

Business Acquisition [Line Items]

Contingent payments based on commercial and development milestones

665,000,000

Aggregate payments contingent upon achieving certain annual sales threshold milestones

$ 2,575,000,000

Anterios, Inc. [Member]

Business Acquisition [Line Items]

Business acquisition date

Jan. 6, 2016

Contingent payments based on commercial and development milestones

$ 387,500,000

Research and development

$ 90,000,000

Upfront payment

$ 90,000,000

AqueSys, Inc. [Member]

Business Acquisition [Line Items]

Acquisition purchase price

$ 298,900,000

Business acquisition date

Oct. 16, 2015

Contingent consideration liability

193,500,000

Goodwill

$ 138,500,000

Kythera Biopharmaceuticals [Member]

Business Acquisition [Line Items]

Acquisition purchase price

$ 2,089,500,000

Business acquisition date

Oct. 1, 2015

Goodwill

$ 328,700,000

Business combination cash consideration for each share | $ / shares

$ 75

Allergan, Inc. [Member]

Business Acquisition [Line Items]

Acquisition purchase price

$ 77,000,000,000

Payments to acquire business, cash

40,100,000,000

Business acquisition date

Mar. 17, 2015

Outstanding indebtedness

2,200,000,000

Equity consideration

$ 34,700,000,000

Shares issued to acquire entity | shares

111.2

Step-up in the value of inventories

$ 923,900,000

Amortization of inventory step-up to cost of sales

274,500,000

$ 21,600,000

778,900,000

Allergan, Inc. [Member] | Non-qualified Options [Member]

Business Acquisition [Line Items]

Shares issued to acquire entity | shares

7

Allergan, Inc. [Member] | Restricted Stock Units (RSUs) [Member]

Business Acquisition [Line Items]

Shares issued to acquire entity | shares

0.5

Naurex, Inc. [Member]

Business Acquisition [Line Items]

Business acquisition date

Aug. 28, 2015

Upfront charge of acquired rights recognized as research and development expenses

$ 571,700,000

Naurex, Inc. [Member] | Maximum [Member]

Business Acquisition [Line Items]

Future contingent payments

$ 1,150,000,000

Durata Therapeutics, Inc. [Member]

Business Acquisition [Line Items]

Payments to acquire business, cash

$ 724,500,000

Contingent consideration liability

$ 49,000,000

Additional consideration for contingent value rights | $ / shares

$ 5

Number of contingent value right per share | Contingent_Value_Right

1

Durata Therapeutics, Inc. [Member] | Contingent Value Right [Member]

Business Acquisition [Line Items]

Contingent consideration liability

$ 49,000,000

$ 49,000,000

Payment of contingent consideration

$ 30,900,000

Forest Laboratories Inc. [Member]

Business Acquisition [Line Items]

Acquisition purchase price

$ 30,900,000,000

Payments to acquire business, cash

7,100,000,000

Business acquisition date

Jul. 1, 2014

Outstanding indebtedness

$ 3,300,000,000

Equity consideration

$ 20,600,000,000

Shares issued to acquire entity | shares

89.8

Step-up in the value of inventories

$ 1,036,300,000

Amortization of inventory step-up to cost of sales

$ 15,400,000

$ 20,100,000

$ 202,000,000

Forest Laboratories Inc. [Member] | Non-qualified Options [Member]

Business Acquisition [Line Items]

Shares issued to acquire entity | shares

6.1

Forest Laboratories Inc. [Member] | Restricted Stock Units (RSUs) [Member]

Business Acquisition [Line Items]

Shares issued to acquire entity | shares

1.1

Acquisitions and Other Agreem56

Acquisitions and Other Agreements - Summary of Fair Values of Assets Acquired and Liabilities Assumed at Acquisition Date (Detail) - USD ($) $ in Millions	Sep. 30, 2016	Sep. 23, 2016	Dec. 31, 2015	Oct. 16, 2015	Oct. 01, 2015
Business Acquisition [Line Items]
Goodwill	$ 46,625.8		$ 46,465.2
ForSight VISION 5 [Member]
Business Acquisition [Line Items]
Cash and cash equivalents		$ 1
Goodwill		54.2
Current liabilities		(15.8)
Contingent consideration		(79.8)
Deferred tax liabilities, net		(43.1)
Net assets acquired		74.5
AqueSys, Inc. [Member]
Business Acquisition [Line Items]
Cash and cash equivalents				$ 6.2
Current assets				1.2
Intangible assets				221
Goodwill				138.5
Current liabilities				(6.9)
Contingent consideration				(193.5)
Deferred tax liabilities, net				(169.6)
Net assets acquired				298.9
Kythera Biopharmaceuticals [Member]
Business Acquisition [Line Items]
Cash and cash equivalents					$ 78.1
Marketable securities					79.9
Inventory					18.2
Other current assets					14.5
Intangible assets					2,120
Goodwill					328.7
Other current liabilities					(48.6)
Deferred tax liabilities, net					(766.7)
Outstanding indebtedness					(54.6)
Net assets acquired					2,089.5
IPR&D [Member] | ForSight VISION 5 [Member]
Business Acquisition [Line Items]
IPR&D intangible asset		$ 158
IPR&D [Member] | AqueSys, Inc. [Member]
Business Acquisition [Line Items]
IPR&D intangible asset				$ 302
IPR&D [Member] | Kythera Biopharmaceuticals [Member]
Business Acquisition [Line Items]
IPR&D intangible asset					$ 320

Acquisitions and Other Agreem57

Acquisitions and Other Agreements - Summary of Transaction and Integration Costs (Detail) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Legacy Allergan [Member]
Business Acquisition [Line Items]
Total transaction and integration costs	$ 99.8	$ 150.6	$ 299.9	$ 1,149.5
Legacy Allergan [Member] | Stock Compensation Plan [Member] | Cost of Sales [Member]
Business Acquisition [Line Items]
Total transaction and integration costs	2.2	4.7	7.4	18.9
Legacy Allergan [Member] | Stock Compensation Plan [Member] | Research and Development Expense [Member]
Business Acquisition [Line Items]
Total transaction and integration costs	9.3	16.6	32.6	108.2
Legacy Allergan [Member] | Stock Compensation Plan [Member] | Selling and Marketing Expense [Member]
Business Acquisition [Line Items]
Total transaction and integration costs	15.8	23.6	53	86.5
Legacy Allergan [Member] | Stock Compensation Plan [Member] | General and Administrative Expense [Member]
Business Acquisition [Line Items]
Total transaction and integration costs	9.9	16.8	28.2	243
Legacy Allergan [Member] | Acquisition, Integration and Restructuring Related Charges [Member] | Cost of Sales [Member]
Business Acquisition [Line Items]
Total transaction and integration costs	6.6	0.3	12.4	12.4
Legacy Allergan [Member] | Acquisition, Integration and Restructuring Related Charges [Member] | Research and Development Expense [Member]
Business Acquisition [Line Items]
Total transaction and integration costs	6.8	17.5	10.6	83.7
Legacy Allergan [Member] | Acquisition, Integration and Restructuring Related Charges [Member] | Selling and Marketing Expense [Member]
Business Acquisition [Line Items]
Total transaction and integration costs	(1.2)	5.4	11.7	65.9
Legacy Allergan [Member] | Acquisition, Integration and Restructuring Related Charges [Member] | General and Administrative Expense [Member]
Business Acquisition [Line Items]
Total transaction and integration costs	50.4	65.7	144	231.4
Legacy Allergan [Member] | Acquisition-Related Expenses [Member] | General and Administrative Expense [Member]
Business Acquisition [Line Items]
Total transaction and integration costs				65.5
Legacy Allergan [Member] | Interest Rate Locks | Other (Expense) Income [Member]
Business Acquisition [Line Items]
Total transaction and integration costs				30.9
Legacy Allergan [Member] | Bridge Loan Facilities Expense [Member] | Other (Expense) Income [Member]
Business Acquisition [Line Items]
Total transaction and integration costs				(264.9)
Forest Laboratories Inc. [Member]
Business Acquisition [Line Items]
Total transaction and integration costs	15.7	46.9	60.8	208.8
Forest Laboratories Inc. [Member] | Stock Compensation Plan [Member] | Cost of Sales [Member]
Business Acquisition [Line Items]
Total transaction and integration costs	0.2	0.9	1.4	3.6
Forest Laboratories Inc. [Member] | Stock Compensation Plan [Member] | Research and Development Expense [Member]
Business Acquisition [Line Items]
Total transaction and integration costs	2	5.5	10.9	30
Forest Laboratories Inc. [Member] | Stock Compensation Plan [Member] | Selling and Marketing Expense [Member]
Business Acquisition [Line Items]
Total transaction and integration costs	6.9	9.4	21.7	37.8
Forest Laboratories Inc. [Member] | Stock Compensation Plan [Member] | General and Administrative Expense [Member]
Business Acquisition [Line Items]
Total transaction and integration costs	5.9	10.7	24.6	43
Forest Laboratories Inc. [Member] | Acquisition, Integration and Restructuring Related Charges [Member] | Cost of Sales [Member]
Business Acquisition [Line Items]
Total transaction and integration costs				1.1
Forest Laboratories Inc. [Member] | Acquisition, Integration and Restructuring Related Charges [Member] | Research and Development Expense [Member]
Business Acquisition [Line Items]
Total transaction and integration costs	0.2	0.4	0.5	9.2
Forest Laboratories Inc. [Member] | Acquisition, Integration and Restructuring Related Charges [Member] | Selling and Marketing Expense [Member]
Business Acquisition [Line Items]
Total transaction and integration costs		0.4		17.3
Forest Laboratories Inc. [Member] | Acquisition, Integration and Restructuring Related Charges [Member] | General and Administrative Expense [Member]
Business Acquisition [Line Items]
Total transaction and integration costs	$ 0.5	$ 19.6	$ 1.7	$ 66.8

Discontinued Operations - Sched

Discontinued Operations - Schedule of Reconciliation of Proceeds Received in Teva Transaction to Gain Recognized in Income from Discontinued Operations (Detail) $ in Millions	9 Months Ended
	Sep. 30, 2016USD ($)
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Net cash proceeds received	$ 33,304.5
Pre-tax gain on sale of generics business	24,203.1
Teva Pharmaceutical Industries Ltd [Member]
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Net cash proceeds received	33,304.5
August 2, 2016 fair value of Teva shares	5,038.6
Total Proceeds	38,343.1
Net assets sold to Teva, excluding cash	(12,076.7)
Other comprehensive income disposed	(1,544.8)
Deferral of proceeds relating to additional elements of agreements with Teva	(518.9)
Pre-tax gain on sale of generics business	24,202.7
Income taxes	(8,321.2)
Net gain on sale of generics business	$ 15,881.5

Discontinued Operations - Addit

Discontinued Operations - Additional Information (Detail) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2016USD ($)	Sep. 30, 2015USD ($)	Sep. 30, 2016USD ($)Manufacturer	Sep. 30, 2015USD ($)	Oct. 03, 2016USD ($)
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Unrealized gains (losses) / gains, net of tax	$ (609.3)	$ 7.5	$ (625.2)	$ 11.1
Deferred tax (benefit) expense related to investment in certain subsidiaries			(474.7)	5,985.4
Deferred income tax benefit			$ (517.1)	$ (7,470.9)
Anda Distribution Business [Member]
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Number of manufacturers | Manufacturer			300
Teva Pharmaceutical Industries Ltd [Member]
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Deferred income tax benefit			$ 5,273.9
Teva Pharmaceutical Industries Ltd [Member] | Anda Distribution Business [Member]
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Discontinued operations definite sale agreement date			Oct. 3, 2016
Teva Pharmaceutical Industries Ltd [Member] | Anda Distribution Business [Member] | Subsequent Event [Member]
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Additional consideration amount on divestiture of business					$ 500
Teva [Member]
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Unrealized gains (losses) / gains, net of tax	$ 664.2		$ 664.2

Discontinued Operations - Summa

Discontinued Operations - Summary of Key Financial Results of Businesses Income from Discontinued Operations (Detail) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Discontinued Operations And Disposal Groups [Abstract]
Net revenues	$ 756.5	$ 1,984.8	$ 4,504.3	$ 6,362.3
Operating expenses:
Cost of sales (excludes amortization and impairment of acquired intangibles including product rights)	531	1,243.3	2,798.3	3,647.1
Research and development	37.3	98.9	269.6	317.4
Selling and marketing	69.1	159.3	352.6	542.2
General and administrative	90.3	204	399.4	528.3
Amortization		36.1	4.8	333.9
Asset sales and impairments, net		3.2		54.1
Total operating expenses	727.7	1,744.8	3,824.7	5,423
Operating income	28.8	240	679.6	939.3
Other (expense) income, net	15,881.5	(0.3)	15,881.1	(8.4)
Provision / (benefit) for income taxes	308.4	(5,937.9)	687.5	(5,770.8)
Net income from discontinued operations	$ 15,601.9	$ 6,177.6	$ 15,873.2	$ 6,701.7

Discontinued Operations - Sch61

Discontinued Operations - Schedule of Aggregate Carrying Amounts of Major Classes of Assets and Liabilities (Detail) - USD ($) $ in Millions	Sep. 30, 2016	Dec. 31, 2015
Assets:
Accounts receivable, net	$ 164.3	$ 2,365.9
Inventories	270.8	1,390.7
Prepaid expenses and other current assets	16.3	329.7
Property, plant and equipment, net	23.6	1,398.2
Investments and other assets	6.6	42.2
Non-current deferred tax assets		162.1
Product rights and other intangibles	90.7	3,014.8
Goodwill	86.3	6,096
Total assets	658.6	14,799.6
Liabilities:
Accounts payable and accrued expenses	223.7	1,656.7
Income taxes payable		34.4
Debt and capital leases		5.8
Other long-term liabilities	3.9	92
Other taxes payable		69
Long-term deferred tax liabilities	19.9	370.7
Total liabilities	$ 247.5	$ 2,228.6

Discontinued Operations - Sch62

Discontinued Operations - Schedule of Depreciation Amortization and Significant Operating and Investing Noncash Items of Discontinued Operations (Detail) - USD ($) $ in Millions	3 Months Ended	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Discontinued Operations And Disposal Groups [Abstract]
Depreciation from discontinued operations		$ 2.1	$ 86.4
Amortization from discontinued operations	$ 36.1	4.8	333.9
Capital expenditures		85.3	182.6
Deferred income taxes expense / (benefit)		$ 5,893.4	$ (6,301.6)

Other Income_(Expense) - Additi

Other Income/(Expense) - Additional Information (Detail) - USD ($) shares in Millions, $ in Millions	Aug. 02, 2016	Sep. 30, 2016	Sep. 30, 2016
Teva Pharmaceutical Industries Ltd [Member]
Other Non Operating Income Expense [Line Items]
Ordinary shares received from divestiture of businesses	100.3
Dividend income received		$ 34.1	$ 34.1
Pfizer Inc [Member]
Other Non Operating Income Expense [Line Items]
Reimbursable expense			150
Transactions related expenses		$ 18	$ 92.9

Share-Based Compensation - Addi

Share-Based Compensation - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock option expiration period			10 years
Restricted stock awards restrictions eliminated period			After one year
Share-based compensation expense related to discontinued operations	$ 3.2	$ 7.9	$ 16	$ 27.4
Unrecognized future stock-based compensation expense	554.3		$ 554.3
Remaining weighted average period (years)			1 year 4 months 24 days
Allergan, Inc. [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrecognized future stock-based compensation expense	178.2		$ 178.2
Forest Laboratories Inc. [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrecognized future stock-based compensation expense	$ 44.4		$ 44.4
Minimum [Member] | Stock Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock option exercisable period			3 years
Minimum [Member] | Restricted Stock [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock option expiration period			1 year
Maximum [Member] | Stock Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock option exercisable period			5 years
Maximum [Member] | Restricted Stock [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock option expiration period			4 years

Share-Based Compensation - Sche

Share-Based Compensation - Schedule of Fair Value Assumptions of Options based on Black-Scholes Valuation Model (Detail)	9 Months Ended
	Sep. 30, 2016
2016 Grants [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Dividend yield	0.00%
Expected volatility	27.00%
Risk-free interest rate, Minimum	1.30%
Risk-free interest rate, Maximum	1.60%
Expected term	7 years
2015 Grants [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Dividend yield	0.00%
Expected volatility, Minimum	26.00%
Expected volatility, Maximum	29.00%
Risk-free interest rate, Minimum	1.90%
Risk-free interest rate, Maximum	2.10%
2015 Acquired Awards [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Dividend yield	0.00%
Expected volatility, Minimum	26.00%
Expected volatility, Maximum	27.00%
Risk-free interest rate, Minimum	0.10%
Risk-free interest rate, Maximum	2.10%
Maximum [Member] | 2015 Grants [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term	7 years 6 months
Maximum [Member] | 2015 Acquired Awards [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term	6 years 10 months 24 days
Minimum [Member] | 2015 Grants [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term	7 years

Share-Based Compensation - Shar

Share-Based Compensation - Share-Based Compensation Expense Recognized in Company's Results of Operations (Detail) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense (benefit)	$ 91.6	$ 130.2	$ 287	$ 658
Equity Based Compensation Awards [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense (benefit)	81.1	109.8	269.9	510.5
Cash-Settled Equity Awards [Member] | ForSight [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense (benefit)	3.1		3.1
Cash-Settled Equity Awards [Member] | Allergan, Inc. [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense (benefit)				127.1
Non Equity-Settled Awards Other [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense (benefit)	$ 7.4	$ 20.4	$ 14	$ 20.4

Share-Based Compensation - Summ

Share-Based Compensation - Summary of Impact of Accelerations and Step-ups Relating to Acquisition Accounting Treatment of Outstanding Awards (Detail) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Recognized share-based compensation expense relating to acquisition accounting treatment of outstanding awards acquired	$ 37.1	$ 62.8	$ 124.3	$ 358.9
Allergan, Inc. [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Recognized share-based compensation expense relating to acquisition accounting treatment of outstanding awards acquired	26.8	44.6	86.8	269.8
Forest Laboratories Inc. [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Recognized share-based compensation expense relating to acquisition accounting treatment of outstanding awards acquired	$ 10.3	$ 18.2	$ 37.5	$ 89.1

Share-Based Compensation - Su68

Share-Based Compensation - Summary of Equity Award Activity for Unvested Restricted Stock and Stock Units (Detail) - Restricted Stock [Member] - USD ($) $ / shares in Units, shares in Millions, $ in Millions	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Restricted shares / units outstanding, beginning balance	2
Shares, Granted	0.6
Shares, Vested	(0.7)
Shares, Forfeited	(0.3)
Restricted shares / units outstanding, ending balance	1.6	2
Weighted Average Grant Date Fair Value, outstanding, beginning balance	$ 209.90
Weighted Average Grant Date Fair Value, Granted	281.26
Weighted Average Grant Date Fair Value, Vested	(168.55)
Weighted Average Grant Date Fair Value, Forfeited	(228.53)
Weighted Average Grant Date Fair Value, outstanding, ending balance	$ 254.37	$ 209.90
Weighted Average Remaining Contractual Term (Years)	1 year 8 months 12 days	1 year 8 months 12 days
Aggregate Grant Date Fair Value, outstanding, beginning balance	$ 419.8
Aggregate Grant Date Fair Value, Granted	168.8
Aggregate Grant Date Fair Value, Vested	(118)
Aggregate Grant Date Fair Value, Forfeited	(70.1)
Aggregate Grant Date Fair Value, outstanding, ending balance	$ 400.5	$ 419.8

Share-Based Compensation - Su69

Share-Based Compensation - Summary of Equity Award Activity for Non-Qualified Options to Purchase Ordinary Shares (Detail) - Non-qualified Options [Member] - USD ($) $ / shares in Units, shares in Millions, $ in Millions	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options, Outstanding, Beginning Balance	10.5
Options, Granted	0.2
Options, Exercised	(1.2)
Options, Cancelled	(0.2)
Options, Outstanding, Ending Balance	9.3	10.5
Options, Vested and expected to vest	8.8
Weighted Average Exercise Price, Outstanding, Beginning Balance	$ 149.11
Weighted Average Exercise Price, Granted	280.72
Weighted Average Exercise Price, Exercised	(113.07)
Weighted Average Exercise Price, Cancelled	(153.42)
Weighted Average Exercise Price, Outstanding, Ending Balance	112.17	$ 149.11
Weighted Average Exercise Price, Vested and expected to vest	$ 112.89
Weighted Average Remaining Contractual Term (Years), Outstanding	6 years	6 years 8 months 12 days
Weighted Average Remaining Contractual Term (Years), Vested and expected to vest	6 years
Aggregate Intrinsic Value, Outstanding	$ 1,098.8	$ 1,707.8
Aggregate Intrinsic Value, Vested and expected to vest	$ 1,036.1

Reportable Segments - Additiona

Reportable Segments - Additional Information (Detail)	9 Months Ended
	Sep. 30, 2016Segment
Segment Reporting [Abstract]
Number of operating segments	3

Reportable Segments - Schedule

Reportable Segments - Schedule of Net Revenues, Operating Expenses Contribution Information by Reportable Segment (Detail) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Segment Reporting Information [Line Items]
Net revenues	$ 3,622.2	$ 3,469.5	$ 10,706.3	$ 9,081.2
Operating expenses:
Cost of sales	462.2	710.3	1,381.1	2,150
Selling and marketing	796	683.6	2,429.6	2,017.2
General and administrative	361.2	339.1	1,033.9	1,188
Research and development	622.8	1,260.5	1,662.4	1,927.9
Amortization			4,836.7	4,192.8
In-process research and development impairments			316.9	497.6
Asset sales and impairments, net	(4.7)	(4.4)	(24)	3.1
Operating (loss)	(266.4)	(1,377.4)	(925.5)	(2,561.5)
US Specialized Therapeutics [Member]
Segment Reporting Information [Line Items]
Net revenues	1,453.2	1,296.6	4,240.8	2,889.6
US General Medicine [Member]
Segment Reporting Information [Line Items]
Net revenues	1,488.1	1,552	4,390.9	4,803.7
Operating Segments [Member]
Segment Reporting Information [Line Items]
Net revenues	3,639.1	3,509.2	10,759.8	9,189.7
Operating expenses:
Cost of sales	379.4	407.4	1,173.9	1,078
Selling and marketing	773.4	654.8	2,330.3	1,836.3
General and administrative	111.5	68	341.1	210.6
Segment Contribution	$ 2,374.8	$ 2,379	$ 6,914.5	$ 6,064.8
Contribution margin	65.30%	67.80%	64.30%	66.00%
Corporate	$ 372	$ 642.5	$ 1,052.8	$ 2,338.8
Research and development	622.8	1,260.5	1,662.4	1,927.9
Amortization	1,609.1	1,557.8	4,831.9	3,858.9
In-process research and development impairments	42	300	316.9	497.6
Asset sales and impairments, net	(4.7)	(4.4)	(24)	3.1
Operating (loss)	$ (266.4)	$ (1,377.4)	$ (925.5)	$ (2,561.5)
Operating margin	(7.30%)	(39.30%)	(8.60%)	(27.90%)
Operating Segments [Member] | US Specialized Therapeutics [Member]
Segment Reporting Information [Line Items]
Net revenues	$ 1,453.2	$ 1,296.6	$ 4,240.8	$ 2,889.6
Operating expenses:
Cost of sales	69.2	71.6	215	160.2
Selling and marketing	292.4	236.2	844.8	525
General and administrative	41.2	17.2	126.4	46.1
Segment Contribution	$ 1,050.4	$ 971.6	$ 3,054.6	$ 2,158.3
Contribution margin	72.30%	74.90%	72.00%	74.70%
Operating Segments [Member] | US General Medicine [Member]
Segment Reporting Information [Line Items]
Net revenues	$ 1,488.1	$ 1,552	$ 4,390.9	$ 4,803.7
Operating expenses:
Cost of sales	215.1	227.5	649.6	674
Selling and marketing	292.8	262.8	902.8	917.1
General and administrative	42.3	17.5	128.2	88.8
Segment Contribution	$ 937.9	$ 1,044.2	$ 2,710.3	$ 3,123.8
Contribution margin	63.00%	67.30%	61.70%	65.00%
Operating Segments [Member] | International [Member]
Segment Reporting Information [Line Items]
Net revenues	$ 697.8	$ 660.6	$ 2,128.1	$ 1,496.4
Operating expenses:
Cost of sales	95.1	108.3	309.3	243.8
Selling and marketing	188.2	155.8	582.7	394.2
General and administrative	28	33.3	86.5	75.7
Segment Contribution	$ 386.5	$ 363.2	$ 1,149.6	$ 782.7
Contribution margin	55.40%	55.00%	54.00%	52.30%

Reportable Segments - Reconcili

Reportable Segments - Reconciliation of Net Revenues for Operating Segments (Detail) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Segment Reporting Information [Line Items]
Net revenues	$ 3,622.2	$ 3,469.5	$ 10,706.3	$ 9,081.2
Operating Segments [Member]
Segment Reporting Information [Line Items]
Net revenues	3,639.1	3,509.2	10,759.8	9,189.7
Corporate Revenues [Member]
Segment Reporting Information [Line Items]
Net revenues	$ (16.9)	$ (39.7)	$ (53.5)	$ (108.5)

Reportable Segments - Presents

Reportable Segments - Presents of Global Net Revenues by Segment (Detail) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	$ 3,622.2	$ 3,469.5	$ 10,706.3	$ 9,081.2
Global [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	3,622.2	3,469.5	10,706.3	9,081.2
Global [Member] | Botox [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	689.7	604.4	2,046.9	1,319.8
Global [Member] | Restasis [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	371.8	328.3	1,076.1	683.2
Global [Member] | Fillers [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	201.8	167.6	629.5	388.2
Global [Member] | Linzess And Constella [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	168.7	118.6	464.7	328
Global [Member] | Lumigan And Ganfort [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	164.9	157.9	509.6	355.6
Global [Member] | Bystolic [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	164.4	155.7	479.1	476.9
Global [Member] | Namenda XR [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	146.9	214.5	486.5	569.8
Global [Member] | Alphagan And Combigan [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	134.7	120.8	401.6	272.3
Global [Member] | Lo Loestrin [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	105.7	90.8	296	253.3
Global [Member] | Estrace Cream [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	98.6	87.4	276.4	229.4
Global [Member] | Viibryd/Fetzima [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	87.6	84.5	252.7	244.8
Global [Member] | Breast Implants [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	86.7	85.5	261.7	198.4
Global [Member] | Asacol/Delzicol [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	86.4	157.2	338.4	455.6
Global [Member] | Minastrin 24 [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	84.9	74.4	248.9	195.9
Global [Member] | Ozurdex [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	64.3	51.6	192	109.6
Global [Member] | Aczone [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	69	48	156.1	114.3
Global [Member] | Carafate And Sulcrate [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	57	52.9	169.4	153.4
Global [Member] | Namenda IR [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	2.9	54.9	12.8	532.9
Global [Member] | Other Products [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	859.9	857.9	2,487.9	2,313.6
Global [Member] | Less Product Sold Through Anda Distribution Business [Member] | Discontinued Operations [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	(23.7)	(43.4)	(80)	(113.8)
U.S. [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	2,924.4	2,808.9	8,578.2	7,584.8
U.S. [Member] | Botox [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	496.3	435.6	1,454	926.4
U.S. [Member] | Restasis [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	356.4	312.8	1,026.4	651.4
U.S. [Member] | Fillers [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	105	89.7	325.3	206.7
U.S. [Member] | Linzess And Constella [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	164.4	117.5	452	325.1
U.S. [Member] | Lumigan And Ganfort [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	78.3	71.7	240.4	165.9
U.S. [Member] | Bystolic [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	163.9	155.3	477.8	476.1
U.S. [Member] | Namenda XR [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	146.9	214.5	486.5	569.8
U.S. [Member] | Alphagan And Combigan [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	93.4	81.4	274.3	184.9
U.S. [Member] | Lo Loestrin [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	105.7	89.8	296	251.7
U.S. [Member] | Estrace Cream [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	98.6	87.4	276.4	229.4
U.S. [Member] | Viibryd/Fetzima [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	87.6	84.5	252.6	244.8
U.S. [Member] | Breast Implants [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	51.1	50.9	149.2	112.8
U.S. [Member] | Asacol/Delzicol [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	72.2	141.9	297.9	407.8
U.S. [Member] | Minastrin 24 [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	84.9	74.4	247.5	195.3
U.S. [Member] | Ozurdex [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	20.9	17.6	61.8	36.9
U.S. [Member] | Aczone [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	69	48	156.1	114.3
U.S. [Member] | Carafate And Sulcrate [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	56.4	52.9	167.7	153.4
U.S. [Member] | Namenda IR [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	2.9	54.9	12.8	532.9
U.S. [Member] | Other Products [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	694.2	671.5	2,003.5	1,913
U.S. [Member] | Less Product Sold Through Anda Distribution Business [Member] | Discontinued Operations [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	(23.7)	(43.4)	(80)	(113.8)
International [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	697.8	660.6	2,128.1	1,496.4
International [Member] | Botox [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	193.4	168.8	592.9	393.4
International [Member] | Restasis [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	15.4	15.5	49.7	31.8
International [Member] | Fillers [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	96.8	77.9	304.2	181.5
International [Member] | Linzess And Constella [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	4.3	1.1	12.7	2.9
International [Member] | Lumigan And Ganfort [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	86.6	86.2	269.2	189.7
International [Member] | Bystolic [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	0.5	0.4	1.3	0.8
International [Member] | Alphagan And Combigan [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	41.3	39.4	127.3	87.4
International [Member] | Lo Loestrin [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues		1		1.6
International [Member] | Viibryd/Fetzima [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues			0.1
International [Member] | Breast Implants [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	35.6	34.6	112.5	85.6
International [Member] | Asacol/Delzicol [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	14.2	15.3	40.5	47.8
International [Member] | Minastrin 24 [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues			1.4	0.6
International [Member] | Ozurdex [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	43.4	34	130.2	72.7
International [Member] | Carafate And Sulcrate [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	0.6		1.7
International [Member] | Other Products [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	$ 165.7	$ 186.4	$ 484.4	$ 400.6

Reportable Segments - Present74

Reportable Segments - Presents of Global Net Revenues by Segment (Parenthetical) (Detail) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	$ 3,622.2	$ 3,469.5	$ 10,706.3	$ 9,081.2
International [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	697.8	660.6	2,128.1	1,496.4
Other Products [Member] | International [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	$ 165.7	186.4	$ 484.4	$ 400.6
Reclassification of Continuing Operations from Discontinued Operations [Member] | Other Products [Member] | International [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues		$ 31.7

Reportable Segments - Schedul75

Reportable Segments - Schedule of Top Product Sales and Revenue, by Segment (Detail) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Segment Reporting Information [Line Items]
Net revenues	$ 3,622.2	$ 3,469.5	$ 10,706.3	$ 9,081.2
US Specialized Therapeutics [Member]
Segment Reporting Information [Line Items]
Net revenues	1,453.2	1,296.6	4,240.8	2,889.6
US Specialized Therapeutics [Member] | Total Eye Care [Member]
Segment Reporting Information [Line Items]
Net revenues	608.5	539.9	1,777.6	1,213.2
US Specialized Therapeutics [Member] | Total Eye Care [Member] | Restasis [Member]
Segment Reporting Information [Line Items]
Net revenues	356.4	312.8	1,026.4	651.4
US Specialized Therapeutics [Member] | Total Eye Care [Member] | Lumigan And Ganfort [Member]
Segment Reporting Information [Line Items]
Net revenues	78.3	71.7	240.4	165.9
US Specialized Therapeutics [Member] | Total Eye Care [Member] | Alphagan And Combigan [Member]
Segment Reporting Information [Line Items]
Net revenues	93.4	81.4	274.3	184.9
US Specialized Therapeutics [Member] | Total Eye Care [Member] | Ozurdex [Member]
Segment Reporting Information [Line Items]
Net revenues	20.9	17.6	61.8	36.9
US Specialized Therapeutics [Member] | Total Eye Care [Member] | Eye Drops [Member]
Segment Reporting Information [Line Items]
Net revenues	50.2	45.3	140.1	131.8
US Specialized Therapeutics [Member] | Total Eye Care [Member] | Other Eye Care [Member]
Segment Reporting Information [Line Items]
Net revenues	9.3	11.1	34.6	42.3
US Specialized Therapeutics [Member] | Total Medical Aesthetics [Member]
Segment Reporting Information [Line Items]
Net revenues	388.9	340.1	1,182.6	761.4
US Specialized Therapeutics [Member] | Facial Aesthetics [Member]
Segment Reporting Information [Line Items]
Net revenues	293.7	249	893.3	547.9
US Specialized Therapeutics [Member] | Facial Aesthetics [Member] | Botox Cosmetics [Member]
Segment Reporting Information [Line Items]
Net revenues	174.5	159.3	529.8	341.2
US Specialized Therapeutics [Member] | Facial Aesthetics [Member] | Fillers [Member]
Segment Reporting Information [Line Items]
Net revenues	105	89.7	325.3	206.7
US Specialized Therapeutics [Member] | Facial Aesthetics [Member] | Kybella [Member]
Segment Reporting Information [Line Items]
Net revenues	14.2		38.2
US Specialized Therapeutics [Member] | Plastic Surgery [Member]
Segment Reporting Information [Line Items]
Net revenues	52.2	54.3	153.1	122.5
US Specialized Therapeutics [Member] | Plastic Surgery [Member] | Breast Implants [Member]
Segment Reporting Information [Line Items]
Net revenues	51.1	50.9	149.2	112.8
US Specialized Therapeutics [Member] | Plastic Surgery [Member] | Other Plastic Surgery [Member]
Segment Reporting Information [Line Items]
Net revenues	1.1	3.4	3.9	9.7
US Specialized Therapeutics [Member] | Skin Care [Member]
Segment Reporting Information [Line Items]
Net revenues	43	36.8	136.2	91
US Specialized Therapeutics [Member] | Skin Care [Member] | SkinMedica [Member]
Segment Reporting Information [Line Items]
Net revenues	25.8	23	81.5	51.6
US Specialized Therapeutics [Member] | Skin Care [Member] | Latisse [Member]
Segment Reporting Information [Line Items]
Net revenues	17.2	13.8	54.7	39.4
US Specialized Therapeutics [Member] | Total Medical Dermatology [Member]
Segment Reporting Information [Line Items]
Net revenues	116.1	107.8	282.2	249.4
US Specialized Therapeutics [Member] | Total Medical Dermatology [Member] | Aczone [Member]
Segment Reporting Information [Line Items]
Net revenues	69	48	156.1	114.3
US Specialized Therapeutics [Member] | Total Medical Dermatology [Member] | Tazorac [Member]
Segment Reporting Information [Line Items]
Net revenues	27.5	27.6	68	65.7
US Specialized Therapeutics [Member] | Total Medical Dermatology [Member] | Botox Hyperhidrosis [Member]
Segment Reporting Information [Line Items]
Net revenues	16.3	15	48.9	35.5
US Specialized Therapeutics [Member] | Total Medical Dermatology [Member] | Other Medical Dermatology [Member]
Segment Reporting Information [Line Items]
Net revenues	3.3	17.2	9.2	33.9
US Specialized Therapeutics [Member] | Total Neuroscience and Urology [Member]
Segment Reporting Information [Line Items]
Net revenues	330.7	291.4	963.8	637.2
US Specialized Therapeutics [Member] | Total Neuroscience and Urology [Member] | Botox Therapeutics [Member]
Segment Reporting Information [Line Items]
Net revenues	305.5	261.3	875.3	549.7
US Specialized Therapeutics [Member] | Total Neuroscience and Urology [Member] | Rapaflo [Member]
Segment Reporting Information [Line Items]
Net revenues	25.2	30.1	87.6	87.5
US Specialized Therapeutics [Member] | Total Neuroscience and Urology [Member] | Other Neuroscience and Urology [Member]
Segment Reporting Information [Line Items]
Net revenues			0.9
US Specialized Therapeutics [Member] | Other Revenues [Member]
Segment Reporting Information [Line Items]
Net revenues	9	17.4	34.6	28.4
US General Medicine [Member]
Segment Reporting Information [Line Items]
Net revenues	1,488.1	1,552	4,390.9	4,803.7
US General Medicine [Member] | Other Revenues [Member]
Segment Reporting Information [Line Items]
Net revenues	54.1	25.9	78.3	57.5
US General Medicine [Member] | Total Central Nervous System (CNS) [Member]
Segment Reporting Information [Line Items]
Net revenues	325.5	406.7	964.6	1,485.1
US General Medicine [Member] | Total Central Nervous System (CNS) [Member] | Namenda XR [Member]
Segment Reporting Information [Line Items]
Net revenues	146.9	214.5	486.5	569.8
US General Medicine [Member] | Total Central Nervous System (CNS) [Member] | Viibryd/Fetzima [Member]
Segment Reporting Information [Line Items]
Net revenues	87.6	84.5	252.6	244.8
US General Medicine [Member] | Total Central Nervous System (CNS) [Member] | Saphris [Member]
Segment Reporting Information [Line Items]
Net revenues	40.8	51.1	123.6	134.3
US General Medicine [Member] | Total Central Nervous System (CNS) [Member] | Vraylar [Member]
Segment Reporting Information [Line Items]
Net revenues	32.4		51.1
US General Medicine [Member] | Total Central Nervous System (CNS) [Member] | Namzaric [Member]
Segment Reporting Information [Line Items]
Net revenues	14.9	1.7	38	3.3
US General Medicine [Member] | Total Central Nervous System (CNS) [Member] | Namenda IR [Member]
Segment Reporting Information [Line Items]
Net revenues	2.9	54.9	12.8	532.9
US General Medicine [Member] | Total Gastrointestinal (GI) [Member]
Segment Reporting Information [Line Items]
Net revenues	431.4	398.6	1,277	1,138.4
US General Medicine [Member] | Total Gastrointestinal (GI) [Member] | Linzess [Member]
Segment Reporting Information [Line Items]
Net revenues	164.4	117.5	452	325.1
US General Medicine [Member] | Total Gastrointestinal (GI) [Member] | Asacol/Delzicol [Member]
Segment Reporting Information [Line Items]
Net revenues	72.2	141.9	297.9	407.8
US General Medicine [Member] | Total Gastrointestinal (GI) [Member] | Carafate And Sulcrate [Member]
Segment Reporting Information [Line Items]
Net revenues	56.4	52.9	167.7	153.4
US General Medicine [Member] | Total Gastrointestinal (GI) [Member] | Zenpep [Member]
Segment Reporting Information [Line Items]
Net revenues	52.5	43.1	145.1	121.5
US General Medicine [Member] | Total Gastrointestinal (GI) [Member] | Canasa/Salofalk [Member]
Segment Reporting Information [Line Items]
Net revenues	47.2	34.6	135	102.2
US General Medicine [Member] | Total Gastrointestinal (GI) [Member] | Viberzi [Member]
Segment Reporting Information [Line Items]
Net revenues	30.9		55.3
US General Medicine [Member] | Total Gastrointestinal (GI) [Member] | Other GI [Member]
Segment Reporting Information [Line Items]
Net revenues	7.8	8.6	24	28.4
US General Medicine [Member] | Total Women's Health [Member]
Segment Reporting Information [Line Items]
Net revenues	305.3	268	865.1	716.7
US General Medicine [Member] | Total Women's Health [Member] | Lo Loestrin [Member]
Segment Reporting Information [Line Items]
Net revenues	105.7	89.8	296	251.7
US General Medicine [Member] | Total Women's Health [Member] | Minastrin 24 [Member]
Segment Reporting Information [Line Items]
Net revenues	84.9	74.4	247.5	195.3
US General Medicine [Member] | Total Women's Health [Member] | Estrace Cream [Member]
Segment Reporting Information [Line Items]
Net revenues	98.6	87.4	276.4	229.4
US General Medicine [Member] | Total Women's Health [Member] | Liletta [Member]
Segment Reporting Information [Line Items]
Net revenues	4.4	5.8	15	10.7
US General Medicine [Member] | Total Women's Health [Member] | Other Women's Health [Member]
Segment Reporting Information [Line Items]
Net revenues	11.7	10.6	30.2	29.6
US General Medicine [Member] | Total Anti-Infectives [Member]
Segment Reporting Information [Line Items]
Net revenues	52.5	52.3	167.1	138.3
US General Medicine [Member] | Total Anti-Infectives [Member] | Teflaro [Member]
Segment Reporting Information [Line Items]
Net revenues	33.3	35.8	101.9	105.3
US General Medicine [Member] | Total Anti-Infectives [Member] | Avycaz [Member]
Segment Reporting Information [Line Items]
Net revenues	4.8	7.5	26.9	12.9
US General Medicine [Member] | Total Anti-Infectives [Member] | Dalvance [Member]
Segment Reporting Information [Line Items]
Net revenues	10.3	4.9	26.7	11.3
US General Medicine [Member] | Total Anti-Infectives [Member] | Other Anti-Infectives [Member]
Segment Reporting Information [Line Items]
Net revenues	4.1	4.1	11.6	8.8
US General Medicine [Member] | Established Brands [Member]
Segment Reporting Information [Line Items]
Net revenues	319.3	400.5	1,038.8	1,267.7
US General Medicine [Member] | Established Brands [Member] | Bystolic [Member]
Segment Reporting Information [Line Items]
Net revenues	163.9	155.3	477.8	476.1
US General Medicine [Member] | Established Brands [Member] | Armour Thyroid [Member]
Segment Reporting Information [Line Items]
Net revenues	39.1	34.7	121.8	88.9
US General Medicine [Member] | Established Brands [Member] | Enablex [Member]
Segment Reporting Information [Line Items]
Net revenues	1.9	17.2	14.7	51.5
US General Medicine [Member] | Established Brands [Member] | Savella [Member]
Segment Reporting Information [Line Items]
Net revenues	28.1	29	74.1	80.6
US General Medicine [Member] | Established Brands [Member] | Lexapro [Member]
Segment Reporting Information [Line Items]
Net revenues	15.6	17.8	50.8	53.6
US General Medicine [Member] | Established Brands [Member] | PacPharma [Member]
Segment Reporting Information [Line Items]
Net revenues	6.2	27.4	49.7	56.6
US General Medicine [Member] | Established Brands [Member] | Other Established Brands [Member]
Segment Reporting Information [Line Items]
Net revenues	64.5	119.1	249.9	460.4
International Brands [Member]
Segment Reporting Information [Line Items]
Net revenues	697.8	660.6	2,128.1	1,496.4
International Brands [Member] | Total Eye Care [Member]
Segment Reporting Information [Line Items]
Net revenues	294.2	281.5	904.4	623.7
International Brands [Member] | Total Eye Care [Member] | Restasis [Member]
Segment Reporting Information [Line Items]
Net revenues	15.4	15.5	49.7	31.8
International Brands [Member] | Total Eye Care [Member] | Lumigan And Ganfort [Member]
Segment Reporting Information [Line Items]
Net revenues	86.6	86.2	269.2	189.7
International Brands [Member] | Total Eye Care [Member] | Alphagan And Combigan [Member]
Segment Reporting Information [Line Items]
Net revenues	41.3	39.4	127.3	87.4
International Brands [Member] | Total Eye Care [Member] | Ozurdex [Member]
Segment Reporting Information [Line Items]
Net revenues	43.4	34	130.2	72.7
International Brands [Member] | Total Eye Care [Member] | Other Eye Care [Member]
Segment Reporting Information [Line Items]
Net revenues	39.8	39.2	121.1	90.7
International Brands [Member] | Total Eye Care [Member] | Optive [Member]
Segment Reporting Information [Line Items]
Net revenues	25.6	23.2	75.7	51.9
International Brands [Member] | Total Eye Care [Member] | Other Eye Drops [Member]
Segment Reporting Information [Line Items]
Net revenues	42.1	44	131.2	99.5
International Brands [Member] | Total Medical Aesthetics [Member]
Segment Reporting Information [Line Items]
Net revenues	251	214.8	780	509.9
International Brands [Member] | Facial Aesthetics [Member]
Segment Reporting Information [Line Items]
Net revenues	212.6	176.5	658.7	416.4
International Brands [Member] | Facial Aesthetics [Member] | Botox Cosmetics [Member]
Segment Reporting Information [Line Items]
Net revenues	115.3	98.6	352.9	234.9
International Brands [Member] | Facial Aesthetics [Member] | Fillers [Member]
Segment Reporting Information [Line Items]
Net revenues	96.8	77.9	304.2	181.5
International Brands [Member] | Facial Aesthetics [Member] | Belkyra (Kybella) [Member]
Segment Reporting Information [Line Items]
Net revenues	0.5		1.6
International Brands [Member] | Plastic Surgery [Member]
Segment Reporting Information [Line Items]
Net revenues	35.8	34.6	112.9	85.6
International Brands [Member] | Plastic Surgery [Member] | Breast Implants [Member]
Segment Reporting Information [Line Items]
Net revenues	35.6	34.6	112.5	85.6
International Brands [Member] | Plastic Surgery [Member] | Earfold [Member]
Segment Reporting Information [Line Items]
Net revenues	0.2		0.4
International Brands [Member] | Skin Care [Member]
Segment Reporting Information [Line Items]
Net revenues	2.6	3.7	8.4	7.9
International Brands [Member] | Other Revenues [Member]
Segment Reporting Information [Line Items]
Net revenues	18	8.8	44.7	41.3
International Brands [Member] | Botox Therapeutics and Other [Member]
Segment Reporting Information [Line Items]
Net revenues	134.6	155.5	399	321.5
International Brands [Member] | Botox Therapeutics and Other [Member] | Botox Therapeutics [Member]
Segment Reporting Information [Line Items]
Net revenues	78.1	70.2	240	158.5
International Brands [Member] | Botox Therapeutics and Other [Member] | Asacol/Delzicol [Member]
Segment Reporting Information [Line Items]
Net revenues	14.2	15.3	40.5	47.8
International Brands [Member] | Botox Therapeutics and Other [Member] | Constella [Member]
Segment Reporting Information [Line Items]
Net revenues	4.3	1.1	12.7	2.9
International Brands [Member] | Botox Therapeutics and Other [Member] | Other Products [Member]
Segment Reporting Information [Line Items]
Net revenues	$ 38	$ 68.9	$ 105.8	$ 112.3

Reportable Segments - Schedul76

Reportable Segments - Schedule of Top Product Sales and Revenue, by Segment (Parenthetical) (Detail) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Segment Reporting Information [Line Items]
Net Revenue	$ 3,622.2	$ 3,469.5	$ 10,706.3	$ 9,081.2
International [Member]
Segment Reporting Information [Line Items]
Net Revenue	697.8	660.6	2,128.1	1,496.4
International [Member] | Other Products [Member]
Segment Reporting Information [Line Items]
Net Revenue	$ 165.7	186.4	$ 484.4	$ 400.6
Reclassification of Continuing Operations from Discontinued Operations [Member] | International [Member] | Other Products [Member]
Segment Reporting Information [Line Items]
Net Revenue		$ 31.7

Inventories - Schedule of Inven

Inventories - Schedule of Inventories (Detail) - USD ($) $ in Millions	Sep. 30, 2016	Dec. 31, 2015
Inventory Disclosure [Abstract]
Raw materials	$ 276.2	$ 242.4
Work-in-process	142.2	149.7
Finished goods	389.5	451.9
Inventories, gross	807.9	844
Less: inventory reserves	102.4	86.5
Total Inventories	$ 705.5	$ 757.5

Inventories - Additional Inform

Inventories - Additional Information (Detail) $ in Millions	12 Months Ended
	Dec. 31, 2015USD ($)
Inventory Disclosure [Abstract]
Inventory, finished goods	$ 46.1

Investments and Other Assets -

Investments and Other Assets - Marketable Securities, Including Cash and Cash Equivalents, Other Investments and Other Assets (Detail) - USD ($) $ in Millions	Sep. 30, 2016	Dec. 31, 2015
Marketable securities:
Total marketable securities	$ 19,837.6	$ 9.3
Investments and other assets:
Legacy Allergan deferred executive compensation investments	114.3	118.1
Equity method investments	13	17.3
Cost method investments	15	16.7
Other long-term investments	70.5	78.2
Taxes receivable	41.4	39.6
Other assets	86.9	138.8
Total investments and other assets	341.1	408.7
U.S. Treasury and Agency Securities - Maturing Within One Year [Member]
Marketable securities:
U.S. Treasury and agency securities	15,463.2	$ 9.3
Teva [Member]
Marketable securities:
U.S. Treasury and agency securities	$ 4,374.4

Investments and Other Assets 80

Investments and Other Assets - Investments in Securities (Detail) - USD ($) $ in Millions	Sep. 30, 2016	Dec. 31, 2015
Schedule Of Available For Sale Securities [Line Items]
Marketable securities	$ 19,837.6	$ 9.3
Level 1 [Member]
Schedule Of Available For Sale Securities [Line Items]
Carrying amount	6,257.1
Estimated fair value	6,257.1
Cash & cash equivalents	6,257.1
Level 1 [Member] | Money Market Funds [Member]
Schedule Of Available For Sale Securities [Line Items]
Carrying amount	4,649.4
Estimated fair value	4,649.4
Cash & cash equivalents	4,649.4
Level 1 [Member] | Commercial Paper [Member]
Schedule Of Available For Sale Securities [Line Items]
Carrying amount	1,357.7
Estimated fair value	1,357.7
Cash & cash equivalents	1,357.7
Level 1 [Member] | Certificates of Deposit [Member]
Schedule Of Available For Sale Securities [Line Items]
Carrying amount	250
Estimated fair value	250
Cash & cash equivalents	250
Level 2 [Member]
Schedule Of Available For Sale Securities [Line Items]
Marketable securities	19,837.6
Carrying amount	20,494.7
Unrecognized gain	7.1
Unrecognized loss	(664.2)
Estimated fair value	19,837.6
Level 2 [Member] | Commercial Paper [Member]
Schedule Of Available For Sale Securities [Line Items]
Carrying amount	11,155.1
Unrecognized gain	6.9
Estimated fair value	11,162
Marketable securities	11,162
Level 2 [Member] | Certificates of Deposit [Member]
Schedule Of Available For Sale Securities [Line Items]
Carrying amount	4,301
Unrecognized gain	0.2
Estimated fair value	4,301.2
Marketable securities	4,301.2
Level 2 [Member] | Investment In Teva Ordinary Shares [Member]
Schedule Of Available For Sale Securities [Line Items]
Marketable securities	4,374.4
Carrying amount	5,038.6
Unrecognized loss	(664.2)
Estimated fair value	$ 4,374.4

Accounts Payable and Accrued 81

Accounts Payable and Accrued Expenses - Summary of Accounts Payable and Accrued Expenses (Detail) - USD ($) $ in Millions	Sep. 30, 2016	Dec. 31, 2015	Sep. 30, 2015
Accrued expenses:
Accrued third-party rebates	$ 1,513.6	$ 1,281.6
Accrued payroll and related benefits	446.2	401
Accrued stock repurchases	400
Accrued pharmaceutical fees	388.1	162.2
Current portion of contingent consideration obligations	349.1	79.9
Accrued returns	283.7	288.4
Interest payable	170.4	312
Royalties payable	167.2	119.1
Litigation-related reserves and legal fees	139.9	191.7
Accrued R&D expenditures	111.7	384.1
Accrued severance, retention and other shutdown costs	83.7	108.5
Accrued non-provision taxes	47.2	98.1
Accrued selling and marketing expenditures	29.6	127.2
Dividends payable	24.2	24	$ 24
Other accrued expenses	472.7	354.9
Total accrued expenses	5,128.9	3,932.7
Accounts payable	296.5	215.9
Total accounts payable and accrued expenses	5,425.4	$ 4,148.6
Teva Pharmaceutical Industries Ltd [Member]
Accrued expenses:
Contractual commitments related to the Teva Transaction	$ 501.6

Goodwill, Product Rights and 82

Goodwill, Product Rights and Other Intangible Assets - Schedule of Goodwill (Detail) $ in Millions	9 Months Ended
	Sep. 30, 2016USD ($)
Goodwill [Line Items]
Balance as of December 31, 2015	$ 46,465.2
Additions through acquisitions	54.2
Foreign exchange and other adjustments	106.4
Balance as of September 30, 2016	46,625.8
US Specialized Therapeutics [Member]
Goodwill [Line Items]
Balance as of December 31, 2015	18,347.2
Additions through acquisitions	54.2
Balance as of September 30, 2016	18,401.4
US General Medicine [Member]
Goodwill [Line Items]
Balance as of December 31, 2015	21,340.5
Foreign exchange and other adjustments	(26.6)
Balance as of September 30, 2016	21,313.9
International [Member]
Goodwill [Line Items]
Balance as of December 31, 2015	6,777.5
Foreign exchange and other adjustments	133
Balance as of September 30, 2016	$ 6,910.5

Goodwill, Product Rights and 83

Goodwill, Product Rights and Other Intangible Assets - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015
Goodwill [Line Items]
Gross balance of goodwill	$ 46,643.1	$ 46,643.1		$ 46,482.5
Goodwill in discontinued operations	86.3	86.3		$ 6,096
Addition to goodwill		54.2
In-process research and development impairments		316.9	$ 497.6
Total Gastrointestinal (GI) [Member]
Goodwill [Line Items]
In-process research and development impairments	42	42
Osteoarthritis Research and Development Project [Member]
Goodwill [Line Items]
In-process research and development impairments		190
International Eye Care Pipeline Project [Member]
Goodwill [Line Items]
In-process research and development impairments		35
Botox Therapeutic Product [Member]
Goodwill [Line Items]
In-process research and development impairments		20
Women's Healthcare Research and Development Project [Member]
Goodwill [Line Items]
In-process research and development impairments		24
ForSight [Member]
Goodwill [Line Items]
Addition to goodwill		54.2
ForSight [Member] | IPR&D [Member]
Goodwill [Line Items]
IPR&D intangible assets	$ 158	$ 158

Goodwill, Product Rights and 84

Goodwill, Product Rights and Other Intangible Assets - Schedule of Cost Basis on Product Rights and Other Intangible Assets (Detail) - USD ($)	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015
Finite And Indefinite Lived Intangible Assets By Major Class [Line Items]
Intangible assets, gross, Amortization	$ (4,836,700,000)	$ (4,192,800,000)
Intangibles with indefinite lives, Impairments	(316,900,000)	$ (497,600,000)
Product rights and other intangibles	63,022,700,000		$ 67,836,200,000
Trade Name [Member]
Finite And Indefinite Lived Intangible Assets By Major Class [Line Items]
Intangibles with indefinite lives, Impairments	0
Cost Basis [Member]
Finite And Indefinite Lived Intangible Assets By Major Class [Line Items]
Intangibles with definite lives, Beginning balance	65,056,000,000
Intangibles with definite lives, Acquisitions	41,600,000
Intangibles with definite lives, IPR&D to CMP Transfers	1,342,400,000
Intangibles with definite lives Disposals/Held for Sale/Other	(194,600,000)
Intangibles with definite lives, Foreign Currency Translation	108,600,000
Intangibles with definite lives, Ending balance	66,354,000,000
Intangibles with indefinite lives, Beginning balance	11,128,200,000
Intangibles with indefinite lives, Acquisitions	158,000,000
Intangibles with indefinite lives, Impairments	(316,900,000)
Intangibles with indefinite lives, IPR&D to CMP Transfers	(1,342,400,000)
Intangibles with indefinite lives, Foreign Currency Translation	15,900,000
Intangibles with indefinite lives, Ending balance	9,642,800,000
Intangible assets, gross, Beginning balance	76,184,200,000
Intangible assets, gross, Acquisitions	199,600,000
Intangible assets, gross, Impairments	(316,900,000)
Intangibles assets, Held For Sale/Disposals/Other	(194,600,000)
Intangibles assets, gross, Foreign Currency Translation	124,500,000
Intangible assets, gross, Ending balance	75,996,800,000
Cost Basis [Member] | Product Rights and Other Related Intangibles [Member]
Finite And Indefinite Lived Intangible Assets By Major Class [Line Items]
Intangibles with definite lives, Beginning balance	64,366,000,000
Intangibles with definite lives, Acquisitions	41,600,000
Intangibles with definite lives, IPR&D to CMP Transfers	1,342,400,000
Intangibles with definite lives Disposals/Held for Sale/Other	(194,600,000)
Intangibles with definite lives, Foreign Currency Translation	108,600,000
Intangibles with definite lives, Ending balance	65,664,000,000
Cost Basis [Member] | Trade Name [Member]
Finite And Indefinite Lived Intangible Assets By Major Class [Line Items]
Intangibles with definite lives, Beginning balance	690,000,000
Intangibles with definite lives, Ending balance	690,000,000
Cost Basis [Member] | IPR&D [Member]
Finite And Indefinite Lived Intangible Assets By Major Class [Line Items]
Intangibles with indefinite lives, Beginning balance	11,128,200,000
Intangibles with indefinite lives, Acquisitions	158,000,000
Intangibles with indefinite lives, Impairments	(316,900,000)
Intangibles with indefinite lives, IPR&D to CMP Transfers	(1,342,400,000)
Intangibles with indefinite lives, Foreign Currency Translation	15,900,000
Intangibles with indefinite lives, Ending balance	9,642,800,000
Accumulated Amortization [Member]
Finite And Indefinite Lived Intangible Assets By Major Class [Line Items]
Intangible assets, Accumulated Amortization, Beginning balance	(8,348,000,000)
Intangible assets, gross, Amortization	(4,831,900,000)
Intangibles with definite lives, Disposals/Other	176,900,000
Intangibles with definite lives, Foreign Currency Translation	28,900,000
Intangibles assets, gross, Foreign Currency Translation	28,900,000
Intangible assets, Accumulated Amortization, Ending balance	(12,974,100,000)
Intangible assets gross, Disposals/Other	176,900,000
Accumulated Amortization [Member] | Product Rights and Other Related Intangibles [Member]
Finite And Indefinite Lived Intangible Assets By Major Class [Line Items]
Intangible assets, Accumulated Amortization, Beginning balance	(8,288,500,000)
Intangible assets, gross, Amortization	(4,773,600,000)
Intangibles with definite lives, Disposals/Other	176,900,000
Intangibles with definite lives, Foreign Currency Translation	28,900,000
Intangible assets, Accumulated Amortization, Ending balance	(12,856,300,000)
Accumulated Amortization [Member] | Trade Name [Member]
Finite And Indefinite Lived Intangible Assets By Major Class [Line Items]
Intangible assets, Accumulated Amortization, Beginning balance	(59,500,000)
Intangible assets, gross, Amortization	(58,300,000)
Intangible assets, Accumulated Amortization, Ending balance	$ (117,800,000)

Goodwill, Product Rights and 85

Goodwill, Product Rights and Other Intangible Assets - Schedule of Annual Amortization Expense on Product Rights and Other Related Intangibles (Detail) - Product Rights and Other Related Intangibles [Member] $ in Millions	Sep. 30, 2016USD ($)
Finite Lived Intangible Assets [Line Items]
2016 remaining	$ 1,610.9
2,017	6,474.4
2,018	5,964.4
2,019	5,857.4
2,020	5,606.1
2,021	$ 4,732.6

Long-Term Debt and Capital Le86

Long-Term Debt and Capital Leases - Schedule of Long-Term Debt and Capital Leases (Detail) - USD ($) $ in Millions	Sep. 30, 2016	Dec. 31, 2015
Debt Instrument [Line Items]
Total Senior Notes Gross	$ 32,750	$ 34,050
Unamortized premium	182.8	225.9
Unamortized discount	(98.7)	(107.4)
Total Senior Notes Net	32,834.1	34,168.5
Senior Notes, Fair Market Value	34,402.1	34,100.5
Total Term Loan Indebtedness		8,256.2
Revolver Borrowings		200
Debt Issuance Costs	(151.5)	(195.8)
Total Other Borrowings	(66.3)	101.6
Total Indebtedness	32,770	42,530.4
Capital Leases [Member]
Debt Instrument [Line Items]
Total Term Loan Indebtedness	2.2	4.1
Floating Rate Notes [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross	1,000	1,500
Senior Notes, Fair Market Value	1,013	1,496.3
Floating Rate Notes [Member] | Notes Due September 1, 2016 [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross		500
Senior Notes, Fair Market Value		500.5
Floating Rate Notes [Member] | Notes Due March 12, 2018 [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross	500	500
Senior Notes, Fair Market Value	504	499.6
Floating Rate Notes [Member] | Notes Due March 12, 2020 [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross	500	500
Senior Notes, Fair Market Value	509	496.2
Fixed Rate Notes [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross	31,750	32,550
Senior Notes, Fair Market Value	33,389.1	32,604.2
Fixed Rate Notes [Member] | 5.750% Notes Due April 1, 2016 [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross		800
Senior Notes, Fair Market Value		808.4
Fixed Rate Notes [Member] | 1.850% Notes Due March 1, 2017 [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross	1,000	1,000
Senior Notes, Fair Market Value	1,002.3	1,001.5
Fixed Rate Notes [Member] | 1.300% Notes Due June 15, 2017 [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross	500	500
Senior Notes, Fair Market Value	499.6	496.3
Fixed Rate Notes [Member] | 1.875% Notes Due October 1, 2017 [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross	1,200	1,200
Senior Notes, Fair Market Value	1,204.2	1,196
Fixed Rate Notes [Member] | 2.350% Notes Due March 12, 2018 [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross	3,000	3,000
Senior Notes, Fair Market Value	3,031	3,004.6
Fixed Rate Notes [Member] | 1.350% Notes Due March 15, 2018 [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross	250	250
Senior Notes, Fair Market Value	248.9	244.9
Fixed Rate Notes [Member] | 4.375% Notes Due February 1, 2019 [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross	1,050	1,050
Senior Notes, Fair Market Value	1,105.8	1,099.5
Fixed Rate Notes [Member] | 2.450% Notes Due June 15, 2019 [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross	500	500
Senior Notes, Fair Market Value	508.2	494.4
Fixed Rate Notes [Member] | 6.125% Senior Notes Due August 14, 2019 [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross	400	400
Senior Notes, Fair Market Value	447.4	444.2
Fixed Rate Notes [Member] | 3.000% notes due March 12, 2020 [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross	3,500	3,500
Senior Notes, Fair Market Value	3,614.5	3,505.1
Fixed Rate Notes [Member] | 3.375% Notes Due September 15, 2020 [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross	650	650
Senior Notes, Fair Market Value	680.3	656.6
Fixed Rate Notes [Member] | 4.875% Notes Due February 15, 2021 [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross	750	750
Senior Notes, Fair Market Value	830.2	807.4
Fixed Rate Notes [Member] | 5.000% Notes Due December 15, 2021 [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross	1,200	1,200
Senior Notes, Fair Market Value	1,345.6	1,299.4
Fixed Rate Notes [Member] | 3.450% notes due March 15, 2022 [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross	3,000	3,000
Senior Notes, Fair Market Value	3,149.5	3,006.8
Fixed Rate Notes [Member] | 3.250% Notes Due October 1, 2022 [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross	1,700	1,700
Senior Notes, Fair Market Value	1,759.6	1,669.6
Fixed Rate Notes [Member] | 2.800% Notes Due March 15, 2023 [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross	350	350
Senior Notes, Fair Market Value	348.1	327.7
Fixed Rate Notes [Member] | 3.850% Notes Due June 15, 2024 [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross	1,200	1,200
Senior Notes, Fair Market Value	1,274	1,202.6
Fixed Rate Notes [Member] | 3.800% notes due March 15, 2025 [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross	4,000	4,000
Senior Notes, Fair Market Value	4,227.2	3,984.6
Fixed Rate Notes [Member] | 4.550% notes due March 15, 2035 [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross	2,500	2,500
Senior Notes, Fair Market Value	2,653.1	2,462.2
Fixed Rate Notes [Member] | 4.625% Notes Due October 1, 2042 [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross	1,000	1,000
Senior Notes, Fair Market Value	1,066.8	956.1
Fixed Rate Notes [Member] | 4.850% Notes Due June 15, 2044 [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross	1,500	1,500
Senior Notes, Fair Market Value	1,653	1,483.6
Fixed Rate Notes [Member] | 4.750% notes due March 15, 2045 [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross	2,500	2,500
Senior Notes, Fair Market Value	2,739.8	2,452.7
Variable Rate Debt [Member] | WC Three Year Tranche Maturing October 1, 2016 [Member]
Debt Instrument [Line Items]
Total Term Loan Indebtedness		191.5
Variable Rate Debt [Member] | WC Five Year Trance Maturing October 1, 2018 [Member]
Debt Instrument [Line Items]
Total Term Loan Indebtedness		498.8
Variable Rate Debt [Member] | WC Term Loan [Member]
Debt Instrument [Line Items]
Total Term Loan Indebtedness		690.3
Variable Rate Debt [Member] | Act Term Loan Agreement Maturing October 31, 2017 [Member]
Debt Instrument [Line Items]
Total Term Loan Indebtedness		572.1
Variable Rate Debt [Member] | Act Term Loan Amendment Maturing July 1, 2019 [Member]
Debt Instrument [Line Items]
Total Term Loan Indebtedness		1,700
Variable Rate Debt [Member] | ACT Term Loan [Member]
Debt Instrument [Line Items]
Total Term Loan Indebtedness		2,272.1
Variable Rate Debt [Member] | AGN Tranche Three Maturing March 17, 2018 [Member]
Debt Instrument [Line Items]
Total Term Loan Indebtedness		2,750
Variable Rate Debt [Member] | AGN Tranche Five Maturing March 17, 2020 [Member]
Debt Instrument [Line Items]
Total Term Loan Indebtedness		2,543.8
Variable Rate Debt [Member] | AGN Term Loan [Member]
Debt Instrument [Line Items]
Total Term Loan Indebtedness		5,293.8
Other [Member]
Debt Instrument [Line Items]
Total Other Borrowings	$ 85.2	$ 97.4

Long-Term Debt and Capital Le87

Long-Term Debt and Capital Leases - Schedule of Long-Term Debt and Capital Leases (Parenthetical) (Detail)	Dec. 17, 2014	Sep. 30, 2016	Dec. 31, 2015
Floating Rate Notes [Member] | Notes Due September 1, 2016 [Member]
Debt Instrument [Line Items]
Senior notes, maturity date		Sep. 1, 2016	Sep. 1, 2016
Floating Rate Notes [Member] | Notes Due March 12, 2018 [Member]
Debt Instrument [Line Items]
Senior notes, maturity date		Mar. 12, 2018	Mar. 12, 2018
Floating Rate Notes [Member] | Notes Due March 12, 2020 [Member]
Debt Instrument [Line Items]
Senior notes, maturity date		Mar. 12, 2020	Mar. 12, 2020
Fixed Rate Notes [Member] | 5.750% Notes Due April 1, 2016 [Member]
Debt Instrument [Line Items]
Senior notes, maturity date		Apr. 1, 2016	Apr. 1, 2016
Senior notes, interest rate		5.75%	5.75%
Fixed Rate Notes [Member] | 1.850% Notes Due March 1, 2017 [Member]
Debt Instrument [Line Items]
Senior notes, maturity date		Mar. 1, 2017	Mar. 1, 2017
Senior notes, interest rate		1.85%	1.85%
Fixed Rate Notes [Member] | 1.300% Notes Due June 15, 2017 [Member]
Debt Instrument [Line Items]
Senior notes, maturity date		Jun. 15, 2017	Jun. 15, 2017
Senior notes, interest rate		1.30%	1.30%
Fixed Rate Notes [Member] | 1.875% Notes Due October 1, 2017 [Member]
Debt Instrument [Line Items]
Senior notes, maturity date		Oct. 1, 2017	Oct. 1, 2017
Senior notes, interest rate		1.875%	1.875%
Fixed Rate Notes [Member] | 2.350% Notes Due March 12, 2018 [Member]
Debt Instrument [Line Items]
Senior notes, maturity date		Mar. 12, 2018	Mar. 12, 2018
Senior notes, interest rate		2.35%	2.35%
Fixed Rate Notes [Member] | 1.350% Notes Due March 15, 2018 [Member]
Debt Instrument [Line Items]
Senior notes, maturity date		Mar. 15, 2018	Mar. 15, 2018
Senior notes, interest rate		1.35%	1.35%
Fixed Rate Notes [Member] | 4.375% Notes Due February 1, 2019 [Member]
Debt Instrument [Line Items]
Senior notes, maturity date		Feb. 1, 2019	Feb. 1, 2019
Senior notes, interest rate		4.375%	4.375%
Fixed Rate Notes [Member] | 2.450% Notes Due June 15, 2019 [Member]
Debt Instrument [Line Items]
Senior notes, maturity date		Jun. 15, 2019	Jun. 15, 2019
Senior notes, interest rate		2.45%	2.45%
Fixed Rate Notes [Member] | 6.125% Senior Notes Due August 14, 2019 [Member]
Debt Instrument [Line Items]
Senior notes, maturity date		Aug. 14, 2019	Aug. 14, 2019
Senior notes, interest rate		6.125%	6.125%
Fixed Rate Notes [Member] | 3.000% notes due March 12, 2020 [Member]
Debt Instrument [Line Items]
Senior notes, maturity date		Mar. 12, 2020	Mar. 12, 2020
Senior notes, interest rate		3.00%	3.00%
Fixed Rate Notes [Member] | 3.375% Notes Due September 15, 2020 [Member]
Debt Instrument [Line Items]
Senior notes, maturity date		Sep. 15, 2020	Sep. 15, 2020
Senior notes, interest rate		3.375%	3.375%
Fixed Rate Notes [Member] | 4.875% Notes Due February 15, 2021 [Member]
Debt Instrument [Line Items]
Senior notes, maturity date		Feb. 15, 2021	Feb. 15, 2021
Senior notes, interest rate		4.875%	4.875%
Fixed Rate Notes [Member] | 5.000% Notes Due December 15, 2021 [Member]
Debt Instrument [Line Items]
Senior notes, maturity date		Dec. 15, 2021	Dec. 15, 2021
Senior notes, interest rate		5.00%	5.00%
Fixed Rate Notes [Member] | 3.450% notes due March 15, 2022 [Member]
Debt Instrument [Line Items]
Senior notes, maturity date		Mar. 15, 2022	Mar. 15, 2022
Senior notes, interest rate		3.45%	3.45%
Fixed Rate Notes [Member] | 3.250% Notes Due October 1, 2022 [Member]
Debt Instrument [Line Items]
Senior notes, maturity date		Oct. 1, 2022	Oct. 1, 2022
Senior notes, interest rate		3.25%	3.25%
Fixed Rate Notes [Member] | 2.800% Notes Due March 15, 2023 [Member]
Debt Instrument [Line Items]
Senior notes, maturity date		Mar. 15, 2023	Mar. 15, 2023
Senior notes, interest rate		2.80%	2.80%
Fixed Rate Notes [Member] | 3.850% Notes Due June 15, 2024 [Member]
Debt Instrument [Line Items]
Senior notes, maturity date		Jun. 15, 2024	Jun. 15, 2024
Senior notes, interest rate		3.85%	3.85%
Fixed Rate Notes [Member] | 3.800% notes due March 15, 2025 [Member]
Debt Instrument [Line Items]
Senior notes, maturity date		Mar. 15, 2025	Mar. 15, 2025
Senior notes, interest rate		3.80%	3.80%
Fixed Rate Notes [Member] | 4.550% notes due March 15, 2035 [Member]
Debt Instrument [Line Items]
Senior notes, maturity date		Mar. 15, 2035	Mar. 15, 2035
Senior notes, interest rate		4.55%	4.55%
Fixed Rate Notes [Member] | 4.625% Notes Due October 1, 2042 [Member]
Debt Instrument [Line Items]
Senior notes, maturity date		Oct. 1, 2042	Oct. 1, 2042
Senior notes, interest rate		4.625%	4.625%
Fixed Rate Notes [Member] | 4.850% Notes Due June 15, 2044 [Member]
Debt Instrument [Line Items]
Senior notes, maturity date		Jun. 15, 2044	Jun. 15, 2044
Senior notes, interest rate		4.85%	4.85%
Fixed Rate Notes [Member] | 4.750% notes due March 15, 2045 [Member]
Debt Instrument [Line Items]
Senior notes, maturity date		Mar. 15, 2045	Mar. 15, 2045
Senior notes, interest rate		4.75%	4.75%
Variable Rate Debt [Member] | WC Three Year Tranche Maturing October 1, 2016 [Member]
Debt Instrument [Line Items]
Senior notes, maturity date		Oct. 1, 2016	Oct. 1, 2016
Variable Rate Debt [Member] | WC Five Year Trance Maturing October 1, 2018 [Member]
Debt Instrument [Line Items]
Senior notes, maturity date		Oct. 1, 2018	Oct. 1, 2018
Variable Rate Debt [Member] | Act Term Loan Agreement Maturing October 31, 2017 [Member]
Debt Instrument [Line Items]
Senior notes, maturity date		Oct. 31, 2017	Oct. 31, 2017
Variable Rate Debt [Member] | Act Term Loan Amendment Maturing July 1, 2019 [Member]
Debt Instrument [Line Items]
Senior notes, maturity date		Jul. 1, 2019	Jul. 1, 2019
Variable Rate Debt [Member] | AGN Tranche Three Maturing March 17, 2018 [Member]
Debt Instrument [Line Items]
Senior notes, maturity date	Mar. 17, 2018	Mar. 17, 2018	Mar. 17, 2018
Variable Rate Debt [Member] | AGN Tranche Five Maturing March 17, 2020 [Member]
Debt Instrument [Line Items]
Senior notes, maturity date	Mar. 17, 2020	Mar. 17, 2020	Mar. 17, 2020

Long-Term Debt and Capital Le88

Long-Term Debt and Capital Leases - Floating Rate Notes - Additional Information (Detail) - Floating Rate Notes [Member]	9 Months Ended
	Sep. 30, 2016
Debt Instrument [Line Items]
Debt instrument variable rate basis	Three-month LIBOR
Interest payment terms	Interest on the 2018 Floating Rate Notes and the 2020 Floating Rate Notes is payable quarterly on March 12, June 12, September 12 and December 12 of each year, and began on June 12, 2015.
Notes Due September 1, 2016 [Member]
Debt Instrument [Line Items]
Percentage of margin	0.875%
Notes Due March 12, 2018 [Member]
Debt Instrument [Line Items]
Percentage of margin	1.08%
Notes Due March 12, 2020 [Member]
Debt Instrument [Line Items]
Percentage of margin	1.255%

Long-Term Debt and Capital Le89

Long-Term Debt and Capital Leases - Fixed Rate Notes - Additional Information (Detail) - USD ($) $ in Millions	Apr. 02, 2016	Mar. 17, 2015	Mar. 31, 2016	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015
Debt Instrument [Line Items]
Senior notes, gross				$ 32,750		$ 34,050
Senior Notes, Fair Market Value				34,402.1		34,100.5
Unamortized premium				182.8		225.9
Proceeds from borrowings on credit facility and other				1,050	$ 2,882
Fixed Rate Notes [Member]
Debt Instrument [Line Items]
Senior notes, gross				31,750		32,550
Senior Notes, Fair Market Value				$ 33,389.1		$ 32,604.2
Repayments of senior notes	$ 800
Fixed Rate Notes [Member] | Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Proceeds from borrowings on credit facility and other			$ 900
Fixed Rate Notes [Member] | 2.800% Notes Due March 15, 2023 [Member]
Debt Instrument [Line Items]
Senior notes, maturity date				Mar. 15, 2023		Mar. 15, 2023
Senior notes, interest rate				2.80%		2.80%
Senior notes, gross				$ 350		$ 350
Senior Notes, Fair Market Value				$ 348.1		$ 327.7
Fixed Rate Notes [Member] | 3.375% Notes Due September 15, 2020 [Member]
Debt Instrument [Line Items]
Senior notes, maturity date				Sep. 15, 2020		Sep. 15, 2020
Senior notes, interest rate				3.375%		3.375%
Senior notes, gross				$ 650		$ 650
Senior Notes, Fair Market Value				$ 680.3		$ 656.6
Fixed Rate Notes [Member] | 1.350% Notes Due March 15, 2018 [Member]
Debt Instrument [Line Items]
Senior notes, maturity date				Mar. 15, 2018		Mar. 15, 2018
Senior notes, interest rate				1.35%		1.35%
Senior notes, gross				$ 250		$ 250
Senior Notes, Fair Market Value				$ 248.9		$ 244.9
Fixed Rate Notes [Member] | 5.750% Notes Due April 1, 2016 [Member]
Debt Instrument [Line Items]
Senior notes, maturity date				Apr. 1, 2016		Apr. 1, 2016
Senior notes, interest rate				5.75%		5.75%
Senior notes, gross						$ 800
Senior Notes, Fair Market Value						$ 808.4
Fixed Rate Notes [Member] | Allergan Acquisition [Member]
Debt Instrument [Line Items]
Senior Notes, Fair Market Value		$ 2,087.5
Unamortized premium		$ 37.5
Fixed Rate Notes [Member] | Allergan Acquisition [Member] | 2.800% Notes Due March 15, 2023 [Member]
Debt Instrument [Line Items]
Senior notes, maturity date		Mar. 15, 2023
Interest payment terms				semi-annually
Senior notes, interest rate		2.80%
Senior notes, gross		$ 350
Fixed Rate Notes [Member] | Allergan Acquisition [Member] | 3.375% Notes Due September 15, 2020 [Member]
Debt Instrument [Line Items]
Senior notes, maturity date		Sep. 15, 2020
Interest payment terms				semi-annually
Senior notes, interest rate		3.375%
Senior notes, gross		$ 650
Fixed Rate Notes [Member] | Allergan Acquisition [Member] | 1.350% Notes Due March 15, 2018 [Member]
Debt Instrument [Line Items]
Senior notes, maturity date		Mar. 15, 2018
Interest payment terms				semi-annually
Senior notes, interest rate		1.35%
Senior notes, gross		$ 250
Fixed Rate Notes [Member] | Allergan Acquisition [Member] | 5.750% Notes Due April 1, 2016 [Member]
Debt Instrument [Line Items]
Senior notes, maturity date		Apr. 1, 2016
Interest payment terms				semi-annually
Senior notes, interest rate		5.75%
Senior notes, gross		$ 800

Long-Term Debt and Capital Le90

Long-Term Debt and Capital Leases - WC Term Loan - Additional Information (Detail) - WC Term Loan Agreement [Member] - USD ($)	Oct. 02, 2013	Sep. 30, 2016	Oct. 01, 2013
Debt Instrument [Line Items]
Maximum borrowing capacity			$ 2,000,000,000
Cash on hand	$ 41,000,000
Three Year Tranche [Member]
Debt Instrument [Line Items]
Maximum borrowing capacity			1,000,000,000
Debt instrument, maturity date		Oct. 1, 2016
Three Year Tranche [Member] | Base Rate [Member] | Minimum [Member]
Debt Instrument [Line Items]
Percentage of margin		0.00%
Three Year Tranche [Member] | Base Rate [Member] | Maximum [Member]
Debt Instrument [Line Items]
Percentage of margin		0.75%
Three Year Tranche [Member] | Eurodollar [Member] | Minimum [Member]
Debt Instrument [Line Items]
Percentage of margin		1.00%
Three Year Tranche [Member] | Eurodollar [Member] | Maximum [Member]
Debt Instrument [Line Items]
Percentage of margin		1.75%
Five Year Tranche [Member]
Debt Instrument [Line Items]
Maximum borrowing capacity			$ 1,000,000,000
Debt instrument, maturity date		Oct. 1, 2018
Five Year Tranche [Member] | Base Rate [Member] | Minimum [Member]
Debt Instrument [Line Items]
Percentage of margin		0.125%
Five Year Tranche [Member] | Base Rate [Member] | Maximum [Member]
Debt Instrument [Line Items]
Percentage of margin		0.875%
Five Year Tranche [Member] | Eurodollar [Member] | Minimum [Member]
Debt Instrument [Line Items]
Percentage of margin		1.125%
Five Year Tranche [Member] | Eurodollar [Member] | Maximum [Member]
Debt Instrument [Line Items]
Percentage of margin		1.875%

Long-Term Debt and Capital Le91

Long-Term Debt and Capital Leases - ACT Term Loan - Additional Information (Detail) - USD ($)	9 Months Ended
	Sep. 30, 2016	Dec. 31, 2015	Jul. 01, 2014	Oct. 01, 2013	Jun. 22, 2012
Debt Instrument [Line Items]
Borrowings outstanding		$ 200,000,000
ACT Term Loan Agreement (2017 Term-Loan) [Member]
Debt Instrument [Line Items]
Loan agreement effective date	Mar. 31, 2014
Maximum borrowing capacity					$ 1,800,000,000
Borrowings outstanding				$ 1,572,500,000
ACT Term Loan Agreement (2017 Term-Loan) [Member] | Minimum [Member] | Base Rate [Member]
Debt Instrument [Line Items]
Percentage of margin	0.00%
ACT Term Loan Agreement (2017 Term-Loan) [Member] | Minimum [Member] | Eurodollar Rate [Member]
Debt Instrument [Line Items]
Percentage of margin	1.00%
ACT Term Loan Agreement (2017 Term-Loan) [Member] | Maximum [Member] | Base Rate [Member]
Debt Instrument [Line Items]
Percentage of margin	1.00%
ACT Term Loan Agreement (2017 Term-Loan) [Member] | Maximum [Member] | Eurodollar Rate [Member]
Debt Instrument [Line Items]
Percentage of margin	2.00%
ACT Term Loan Amendment (2019 Term-Loan) [Member] | Minimum [Member] | Base Rate [Member]
Debt Instrument [Line Items]
Percentage of margin	0.125%
ACT Term Loan Amendment (2019 Term-Loan) [Member] | Minimum [Member] | Eurodollar Rate [Member]
Debt Instrument [Line Items]
Percentage of margin	1.125%
ACT Term Loan Amendment (2019 Term-Loan) [Member] | Maximum [Member] | Base Rate [Member]
Debt Instrument [Line Items]
Percentage of margin	0.875%
ACT Term Loan Amendment (2019 Term-Loan) [Member] | Maximum [Member] | Eurodollar Rate [Member]
Debt Instrument [Line Items]
Percentage of margin	1.875%
ACT Term Loan Amendment (2019 Term-Loan) [Member] | Forest Laboratories Inc. [Member]
Debt Instrument [Line Items]
Maximum borrowing capacity			$ 2,000,000,000
Debt instrument, maturity date	Jul. 1, 2019

Long-Term Debt and Capital Le92

Long-Term Debt and Capital Leases - AGN Term Loan - Additional Information (Detail) - Variable Rate Debt [Member] - USD ($)	Dec. 17, 2014	Sep. 30, 2016	Dec. 31, 2015
AGN Tranche Three Maturing March 17, 2018 [Member]
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 2,750,000,000
Debt instrument, maturity date	Mar. 17, 2018	Mar. 17, 2018	Mar. 17, 2018
Debt instrument, maturity term	3 years
AGN Tranche Three Maturing March 17, 2018 [Member] | Minimum [Member] | Base Rate [Member]
Debt Instrument [Line Items]
Percentage of margin	0.00%
AGN Tranche Three Maturing March 17, 2018 [Member] | Minimum [Member] | Eurodollar [Member]
Debt Instrument [Line Items]
Percentage of margin	1.00%
AGN Tranche Three Maturing March 17, 2018 [Member] | Maximum [Member] | Base Rate [Member]
Debt Instrument [Line Items]
Percentage of margin	1.00%
AGN Tranche Three Maturing March 17, 2018 [Member] | Maximum [Member] | Eurodollar [Member]
Debt Instrument [Line Items]
Percentage of margin	2.00%
AGN Tranche Five Maturing March 17, 2020 [Member]
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 2,750,000,000
Debt instrument, maturity date	Mar. 17, 2020	Mar. 17, 2020	Mar. 17, 2020
Debt instrument, maturity term	5 years
Quarterly payable principal percentage	2.50%
AGN Tranche Five Maturing March 17, 2020 [Member] | Minimum [Member] | Base Rate [Member]
Debt Instrument [Line Items]
Percentage of margin	0.125%
AGN Tranche Five Maturing March 17, 2020 [Member] | Minimum [Member] | Eurodollar [Member]
Debt Instrument [Line Items]
Percentage of margin	1.125%
AGN Tranche Five Maturing March 17, 2020 [Member] | Maximum [Member] | Base Rate [Member]
Debt Instrument [Line Items]
Percentage of margin	1.25%
AGN Tranche Five Maturing March 17, 2020 [Member] | Maximum [Member] | Eurodollar [Member]
Debt Instrument [Line Items]
Percentage of margin	2.25%
AGN Term Loan [Member]
Debt Instrument [Line Items]
Term loan credit agreement payment terms		The outstanding principal amount of loans under the AGN Five Year Tranche was payable in equal quarterly amounts of 2.50% per quarter prior to March 17, 2020, with the remaining balance payable on March 17, 2020.

Long-Term Debt and Capital Le93

Long-Term Debt and Capital Leases - Cash Bridge Loan Facility - Additional Information (Detail) - USD ($)	Apr. 09, 2015	Mar. 11, 2015	Dec. 31, 2015	Mar. 17, 2015
Debt Instrument [Line Items]
Borrowings outstanding			$ 200,000,000
Cash Bridge Loan Facility [Member]
Debt Instrument [Line Items]
Maximum borrowing capacity		$ 2,800,000,000
Borrowings outstanding				$ 2,800,000,000
Facility repayment	$ 2,800,000,000
Cash Bridge Loan Facility [Member] | Base Rate [Member] | Minimum [Member]
Debt Instrument [Line Items]
Percentage of margin		0.00%
Cash Bridge Loan Facility [Member] | Base Rate [Member] | Maximum [Member]
Debt Instrument [Line Items]
Percentage of margin		1.00%
Cash Bridge Loan Facility [Member] | Eurodollar [Member] | Minimum [Member]
Debt Instrument [Line Items]
Percentage of margin		1.00%
Cash Bridge Loan Facility [Member] | Eurodollar [Member] | Maximum [Member]
Debt Instrument [Line Items]
Percentage of margin		2.00%

Long-Term Debt and Capital Le94

Long-Term Debt and Capital Leases - Schedule of Annual Debt Maturities (Detail) - USD ($) $ in Millions	Sep. 30, 2016	Dec. 31, 2015
Debt Disclosure [Abstract]
2,017	$ 2,700
2,018	3,750
2,019	1,950
2,020	4,650
2,021	1,950
2022 and after	17,750
Long Term Debt, Gross	32,750
Capital leases	2.2
Debt issuance costs	(151.5)
Other short-term borrowings	85.2
Unamortized premium	182.8	$ 225.9
Unamortized discount	(98.7)	(107.4)
Total Indebtedness	$ 32,770	$ 42,530.4

Other Long-Term Liabilities - S

Other Long-Term Liabilities - Summary of Other Long-Term Liabilities (Detail) - USD ($) $ in Millions	Sep. 30, 2016	Dec. 31, 2015
Other Liabilities Disclosure [Abstract]
Acquisition related contingent consideration liabilities	$ 602	$ 788.1
Long-term pension and post retirement liability	190.1	222.1
Legacy Allergan deferred executive compensation	114.3	117.9
Product warranties	28.1	28.4
Long-term contractual obligations	26.8	26.4
Long-term severance and restructuring liabilities	24.9	34.9
Deferred revenue	16.9	18.2
Other long-term liabilities	19.6	26
Total other long-term liabilities	$ 1,022.7	$ 1,262

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Income Tax [Line Items]
Company's effective tax rate	48.00%	40.90%
Income tax expense (benefit) due to change in valuation allowance	$ 179.5	$ (318.9)
Tax benefit change in tax rates	48.2
Tax benefit of recognition of unrecognized tax benefits	40.3	36.8
Benefit for acquired tax attributes		44
Increase in non-current deferred tax liabilities	4,842.7
Non-U.S. [Member]
Income Tax [Line Items]
Reversal of deferred tax liabilities	673.9
US
Income Tax [Line Items]
Reversal of deferred tax assets	5,273.9
IPR&D [Member]
Income Tax [Line Items]
Tax benefit for impairment		$ 41.3
New Jersey Grow [Member]
Income Tax [Line Items]
Income tax credit	$ 37.9

Income Taxes - Summary of Acqui

Income Taxes - Summary of Acquired U.S. Entities and Taxable Years that are Currently under Audit by IRS (Detail) - U.S. Federal Income Tax Authority [Member]	9 Months Ended
	Sep. 30, 2016
Actavis W C Holding Inc | Tax Year 2013 [Member]
Income Tax Examination [Line Items]
Tax Years	2,013
Actavis W C Holding Inc | Tax Year 2014 [Member]
Income Tax Examination [Line Items]
Tax Years	2,014
Forest Laboratories Inc. [Member] | Tax Year 2013 [Member]
Income Tax Examination [Line Items]
Tax Years	2,013
Forest Laboratories Inc. [Member] | Tax Year 2014 [Member]
Income Tax Examination [Line Items]
Tax Years	2,014
Forest Laboratories Inc. [Member] | Tax Year 2010 [Member]
Income Tax Examination [Line Items]
Tax Years	2,010
Forest Laboratories Inc. [Member] | Tax Year 2011 [Member]
Income Tax Examination [Line Items]
Tax Years	2,011
Forest Laboratories Inc. [Member] | Tax Year 2012 [Member]
Income Tax Examination [Line Items]
Tax Years	2,012
Warner Chilcott Corporation [Member] | Tax Year 2013 [Member]
Income Tax Examination [Line Items]
Tax Years	2,013
Warner Chilcott Corporation [Member] | Tax Year 2010 [Member]
Income Tax Examination [Line Items]
Tax Years	2,010
Warner Chilcott Corporation [Member] | Tax Year 2011 [Member]
Income Tax Examination [Line Items]
Tax Years	2,011
Warner Chilcott Corporation [Member] | Tax Year 2012 [Member]
Income Tax Examination [Line Items]
Tax Years	2,012
Durata Therapeutics, Inc. [Member] | Tax Year 2012 [Member]
Income Tax Examination [Line Items]
Tax Years	2,012
Allergan, Inc. [Member] | Tax Year 2013 [Member]
Income Tax Examination [Line Items]
Tax Years	2,013
Allergan, Inc. [Member] | Tax Year 2010 [Member]
Income Tax Examination [Line Items]
Tax Years	2,010
Allergan, Inc. [Member] | Tax Year 2011 [Member]
Income Tax Examination [Line Items]
Tax Years	2,011
Allergan, Inc. [Member] | Tax Year 2012 [Member]
Income Tax Examination [Line Items]
Tax Years	2,012
Allergan, Inc. [Member] | Tax Year 2009 [Member]
Income Tax Examination [Line Items]
Tax Years	2,009

Shareholders' Equity - Summary

Shareholders' Equity - Summary of Changes in Shareholders' Equity (Detail) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Shareholders Equity [Line Items]
Shareholders' equity, Beginning Balance			$ 76,591.4
Net income attributable to members	$ 15,220	$ 5,301.2	14,974	$ 4,546.1
Increase in additional paid in capital for share-based compensation plans			269.9
Net income attributable to ordinary shareholders	15,150.4	5,231.6	14,765.2	4,383.7
Proceeds from stock plans			138	195.8
Excess tax benefit from employee stock plans			26.6
Repurchase of ordinary shares, including accrued repurchases, under the Share Repurchase Program			(3,089.9)
Repurchase of ordinary shares			(68.7)
Other comprehensive income			(451.4)
Shareholders' equity, Ending Balance	89,725.9		89,725.9
Warner Chilcott Limited [Member]
Shareholders Equity [Line Items]
Members' equity, Beginning Balance			75,573.7
Net income attributable to members	15,269	$ 5,306.5	14,891.7	$ 4,559.2
Dividend to Parent			(1,244.8)
Other comprehensive income			(451.4)
Members' equity, Ending Balance	90,314		90,314
Teva Pharmaceutical Industries Ltd [Member]
Shareholders Equity [Line Items]
Other comprehensive income of the Teva Transaction	1,544.8		1,544.8
Teva Pharmaceutical Industries Ltd [Member] | Warner Chilcott Limited [Member]
Shareholders Equity [Line Items]
Other comprehensive income of the Teva Transaction	$ 1,544.8		1,544.8
2016 Share Repurchase Program [Member]
Shareholders Equity [Line Items]
Repurchase of ordinary shares, including accrued repurchases, under the Share Repurchase Program			$ (3,089.9)

Shareholders' Equity - Addition

Shareholders' Equity - Additional Information (Detail) - USD ($)	3 Months Ended	9 Months Ended
	Dec. 31, 2016	Sep. 30, 2016
Shareholders Equity [Line Items]
Share repurchase program, Approved amount		$ 10,000,000,000
Repurchased/accrued ordinary shares		$ 3,089,900,000
Scenario, Forecast [Member]
Shareholders Equity [Line Items]
Share repurchased during period, value	$ 5,000,000,000

Shareholders' Equity - Summa100

Shareholders' Equity - Summary of Movements in Accumulated Other Comprehensive Income /(Loss) (Detail) - USD ($) $ in Millions	3 Months Ended		6 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Jun. 30, 2016	Jun. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Accumulated Other Comprehensive Income Loss [Line Items]
Beginning balance	$ (317.1)	$ (10.4)	$ (494.1)	$ (465.4)	$ (494.1)	$ (465.4)
Other comprehensive gain / (loss) before reclassifications into general and administrative	35.8	(34.9)	177	455
Total other comprehensive income / (loss), net of tax	916.4	(34.9)	177	455	1,093.4	420.1
Ending balance	599.3	(45.3)	(317.1)	(10.4)	599.3	(45.3)
Investment in Teva ordinary shares fair value movement	609.3	(7.5)			625.2	(11.1)
Teva Pharmaceutical Industries Ltd [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Impact of Teva Transaction	1,544.8				1,544.8
Investment in Teva ordinary shares fair value movement	(664.2)
Foreign Currency Translation Items [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Beginning balance	(371.4)	17	(564.3)	(434.4)	(564.3)	(434.4)
Other comprehensive gain / (loss) before reclassifications into general and administrative	(19.1)	(42.4)	192.9	451.4
Total other comprehensive income / (loss), net of tax	1,521.5	(42.4)	192.9	451.4
Ending balance	1,150.1	(25.4)	(371.4)	17	1,150.1	(25.4)
Foreign Currency Translation Items [Member] | Teva Pharmaceutical Industries Ltd [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Impact of Teva Transaction	1,540.6
Unrealized (Loss)/Gains Net of Tax [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Beginning balance	54.3	(27.4)	70.2	(31)	70.2	(31)
Other comprehensive gain / (loss) before reclassifications into general and administrative	54.9	7.5	(15.9)	3.6
Total other comprehensive income / (loss), net of tax	(605.1)	7.5	(15.9)	3.6
Ending balance	(550.8)	$ (19.9)	$ 54.3	$ (27.4)	$ (550.8)	$ (19.9)
Unrealized (Loss)/Gains Net of Tax [Member] | Teva Pharmaceutical Industries Ltd [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Impact of Teva Transaction	4.2
Investment in Teva ordinary shares fair value movement	$ (664.2)

Derivative Instruments and H101

Derivative Instruments and Hedging Activities - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015
Derivative Instruments And Hedging Activities Disclosures [Line Items]
Gains (losses) recognized on foreign currency forward contracts	$ 9.1	$ (6.4)	$ 5.7	$ (5.8)
Foreign Exchange Option Contracts [Member] | Prepaid Expenses and Other Current Assets [Member]
Derivative Instruments And Hedging Activities Disclosures [Line Items]
Foreign currency derivative assets	23.2		23.2		$ 25
Foreign Exchange Option Contracts [Member] | Investments and Other Assets [Member]
Derivative Instruments And Hedging Activities Disclosures [Line Items]
Foreign currency derivative assets	$ 28.8		$ 28.8		48.5
Foreign Exchange Option Contracts [Member] | Within Accounts Payable and Accrued Expenses [Member]
Derivative Instruments And Hedging Activities Disclosures [Line Items]
Foreign currency derivative liabilities					$ 0.3

Fair Value Measurement - Schedu

Fair Value Measurement - Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) - USD ($) $ in Millions	Sep. 30, 2016	Dec. 31, 2015
ASSETS
Marketable securities	$ 15,463.2	$ 29.9
Deferred executive compensation investments	114.3	118.1
Foreign currency derivatives	52	73.2
Investment in Teva ordinary shares	4,374.4
Investments and other	98.5	112.2
Total assets	26,359.5	333.4
Liabilities:
Deferred executive compensation liabilities	114.3	117.9
Contingent consideration obligations	951.1	868
Total liabilities	1,065.4	985.9
Cash Equivalents [Member]
ASSETS
Cash & cash equivalents	6,257.1
Quoted Prices In Active Markets for Identical Assets (Level 1) [Member]
ASSETS
Cash & cash equivalents	6,257.1
Marketable securities		29.9
Deferred executive compensation investments	92	102.3
Investments and other	98.5	112.2
Total assets	6,447.6	244.4
Liabilities:
Deferred executive compensation liabilities	92	102.1
Total liabilities	92	102.1
Quoted Prices In Active Markets for Identical Assets (Level 1) [Member] | Cash Equivalents [Member]
ASSETS
Cash & cash equivalents	6,257.1
Significant Other Observable Inputs (Level 2) [Member]
ASSETS
Marketable securities	15,463.2
Deferred executive compensation investments	22.3	15.8
Foreign currency derivatives	52	73.2
Investment in Teva ordinary shares	4,374.4
Total assets	19,911.9	89
Liabilities:
Deferred executive compensation liabilities	22.3	15.8
Total liabilities	22.3	15.8
Significant Unobservable Inputs (Level 3) [Member]
Liabilities:
Contingent consideration obligations	951.1	868
Total liabilities	$ 951.1	$ 868

Fair Value Measurement - Summar

Fair Value Measurement - Summary of Notional Principal and Fair Value of Company's Outstanding Foreign Currency Derivative Financial Instruments (Detail)	Sep. 30, 2016USD ($)$ / ForeignCurrency	Dec. 31, 2015USD ($)$ / ForeignCurrency
Foreign Currency Forward Exchange Contracts [Member]
Derivatives Fair Value [Line Items]
Notional Principal	$ 21,600,000	$ 18,800,000
Estimated fair value	100,000	(300,000)
Foreign Currency Forward Exchange Contracts [Member] | Russian Ruble [Member]
Derivatives Fair Value [Line Items]
Notional Principal	$ 21,600,000	$ 18,800,000
Average Contract Rate or Strike Amount | $ / ForeignCurrency	63.73	72.97
Foreign Currency Sold - Put Options [Member]
Derivatives Fair Value [Line Items]
Notional Principal	$ 259,900,000	$ 340,500,000
Estimated fair value	51,900,000	73,500,000
Foreign Currency Sold - Put Options [Member] | Euro [Member]
Derivatives Fair Value [Line Items]
Notional Principal	$ 259,900,000	$ 340,500,000
Average Contract Rate or Strike Amount | $ / ForeignCurrency	1.41	1.41

Fair Value Measurement - Change

Fair Value Measurement - Change in Fair Value of Contingent Consideration Obligations (Detail) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Change in fair value of contingent consideration obligation	$ 15.9	$ 81.3	$ 79.3	$ 87.3
Cost of Sales [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Change in fair value of contingent consideration obligation	10.4	20.6	13.4	53.1
Research and Development Expense [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Change in fair value of contingent consideration obligation	$ 5.5	60.1	65.8	34.7
General and Administrative Expense [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Change in fair value of contingent consideration obligation		$ 0.6	$ 0.1	$ (0.5)

Fair Value Measurement - Sum105

Fair Value Measurement - Summary of Changes in Fair Value of all Financial Assets and Liabilities Measured at Fair Value on Recurring Basis Using Significant Unobservable Inputs (Detail) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance	$ 868
Purchases and settlements, net	(76)
Ending balance	951.1
Contingent Consideration Obligations [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance	868	$ 373.8
Purchases and settlements, net	3.7	317.8
Net accretion and fair value adjustments	79.3	87.3
Foreign currency translation	0.1	(5)
Ending balance	$ 951.1	$ 773.9

Fair Value Measurement - Sch106

Fair Value Measurement - Schedule of Contingent Consideration Obligations (Detail) $ in Millions	9 Months Ended
	Sep. 30, 2016USD ($)
Business Acquisition [Line Items]
Beginning balance	$ 868
Acquisitions	79.8
Fair Value Adjustments and Accretion	79.3
Payments and Other	(76)
Ending balance	951.1
Allergan, Inc. [Member]
Business Acquisition [Line Items]
Beginning balance	329.7
Fair Value Adjustments and Accretion	41.4
Payments and Other	(40)
Ending balance	331.1
AqueSys Acquisition [Member]
Business Acquisition [Line Items]
Beginning balance	193.5
Fair Value Adjustments and Accretion	13.8
Ending balance	207.3
Medicines 360 Acquisition [Member]
Business Acquisition [Line Items]
Beginning balance	144.1
Fair Value Adjustments and Accretion	13.6
Payments and Other	(0.5)
Ending balance	157.2
Oculeve Acquisition [Member]
Business Acquisition [Line Items]
Beginning balance	90
Fair Value Adjustments and Accretion	8.8
Ending balance	98.8
ForSight [Member]
Business Acquisition [Line Items]
Acquisitions	79.8
Ending balance	79.8
Forest Laboratories Inc. [Member]
Business Acquisition [Line Items]
Beginning balance	20.4
Fair Value Adjustments and Accretion	(4.7)
Payments and Other	(1)
Ending balance	14.7
Metrogel Acquisition [Member]
Business Acquisition [Line Items]
Beginning balance	30.9
Fair Value Adjustments and Accretion	(7.5)
Payments and Other	(4.5)
Ending balance	18.9
Uteron Pharma, SA [Member]
Business Acquisition [Line Items]
Beginning balance	8.2
Payments and Other	0.1
Ending balance	8.3
Durata Therapeutics, Inc. [Member]
Business Acquisition [Line Items]
Beginning balance	24.5
Fair Value Adjustments and Accretion	2.2
Payments and Other	(26.7)
Other Acquisition [Member]
Business Acquisition [Line Items]
Beginning balance	26.7
Fair Value Adjustments and Accretion	11.7
Payments and Other	(3.4)
Ending balance	$ 35

Business Restructuring Charg107

Business Restructuring Charges - Schedule of Activity Related to Business Restructuring and Facility Rationalization Activities (Detail) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Restructuring Cost And Reserve [Line Items]
Reserve beginning balance			$ 145.3
Charged to expense	$ 37.7	$ 42.1	72	$ 674.8
Cash payments			(88)
Other reserve impact			(20.7)
Reserve ending balance	108.6		108.6
Severance and Retention [Member]
Restructuring Cost And Reserve [Line Items]
Reserve beginning balance			96.7
Charged to expense			35.4
Cash payments			(62.9)
Reserve ending balance	69.2		69.2
Share-Based Compensation [Member]
Restructuring Cost And Reserve [Line Items]
Charged to expense			20.4
Other reserve impact			(20.4)
Other [Member]
Restructuring Cost And Reserve [Line Items]
Reserve beginning balance			48.6
Charged to expense			16.2
Cash payments			(25.1)
Other reserve impact			(0.3)
Reserve ending balance	$ 39.4		39.4
Cost of Sales [Member]
Restructuring Cost And Reserve [Line Items]
Charged to expense			9.2
Cost of Sales [Member] | Severance and Retention [Member]
Restructuring Cost And Reserve [Line Items]
Charged to expense			3.5
Cost of Sales [Member] | Share-Based Compensation [Member]
Restructuring Cost And Reserve [Line Items]
Charged to expense			0.5
Cost of Sales [Member] | Other [Member]
Restructuring Cost And Reserve [Line Items]
Charged to expense			5.2
Research and Development Expense [Member]
Restructuring Cost And Reserve [Line Items]
Charged to expense			8.1
Research and Development Expense [Member] | Severance and Retention [Member]
Restructuring Cost And Reserve [Line Items]
Charged to expense			6.5
Research and Development Expense [Member] | Share-Based Compensation [Member]
Restructuring Cost And Reserve [Line Items]
Charged to expense			0.9
Research and Development Expense [Member] | Other [Member]
Restructuring Cost And Reserve [Line Items]
Charged to expense			0.7
Selling and Marketing Expense [Member]
Restructuring Cost And Reserve [Line Items]
Charged to expense			18.6
Selling and Marketing Expense [Member] | Severance and Retention [Member]
Restructuring Cost And Reserve [Line Items]
Charged to expense			8
Selling and Marketing Expense [Member] | Share-Based Compensation [Member]
Restructuring Cost And Reserve [Line Items]
Charged to expense			9.3
Selling and Marketing Expense [Member] | Other [Member]
Restructuring Cost And Reserve [Line Items]
Charged to expense			1.3
General and Administrative Expense [Member]
Restructuring Cost And Reserve [Line Items]
Charged to expense			36.1
General and Administrative Expense [Member] | Severance and Retention [Member]
Restructuring Cost And Reserve [Line Items]
Charged to expense			17.4
General and Administrative Expense [Member] | Share-Based Compensation [Member]
Restructuring Cost And Reserve [Line Items]
Charged to expense			9.7
General and Administrative Expense [Member] | Other [Member]
Restructuring Cost And Reserve [Line Items]
Charged to expense			$ 9

Business Restructuring Charg108

Business Restructuring Charges - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Restructuring And Related Activities [Abstract]
Restructuring charges recognized	$ 37.7	$ 42.1	$ 72	$ 674.8

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail) $ in Thousands

Jun. 29, 2016Litigation

Feb. 16, 2016

Feb. 05, 2016Cases

Jan. 05, 2016

Sep. 21, 2015Litigation

Aug. 24, 2015

Jun. 24, 2015

Jun. 22, 2015Litigation

Jun. 08, 2015Litigation

May 29, 2015Litigation

Apr. 29, 2015

Feb. 24, 2015Litigation

Apr. 05, 2013LitigationCases

Jul. 31, 2012LitigationCases

Jan. 31, 2016

Sep. 30, 2016USD ($)DefendantClaimPlaintiff

Loss Contingencies [Line Items]

Accrued loss contingencies | $

$ 115,000

Saphris [Member]

Loss Contingencies [Line Items]

Trial date

2016-10

Teflaro [Member]

Loss Contingencies [Line Items]

Trial date

2017-06

Asacol Litigation [Member]

Loss Contingencies [Line Items]

Number of putative class actions filed

2

Number of additional putative class actions filed

2

3

Botox [Member]

Loss Contingencies [Line Items]

Number of putative class actions filed

1

Doryx Litigation Direct Purchasers [Member]

Loss Contingencies [Line Items]

Number of putative class actions filed

3

Doryx Litigation Indirect Purchasers [Member]

Loss Contingencies [Line Items]

Number of putative class actions filed

1

Doryx Antitrust Complaints [Member]

Loss Contingencies [Line Items]

Number of defendant cases | Cases

4

Loestrin 24 [Member]

Loss Contingencies [Line Items]

Number of putative class actions filed

2

Namenda Litigation Direct Purchasers [Member]

Loss Contingencies [Line Items]

Number of putative class actions filed

1

Namenda Litigation Indirect Purchasers [Member]

Loss Contingencies [Line Items]

Number of putative class actions filed

1

Zymar/Zymaxid Litigation [Member]

Loss Contingencies [Line Items]

Dismissal date

May 2, 2015

Prescription Drug Abuse Litigation [Member]

Loss Contingencies [Line Items]

Dismissal date

May 8, 2015

Xaleron Pharmaceuticals, Inc [Member]

Loss Contingencies [Line Items]

Number of lawsuit filed | Cases

1

PSP [Member]

Loss Contingencies [Line Items]

Dismissal date

Oct. 20, 2016

Settlement agreement date

October 13, 2016

Forest Laboratories Inc. [Member] | Savella [Member]

Loss Contingencies [Line Items]

Settlement agreement date

April 29, 2015

Actonel Litigation [Member]

Loss Contingencies [Line Items]

Number of defendant cases | Defendant

171

Number of cases pending | Claim

374

Number of plaintiffs | Plaintiff

554

Teva [Member]

Loss Contingencies [Line Items]

Accrued loss contingencies | $

$ 22,000

Trial commencement date

Feb. 16, 2016

Antitrust Litigation [Member] | Loestrin Twenty Four Direct Payors [Member]

Loss Contingencies [Line Items]

Number of cases pending | Cases

2

Commercial Litigation [Member] | Celexa/Lexapro Litigation [Member]

Loss Contingencies [Line Items]

Number of defendant cases | Defendant

3

Payment of legal settlement costs | $

$ 7,650

Agreement in principle to settle claims, amount | $

$ 10,350

Mylan [Member]

Loss Contingencies [Line Items]

Settlement agreement date

November 16, 2015

Mylan [Member] | Aptalis [Member]

Loss Contingencies [Line Items]

Settlement agreement date

November 11, 2015

Mylan [Member] | Forest and Royalty [Member]

Loss Contingencies [Line Items]

Dismissal date

Sep. 30, 2016

Settlement agreement date

September 30, 2016

Patent Litigation [Member] | Canasa [Member]

Loss Contingencies [Line Items]

Trial date

2017-11

Patent Litigation [Member] | Delzicol [Member]

Loss Contingencies [Line Items]

Trial date

2017-10

Patent Litigation [Member] | Namenda XR [Member] | Anchen and Par [Member]

Loss Contingencies [Line Items]

Settlement agreement date

January 13, 2015

Settlement agreement terms

Under the terms of the settlement agreement, and subject to review of the settlement terms by the U.S. Federal Trade Commission, Plaintiffs will provide a license to Wockhardt that will permit it to launch its generic version of Namenda XR® as of the date that is the later of (a) two (2) calendar months prior to the expiration date of the last to expire of the ‘703 patent, the ‘209 patent, the ‘708 patent, the ‘379 patent, the ‘752 patent, the ‘085 patent, and the ‘233 patent, including any extensions and/or pediatric exclusivities; or (b) the date that Wockhardt obtains final FDA approval of its ANDA, or earlier in certain circumstances.

Patent Litigation [Member] | Namzaric [Member]

Loss Contingencies [Line Items]

Trial date

2017-10

Patent Litigation [Member] | Viibryd [Member]

Loss Contingencies [Line Items]

Trial date

2018-01

Delcor [Member] | Aptalis [Member]

Loss Contingencies [Line Items]

Settlement agreement date

April 8, 2016

Ranbaxy [Member] | Forest Laboratories Inc. [Member]

Loss Contingencies [Line Items]

Settlement agreement date

May 1, 2015

Amerigen [Member]

Loss Contingencies [Line Items]

Settlement agreement date

October 20, 2015

Amerigen [Member] | Namzaric [Member]

Loss Contingencies [Line Items]

Settlement agreement date

October 21, 2016

Lupin [Member]

Loss Contingencies [Line Items]

Settlement agreement date

December 22, 2015

Lupin [Member] | Forest and Royalty [Member]

Loss Contingencies [Line Items]

Settlement agreement date

June 2,016

Apotex [Member]

Loss Contingencies [Line Items]

Settlement agreement date

February 11, 2016

Apotex [Member] | Restasis [Member]

Loss Contingencies [Line Items]

Settlement agreement date

December 15, 2015

Trial date

2017-08

Apotex [Member] | Forest and Royalty [Member]

Loss Contingencies [Line Items]

Settlement agreement date

January 19, 2016

Accord [Member] | Forest Laboratories Inc. [Member]

Loss Contingencies [Line Items]

Settlement agreement date

January 14, 2016

Accord [Member] | Namzaric [Member]

Loss Contingencies [Line Items]

Settlement agreement date

July 20, 2016

Amneal [Member] | Forest Laboratories Inc. [Member]

Loss Contingencies [Line Items]

Settlement agreement date

January 8, 2016

Amneal [Member] | Namzaric [Member]

Loss Contingencies [Line Items]

Settlement agreement date

August 30, 2016

First Time US Generics [Member]

Loss Contingencies [Line Items]

Settlement agreement date

May 12, 2014

Hetero and Glenmark [Member]

Loss Contingencies [Line Items]

Settlement agreement date

December 11, 2015

Commitments and Contingencie110

Commitments and Contingencies - Additional Information 1 (Detail)	Dec. 28, 2015Claim	Sep. 30, 2016CasesDefendant
Celexa/Lexapro Litigation [Member] | Product Liability Litigation [Member]
Loss Contingencies [Line Items]
Number of defendant cases | Defendant		179
Celexa/Lexapro Litigation [Member] | Pending Litigation [Member] | Product Liability Litigation [Member] | New Jersey [Member]
Loss Contingencies [Line Items]
Number of cases pending		4
Testosterone Litigation [Member] | Product Liability Litigation [Member]
Loss Contingencies [Line Items]
Number of cases pending		547
Testosterone Litigation [Member] | State Courts [Member] | Product Liability Litigation [Member]
Loss Contingencies [Line Items]
Number of cases pending		1
Putative Class of Private Payers [Member]
Loss Contingencies [Line Items]
Number of putative class actions filed | Claim	1

Warner Chilcott Limited ("WC111

Warner Chilcott Limited ("WCL") Guarantor and Non-Guarantor Condensed Consolidating Financial Information - Consolidating Balance Sheets (Detail) - USD ($) $ in Millions	Sep. 30, 2016	Dec. 31, 2015	Sep. 30, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$ 7,554.7	$ 1,096	$ 2,063.9	$ 250
Marketable securities	19,837.6	9.3
Accounts receivable, net	2,398.5	2,125.4
Inventories	705.5	757.5
Prepaid expenses and other current assets	771.7	495.3
Current assets held for sale	455.9	4,095.6
Total current assets	31,723.9	8,579.1
Property, plant and equipment, net	1,566.3	1,531.3
Investments and other assets	341.1	408.7
Non current assets held for sale	207.2	10,713.3
Deferred tax assets	120.7	49.5
Product rights and other intangibles	63,022.7	67,836.2
Goodwill	46,625.8	46,465.2
Total assets	143,607.7	135,583.3
Current liabilities:
Accounts payable and accrued expenses	5,425.4	4,148.6
Income taxes payable	784.6	53.7
Current portion of long-term debt and capital leases	1,591.8	2,396.5
Current liabilities held for sale	223.7	1,693.2
Total current liabilities	8,025.5	8,292
Long-term debt and capital leases	31,178.2	40,133.9
Other long-term liabilities	1,022.7	1,262
Long-term liabilities held for sale	23.8	535.4
Other taxes payable	815.6	801.9
Deferred tax liabilities	12,811.5	7,968.8
Total liabilities	53,877.3	58,994
Total equity / (deficit)	89,730.4	76,589.3
Total liabilities and equity	143,607.7	135,583.3
Warner Chilcott Limited Parent Guarantor [Member]
Current assets:
Cash and cash equivalents	0.1			0.1
Total current assets	0.1
Investment in subsidiaries	90,318.4	75,571.6
Total assets	90,318.5	75,571.6
Current liabilities:
Total equity / (deficit)	90,318.5	75,571.6
Total liabilities and equity	90,318.5	75,571.6
Actavis Capital S.a.r.l. (Guarantor) [Member]
Current assets:
Cash and cash equivalents	2,101.1	13.5	1.2	5.5
Intercompany receivables	22,969.8	55,415.1
Prepaid expenses and other current assets	9.2	5
Total current assets	25,080.1	55,433.6
Investment in subsidiaries	90,267.6	79,597.3
Non current intercompany receivables	46,647.4	39,584.1
Total assets	161,995.1	174,615
Current liabilities:
Accounts payable and accrued expenses		3.9
Intercompany payables	12,347.1	51,148.7
Payable to Parents	5,000
Current portion of long-term debt and capital leases		749.1
Total current liabilities	17,347.1	51,901.7
Long-term debt and capital leases		6,995
Long-term intercompany payables	57,859.6	40,944.8
Total liabilities	75,206.7	99,841.5
Total equity / (deficit)	86,788.4	74,773.5
Total liabilities and equity	161,995.1	174,615
Actavis Funding SCS (Issuer) [Member]
Current assets:
Intercompany receivables	3,400.3	25,225.6
Total current assets	3,400.3	25,225.6
Non current intercompany receivables	22,483.3
Total assets	25,883.6	25,225.6
Current liabilities:
Accounts payable and accrued expenses	74.1	210.5
Intercompany payables	1,796.5	526.3
Current portion of long-term debt and capital leases	1,527.3	475.5
Total current liabilities	3,397.9	1,212.3
Long-term debt and capital leases	22,483.3	24,013
Total liabilities	25,881.2	25,225.3
Total equity / (deficit)	2.4	0.3
Total liabilities and equity	25,883.6	25,225.6
Actavis Finance, LLC [Member]
Current assets:
Cash and cash equivalents		2	4	1.5
Intercompany receivables	78.7	302.4
Prepaid expenses and other current assets	21.3	6.1
Total current assets	100	310.5
Property, plant and equipment, net		34.3
Investments and other assets	16.4	33.6
Investment in subsidiaries	73,710.3	73,037.7
Non current assets held for sale		45.8
Total assets	73,826.7	73,461.9
Current liabilities:
Accounts payable and accrued expenses		171.5
Intercompany payables	9,327.6	8,789
Income taxes payable		44.1
Current liabilities held for sale		23.3
Total current liabilities	9,327.6	9,027.9
Long-term debt and capital leases	4,275.6	4,269.4
Long-term intercompany payables		456
Other taxes payable		72.1
Total liabilities	13,603.2	13,825.4
Total equity / (deficit)	60,223.5	59,636.5
Total liabilities and equity	73,826.7	73,461.9
Non-Guarantors [Member]
Current assets:
Cash and cash equivalents	5,421.6	1,020.7	2,040.5	237.2
Marketable securities	19,837.6	9.3
Accounts receivable, net	2,398.5	2,125.4
Receivable from Parents	2,828.7	457.3
Inventories	705.5	757.5
Intercompany receivables	23,471.2	60,464
Prepaid expenses and other current assets	739.1	481.7
Current assets held for sale	455.9	4,095.6
Total current assets	55,858.1	69,411.5
Property, plant and equipment, net	1,566.3	1,497
Investments and other assets	324.7	375.1
Non current intercompany receivables	57,859.6	41,400.8
Non current receivables from Parents	3,985
Non current assets held for sale	207.2	10,667.5
Deferred tax assets	120.7	49.5
Product rights and other intangibles	63,022.7	67,836.2
Goodwill	46,625.8	46,465.2
Total assets	229,570.1	237,702.8
Current liabilities:
Accounts payable and accrued expenses	4,921.7	3,708.6
Intercompany payables	26,448.8	80,943.1
Payable to Parents	1,202.2	1,466.8
Income taxes payable	784.6	9.6
Current portion of long-term debt and capital leases	64.5	1,171.9
Current liabilities held for sale	223.7	1,669.9
Total current liabilities	33,645.5	88,969.9
Long-term debt and capital leases	4,419.3	4,856.5
Other long-term liabilities	1,022.7	1,262
Long-term intercompany payables	69,130.7	39,584.1
Long-term payables to Parents	419
Long-term liabilities held for sale	23.8	535.4
Other taxes payable	815.6	729.8
Deferred tax liabilities	12,811.5	7,968.8
Total liabilities	122,288.1	143,906.5
Total equity / (deficit)	107,282	93,796.3
Total liabilities and equity	229,570.1	237,702.8
Warner Chilcott Limited [Member]
Current assets:
Cash and cash equivalents	7,522.8	1,036.2	$ 2,045.7	$ 244.3
Marketable securities	19,837.6	9.3
Accounts receivable, net	2,398.5	2,125.4
Receivable from Parents	2,828.7	457.3
Inventories	705.5	757.5
Prepaid expenses and other current assets	769.6	492.8
Current assets held for sale	455.9	4,095.6
Total current assets	34,518.6	8,974.1
Property, plant and equipment, net	1,566.3	1,531.3
Investments and other assets	341.1	408.7
Non current receivables from Parents	3,985
Non current assets held for sale	207.2	10,713.3
Deferred tax assets	120.7	49.5
Product rights and other intangibles	63,022.7	67,836.2
Goodwill	46,625.8	46,465.2
Total assets	150,387.4	135,978.3
Current liabilities:
Accounts payable and accrued expenses	4,995.8	4,094.5
Payable to Parents	6,202.2	1,466.8
Income taxes payable	784.6	53.7
Current portion of long-term debt and capital leases	1,591.8	2,396.5
Current liabilities held for sale	223.7	1,693.2
Total current liabilities	13,798.1	9,704.7
Long-term debt and capital leases	31,178.2	40,133.9
Other long-term liabilities	1,022.7	1,262
Long-term payables to Parents	419
Long-term liabilities held for sale	23.8	535.4
Other taxes payable	815.6	801.9
Deferred tax liabilities	12,811.5	7,968.8
Total liabilities	60,068.9	60,406.7
Total equity / (deficit)	90,318.5	75,571.6
Total liabilities and equity	150,387.4	135,978.3
Eliminations [Member]
Current assets:
Intercompany receivables	(49,920)	(141,407.1)
Total current assets	(49,920)	(141,407.1)
Investment in subsidiaries	(254,296.3)	(228,206.6)
Non current intercompany receivables	(126,990.3)	(80,984.9)
Total assets	(431,206.6)	(450,598.6)
Current liabilities:
Intercompany payables	(49,920)	(141,407.1)
Total current liabilities	(49,920)	(141,407.1)
Long-term intercompany payables	(126,990.3)	(80,984.9)
Total liabilities	(176,910.3)	(222,392)
Total equity / (deficit)	(254,296.3)	(228,206.6)
Total liabilities and equity	$ (431,206.6)	$ (450,598.6)

Warner Chilcott Limited ("WC112

Warner Chilcott Limited ("WCL") Guarantor and Non-Guarantor Condensed Consolidating Financial Information - Consolidating Statements of Operations (Detail) - USD ($) $ in Millions	3 Months Ended		6 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Jun. 30, 2016	Jun. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Condensed Income Statements Captions [Line Items]
Net revenues	$ 3,622.2	$ 3,469.5			$ 10,706.3	$ 9,081.2
Operating expenses:
Cost of sales (excludes amortization and impairment of acquired intangibles including product rights)	462.2	710.3			1,381.1	2,150
Research and development	622.8	1,260.5			1,662.4	1,927.9
Selling and marketing	796	683.6			2,429.6	2,017.2
General and administrative	361.2	339.1			1,033.9	1,188
Amortization	1,609.1	1,557.8			4,831.9	3,858.9
In-process research and development impairments	42	300			316.9	497.6
Asset sales and impairments, net	(4.7)	(4.4)			(24)	3.1
Total operating expenses	3,888.6	4,846.9			11,631.8	11,642.7
Operating (loss)	(266.4)	(1,377.4)			(925.5)	(2,561.5)
Non-operating income (expense):
Other income / (expense)	33.6	0.2			184.2	(238.1)
Total other (expense), net	(272.6)	(336.5)			(795.2)	(1,082.5)
(Loss) before income taxes and noncontrolling interest	(539)	(1,713.9)			(1,720.7)	(3,644)
Provision / (benefit) for income taxes	(158.9)	(838.9)			(825.8)	(1,491)
Net (loss) from continuing operations, net of tax	(380.1)	(875)			(894.9)	(2,153)
Income from discontinued operations	15,601.9	6,177.6			15,873.2	6,701.7
Net income	15,221.8	5,302.6			14,978.3	4,548.7
(Income) attributable to noncontrolling interest	(1.8)	(1.4)			(4.3)	(2.6)
Net income attributable to shareholders	15,220	5,301.2			14,974	4,546.1
Other comprehensive income / (loss)	916.4	(34.9)	$ 177	$ 455	1,093.4	420.1
Comprehensive income attributable to ordinary shareholders	16,136.4	5,266.3			16,067.4	4,966.2
Warner Chilcott Limited Parent Guarantor [Member]
Non-operating income (expense):
(Earnings) / losses of equity interest subsidiaries	(15,269)	(5,306.5)			(14,891.7)	(4,559.2)
Net (loss) from continuing operations, net of tax	15,269	5,306.5			14,891.7	4,559.2
Net income	15,269	5,306.5			14,891.7	4,559.2
Net income attributable to shareholders	15,269	5,306.5			14,891.7	4,559.2
Other comprehensive income / (loss)	916.4	(34.9)			1,093.4	420.1
Comprehensive income attributable to ordinary shareholders	16,185.4	5,271.6			15,985.1	4,979.3
Actavis Capital S.a.r.l. (Guarantor) [Member]
Operating expenses:
General and administrative	4.1				4.6	213.2
Total operating expenses	4.1				4.6	213.2
Operating (loss)	(4.1)				(4.6)	(213.2)
Non-operating income (expense):
Interest income / (expense), net	911.6	444.3			1,349.2	732.6
Other income / (expense)						(265.4)
Total other (expense), net	911.6	444.3			1,349.2	467.2
(Loss) before income taxes and noncontrolling interest	907.5	444.3			1,344.6	254
(Earnings) / losses of equity interest subsidiaries	(11,485)	1,857.2			(10,701.3)	2,466.7
Net (loss) from continuing operations, net of tax	12,392.5	(1,412.9)			12,045.9	(2,212.7)
Net income	12,392.5	(1,412.9)			12,045.9	(2,212.7)
Net income attributable to shareholders	12,392.5	(1,412.9)			12,045.9	(2,212.7)
Other comprehensive income / (loss)	958.4	(35.3)			1,213.8	485.3
Comprehensive income attributable to ordinary shareholders	13,350.9	(1,448.2)			13,259.7	(1,727.4)
Actavis Funding SCS (Issuer) [Member]
Operating expenses:
General and administrative						16.1
Total operating expenses						16.1
Operating (loss)						(16.1)
Non-operating income (expense):
Interest income / (expense), net	(216.6)	0.3			2.2	(14.4)
Other income / (expense)						31
Total other (expense), net	(216.6)	0.3			2.2	16.6
(Loss) before income taxes and noncontrolling interest	(216.6)	0.3			2.2	0.5
Net (loss) from continuing operations, net of tax	(216.6)	0.3			2.2	0.5
Net income	(216.6)	0.3			2.2	0.5
Net income attributable to shareholders	(216.6)	0.3			2.2	0.5
Comprehensive income attributable to ordinary shareholders	(216.6)	0.3			2.2	0.5
Actavis Finance, LLC [Member]
Operating expenses:
General and administrative		79.1			19.8	148.8
Total operating expenses		79.1			19.8	148.8
Operating (loss)		(79.1)			(19.8)	(148.8)
Non-operating income (expense):
Interest income / (expense), net	(40.3)	(40.3)			(117.2)	(127.7)
Other income / (expense)		(0.1)
Total other (expense), net	(40.3)	(40.4)			(117.2)	(127.7)
(Loss) before income taxes and noncontrolling interest	(40.3)	(119.5)			(137)	(276.5)
Provision / (benefit) for income taxes	(22.6)	(28)			(51.4)	(95.8)
(Earnings) / losses of equity interest subsidiaries	747.6	117.7			198.6	(242.2)
Net (loss) from continuing operations, net of tax	(765.3)	(209.2)			(284.2)	61.5
Net income	(765.3)	(209.2)			(284.2)	61.5
Net income attributable to shareholders	(765.3)	(209.2)			(284.2)	61.5
Other comprehensive income / (loss)	900.2	24			871.1	859.8
Comprehensive income attributable to ordinary shareholders	134.9	(185.2)			586.9	921.3
Non-Guarantors [Member]
Condensed Income Statements Captions [Line Items]
Net revenues	3,622.2	3,469.5			10,706.3	9,081.2
Operating expenses:
Cost of sales (excludes amortization and impairment of acquired intangibles including product rights)	462.2	710.3			1,381.1	2,150
Research and development	622.8	1,260.5			1,662.4	1,927.9
Selling and marketing	796	683.6			2,429.6	2,017.2
General and administrative	308.1	254.7			941.8	796.8
Amortization	1,609.1	1,557.8			4,831.9	3,858.9
In-process research and development impairments	42	300			316.9	497.6
Asset sales and impairments, net	(4.7)	(4.4)			(24)	3.1
Total operating expenses	3,835.5	4,762.5			11,539.7	11,251.5
Operating (loss)	(213.3)	(1,293)			(833.4)	(2,170.3)
Non-operating income (expense):
Interest income / (expense), net	(960.9)	(741)			(2,213.6)	(1,434.9)
Other income / (expense)	33.6	0.3			34.2	(3.7)
Total other (expense), net	(927.3)	(740.7)			(2,179.4)	(1,438.6)
(Loss) before income taxes and noncontrolling interest	(1,140.6)	(2,033.7)			(3,012.8)	(3,608.9)
Provision / (benefit) for income taxes	(136.3)	(810.9)			(774.4)	(1,395.2)
Net (loss) from continuing operations, net of tax	(1,004.3)	(1,222.8)			(2,238.4)	(2,213.7)
Income from discontinued operations	15,601.9	6,177.6			15,873.2	6,701.7
Net income	14,597.6	4,954.8			13,634.8	4,488
(Income) attributable to noncontrolling interest	(1.8)	(1.4)			(4.3)	(2.6)
Net income attributable to shareholders	14,595.8	4,953.4			13,630.5	4,485.4
Other comprehensive income / (loss)	916.4	(34.9)			1,093.4	420.1
Comprehensive income attributable to ordinary shareholders	15,512.2	4,918.5			14,723.9	4,905.5
Warner Chilcott Limited [Member]
Condensed Income Statements Captions [Line Items]
Net revenues	3,622.2	3,469.5			10,706.3	9,081.2
Operating expenses:
Cost of sales (excludes amortization and impairment of acquired intangibles including product rights)	462.2	710.3			1,381.1	2,150
Research and development	622.8	1,260.5			1,662.4	1,927.9
Selling and marketing	796	683.6			2,429.6	2,017.2
General and administrative	312.2	333.8			966.2	1,174.9
Amortization	1,609.1	1,557.8			4,831.9	3,858.9
In-process research and development impairments	42	300			316.9	497.6
Asset sales and impairments, net	(4.7)	(4.4)			(24)	3.1
Total operating expenses	3,839.6	4,841.6			11,564.1	11,629.6
Operating (loss)	(217.4)	(1,372.1)			(857.8)	(2,548.4)
Non-operating income (expense):
Interest income / (expense), net	(306.2)	(336.7)			(979.4)	(844.4)
Other income / (expense)	33.6	0.2			34.2	(238.1)
Total other (expense), net	(272.6)	(336.5)			(945.2)	(1,082.5)
(Loss) before income taxes and noncontrolling interest	(490)	(1,708.6)			(1,803)	(3,630.9)
Provision / (benefit) for income taxes	(158.9)	(838.9)			(825.8)	(1,491)
Net (loss) from continuing operations, net of tax	(331.1)	(869.7)			(977.2)	(2,139.9)
Income from discontinued operations	15,601.9	6,177.6			15,873.2	6,701.7
Net income	15,270.8	5,307.9			14,896	4,561.8
(Income) attributable to noncontrolling interest	(1.8)	(1.4)			(4.3)	(2.6)
Net income attributable to shareholders	15,269	5,306.5			14,891.7	4,559.2
Other comprehensive income / (loss)	916.4	(34.9)			1,093.4	420.1
Comprehensive income attributable to ordinary shareholders	16,185.4	5,271.6			15,985.1	4,979.3
Eliminations [Member]
Non-operating income (expense):
(Earnings) / losses of equity interest subsidiaries	26,006.4	3,331.6			25,394.4	2,334.7
Net (loss) from continuing operations, net of tax	(26,006.4)	(3,331.6)			(25,394.4)	(2,334.7)
Net income	(26,006.4)	(3,331.6)			(25,394.4)	(2,334.7)
Net income attributable to shareholders	(26,006.4)	(3,331.6)			(25,394.4)	(2,334.7)
Other comprehensive income / (loss)	(2,775)	46.2			(3,178.3)	(1,765.2)
Comprehensive income attributable to ordinary shareholders	$ (28,781.4)	$ (3,285.4)			$ (28,572.7)	$ (4,099.9)

Warner Chilcott Limited ("WC113

Warner Chilcott Limited ("WCL") Guarantor and Non-Guarantor Condensed Consolidating Financial Information - Consolidating Statement of Cash Flows (Detail) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Cash Flows From Operating Activities:
Net income / (loss)	$ 15,221.8	$ 5,302.6	$ 14,978.3	$ 4,548.7
Reconciliation to net cash provided by operating activities:
Depreciation			117.6	183.9
Amortization			4,836.7	4,192.8
Provision for inventory reserve			162.7	108.6
Share-based compensation			269.9	510.5
Deferred income tax benefit			(517.1)	(7,470.9)
Pre-tax gain sale of generics business			(24,203.1)
Non-cash tax effect of gain on sale of generics business			5,749.9
In-process research and development impairments			316.9	497.6
Loss / (gain) on asset sales and impairments, net			(24)	57.2
Amortization of inventory step-up			42.4	1,019.8
Amortization of deferred financing costs			44.6	289.2
Contingent consideration adjustments, including accretion			76.7	89.2
Other, net			(16)	54.9
Cash Flows From Investing Activities:
Additions to property, plant and equipment			(250.5)	(350.7)
Additions to product rights and other intangibles				(91.1)
Sale of generics business			33,304.5
Additions to investments			(15,445.5)	(27)
Proceeds from sale of investments and other assets			40	855.8
Proceeds from sales of property, plant and equipment			33.3	133.6
Acquisitions of businesses, net of cash acquired			(74.5)	(35,242.7)
Cash Flows From Financing Activities:
Proceeds from borrowings of long-term indebtedness				26,456.4
Proceeds from borrowings on credit facility and other			1,050	2,882
Debt issuance and other financing costs				(310.8)
Payments on debt, including capital lease obligations and credit facility			(10,831)	(4,326.7)
Payments of contingent consideration			(77.7)	(138.3)
Effect of currency exchange rate changes on cash and cash equivalents			4.3	(5.1)
Net increase in cash and cash equivalents			6,458.7	1,813.9
Cash and cash equivalents at beginning of period			1,096	250
Cash and cash equivalents at end of period	7,554.7	2,063.9	7,554.7	2,063.9
Warner Chilcott Limited Parent Guarantor [Member]
Cash Flows From Operating Activities:
Net income / (loss)	15,269	5,306.5	14,891.7	4,559.2
Reconciliation to net cash provided by operating activities:
(Earnings) / losses of equity interest subsidiaries	(15,269)	(5,306.5)	(14,891.7)	(4,559.2)
Dividends from subsidiaries			1,244.8	138.4
Changes in assets and liabilities (net of effects of acquisitions)			0.1	(0.1)
Net cash provided by / (used in) operating activities			1,244.9	138.3
Cash Flows From Investing Activities:
Additions to investments				(9,000.8)
Net cash provided by / (used in) investing activities				(9,000.8)
Cash Flows From Financing Activities:
Dividend to Parent			(1,244.8)	(138.4)
Contribution from Parent				9,000.8
Net cash provided by / (used in) financing activities			(1,244.8)	8,862.4
Net increase in cash and cash equivalents			0.1	(0.1)
Cash and cash equivalents at beginning of period				0.1
Cash and cash equivalents at end of period	0.1		0.1
Actavis Capital S.a.r.l. (Guarantor) [Member]
Cash Flows From Operating Activities:
Net income / (loss)	12,392.5	(1,412.9)	12,045.9	(2,212.7)
Reconciliation to net cash provided by operating activities:
(Earnings) / losses of equity interest subsidiaries	(11,485)	1,857.2	(10,701.3)	2,466.7
Amortization of deferred financing costs			21.7	268.8
Dividends from subsidiaries			1,244.8	138.4
Changes in assets and liabilities (net of effects of acquisitions)			8,487.2	(4,977.5)
Net cash provided by / (used in) operating activities			11,098.3	(4,316.3)
Cash Flows From Investing Activities:
Additions to investments				(9,000.8)
Net cash provided by / (used in) investing activities				(9,000.8)
Cash Flows From Financing Activities:
Proceeds from borrowings of long-term indebtedness				5,500
Proceeds from borrowings on credit facility and other			1,050	2,810
Debt issuance and other financing costs				(167.1)
Payments on debt, including capital lease obligations and credit facility			(8,815.9)	(3,692.5)
Dividend to Parent			(1,244.8)	(138.4)
Contribution from Parent				9,000.8
Net cash provided by / (used in) financing activities			(9,010.7)	13,312.8
Net increase in cash and cash equivalents			2,087.6	(4.3)
Cash and cash equivalents at beginning of period			13.5	5.5
Cash and cash equivalents at end of period	2,101.1	1.2	2,101.1	1.2
Actavis Funding SCS (Issuer) [Member]
Cash Flows From Operating Activities:
Net income / (loss)	(216.6)	0.3	2.2	0.5
Reconciliation to net cash provided by operating activities:
Amortization of deferred financing costs			18.3	14.8
Changes in assets and liabilities (net of effects of acquisitions)			479.5	(20,827.2)
Net cash provided by / (used in) operating activities			500	(20,811.9)
Cash Flows From Financing Activities:
Proceeds from borrowings of long-term indebtedness				20,955.6
Debt issuance and other financing costs				(143.7)
Payments on debt, including capital lease obligations and credit facility			(500)
Net cash provided by / (used in) financing activities			(500)	20,811.9
Actavis Finance, LLC [Member]
Cash Flows From Operating Activities:
Net income / (loss)	(765.3)	(209.2)	(284.2)	61.5
Reconciliation to net cash provided by operating activities:
(Earnings) / losses of equity interest subsidiaries	747.6	117.7	198.6	(242.2)
Depreciation				0.2
Share-based compensation				35.6
Amortization of deferred financing costs			3.2	3.1
Changes in assets and liabilities (net of effects of acquisitions)			80.4	179.8
Net cash provided by / (used in) operating activities			(2)	38
Cash Flows From Investing Activities:
Additions to property, plant and equipment				(35.5)
Net cash provided by / (used in) investing activities				(35.5)
Cash Flows From Financing Activities:
Net increase in cash and cash equivalents			(2)	2.5
Cash and cash equivalents at beginning of period			2	1.5
Cash and cash equivalents at end of period		4		4
Non-Guarantors [Member]
Cash Flows From Operating Activities:
Net income / (loss)	14,597.6	4,954.8	13,634.8	4,488
Reconciliation to net cash provided by operating activities:
Depreciation			117.6	183.7
Amortization			4,836.7	4,192.8
Provision for inventory reserve			162.7	108.6
Share-based compensation			269.9	474.9
Deferred income tax benefit			(517.1)	(7,470.9)
Pre-tax gain sale of generics business			(24,203.1)
Non-cash tax effect of gain on sale of generics business			5,749.9
In-process research and development impairments			316.9	497.6
Loss / (gain) on asset sales and impairments, net			(24)	57.2
Amortization of inventory step-up			42.4	1,019.8
Amortization of deferred financing costs			1.4	2.5
Contingent consideration adjustments, including accretion			76.7	89.2
Other, net			(16)	54.9
Changes in assets and liabilities (net of effects of acquisitions)			(10,821.9)	24,634
Net cash provided by / (used in) operating activities			(10,373.1)	28,332.3
Cash Flows From Investing Activities:
Additions to property, plant and equipment			(250.5)	(315.2)
Additions to product rights and other intangibles				(91.1)
Sale of generics business			33,304.5
Additions to investments			(15,445.5)	(27)
Proceeds from sale of investments and other assets			40	855.8
Proceeds from sales of property, plant and equipment			33.3	133.6
Acquisitions of businesses, net of cash acquired			(74.5)	(35,242.7)
Net cash provided by / (used in) investing activities			17,607.3	(34,686.6)
Cash Flows From Financing Activities:
Proceeds from borrowings of long-term indebtedness				0.8
Proceeds from borrowings on credit facility and other				72
Payments on debt, including capital lease obligations and credit facility			(1,515.1)	(634.2)
Payments of contingent consideration			(77.7)	(138.3)
Dividend to Parent			(1,244.8)	(138.4)
Contribution from Parent				9,000.8
Net cash provided by / (used in) financing activities			(2,837.6)	8,162.7
Effect of currency exchange rate changes on cash and cash equivalents			4.3	(5.1)
Net increase in cash and cash equivalents			4,400.9	1,803.3
Cash and cash equivalents at beginning of period			1,020.7	237.2
Cash and cash equivalents at end of period	5,421.6	2,040.5	5,421.6	2,040.5
Warner Chilcott Limited [Member]
Cash Flows From Operating Activities:
Net income / (loss)	15,270.8	5,307.9	14,896	4,561.8
Reconciliation to net cash provided by operating activities:
Depreciation			117.6	183.9
Amortization			4,836.7	4,192.8
Provision for inventory reserve			162.7	108.6
Share-based compensation			269.9	510.5
Deferred income tax benefit			(517.1)	(7,470.9)
Pre-tax gain sale of generics business			(24,203.1)
Non-cash tax effect of gain on sale of generics business			5,749.9
In-process research and development impairments			316.9	497.6
Loss / (gain) on asset sales and impairments, net			(24)	57.2
Amortization of inventory step-up			42.4	1,019.8
Amortization of deferred financing costs			44.6	289.2
Contingent consideration adjustments, including accretion			76.7	89.2
Other, net			(16)	54.9
Changes in assets and liabilities (net of effects of acquisitions)			(1,774.7)	(991)
Net cash provided by / (used in) operating activities			(21.5)	3,103.6
Cash Flows From Investing Activities:
Additions to property, plant and equipment			(250.5)	(350.7)
Additions to product rights and other intangibles				(91.1)
Sale of generics business			33,304.5
Additions to investments			(15,445.5)	(27)
Proceeds from sale of investments and other assets			40	855.8
Proceeds from sales of property, plant and equipment			33.3	133.6
Acquisitions of businesses, net of cash acquired			(74.5)	(35,242.7)
Net cash provided by / (used in) investing activities			17,607.3	(34,722.1)
Cash Flows From Financing Activities:
Proceeds from borrowings of long-term indebtedness				26,456.4
Proceeds from borrowings on credit facility and other			1,050	2,882
Debt issuance and other financing costs				(310.8)
Payments on debt, including capital lease obligations and credit facility			(10,831)	(4,326.7)
Payments of contingent consideration			(77.7)	(138.3)
Dividend to Parent			(1,244.8)	(138.4)
Contribution from Parent				9,000.8
Net cash provided by / (used in) financing activities			(11,103.5)	33,425
Effect of currency exchange rate changes on cash and cash equivalents			4.3	(5.1)
Net increase in cash and cash equivalents			6,486.6	1,801.4
Cash and cash equivalents at beginning of period			1,036.2	244.3
Cash and cash equivalents at end of period	7,522.8	2,045.7	7,522.8	2,045.7
Eliminations [Member]
Cash Flows From Operating Activities:
Net income / (loss)	(26,006.4)	(3,331.6)	(25,394.4)	(2,334.7)
Reconciliation to net cash provided by operating activities:
(Earnings) / losses of equity interest subsidiaries	$ 26,006.4	$ 3,331.6	25,394.4	2,334.7
Dividends from subsidiaries			(2,489.6)	(276.8)
Net cash provided by / (used in) operating activities			(2,489.6)	(276.8)
Cash Flows From Investing Activities:
Additions to investments				18,001.6
Net cash provided by / (used in) investing activities				18,001.6
Cash Flows From Financing Activities:
Dividend to Parent			2,489.6	276.8
Contribution from Parent				(18,001.6)
Net cash provided by / (used in) financing activities			$ 2,489.6	$ (17,724.8)

Subsequent Events - Additional

Subsequent Events - Additional Information (Detail)	Nov. 02, 2016USD ($)$ / shares	Oct. 27, 2016USD ($)	Oct. 02, 2016USD ($)	Nov. 01, 2016USD ($)Program$ / shares	Oct. 25, 2016USD ($)$ / shares	Sep. 30, 2016USD ($)
Subsequent Event [Line Items]
Share repurchase program, Approved amount						$ 10,000,000,000
Subsequent Event [Member] | Common Stock [Member]
Subsequent Event [Line Items]
Accelerated share repurchase agreement additional purchase amount	$ 10,000,000,000
Share repurchase program, Approved amount	$ 5,000,000,000
Quarterly dividends payable, amount per share | $ / shares	$ 0.70
Dividends payable date	Mar. 28, 2017
Dividends payable, date of record	Feb. 28, 2017
Subsequent Event [Member] | AstraZeneca [Member]
Subsequent Event [Line Items]
Maximum amount of contingent consideration			$ 1,270,000,000
License fees for development and commercialization			250,000,000
Sales-based milestone payments			$ 725,000,000
Maximum [Member] | Subsequent Event [Member] | AstraZeneca [Member]
Subsequent Event [Line Items]
Contingent consideration payments period			15 years
Development and launch milestone payments			$ 435,000,000
Tobira Therapeutics Inc. [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Business combination cash consideration for each share | $ / shares				$ 28.35
Maximum amount of contingent consideration				$ 1,700,000,000
Number of differentiated, complementary development programs added | Program				2
Tobira Therapeutics Inc. [Member] | Maximum [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Contingent consideration for acquisition CVRs per share value | $ / shares				$ 49.84
Vitae Pharmaceuticals Inc. [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Business combination cash consideration for each share | $ / shares					$ 21
Acquisition transaction value					$ 600,000,000
CNS Other
Subsequent Event [Line Items]
Upfront fee payable for license						125,000,000
CNS Other | Maximum [Member]
Subsequent Event [Line Items]
Potential regulatory and commercial milestones payments						$ 875,000,000
Motus Therapeutics [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Maximum amount of contingent consideration		$ 185,000,000
Business combination, consideration transferred		$ 200,000,000